<SEC-DOCUMENT>0001213900-21-044387.txt : 20220304
<SEC-HEADER>0001213900-21-044387.hdr.sgml : 20220304
<ACCEPTANCE-DATETIME>20210823171225
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-21-044387
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		11
FILED AS OF DATE:		20210823
<PUBLIC-REL-DATE>20220304
DATE AS OF CHANGE:		20210823

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-05402
		FILM NUMBER:		211197676

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Confidential Draft submitted to the Securities and Exchange Commission
on August 23, 2021. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information
contained herein remains confidential</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Registration Statement No. 333-[_______]</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form F-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OKYO Pharma Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of Registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of Registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OKYO Pharma Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Martello Court</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Admiral Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>St. Peter Port</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Guernsey GY1 3HB</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>+44 020 7495 2379</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone number,
including area code, of Registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 32%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Guernsey </B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2836</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Not Applicable</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other Jurisdiction of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Incorporation or Organization)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard Industrial</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Classification Code Number)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OKYO Pharma US, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>420 Lexington Avenue, Suite 1405</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10170</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(212) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: center; vertical-align: top; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jeffrey Fessler</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Justin Anslow</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sheppard, Mullin, Richter &amp;<BR>
 Hampton LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>30 Rockefeller Plaza</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10112-0015</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(212) 653 8700 </B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ed Lukins</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ed Dyson</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Orrick, Herrington &amp; Sutcliffe <BR>
(UK) LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>107 Cheapside</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>London EC2V 6DN</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>United Kingdom</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+44 (0) 207 862 4620 </B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Anthony J. Marsico</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dorsey &amp; Whitney LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>51 West 52nd Street</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10019</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(212) 415-9200</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Approximate date of commencement of proposed
sale to the public: As soon as practicable after this Registration Statement becomes effective.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the
following box. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act of 1933, check the following box and list the Securities Act of 1933
registration statement number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act of 1933, check the following box and list the Securities Act of 1933 registration statement
number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act of 1933, check the following box and list the Securities Act of 1933 registration statement
number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%"><FONT STYLE="font-size: 10pt">Large Accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 16%"><FONT STYLE="font-size: 10pt">Accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt">Non-accelerated filer &#9746;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 27%"><FONT STYLE="font-size: 10pt">Smaller reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Emerging growth company &#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U. S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period* for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities
Act of 1933. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">AMOUNT<BR> TO BE REGISTERED(2)(3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">PROPOSED<BR> MAXIMUM<BR> OFFERING<BR> PRICE<BR> PER&nbsp;SHARE</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">PROPOSED<BR> MAXIMUM<BR> AGGREGATE<BR> OFFERING <BR> PRICE(4)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">AMOUNT OF<BR> REGISTRATION<BR> FEE</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 52%">Ordinary shares, no par value, as represented by American Depositary Shares&nbsp;&nbsp;(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">These ordinary shares are represented by ADSs, each of which represents ordinary shares of the registrant. ADSs issuable on deposit of the ordinary shares registered hereby are being registered pursuant to a separate registration statement on Form F-6 (File [__]).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the ordinary shares registered hereby also include an indeterminate number of additional ordinary shares as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other similar transactions</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents ___ ordinary shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section
8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The information contained in this preliminary
prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities
and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an
offer to buy these securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="color: Red; vertical-align: top">
    <TD STYLE="color: Red; width: 34%"><FONT STYLE="font-size: 10pt">PRELIMINARY PROSPECTUS</FONT></TD>
    <TD STYLE="color: Red; width: 1%">&nbsp;</TD>
    <TD STYLE="color: Red; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt">SUBJECT TO COMPLETION</FONT></TD>
    <TD STYLE="color: Red; width: 1%">&nbsp;</TD>
    <TD STYLE="color: Red; width: 32%; text-align: right"><FONT STYLE="font-size: 10pt">DATED AUGUST 23, 2021</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Up to [__] American Depositary Shares</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Representing [__] Ordinary Shares</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0"><B>OKYO Pharma Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the resale, by the
selling shareholders identified in this prospectus of up to ___ American Depositary Shares, or ADSs. <FONT STYLE="background-color: white">The
selling shareholders are identified in the table commencing on page&nbsp;81. No ADSs are being registered hereunder for sale by us. Each
ADS will represent __ ordinary shares. The selling shareholders may sell all or a portion of the ordinary shares represented by ADSs from
time to time in market transactions through any market on which our ADSs are then traded, in negotiated transactions or otherwise, and
at prices and on terms that will be determined by the then prevailing market price or at negotiated prices directly or through a broker
or brokers, who may act as agent or as principal or by a combination of such methods of sale. See &ldquo;Plan of Distribution.&rdquo;</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, there has been no public
market for our ADSs. We intend to apply to list our ADSs for trading on the Nasdaq Capital Market or Nasdaq, under the symbol &ldquo;[__].&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ordinary shares are admitted to listing on
the standard segment of Official List of the UK Financial Conduct Authority, or FCA, and to trading on the main market for listed securities,
or Main Market of London Stock Exchange plc, or London Stock Exchange, under the symbol &ldquo;OKYO.&rdquo; On [____], 2021, the last
reported sale price of our ordinary shares was &pound;[__] per share (equivalent to $[__] per ADS based on an exchange rate of &pound;1.00
to $[__]). The price of our ADSs will be determined in part by reference to the trading price of our ordinary shares on the Main Market
of the London Stock Exchange. For a discussion of the factors considered in determining the initial public offering price of our ADSs,
see &ldquo;Underwriting&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our ADSs involves a high degree
of risk. See &ldquo;Risk Factors&rdquo; beginning on page 9 of this prospectus for a discussion of information that you should consider
before investing in our ADSs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the SEC, nor any state securities commission
has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary
is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company,&rdquo;
or EGC, as defined under applicable Securities and Exchange Commission, or SEC, rules and, as such, have elected to comply with certain
reduced public company reporting requirements for this and future filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 48px; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001"><FONT STYLE="font-size: 10pt">About This Prospectus</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Presentation of Financial Information</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Cautionary Statement Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Market and Industry Data</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Trademarks, Service Marks and Tradenames</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Exchange Rate Information</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Price Range of Our Ordinary Shares</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Selected Consolidated Financial Data</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_014"><FONT STYLE="font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Management</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_016"><FONT STYLE="font-size: 10pt">Certain Relationships and Related Party Transactions</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">80</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_017"><FONT STYLE="font-size: 10pt">Principal Shareholders</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">82</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Selling Shareholders</FONT></A></TD>
    <TD STYLE="text-align: center">81</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_019"><FONT STYLE="font-size: 10pt">Description of Share Capital and Memorandum and Articles of Incorporation</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">83</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_020"><FONT STYLE="font-size: 10pt">ADSs Eligible For Future Sale</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">115</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_021"><FONT STYLE="font-size: 10pt">Certain U.S. and Guernsey Tax Considerations</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">116</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_022"><FONT STYLE="font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">121</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_023"><FONT STYLE="font-size: 10pt">Expenses of This Offering</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">124</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_024"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">125</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_025"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">125</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_026"><FONT STYLE="font-size: 10pt">Service of Process and Enforcement of Liabilities</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">125</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_027"><FONT STYLE="font-size: 10pt">Where You Can Find Additional Information</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">125</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_028"><FONT STYLE="font-size: 10pt">Index to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>We are responsible for
the information contained in this prospectus and any free-writing prospectus we prepare or authorize. We have not, and none of the selling
shareholders have, authorized anyone to provide you with different information, and we and the selling shareholders take no responsibility
for any other information others may give you. We are not, and none of the selling shareholders are, making an offer to sell our ADSs
in any jurisdiction where the offer or sale is not permitted. For the avoidance of doubt, we are not, and none of the selling shareholders
are, making an offer to sell our ordinary shares in any jurisdiction. You should not assume that the information contained in this prospectus
is accurate as of any date other than the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus
or the sale of any ADSs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For investors outside the
United States, neither we nor any of the selling shareholders have done anything that would permit this offering or possession or distribution
of this prospectus in any jurisdiction, other than the United States, where action for that purpose is required. Persons outside the United
States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering
and the distribution of this prospectus outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a non-cellular company
limited by shares incorporated under the Companies (Guernsey) Law 2008, or the Guernsey Companies Law and a majority of our outstanding
securities are owned by non-U.S. residents. Under the rules of the SEC, we are currently eligible for treatment as a &ldquo;foreign private
issuer,&rdquo; or FPI. As an FPI, we will not be required to file periodic reports and financial statements with the SEC as frequently
or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, or Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_001"></A><B>About
This Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise indicated
or the context otherwise requires, all references in this registration statement to the terms &ldquo;OKYO,&rdquo; &ldquo;OKYO Pharma Limited,&rdquo;
&ldquo;the company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to OKYO Pharma Limited and our wholly owned
subsidiary OKYO Pharma US Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Solely for convenience, the
trademarks, service marks and trade names in this registration statement may be referred to without the &reg; and &trade; symbols, but
such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable
law, their rights thereto. This registration statement contains additional trademarks, service marks and trade names of others, which
are the property of their respective owners. We do not intend to use or display other companies&rsquo; trademarks, service marks and trade
names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In this registration statement,
unless otherwise stated, all references to &ldquo;U.S. dollars&rdquo; or &ldquo;US$&rdquo; or &ldquo;$&rdquo; or &ldquo;cents&rdquo; are
to the currency of the United States of America, and all references to &ldquo;Pounds Sterling&rdquo; or &ldquo;&pound;&rdquo; or &ldquo;pence&rdquo;
are to the currency of the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In this registration statement,
any reference to any provision of any legislation shall include any amendment, modification, re-enactment or extension thereof. Words
importing the singular shall include the plural and vice versa, and words importing the masculine gender shall include the feminine or
neutral gender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_002"></A><B>Presentation
of Financial Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus includes
our audited consolidated financial statements as of and for the years ended March 31, 2021, March 31, 2020 and March 31, 2019 which are
prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards
Board, or IASB. None of our financial statements were prepared in accordance with generally accepted accounting principles in the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our financial information
is presented in U.S. dollars. For the convenience of the reader, in this prospectus, unless otherwise indicated, translations from Pounds
Sterling into U.S. dollars were made at the rate of &pound;1.00 to $1.3795 which was the noon buying rate of the Federal Reserve Bank
of New York on July 2, 2021. Such U.S. dollar amounts are not necessarily indicative of the amounts of U.S. dollars that could actually
have been purchased upon exchange of Pounds Sterling at the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have made rounding adjustments
to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic
aggregation of the figures that preceded them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B><A NAME="a_003"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>This summary highlights
information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your
investment decision. Before investing in our ADSs or ordinary shares, you should carefully read this entire prospectus, including our
consolidated financial statements and the related notes and the information set forth under the sections titled &ldquo;Risk Factors,&rdquo;
&ldquo;Special Note Regarding Forward-Looking Statements,&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations,&rdquo; in each case included elsewhere in this prospectus. Unless the context otherwise requires, we use the
terms &ldquo;OKYO,&rdquo; &ldquo;Company,&rdquo; &ldquo;our,&rdquo; &ldquo;us,&rdquo; and &ldquo;we&rdquo; in this prospectus to refer
to OKYO Pharma Limited and, where appropriate, our consolidated subsidiary, OKYO Pharma US, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a preclinical biopharmaceutical
company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain.
Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays a key role in the pathology of
these inflammatory eye diseases of high unmet medical need. We are presently developing OK-101, our lead preclinical product candidate,
for the treatment of dry-eye, uveitis and allergic conjunctivitis, and OK-201, a bovine adrenal medulla, or BAM, lipidated-peptide preclinical
analogue candidate for the treatment of neuropathic ocular pain. Our therapeutic approach is focused on targeting inflammatory and pain
modulation pathways that drive these conditions. We have not, as of yet, submitted an application to the U.S. Food and Drug Administration,
or FDA, for any of our product candidates. We are planning to file an investigational new drug application, or IND, on OK-101 to treat
dry eye disease, or DED, in the third quarter of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 21, 2018, we announced
that we successfully obtained (via assignment from Panetta Partners Limited, a related party) a license from On Target Therapeutics LLC,
or OTT, to patents owned or controlled by OTT and a sub-license from OTT to certain patents licensed by OTT from Tufts Medical Center
Inc., or TMC, to support our ophthalmic disease drug programs. These licenses gave us the right to exploit the intellectual property,
or IP estate which is directed to compositions-of-matter and methodologies for treating ocular inflammation, DED, with chemerin or lipid-linked
chemerin analogues. We also have a license from TMC to a separate IP estate for treating symptoms of ocular neuropathic pain and uveitis
associated pain. On August 6, 2019 we signed a collaborative agreement with TMC on a research program focused on ocular neuropathic pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 7, 2021 we announced
the appointment of Mr. Gabriele Cerrone as Executive Chairman and Director, and Gary S. Jacob, Ph.D. as Chief Executive Officer and Director.
The addition of these two individuals is a significant step for us, highlighting a careful realignment of the strategic focus of our research
and development program, with the aim of facilitating advancement of both of our preclinical programs. We believe this realignment will
allow us to file investigational new drug, or IND, applications on our drug candidates with the FDA in the shortest time possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>OK-101 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">OK-101, our lead preclinical
product candidate, is focused on keratoconjunctivitis sicca, commonly referred to as dry eye disease, or DED, which is a multifactorial
disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. DED is one of
the most common ophthalmic conditions encountered in clinical practice. Symptoms of DED include constant discomfort and irritation accompanied
by inflammation of the ocular surface, visual impairment and potential damage to the ocular surface. The disease affects over 35% of the
population aged 50+, with women representing approximately two-thirds of those affected. Prevalence of DED is anticipated to increase
substantially in the next 10-20 years due to aging populations in the U.S., Europe, Japan and China and use of contact lenses in the younger
population. We believe this increase in prevalence of dry eye syndrome represents a major expanding economic burden to public healthcare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At present, there are essentially
three major prescription drugs used to treat DED: 1) Restasis (cyclosporine), 2) Lacrisert (hydroxypropyl cellulose), and 3) Xiidra (liftegrast).
However, DED continues to be a major unmet medical need due to the large number of patients not well served by the treatments available
to them through the medical community. The development of new drugs to treat DED has been particularly challenging due to the heterogeneous
nature of the patient population suffering from DED, and due to the difficulties in demonstrating an improvement in both signs and symptoms
of the disease in well-controlled clinical trials.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The evidence from over 40
years of scientific literature, however, suggests inflammation as the most common underlying cause of DED. An increase in the levels of
inflammatory cytokines in both conjunctiva and tears is known to cause the chronic inflammation associated with DED. Consequently, development
of new therapeutic agents that target inflammatory pathways is crucial in improving symptoms in DED patients. OK-101 is focused on an
anti-inflammatory pathway for treating dry eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The chemerin receptor (CMKLR1
or ChemR23) is a chemokine like GCPR expressed on select populations of cells including inflammatory mediators as well as epithelial cells.
Activation of CMKLR1 by chemerin has been shown to resolve the inflammation in animal models of asthma. We have been pioneering the development
of OK-101, a lipidated-OK-101 analogue, which is an agonist of CMKLR1, in treating DED and other ocular inflammatory conditions. OK-101
was first identified in a program developed by On Target Therapeutics LLC using membrane-tethered ligand technology.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>



<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To expand our understanding
of the structure-activity relationships of the lipidated-chemerin analogues, such as OK-101. as agonists of the chemerin receptor, we
synthesized a small library of analogues of OK-101. We screened these analogues in a cell-line based receptor binding assay to characterize
the agonist potency of these lipidated-chemerin analogues. This work has also been coupled to an evaluation of a subset of these analogues&rsquo;
potential in treating DED by using a variety of preclinical studies and dry eye animal model studies. After evaluating a number of our
analogues in a mouse model of acute dry eye disease by looking at their ability to reduce corneal permeability, a measure of dry-eye effectiveness,
as well as the analogues&rsquo; impact on immune response, we determined that OK-101 was the most potent analogue in reducing corneal
permeability and down-regulating immune response. Following these studies, we evaluated the ocular tolerance of OK-101 <I>via</I> repeated
ocular instillation in rabbits followed by clinical ophthalmic observations. Rabbit ocular tolerance tests on OK-101 showed no adverse
signs such as inflammation, chemosis or hyperemia and no signs of local irritation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on the results from
the DED animal model and ocular tolerance studies, we are moving forward with plans to file an IND in the third quarter of 2022 on our
preclinical candidate OK-101 to treat DED to enable us to begin clinical trials soon thereafter. We recently completed manufacturing a
25-gram batch of OK-101 drug substance needed for initiating the IND-enabling studies. To support this work, we also recently signed an
agreement with a major clinical CRO specializing in ophthalmic drug development who will be providing the following services:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Preparation of the OK-101 Pre-IND briefing document</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
                                                                                                                                                                                                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Support in requesting and preparing for the OK-101 Pre-IND meeting with FDA</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
                                                                                                                                                                                                                              </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Support for regulatory publishing and submission of IND in eCTD format</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
                                                                                                                                                                                                                         </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Providing quality oversight for development of topical formulation for OK-101</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
                                                                                                                                                                                                                                </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Providing quality oversight for development and qualification of a drug stability analysis method for OK-101 along with conducting
stability studies to establish formulated drug product is stable for at least 90 days</TD></TR><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
                                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>Support for completing animal toxicology studies in two animal species</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the next 12 months, OKYO is committed to
a major effort to accomplish the IND enabling activities necessary for filing an IND on OK-101 to treat DED. These include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Topical formulation of the OK-101 drug product and initial stability studies</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Bioanalytical method development to support the OK-101 clinical program</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                      </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Engineering batch manufacture of cGMP OK-101 for clinical trials</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Toxicokinetic method development</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Toxicology studies in rabbits and dogs</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Clinical batch manufacturing and stability studies of OK-101</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Additional Applicable Disease Indications
for OK-101</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A second related ophthalmic
disease indication that is the target of our chemerin-based technology is uveitis. Uveitis is the third leading cause of blindness worldwide.
The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis can damage vital eye tissue,
leading to permanent vision loss. Uveitis is currently treated with corticosteroid eyedrops and injections that reduce inflammation, however,
the long-term use of corticosteroids causes risk of cataract and glaucoma, requiring close monitoring for their potential side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that OK-101, in
addition to its potential to treat DED, should also be evaluated to treat allergic conjunctivitis and uveitis. Correspondingly, once we
have an IND on OK-101 in place and are clinically evaluating OK-101 to treat dry eye, we also plan to explore the drug candidate&rsquo;s
potential to suppress the inflammation associated with allergic conjunctivitis and uveitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 5pt; text-align: justify; text-indent: 0.25in">On January 19, 2021, we
announced that we submitted a patent application to the United States Patent and Trademark Office covering the use of chemerin and chemerin
analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions such as acute respiratory distress
syndrome (ARDS). On January 15, 2021 we signed a research and material transfer agreement with the University of Alabama at Birmingham
to evaluate the potential of chemerin analogs to minimize the inflammation triggered by SARS-CoV-2 in a model of lung inflammation. <I>Ex
vivo</I> lung tissue will be experimentally induced to produce inflammation, and during the course of inflammation in the absence and
presence, respectively, of a chemerin analogue, a panel of cytokines including TNF&alpha;, IL-6, IL-1&beta; will be measured. Currently,
experiments are underway at the University of Alabama, but there is nothing to report yet on the results of this study. Assuming the
results are encouraging, our plan is to advance this program as a potential prophylaxis to treat COVID-19 infections, and to treat other
conditions such as acute respiratory distress syndrome (ARDS). We plan this work to be under the direction of Dr. Napoleone Ferrara,
a member of our Scientific Advisory Board.</P>
</DIV>
<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>OK-201</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ocular pain, that occurs in
several conditions such as DED, uveitis, diabetic retinopathy, accidental trauma and surgery, is typically treated with topical steroid.
Damage to the ocular surface (nociceptive pain in response to inflammation) or to the somatosensory nervous system (chronic neuropathic
pain) due to the underlying pathogenesis of eye disease is the main cause of pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our immediate focus is to
develop first-in-class drug candidates as analgesics for ocular pain management. On August 6, 2019 we signed a collaborative agreement
with TMC and Pedram Hamrah, MD, Professor of Ophthalmology at Tufts University School of Medicine, Boston, MA as Principal Investigator
to evaluate our proprietary lead compounds to suppress corneal neuropathic pain using a mouse ocular pain model recently developed in
Dr. Hamrah&rsquo;s laboratory. A lipidated cyclized BAM analogue (OK-201), a promising candidate for the treatment of neuropathic and
inflammatory pain, was licensed from TMC on May 1, 2018. Our goal is to further develop this lipidated peptide, as well as explore additional
analogues, for their potential use in treating ocular pain, and for potentially treating long-term chronic pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">OK-201 is focused on activating
a human MAS-Related G Protein-Coupled Receptor, or MRGPR, which is a promising analgesic target. This receptor is expressed mainly in
sensory neurons and is involved in the perception of pain. Activation of MRGPR by Bovine Adrenal Medulla, or BAM, inhibits pain by modulating
Ca2+ influx. Since acquiring the rights to OK-201, we have also synthesized a small library of BAM analogues. The potencies of these analogues
were determined using a cell-based assay, and a small number of these analogues were evaluated for their analgesic properties in the neuropathic
pain model developed by Dr. Hamrah&rsquo;s laboratory at TMC. These collaborative studies have provided additional &lsquo;proof-of-concept&rsquo;
results for the BAM analogues as potential analgesics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the next year, we plan
to utilize the capabilities assembled to advance the OK-201 preclinical candidate in a series of preclinical studies that also include
further use of the corneal neuropathic animal model developed at TMC. A supplemental study characterizing corneal permeability of our
class of analogs is also needed for the development of future topical formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Selected Risks Affecting Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our business is subject to
a number of risks of which you should be aware before making an investment decision. You should carefully consider all of the information
set forth in this prospectus and, in particular, should evaluate the specific factors set forth in the section titled &ldquo;Risk Factors&rdquo;
before deciding whether to invest in our ADSs. These important risks include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Relating To Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>We have only recently committed
to our new business and our product candidates are in the early stages of development and it may be some years until we generate revenue,
if at all.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Our product candidates have
not been evaluated in clinical trials and results in the clinic may not be reproduced in human trials.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>There is a high degree of
failure for product candidates as they progress through clinical trials and clinical trial data may be interpreted in varying ways which
may delay, limit or prevent future regulatory approvals.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>The development of pharmaceutical
products carries significant risk of failure in early and late stage development programs.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
</DIV>
<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Financial Position and
Need for Capital.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>We anticipate that we will
continue to incur significant losses for the foreseeable future.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>We will need to spend extensively
on further research activities and there can be no guarantee that we will have access to sufficient funds to fully realize our research
and development plan or to commercialize any products derived from research activities.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Commercialization Of Our Product
Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Even if we successfully
develop a product which shows efficacy in human subjects there remain high barriers to commercial success.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>We face significant competition
from pharmaceutical companies. We have competitors internationally, including major multinational pharmaceutical companies, universities
and research institutions. In respect of OK-101 as an indication for the treatment of DED, there are a number of established companies
engaged in the development and marketing of preparations addressing the DED market. In addition, there are a wide range of products addressing
the DED market currently approved and marketed by a number of large and small pharmaceutical companies.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Intellectual Property
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>The expiration of certain intellectual property rights or an inability to obtain, maintain or enforce adequate intellectual property rights for products that are marketed or in development may result in additional competition from other third-party products. Third parties may have blocking intellectual property rights which could prevent the sale of products by us or require that compensation be paid to such third parties.</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Our product candidates could
infringe patents and other intellectual property rights of third parties.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>COVID-19 has adversely affected
our business, and any new pandemic, epidemic or outbreak of an infectious disease may further adversely affect our business.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>The relationship of the
UK with the EU could impact our ability to operate efficiently in certain jurisdictions or in certain markets.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related To Government Regulation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Even if we complete the
necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our product candidates
and the approval may be for a more narrow indication than we seek.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>If our competitors are able
to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates,
we may not be able to have competing products approved by applicable regulatory authorities for a significant period of time. In addition,
even if we obtain orphan drug exclusivity for any of our products, such exclusivity may not protect us from competition.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Even if we obtain regulatory
approval for a product candidate, our product candidates will remain subject to regulatory oversight.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Even if we obtain and maintain
approval for our product candidates in a major pharmaceutical market such as the United States, we may never obtain approval for our
product candidates in other major markets.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>We may seek a conditional
marketing authorization in Europe for some or all of our current product candidates, but we may not be able to obtain or maintain such
designation.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Healthcare legislative reform
measures may have a negative impact on our business and results of operations.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>We are subject to governmental
regulation and other legal obligations related to privacy, data protection and data security. Our actual or perceived failure to comply
with such obligations could harm our business.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</DIV>
<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Ownership of Our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>We do not know whether an
active, liquid and orderly trading market will develop for our ADSs or what the market price of our ADSs will be. As a result, it may
be difficult for shareholders to sell their ADSs.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>If you purchase ADSs in
this offering, you will suffer immediate dilution of your investment.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Holders of our ADSs may
experience substantial dilution upon the exercise of outstanding options and warrants.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Holders of our ADSs have
fewer rights than our shareholders and must act through the depositary to exercise their rights.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>The rights of our shareholders
may differ from the rights typically offered to shareholders of a U.S. corporation.</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>If we are a passive foreign
investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We were originally incorporated
in the British Virgin Islands as a British Virgin Islands Business Company on July 4, 2007 under the BVI Business Companies Act 2004 with
company number 1415559 under the name Jellon Enterprises, Inc. Our legal and commercial name was changed to Minor Metals &amp; Mining,
Inc. on October 24, 2007, to Emerging Metals Limited on November 28, 2007, to West African Minerals Corporation on December 9, 2011, and
to OKYO Pharma Corporation on January 10, 2018. On March 9, 2018, shareholders approved the cancellation of our AIM listing and migration
to Guernsey. On July 3, 2018, following the approval of the Guernsey Companies Registry, we were registered under the Guernsey Companies
Law under the name OKYO Pharma Limited, as a Guernsey company with limited liability, an indefinite life and company number 65220. We
are domiciled in Guernsey. On July 17, 2018 our Ordinary Shares were admitted to listing on the standard segment of the Official List
of the FCA and admitted to trading on the Main Market for listed securities of the London Stock Exchange. We are subject to the Takeover
Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our registered office is
located at Martello Court, Admiral Park, St. Peter Port, Guernsey GY1 3HB and our telephone number is +44 (0) 20 7495 2379. Our website
address is www.okyopharma.com. The reference to our website is an inactive textual reference only and the information contained in, or
that can be accessed through, our website is not a part of this registration statement. Our agent for service of process in the United
States is [&nbsp; ].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;OKYO,&rdquo; the OKYO
logo and other trademarks or service marks of OKYO Pharma Limited appearing in this prospectus are the property of OKYO or our subsidiary.
This prospectus contains additional trade names, trademarks and service marks of others, which are the property of their respective owners.
Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the &reg; or <SUP>TM</SUP> symbols.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being an Emerging Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an EGC as defined in
the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we may take advantage of certain exemptions from various reporting
requirements that are applicable to other publicly traded entities that are not EGCs. These exemptions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the option to present only
two years of audited financial statements and related discussion in the section titled &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations&rdquo; in this prospectus;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">not being required to comply
with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">not being required to comply
with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or
a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial statements (i.e., an auditor
discussion and analysis);</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">not being required to submit
certain executive compensation matters to stockholder advisory votes, such as &ldquo;say-on-pay,&rdquo; &ldquo;say-on-frequency,&rdquo;
and &ldquo;say-on-golden parachutes;&rdquo; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">not being required to disclose
certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of
the chief executive officer&rsquo;s compensation to median employee compensation.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section 107 of the JOBS Act
also provides that an EGC can take advantage of the extended transition period provided in Section 13(a) of the Exchange Act, for complying
with new or revised accounting standards. As a result, an EGC can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will remain an EGC until
the earliest of: (1) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion; (2) the last day of
2023; (3) the date that we become a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under the Exchange Act, which would
occur on the last day of any fiscal year that the aggregate worldwide market value of our common equity held by non-affiliates exceeds
$700 million as of the last business day of our most recently completed second fiscal quarter; or (iv) the date on which we have issued
more than $1.0 billion in non-convertible debt securities during any three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being a Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the completion of this
offering, we will report under the Exchange Act as a non-U.S. company with FPI status. Even after we no longer qualify as an EGC, as long
as we qualify as an FPI under the Exchange Act we will be exempt from certain provisions of the Exchange Act that are applicable to U.S.
domestic public companies, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the sections of the Exchange
Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the sections of the Exchange
Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from
trades made in a short period of time; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the rules under the Exchange
Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specific information,
and current reports on Form 8-K upon the occurrence of specified significant events.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">FPIs are also exempt from
certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an EGC, but remain an FPI, we will
continue to be exempt from the more stringent compensation disclosures required of companies that are neither an EGC nor an FPI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 24%"><FONT STYLE="font-size: 10pt">Ordinary shares currently outstanding</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-size: 10pt">[__] ordinary shares </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">ADSs offered by the selling shareholders</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Up to [__] ADSs representing ___ ordinary shares</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">ADSs</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each ADS represents [__] ordinary shares of no par value. The depositary will hold the ordinary shares underlying your ADSs and you will have rights as provided in the deposit agreement among us, the depositary, and holders and beneficial owners of ADSs from time to time. To better understand the terms of our ADSs, see &ldquo;Description of the American Depositary Shares.&rdquo; We also encourage you to read the deposit agreement, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Depositary</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[__]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">See &ldquo;Risk Factors&rdquo; and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our ADSs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Proposed Nasdaq Capital Market symbol</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;OKYO&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The number of shares of our
ordinary shares that will be outstanding after this offering is based on 970,686,108 ordinary shares outstanding as of July 2, 2021, and
excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">61,625,000 ordinary shares
issuable upon the exercise of share options at exercise prices of between $0.062 and $0.214 per ordinary share of which 13,875,000 ordinary
shares are currently exercisable and 47,750,000 are exercisable between July 6, 2021 and March 25, 2031;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">113,659,090 ordinary shares
that currently may be issued upon the exercise of warrants to purchase ordinary shares at exercise prices of between $0.006 and $0.14
per ordinary share.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">97,045,464 ordinary shares
that currently may be issued upon the conversion of loan notes to purchase ordinary shares at exercise prices of $0.0055 per ordinary
share.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">97,045,464 ordinary shares
that currently may be issued upon the exercise of warrants issued along with the conversion of loan notes to purchase ordinary shares
at exercise prices of $0.0055.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">Unless</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">otherwise indicated, this prospectus
reflects and assumes the following:</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">no exercise of outstanding
share options or warrants after July 2, 2021</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 5pt; padding-left: 5pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Summary
Consolidated Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following tables set
forth our summary consolidated financial data for the periods indicated. We have derived the consolidated statement of operations data
for the years ended March 31, 20201, 2020 and 2019 and the consolidated balance sheet data as of March 31, 2021 from our audited consolidated
financial statements included elsewhere in this prospectus. The unaudited consolidated statement of operations data for the six months
ended September 30, 2020 and 2019 and the unaudited consolidated balance sheet data as at September 30, 2020 have been derived from our
unaudited consolidated financial statements for the periods included elsewhere in this prospectus. Our historical results are not necessarily
indicative of the results that should be expected for any future period. You should read the following summary consolidated financial
data together with the audited consolidated financial statements included elsewhere in this prospectus and the sections titled &ldquo;Exchange
Rate Information&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We maintain our books and
records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB. We report our financial
results in U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consolidated Statement of Operations Data:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended&nbsp;March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenue</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">-</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">-</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(173,821</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(518,098</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,064,296</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,192,385</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,016,548</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,505,532</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,366,206</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,534,646</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,569,828</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,366,206</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,534,646</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,569,828</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,295</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(85,701</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(365,477</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tax provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,289</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss attributable to ordinary shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,378,507</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,544,059</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,935,305</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Foreign currency translation adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346,365</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86,654</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(289,249</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,007,142</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,457,405</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,244,554</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Basic and diluted net loss per ordinary share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consolidated Balance Sheet Data:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended March 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actual </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pro</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Forma (1)</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,889,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,889,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Working capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,279,384</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,441,216</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,091,322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,091,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total shareholders&rsquo; equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,319,408</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,481,240</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">On a pro forma basis to give effect to (i) the issuance of 149,900,410
ordinary shares in satisfaction of the conversion of outstanding convertible loan notes in May 2021 and (ii) the issuance of 147,969,396
ordinary shares in satisfaction of conversion of warrants in May 2021.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_004"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>You should carefully consider
the risks described below, together with all of the other information in this registration statement. The risks and uncertainties below
are not the only ones we face. Additional risks and uncertainties not presently known to us or that we believe to be immaterial may also
adversely affect our business. If any of the following risks occur, our business, financial condition and results of operations could
be seriously harmed and potential future investors in our ADSs could lose all or part of their investment. Further, if we fail to meet
the expectations of the public market in any given period, the potential market price of our ADSs could decline. We operate in a highly
competitive environment that involves significant risks and uncertainties, some of which are outside of our control. If any of these risks
actually occurs, our business and financial condition could suffer and the potential market price of our ADSs could decline. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Relating To Our Business </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have only recently committed to our new
business and our product candidates are in the early stages of development and it may be some years until we generate revenue, if at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our product candidates, OK-101and
OK-201, are both very early in the development stage and even the lead product candidate, OK-101, is still in the pre-clinical stage.
Through our scientific collaborators, we have only recently completed initial pre-clinical studies with respect to OK-101 and OK-201 and
our ability to generate product revenue, which is not expected to occur for several years, if ever, will depend heavily on the successful
development of the product candidates, many stages of clinical trials, regulatory approval and eventual commercialization. We have only
recently committed to our new business operating as a life sciences and biotechnology business. We currently generate no revenue from
sales of any product and may never be able to develop or commercialize a marketable product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product candidates have not been evaluated
in clinical trials and results in the clinic may not be reproduced in human trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The early stages of our business
strategy carry significant risks associated with product candidates which have not been evaluated in human clinical trials. Not only may
encouraging results seen in pre-clinical trials not be indicative of results in later clinical trials but given that the product candidates
have only been evaluated in mouse models to date, unexpected or adverse effects may be seen once the product candidates enter the human
clinical trials stage which in turn may create significant hurdles to further development or lead to the abandonment of further development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is a high degree of failure for product
candidates as they progress through clinical trials and clinical trial data may be interpreted in varying ways which may delay, limit
or prevent future regulatory approvals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many companies in the life
sciences and biotechnology sector have made significant initial progress only to suffer significant setbacks in later stage clinical trials
and there is a high failure rate for product candidates as they proceed through clinical trials. Data obtained from pre-clinical and clinical
activities is subject to varying interpretations which may delay, limit or prevent applications for regulatory approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The development of pharmaceutical products
carries significant risk of failure in early and late stage development programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The development of pharmaceutical
products is inherently uncertain, even in late-stage product development programs. There is a high failure rate in the development of
pharmaceutical products and there is a substantial risk of adverse, undesirable, unintended or inconclusive results from testing or pre-clinical
or clinical trials, which may substantially delay, or halt entirely, or make uneconomic, any further development of our products and may
prevent or limit the commercial use of such products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While the pre-clinical development
of OK-101 and initial studies in animal models have been encouraging, the scope of these studies is limited and significant risks exist
that OK-101 may never progress to a commercially viable product. Laboratory studies in animal models carry the risk that similar results
may not be seen or reproduced in future tests and trials, and there can be no guarantee that a successful test in a mouse or other animal
model will be capable of being reproduced in a human clinical trial. Small scale trials and the results thereof, can be misleading as
to efficacy, safety and other findings, as the outcome may be influenced by laboratory or demographic factors and not due to the chemistry
or biological effect of the drug candidate being evaluated. Larger scale trials often fail to produce the same positive results seen in
small scale trials for a variety of reasons and clinical trials in humans frequently fail to reproduce efficacy seen in animal trials
in the laboratory. Failure can often result after significant sums have been expended on research and often where initial trial results
(both in animals and in humans) have shown very encouraging results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Management initially intends
to conduct laboratory and pre-clinical trials to establish safety and efficacy of our products. Due to the inherent risks involved in
developing pharmaceutical products, there is a risk that some or all of our products will not ultimately be successfully developed or
launched. In addition, the planned clinical trials may fail to show the desired safety and efficacy. This may be the case even if the
FDA approves an investigational new drug application, or IND, as positive data in animal studies may not be reflected or reproduced in
human trials. Successful completion of one stage of development of a pharmaceutical product does not ensure that subsequent stages of
development will be successful. Our inability to market any of our products currently under development would adversely affect our business
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are currently primarily
dependent for our short to medium-term success on a single early-stage product, OK-101, which is a research product that has shown pre-clinical
potential but has not yet been tested on humans and has not obtained the necessary approvals required to conduct Phase I clinical trials
in humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any commercial development
of OK-101 is highly dependent on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71.45pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the successful conduct of human
trials in the initial indications of DED;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">receipt of marketing approvals
for OK-101 in the United States and other jurisdictions where separate approval is required and where we subsequently choose to market
OK-101;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">launching commercial sales
of OK-101, if and when approved;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">acceptance of OK-101 by patients,
the medical community and third-party payers;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">OK-101 competing effectively
with existing therapies and in particular with established products addressing the same clinical needs;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">OK-101 influencing the treatment
guidelines in relevant territories; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">further clinical trials to
provide additional data to support commercialization of OK-101 and to permit wider label claims.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of these milestones
are not met, our business, financial condition, prospects and results of operations could be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Financial Position and
Need for Capital.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to raise substantial additional
capital to develop and commercialize our product candidates and our failure to obtain funding when needed may force us to delay, reduce
or eliminate our product development programs or collaboration efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 31, 2021, our
cash and cash equivalents balance was approximately $6.9 million and our working capital was approximately $5.3 million. Due to our recurring
losses from operations and the expectation that we will continue to incur losses in the future, we will be required to raise additional
capital to complete the development and commercialization of our current product candidates. We have historically relied upon private
and public sales of our equity, as well as debt financings to fund our operations. In order to raise additional capital, we may seek to
sell additional equity and/or debt securities or obtain a credit facility or other loan, which we may not be able to do on favorable terms,
or at all. Our ability to obtain additional financing will be subject to a number of factors, including market conditions, our operating
performance and investor sentiment. If we are unable to raise additional capital when required or on acceptable terms, we may have to
significantly delay, scale back or discontinue the development and/or commercialization of our product candidate, restrict our operations
or obtain funds by entering into agreements on unfavorable terms. Failure to obtain additional capital at acceptable terms would result
in a material and adverse impact on our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our independent registered public accounting
firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Mazars LLP, our independent
registered public accounting firm for the fiscal year ended March 31, 2021, has included an explanatory paragraph in their opinion that
accompanies our audited consolidated financial statements as of and for the year ended March 31, 2021, indicating that liquidity position
post December 2022 raises substantial doubt about our ability to continue as a going concern. If we are unable to improve our liquidity
position by December 2022, we may not be able to continue as a going concern. The accompanying consolidated financial statements do not
include any adjustments that might result if we are unable to continue as a going concern and, therefore, be required to realize our assets
and discharge our liabilities other than in the normal course of business which could cause investors to suffer the loss of all or a substantial
portion of their investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We anticipate that we will continue to incur
significant losses for the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The amount of our future net
losses will depend, in part, on the rate of our future expenditures, including further research and development activity. The amount of
net losses will also depend on our success in developing and commercializing OK-101 and other products that generate significant revenue.
Any failure by us to become and remain profitable could depress the value of the ADSs and could impair our ability to expand our business,
maintain our research and development efforts, diversify our product offerings or continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to spend extensively on further
research activities and there can be no guarantee that we will have access to sufficient funds to fully realize our research and development
plan or to commercialize any products derived from research activities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect to incur further
significant expenses in connection with our ongoing research and development activities in relation to our products, including for funding
clinical studies, registration, manufacturing, marketing, sales and distribution. In order to finance fully our strategy, we may require
more capital than is available from our existing cash balances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Access to adequate additional
financing, whether through debt financing, an equity capital raise or a suitable partnering transaction may not be available to us on
acceptable terms, or at all. Further, while the potential economic impact brought by, and the duration of the COVID-19 pandemic is difficult
to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which
could negatively impact our short-term and long-term liquidity. If we are unable to raise capital, we could be forced to delay, reduce
or eliminate our research and development programs or commercialization efforts. Any additional equity fundraising may be dilutive for
our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any of these events could
have a material adverse effect on our business financial condition, prospects and results of operation and may lead us to delay, reduce
or abandon research and development programs or commercialization of some of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Commercialization of Our Product
Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we successfully develop a product
which shows efficacy in human subjects there remain high barriers to commercial success</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we were to receive
regulatory approval for OK-101 or any other products, we may be unable to commercialize them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are a number of factors
that may inhibit our efforts to commercialize OK-101 or any other products on our own, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our inability to recruit, train
and retain adequate numbers of effective sales and marketing personnel;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the inability of sales personnel
to obtain access to or persuade adequate numbers of potential practitioners to prescribe any future products;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">unforeseen costs and expenses
associated with creating an independent sales and marketing organization;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">costs of marketing and promotion
above those anticipated by us; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the inability to secure a suitable
level of pricing and/or reimbursement approval from the relevant regulatory authorities in the countries we are targeting.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While we may only seek to
enter into arrangements with third parties to perform sales and marketing services in non-core territories, any such arrangements could
result in our product revenues (or the profitability of such product revenues) being lower than if we were to market and sell the products
itself. In addition, we may not be successful in entering into arrangements with third parties to sell and market our products or may
be unable to do so on terms that are favorable to us. Acceptable third parties may fail to devote the necessary resources and attention
to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or
in collaboration with third parties, we will not be successful in commercializing our products, which in turn would have a material adverse
effect on our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have also invested and
will continue to invest resources into the development of other products, such as OK-201. Even where these products are successfully developed
and marketing approval is secured from relevant regulatory authorities, these products might not achieve commercial success. Factors which
could limit commercial success of a product include but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limited market acceptance or
a lack of recognition of the unmet medical need for the product amongst prescribers;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">new competitor products entering
the market;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number and relative efficacy,
safety or cost of competitive products;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an inability to supply a sufficient
amount of the product to meet market demand;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">insufficient funding being
available to market the product adequately;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an inability to enforce intellectual
property rights, or the existence of third-party intellectual property rights;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">safety concerns arising pre-
or post-launch resulting in negative publicity or product withdrawal or narrowing of the product label and the group of persons who may
receive the product;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">labelling being restricted/narrowed
in the future and in the future by regulatory agencies; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusals by government or other
healthcare payors to fund the purchase of the products by healthcare providers at a commercially viable level (or at all) or otherwise
to restrict the availability of approved products on other grounds.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of the foregoing were
to occur, it could materially and adversely affect our business, financial condition, prospects and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face significant competition from pharmaceutical
companies. We have competitors internationally, including major multinational pharmaceutical companies, universities and research institutions.
In respect of OK-101 as an indication for the treatment of DED, there are a number of established companies engaged in the development
and marketing of preparations addressing the DED market. In addition, there are a wide range of products addressing the DED market currently
approved and marketed by a number of large and small pharmaceutical companies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many of our competitors have
substantially greater financial, technical and other resources, such as larger research and development teams, proven marketing and manufacturing
organizations and well-established sales forces. Our competitors may succeed in developing, acquiring or licensing drug products that
are more effective or less costly than products which we are currently developing or which it may develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Established pharmaceutical
companies may invest heavily to accelerate the discovery and development of products that could make our products less competitive. In
addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability
or safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining
patent protection, receiving approval from the FDA, the European Medicines Agency, or EMA, or that of another relevant regulatory authority
or discovering, developing and commercializing pharmaceutical products before we do, which would have a material adverse effect on our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The availability and price
of our competitors&rsquo; products could limit the demand, and the price we are able to charge, for any of our products, if approved for
sale. We will not achieve our business plan if acceptance is inhibited by price competition or the reluctance of physicians to switch
from existing drug products to our products, or if physicians switch to other new drug products or choose to reserve our products for
use in limited circumstances. Competition from lower-cost generic pharmaceuticals may also result in significant reductions in sales volumes
or prices for our products, which could materially adversely affect our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are dependent on third
party supply, development and manufacturing and clinical service relationships and on single manufacturing sites for certain products.
Our business strategy utilizes the expertise and resources of third parties in a number of areas, including the conduct of clinical trials,
other product development, manufacture and the protection of our intellectual property rights in various geographical locations. This
strategy creates risks for us by placing critical aspects of our business in the hands of third parties whom we may not be able to manage
or control adequately and who may not always act in our best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Where we are dependent upon
third parties for the development or manufacture of certain products, our ability to procure our development or manufacture in a manner
which complies with regulatory requirements may be constrained, and our ability to develop and deliver such material on a timely and competitive
basis may be materially adversely affected, which may impact revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Regulatory requirements for
pharmaceutical products tend to make the substitution of suppliers and contractors costly and time-consuming. Alternative suppliers may
not be able to manufacture products effectively or obtain the necessary manufacturing licenses from relevant regulatory authorities. The
unavailability of adequate commercial quantities, the inability to develop alternative sources, a reduction or interruption in supply
of contracted services, or a significant increase in the price of materials and services, could have a material adverse effect on our
ability to manufacture and market our products or to fulfill orders from our distributors or licensees, which in turn would have a material
adverse impact on our cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Insurance coverage and reimbursement may
be limited, unavailable or may be reduced over time in certain market segments for our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Government authorities and
third-party payers, such as private health insurers, decide which pharmaceutical products they will cover and the amount of reimbursement.
Reimbursement may depend upon a number of factors, including the payer&rsquo;s determination that use of a product is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a covered benefit under the
payor&rsquo;s health plan;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">safe, effective and medically
necessary;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appropriate for the specific
patient;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">cost-effective; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">neither experimental nor investigational.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Obtaining coverage and reimbursement
approval for a product from a government or other third- party payer is a time-consuming and costly process that could require us to provide
supporting scientific, clinical and cost-effectiveness data for the use of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may not be able to provide
data sufficient to gain acceptance with respect to coverage and reimbursement, or to demonstrate commercial value compared to existing
established treatments. Even if we are able to furnish the requested data, there is no guarantee that a third-party payor will cover a
product. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels,
we may be unable to achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may, in the future, seek
approval to market our products in the EU, the US and in selected other jurisdictions. In the EU, the pricing of prescription pharmaceuticals
is subject to national governmental control and pricing negotiations with governmental authorities can, in some circumstances, take several
years after obtaining marketing approval for a product. In addition, market acceptance and sales of our products will depend significantly
on the availability of adequate coverage and reimbursement from third-party payers and may be affected by existing and future healthcare
reform measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The continuing efforts of
governments, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare
and/or impose price controls may materially adversely affect our ability to set prices for our products, generate revenues and achieve
or maintain profitability. Any reduction in government reimbursement programs may result in a similar reduction in payments from private
payers, which may materially adversely affect our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Intellectual Property
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The expiration of certain intellectual property
rights or an inability to obtain, maintain or enforce adequate intellectual property rights for products that are marketed or in development
may result in additional competition from other third-party products. Third parties may have blocking intellectual property rights which
could prevent the sale of products by us or require that compensation be paid to such third parties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The extent of our success
will, to a significant degree, depend on our ability to establish, maintain, defend and enforce adequate intellectual property rights
and to operate without infringing the proprietary or intellectual property rights of third parties. We have been granted, or have in-licensed
rights under, a number of key patent families for OK-101 (or other proprietary rights), and patent applications are pending in the U.S.,
the EU, and certain other jurisdictions. We may develop or acquire further technology or products that are not patentable or otherwise
protectable. The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can be uncertain.
Patents or other rights might not be granted under any pending or future applications filed or in-licensed by us and any claims allowed
might not be sufficiently broad to protect our technologies and products from competition. Competitors may also successfully design around
key patents held by us, thereby avoiding a claim of infringement. There is a risk that not all relevant prior art has been identified
with respect to any particular patent or patent application and the existence of such prior art may invalidate any patents granted (or
result in a patent application not proceeding to grant). Patents or other registerable rights might also be revoked for other reasons
after grant. Third parties may challenge the validity, enforceability or scope of any granted patents. Our defense of our proprietary
rights could involve substantial costs (even if successful) and could result in declarations of invalidity or significantly narrow the
scope of those rights, limiting their value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Competitors may have filed
applications or been granted patents, or obtained additional patents and proprietary rights, which relate to and could be infringed by
our products. An adverse outcome with respect to third party rights such as claims of infringement of patents or third-party proprietary
rights by us could subject us to significant liabilities or require us to obtain a license for the continued use of the affected rights,
which may not be available on acceptable terms or at all, or require us to cease commercialization and development efforts, or the sale
of the relevant products, in whole or in part in the relevant jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We could be subject to claims
for compensation by third parties claiming an ownership interest in the intellectual property rights relating to a commercially successful
product. This may include claims from employee inventors in territories which permit such claims even where we own the intellectual property
rights in question. Any such failure to defend our proprietary intellectual property could have a material adverse effect on our business,
prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to obtain, maintain,
defend or enforce the intellectual property rights covering our products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To date, we have had certain
patents licensed to us in jurisdictions we consider to be important to our business. However, we cannot predict:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the degree and range of protection
any patents will afford against competitors and competing technologies, including whether third parties will find ways to invalidate
or otherwise circumvent the patents by developing a competitive product that falls outside its scope;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if, or when any patents will
be granted;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">that granted patents will not
be contested, invalidated or found unenforceable;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether or not others will
obtain patents claiming aspects similar to those covered by the Company&rsquo;s patents and patent applications;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether we will need to initiate
litigation or administrative proceedings, or whether such litigation or proceedings will be initiated by third parties against us, which
may be costly and time consuming; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether third parties will
claim that our technology infringes upon their rights.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While we believe that we have
novel composition of matter on the OK-101 peptide and novel methods of its use in treating DED, we cannot be sure that these patent applications
will issue as patents. Each patent office has different patentability requirements, but we believe that the license patent applications
contain patentable subject matter. The process for issuance of a patent involves a correspondence with each local patent office in the
jurisdictions in which the patent application is filed. That process, patent prosecution, involves a discussion of any relevant prior
art and typically a discussion of the scope of the claims. The patent prosecution process can take several years depending on the jurisdiction
and is not in the control of the patent owner, but in the control of the local patent office. We cannot be sure the outcome of the patent
prosecution will be successful and result in issued patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Patent protection is of importance
to us in maintaining our competitive position in our planned product lines and a failure to obtain or retain adequate protection could
have a material adverse effect on our business, prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to prevent disclosure
of our trade secrets, know-how or other proprietary information.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We rely on trade secret protection
to protect our interests in proprietary know-how and in processes for which patents are difficult to obtain or enforce. If we are unable
to protect our trade secrets adequately the value of our technology and products could be significantly diminished. Furthermore, our employees,
consultants, contract personnel or third-party partners, either accidentally or through willful misconduct, may cause serious damage to
our programs and/or our strategy by disclosing confidential information to third parties. It is also possible that confidential information
could be obtained by third parties as a result of breaches of our physical or electronic security systems. Any disclosure of confidential
data into the public domain or to third parties could allow third parties to access confidential information and use it in competition
with us. In addition, others may independently discover the confidential information. Any action to enforce our rights against any misappropriation
or unauthorized use and/or disclosure of confidential information is likely to be time-consuming and expensive, and may ultimately be
unsuccessful, or may result in a remedy that is not commercially valuable. Any such loss of confidential information or failure to enforce
our rights in relation to such confidential information, or unsatisfactory outcome of any related litigation could have a material adverse
effect on our business, prospects, financial condition or results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product candidates could infringe patents
and other intellectual property rights of third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial success depends
upon our ability, and the ability of any third party with which we may partner to develop, manufacture, market and sell our products and
use our patent- protected technologies without infringing the patents of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our products may infringe
or may be alleged to infringe existing patents or patents that may be granted in the future which may result in costly litigation and
could result in our having to pay substantial damages or limit our ability to commercialize our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because some patent applications
in Europe, the U.S. and many foreign jurisdictions may be maintained in secrecy until the patents are issued, patent applications in such
jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind
actual discoveries. Accordingly, we cannot be certain that others have not filed patents that may cover our technologies, our products
or the use of our products. Additionally, pending patent applications which have been published can, subject to certain limitations, be
later amended in a manner that could cover our technologies, our products or the use of our products. As a result, we may become party
to, or threatened with, future adversarial proceedings or litigation regarding patents with respect to our products and technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are sued for patent
infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent
or that the patent claims are invalid, and we may not be able to do this. If we are found to infringe a third party&rsquo;s patent, we
could be required to obtain a license from such third party to continue developing and marketing our products and technology or we may
elect to enter into such a license in order to settle litigation or in order to resolve disputes prior to litigation. However, we may
not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain a license, it could
be non- exclusive, thereby giving our competitors access to the same technologies that are licensed to us and could require us to make
substantial royalty payments. We could also be forced, including by court order, to cease commercializing the infringing technology or
products. A finding of infringement could prevent us from commercializing our products or force us to cease some of our business operations,
which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similarly negative impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any such claims are likely
to be expensive to defend, and some of our competitors may be able to sustain the costs of complex patent litigation more effectively
than us can because they have substantially greater resources. Moreover, even if we are successful in defending any infringement proceedings,
we may incur substantial costs and divert management&rsquo;s time and attention in doing so, which could materially adversely affect our
business, prospects, results of operations or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks relating to managing growth, employee
matters and other risks relating to our business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Growth may place significant
demands on our management and resources. We expect to experience growth in the number of our employees and the scope of our operations
in connection with the continued development and, in due course, the potential commercialization of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This potential growth will
place a significant strain on our management and operations, and we may have difficulty managing this future potential growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are highly dependent on
our current executive officers and their services are critical to the successful implementation of our product development and regulatory
strategies. While suitable contracts of employment are in place including six to 12 months&rsquo; notice periods for all executive officers,
they may give notice to terminate their employment with us at any time. The loss of the services of any of our executive officers and
our inability to find suitable replacements could harm our business, prospects, financial condition, results of operations and ability
to achieve the successful development or commercialization of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Challenges in identifying
and retaining key personnel could impair our ability to conduct and grow our operations effectively. Our ability to compete in the highly
competitive pharmaceutical industry depends upon our ability to attract and retain highly qualified management and sales teams. We are
intending to recruit our own commercial team and expand our existing central infrastructure team. Many of the other pharmaceutical companies
and academic institutions that we compete against for qualified personnel have greater financial and other resources, different risk profiles
and a longer history in the industry than we do. We might not be able to attract or retain these key persons on conditions that are economically
acceptable. Our inability to attract and retain these key persons could have a material adverse effect on our business, prospects, financial
conditions and results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>COVID-19 has adversely affected our business,
and any new pandemic, epidemic or outbreak of an infectious disease may further adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2019, a novel
strain of coronavirus, COVID-19, spread globally, substantially impacting the global economy and our operations, including interrupting
preclinical and clinical trial activities and disrupting our supply chain. The spread of an infectious disease, including COVID-19, may
also result in the inability of our suppliers to source or deliver components or raw materials necessary for our clinical supply on a
timely basis or at all. In addition, hospitals may reduce staffing and reduce or postpone certain treatments in response to the spread
of an infectious disease. Such events may result in a period of business disruption, and in reduced operations, or doctors and medical
providers may be unwilling to participate in our clinical trials, any of which could materially affect our business, financial condition
and results of operations. The extent to which COVID-19 impacts our business will depend on future developments, which are highly uncertain
and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain
the coronavirus or treat its impact, among others. A significant pandemic as with COVID-19, or any other infectious disease, could result
in a widespread health crisis that could adversely affect the economies and financial markets worldwide, resulting in an economic downturn
that could impact our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may become subject to product liability
claims.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We face an inherent risk of
product liability and associated adverse publicity as a result of the clinical testing of our products and sales of our products once
marketing approval is received from relevant regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Criminal or civil proceedings
might be filed against us any by study subjects, patients, relevant regulatory authorities, pharmaceutical companies, and any other third
party using or marketing our products. Any such product liability claims may include allegations of defects in manufacturing or design,
negligence, strict liability, a breach of warranties and a failure to warn of dangers inherent in the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we cannot successfully
defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our
products, if approved. Even if we successfully defend ourselves against such product liability claims it could require significant financial
and management resources. Regardless of the merits or eventual outcome, product liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">decreased demand for our products
due to negative public perception;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">injury to our reputation;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">withdrawal of clinical study
participants or difficulties in recruiting new study participants;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">initiation of investigations
by regulators;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">costs to defend or settle the
related litigation;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">diversion of management&rsquo;s
time and our resources;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">substantial monetary awards
to patients, study participants or subjects;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">product recalls, withdrawals
or labelling, marketing or promotional restrictions;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">loss of revenues from product
sales; or</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the inability to commercialize
any of our products, if approved.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we will maintain
levels of insurance customary for our sector to cover our current and future business operations, any claim that may be brought against
us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in
excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product
liability claim for which we have no coverage. In such cases, we would have to pay any amounts awarded by a court or negotiated in a settlement
that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital
to pay such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we or our partners, licensees
and subcontractors were unable to obtain and maintain appropriate insurance coverage at an acceptable cost, or to protect ourselves in
any way against actions for damages, this would seriously affect the marketing of our products and, more generally, be detrimental to
our business, prospects, results of operations or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our employees, contractors, consultants
and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are exposed to the risk
of employees, independent contractors, principal investigators, consultants, commercial partners or vendors engaging in fraud or other
misconduct. Misconduct could include intentional failures to comply with FDA or EMA regulations or those of other relevant regulatory
authorities, to provide accurate information to the FDA, EMA or other relevant regulatory authorities, or to comply with manufacturing
standards we have established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In particular, sales, marketing
and business arrangements in the life sciences and biotechnology sector are subject to extensive laws and regulations intended to prevent
fraud, misconduct, bribery and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Employee misconduct could
also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and
serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect
and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
or relevant regulatory authority investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws
or regulations. If any such actions are instituted against us, and we are not successful in defending ourself or asserting our rights,
those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions, and our
reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may be vulnerable to disruptions
of information technology systems or breaches of data security. We are dependent on information technology systems and infrastructure
to operate our business. In the ordinary course of our business, we collect, store and transmit confidential information, including intellectual
property, proprietary business information and personal information. It is important that we do so in a secure manner to maintain confidentiality
and integrity of such confidential information. Any failure to do so could adversely affect our business, prospects, results of operation
or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The relationship of the UK with the EU could
impact our ability to operate efficiently in certain jurisdictions or in certain markets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The UK formally exited the
EU on 31 January 2020 which is commonly known as Brexit. Under the terms of its departure, the UK entered a transition period during which
it continued to follow all EU rules until 31 December 2020, or the Transition Period. On 30 December 2020, the UK and EU signed the Trade
and Cooperation Agreement, which includes an agreement on free trade between the two parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is considerable uncertainty
resulting from a lack of precedent and the complexity of the UK and EU&rsquo;s intertwined legal regimes as to how Brexit (following the
Transition Period) will impact the medical devices industry in Europe. Since a significant proportion of the regulatory framework in the
UK applicable to our business and product candidates is derived from EU directives and regulations, Brexit could materially impact the
regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates
in the UK or the EU. The impact will largely depend on the model and means by which the UK&rsquo;s relationship with the EU is governed
post-Brexit and the extent to which the UK chooses to diverge from the EU regulatory framework. For example, following the Transition
Period, the UK will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorizations and our product
candidates will therefore require a separate marketing authorization for such products to be marketed in the UK. It is also unclear as
to whether the relevant authorities in the EU and the UK are adequately prepared for the additional administrative burden caused by Brexit.
Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from,
or delay commercialization of, product candidates in the UK and/or the EEA and restrict our ability to generate revenue and achieve and
sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of these outcomes occur,
we may be forced to restrict or delay efforts to seek regulatory approval in the UK for its product candidates, which could significantly
and materially harm our business. There is a degree of uncertainty regarding the overall impact that Brexit will have on process to obtain
regulatory approval in the UK for product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Further, the UK&rsquo;s withdrawal
from the EU has resulted in the relocation of the EMA from the UK to the Netherlands. This relocation has caused, and may continue to
cause, disruption in the administrative and medical scientific links between the EMA and the MHRA, including delays in granting clinical
trial authorization or marketing authorization, disruption of importation and export of medical devices, active substance and other components
of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations. The cumulative
effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and
commercialization of product candidates in the EU and/or the UK. Brexit may also result in a reduction of funding to the EMA once the
UK no longer makes financial contributions to EU institutions, such as the EMA. If funding to the EMA is so reduced, it could create delays
in the EMA issuing regulatory approvals for our product candidates and, accordingly, have a material adverse effect on our business, financial
condition, results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we complete the necessary clinical
trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our product candidates and whether the approval
may be for a narrower indication than we seek.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We cannot commercialize a
product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. The FDA must review and
approve any new pharmaceutical product before it can be marketed and sold in the United States. The FDA regulatory review and approval
process, which includes evaluation of preclinical studies and clinical trials of a product candidate and proposed labeling, as well as
the evaluation of the manufacturing process and manufacturers&rsquo; facilities, all of which is lengthy, expensive and uncertain. To
obtain approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that the product
candidate is both safe and effective for each indication where approval is sought. Even if our product candidates meet the FDA&rsquo;s
safety and effectiveness endpoints in clinical trials, the FDA may not complete their review processes in a timely manner, or we may not
be able to obtain regulatory approval. The FDA has substantial discretion in the review and approval process and may refuse to file our
application for substantive review or may determine after review of our data that our application is insufficient to allow approval of
our product candidates. The FDA may require that we conduct additional preclinical studies, clinical trials or manufacturing validation
studies and submit that data before it will reconsider our application. Additional delays may result if an FDA Advisory Committee or other
regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon
additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the
period of product development, clinical trials and the review process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA, EMA or other regulatory
authorities also may approve a product candidate for more limited indications than requested or may impose significant limitations in
the form of narrow indications, warnings or a risk evaluation and mitigation strategy, or REMS. These regulatory authorities may require
precautions or contraindications with respect to conditions of use or may grant approval subject to the performance of costly post-marketing
clinical trials. In addition, the FDA, EMA or other regulatory authorities may not approve the labeling claims that are necessary or desirable
for the successful commercialization of our product candidates. Any of the foregoing scenarios could harm the commercial prospects for
our product candidates and negatively impact our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delays in obtaining regulatory approval
of our manufacturing process and facility or disruptions in our manufacturing process may delay or disrupt our product development and
commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not currently operate
manufacturing facilities for clinical or commercial production of our product candidates. Before we can begin to commercially manufacture
our product candidates, whether in a third-party facility or in our own facility, if and when established, we must obtain regulatory approval
from the FDA for our manufacturing process and facility. A manufacturing authorization must also be obtained from the appropriate European
Union regulatory authorities and from other foreign regulatory authorities, as applicable. In order to obtain approval, we will need to
ensure that all of our processes, methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories
and suppliers. If any of our vendors, contract laboratories or suppliers are found to be non-compliant with cGMP, we may experience delays
or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement
vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying
with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the
product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible
regulatory action and may not be permitted to sell any product candidate that we may develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we or our third-party manufacturers
fail to comply with applicable cGMP regulations, the FDA, EMA and other regulatory authorities can impose regulatory sanctions including,
among other things, refusal to approve a pending application for a new product candidate or suspension or revocation of a pre-existing
approval. Such an occurrence may cause our business, financial condition, results of operations and prospects to be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, if the supply
of our products from our third-party manufacturers to us is interrupted for any reason, including due to regulatory requirements or actions
(including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMP requirements,
contamination, business interruptions or labor shortages or disputes, there could be a significant disruption in commercial supply of
our products. We do not currently have a backup manufacturer of our product candidate supply for clinical trials or commercial sale. An
alternative manufacturer would need to be qualified through a supplement to its regulatory filing, which could result in further delays.
The regulatory authorities also may require additional clinical trials if a new manufacturer is relied upon for commercial production.
Switching manufacturers may involve substantial costs and could result in a delay in our desired clinical and commercial timelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our competitors are able to obtain orphan
drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates, we may not be able
to have competing products approved by applicable regulatory authorities for a significant period of time. In addition, even if we obtain
orphan drug exclusivity for any of our products, such exclusivity may not protect us from competition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Regulatory authorities in
some jurisdictions, including the United States and the European Union, may designate products for relatively small patient populations
as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is intended to treat
a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United
States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing
the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial
incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In the European
Union, the EMA&rsquo;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that
are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more
than five in 10,000 persons in the European Union. Additionally, orphan drug designation is granted for products intended for the diagnosis,
prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it
is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug
or biologic product. In Europe, orphan drug designation entitles a party to a number of incentives, such as protocol assistance and scientific
advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The designation as an orphan
product does not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve, that product candidate,
nor does it limit the ability of any regulatory agency to grant orphan drug designation to product candidates of other companies that
treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, if a product candidate
with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product
is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for
a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances.
If another sponsor receives such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving
marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the United States and
ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets
the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified.
Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or
if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we obtain orphan drug
exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different
drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA may subsequently approve
another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it
is shown to be safer, more effective or makes a major contribution to patient care. In the European Union, marketing authorization may
be granted to a similar medicinal product for the same orphan indication if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the second applicant can establish
in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective
or otherwise clinically superior;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the holder of the marketing
authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the holder of the marketing
authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we obtain regulatory approval for
a product candidate, our product candidates will remain subject to regulatory oversight.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we obtain regulatory
approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage,
advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals
that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may
be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4
clinical trials, and surveillance to monitor the quality, safety and clinical effectiveness of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some of our product candidates
are classified as biologics in the United States, and therefore, can only be sold if we obtain a biologics license application, or BLA,
from the FDA. The holder of an approved BLA also must submit new or supplemental applications and obtain FDA approval for certain changes
to the approved product, product labeling or manufacturing process. In addition, the holder of a BLA approval must comply with the FDA&rsquo;s
advertising and promotion requirements, such as those related to the prohibition on promoting products for uses or in patient populations
that are not described in the product&rsquo;s approved labeling (known as &ldquo;off-label use&rdquo;). Advertising and promotional materials
must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, product manufacturers
and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory
authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application. If we,
or a regulatory authority, discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency,
or problems with the facility where the product is manufactured or if a regulatory authority disagrees with the promotion, marketing or
labeling of that product (in addition to our being obligated as holder of a BLA to monitor and report adverse events and any failure of
a product to meet the BLA specifications), a regulatory authority may impose restrictions relative to that product, the manufacturing
facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we fail to comply with
applicable regulatory requirements following approval of our product candidates, a regulatory or enforcement authority may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">issue a warning letter asserting
that we are in violation of the law;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">seek an injunction or impose
administrative, civil or criminal penalties or monetary fines;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">suspend or withdraw regulatory
approval;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">suspend any ongoing clinical
trials;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refuse to approve a pending
BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restrict the marketing or manufacturing
of the product;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">seize or detain the product
or otherwise require the withdrawal of the product from the market;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refuse to permit the import
or export of the product; or</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refuse to allow us to enter
into supply contracts, including government contracts.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any government investigation
of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and adversely affect
our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the FDA&rsquo;s
policies, and those of the EMA and other regulatory authorities, may change and additional government regulations may be enacted that
could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable
to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory
compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would
negatively impact our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we obtain and maintain approval
for our product candidates in a major pharmaceutical market such as the United States, we may never obtain approval for our product candidates
in other major markets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to market any products
in a country or territory, we must establish and comply with numerous and varying regulatory requirements of such countries or territories
regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries,
and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures
vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory
approvals in all major markets could result in significant delays, difficulties and costs for us and may require additional preclinical
studies or clinical trials, which would be costly and time consuming. Regulatory requirements can vary widely from country to country
and could delay or prevent the introduction of our product candidates in those countries. For example, in many jurisdictions outside of
the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In
some cases, the price that we intend to charge for our products would also be subject to approval. Satisfying these and other regulatory
requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval
in any country may delay or have negative effects on the process for regulatory approval in other countries. We currently do not have
any product candidates approved for sale in any jurisdiction, whether in the United States, Europe or any other international markets,
and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements
in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the
full market potential of our product candidates will be compromised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may seek a conditional marketing authorization
in Europe for some or all of our current product candidates, but we may not be able to obtain or maintain such designation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As part of its marketing authorization
process, the EMA may grant marketing authorizations for certain categories of medicinal products on the basis of less complete data than
is normally required, when doing so may meet unmet medical needs of patients and serve the interest of public health. In such cases, it
is possible for the Committee for Medicinal Products for Human Use, or CHMP, to recommend the granting of a marketing authorization, subject
to certain specific obligations to be reviewed annually, which is referred to as a conditional marketing authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This may apply to medicinal
products for human use that fall under the jurisdiction of the EMA, including those that aim at the treatment, the prevention, or the
medical diagnosis of seriously debilitating or life-threatening diseases and those designated as orphan medicinal products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A conditional marketing authorization
may be granted when the CHMP finds that, although comprehensive clinical data referring to the safety and therapeutic utility of the medicinal
product have not been supplied, all the following requirements are met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the risk-benefit balance of
the medicinal product is positive;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it is likely that the applicant
will be in a position to provide the comprehensive clinical data;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">unmet medical needs will be
fulfilled; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the benefit to public health
of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional
data is still required.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The granting of a conditional
marketing authorization is restricted to situations in which only the clinical part of the application is not yet fully complete. Incomplete
preclinical or quality data may only be accepted if duly justified and only in the case of a product intended to be used in emergency
situations in response to public health threats. Conditional marketing authorizations are valid for one year, on a renewable basis. The
holder will be required to complete ongoing trials or to conduct new trials with a view to confirming that the benefit-risk balance is
positive. In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Granting a conditional marketing
authorization allows medicines to reach patients with unmet medical needs earlier than might otherwise be the case and will ensure that
additional data on a product is generated, submitted, assessed and acted upon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Healthcare legislative reform measures may
have a negative impact on our business and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States and some
foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding
the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities
and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States, the
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical
products. The MMA expanded Medicare coverage for outpatient drug purchases by adding a new Medicare Part D program and introduced a new
reimbursement methodology based on average sales prices for Medicare Part B physician-administered drugs. In addition, the MMA authorized
Medicare Part D prescription drug plans to limit the number of drugs that will be covered in any therapeutic class in their formularies.
The MMA&rsquo;s cost reduction initiatives and other provisions could decrease the coverage and price that we receive for any approved
products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy
and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA
may result in a similar reduction in payments from private payors. Similar regulations or reimbursement policies may be enacted in international
markets, which could similarly impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In March 2010, the PPACA (as
amended by the Health Care and Education Reconciliation Act of 2010) was passed, which substantially changes the way healthcare is financed
by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The PPACA, among other things:
(i) addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs
that are inhaled, infused, instilled, implanted or injected; (ii) increases the minimum Medicaid rebates owed by manufacturers under the
Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; (iii) establishes
annual fees and taxes on manufacturers of certain branded prescription drugs; (iv) expands the availability of lower pricing under the
340B drug pricing program by adding new entities to the program; and (v) establishes a new Medicare Part D coverage gap discount program,
in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries
during their coverage gap period, as a condition for the manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part D. Additionally,
in the United States, the Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biologic
products that are demonstrated to be biosimilar or &ldquo;interchangeable&rdquo; with an FDA-approved biologic product. This new pathway
could allow competitors to reference data from biologic products already approved after 12 years from the time of approval. This could
expose us to potential competition by lower-cost biosimilars even if we commercialize a product candidate faster than our competitors.
Moreover, the creation of this abbreviated approval pathway does not preclude or delay a third party from pursuing approval of a competitive
product candidate via the traditional approval pathway based on their own clinical trial data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additional changes that may
affect our business include those changes governing enrollment in federal healthcare programs, reimbursement changes, rules regarding
prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation of the PPACA
and the passage of additional laws and regulations may result in the expansion of new programs such as Medicare payment for performance
initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting system and feedback
program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For each state that does not
choose to expand its Medicaid program, there likely will be fewer insured patients overall, which could impact the sales, business and
financial condition of manufacturers of branded prescription drugs. Where patients receive insurance coverage under any of the new options
made available through the PPACA, manufacturers may be required to pay Medicaid rebates on that resulting drug utilization. The U.S. federal
government also has announced delays in the implementation of key provisions of the PPACA. The implications of these delays for our and
our potential partners&rsquo; business and financial condition, if any, are not yet clear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, there have been
judicial and congressional challenges to certain aspects of the PPACA, and we expect the current administration and Congress will likely
continue to seek legislative and regulatory changes, including repeal and replacement of certain provisions of the PPACA. In January 2017,
President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the PPACA to waive, defer,
grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states,
individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. More recently, the U.S. House
of Representatives passed legislation known as the American Health Care Act of 2017, and Senate Republicans have released a draft bill
known as the Better Care Reconciliation Act of 2017, each of which would repeal certain aspects of the PPACA if ultimately enacted. The
prospects for enactment of these legislative initiatives remain uncertain. Further, Congress also could consider other legislation to
replace elements of the PPACA. We cannot know how efforts to repeal and replace the PPACA or any future healthcare reform legislation
will impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect that the PPACA,
as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional
downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government
programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Department of Health and
Human Services Office of Inspector General issued final regulations on November 30, 2020 to eliminate safe harbor protection under the
anti-kickback statute for drug price reductions that pharmaceutical manufacturers pay to Medicare and Medicaid plan sponsors and their
pharmacy benefit managers. The proposal reflects a clear intent to substantially alter many of the current drug discount and services
compensation practices among pharmaceutical manufacturers and Medicare and Medicaid managed care organizations and their pharmacy benefit
managers. The proposal also reflects a skepticism that current drug discount and compensation practices among manufacturers and pharmacy
benefit managers are sufficiently transparent to health plans to ensure that all appropriate cost reductions and value is passed through
to health plans and reflected in lower health plans costs and lower premiums for beneficiaries. The Biden Administration has delayed the
effective date of this rule until January 1, 2023, and a lawsuit initiated by the Pharmaceutical Care Management Administration has challenged
this final rule. If the regulation becomes effective it could result in lower prices for pharmaceutical products in general.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Centers for Medicare and
Medicaid Services issued an interim final rule on November 20, 2020 that would tie prices for certain drugs under Medicare Part B to the
lowest price for those drugs available in certain countries that are members of the Organization for Economic Co-operation and Development.
This &ldquo;most favored nation&rdquo; drug pricing rule is also the subject of lawsuits, and a federal court has placed an injunction
on the implementation of the rule. This rule, if finalized, could also result in lower prices for pharmaceutical products in general.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Biden Administration will
have the opportunity to address these regulations as well as drug pricing, health care access, and other health care reform issues. Any
further legislative or administrative action to reduce reimbursement or health benefits to beneficiaries under the Medicare or Medicaid
program could affect the payment we could collect from sale of any product in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect that additional
state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state
governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional
pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to stringent and changing
privacy laws, regulations and standards as well as contractual obligations related to data privacy and security. Our actual or perceived
failure to comply with such obligations could harm our reputation, subject us to significant fines and liability, or otherwise adversely
affect our business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>or prospects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to data privacy
and protection laws, regulations, policies and contractual obligations that apply to the collection, transmission, storage, processing
and use of personal information or personal data, which among other things, impose certain requirements relating to the privacy, security
and transmission of personal information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The legislative and regulatory
landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy
and data protection issues with the potential to affect our business. Failure to comply with laws, regulations and other obligations governing
personal information could result in enforcement actions against us, including fines, imprisonment of company officials and public censure,
processing penalties, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have
a material adverse effect on our business, financial condition, results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The regulatory framework for
the collection, use, retention, safeguarding, disclosure, sharing, transfer and other processing of personal information worldwide is
rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate
has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure,
transfer or other processing of personal data regarding individuals in the United Kingdom and European Union, including personal health
data, is subject to the European Union General Data Protection Regulation (EU) 2016/679, or the GDPR, which took effect across all member
states of the European Union, or EU, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that
process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals
to whom the personal data relates, establishing a legal basis for processing, providing information to individuals regarding data processing
activities, implementing safeguards to protect the security and confidentiality of personal data that requires the adoption of administrative,
physical and technical safeguards, providing notification of data breaches to appropriate data protection authorities or data subjects,
establishing means for data subjects to exercise rights in relation to their personal data and taking certain measures when engaging third-party
processors. The GDPR increases our obligations with respect to clinical trials conducted in the EU by expanding the definition of personal
data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and
investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Economic
Area, or EEA, including the United States and, as a result, increases the scrutiny for transfers of personal data from clinical trial
sites located in the EU to the United States. The United Kingdom and Switzerland have adopted similar restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Further, the United Kingdom&rsquo;s
decision to leave the EU, often referred to as Brexit, and ongoing developments in the United Kingdom have created uncertainty with regard
to data protection regulation in the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Privacy and data security
requirements are also either in place or underway in the United States. There are a broad variety of data protection laws that may be
applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy
and data security concerns based on general consumer protection laws. The Federal Trade Commission and state attorneys general can all
be aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered or have been implemented
at both the state and federal levels. For example, the California Consumer Privacy Act of 2018, or the CCPA, which became effective on
January 1, 2020, requires companies that process information on California residents to make new disclosures to consumers about their
data collection, use and sharing practices, provides such individuals with new data privacy rights (including the ability to opt out of
certain disclosures of personal information), imposes new operational requirements for covered businesses, provides a private right of
action for data breaches and creates a statutory damages framework. Virginia became the second state to adopt a comprehensive privacy
legislation on March 2, 2021 with enactment of the Virginia Consumer Data Protection Act. Many other states are considering similar legislation,
and a broad range of legislative measures also have been introduced at the federal level. Although there are limited exemptions for clinical
trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how it is interpreted and
exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, regulations
promulgated pursuant to the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended, establish privacy
and security standards that limit the use and disclosure of individually identifiable health information, or protected health information,
and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information
and ensure the confidentiality, integrity and availability of electronic protected health information. These provisions may be applicable
to our business or that of our collaborators, service providers, contractors or consultants. Determining whether protected health information
has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to
changing interpretation. If we are unable to properly protect the privacy and security of protected health information, we could be found
to have violated these privacy and security laws and/or breached certain contracts with our business partners (including as a business
associate). Further, if we fail to comply with applicable privacy laws, such as, to the extent applicable, HIPAA privacy and security
standards, we could face significant civil and criminal penalties. In the United States, the Department of Health and Human Services&rsquo;
and state attorney&rsquo;s general enforcement activity can result in financial liability and reputational harm, and responses to such
enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions
seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these
regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities
and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level
may be costly and require ongoing modifications to our policies, procedures and systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Given the breadth and depth
of changes in data protection obligations, preparing for and complying with the GDPR, CCPA and similar laws&rsquo; requirements are rigorous
and time-intensive and require significant resources and a review of our technologies, systems and practices, as well as those of any
third-party collaborators, service providers, contractors or consultants that process or transfer personal data. Changes involving the
GDPR, CCPA or other laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare
data or other personal information from our clinical trials, could require us to change our business practices and put in place additional
compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing
business, and could expose us to government enforcement actions, regulatory investigations, private litigation and significant fines,
penalties and remediation costs and could have a material adverse effect on our business, financial condition or results of operations.
Additionally, any failure by our third-party collaborators, service providers, contractors or consultants to comply with applicable law,
regulations or contractual obligations related to data privacy or security could result in proceedings against us by governmental entities
or others, fines, reputational harm and other liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may publish privacy policies
and other documentation regarding our collection, processing, use and disclosure of personal information and/or other confidential information.
Although we endeavor to comply with our published policies and other documentation, we may at times fail to do so or may be perceived
to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees or vendors fail
to comply with our published policies and documentation. Such failures can subject us to potential foreign, local, state and federal action
if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Moreover, subjects about whom we or our partners
obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose
the information. Claims that we have violated individuals&rsquo; privacy rights or failed to comply with data protection laws or applicable
privacy notices even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity
that could harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">It is possible that new and
existing laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving
data protection rules may be unsuccessful. If so, this could result in government-imposed fines, or penalties or orders requiring that
we change our practices, which could adversely affect our business. We must devote significant resources to understanding and complying
with this changing landscape. Failure to comply with federal, state and foreign laws regarding privacy and security of personal information
could expose us to government-imposed fines and penalties under such laws, penalties or orders requiring that we change our practices,
claims for damages or other liabilities, regulatory investigations and enforcement actions, litigation and significant costs for remediation,
reputational harm, diminished profits and earnings, additional reporting requirements and/or oversight, any of which could adversely affect
our business, our results of operations or prospects. We also face a threat of consumer class actions related to these laws and the overall
protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically
require the expenditure of significant resources and generate negative publicity. Any of the foregoing could have a materially adverse
effect on our reputation and our business, financial condition, results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to the U.K. Bribery Act,
the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade
and economic sanctions laws and other laws governing our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our operations are subject
to anti-corruption laws, including the U.K. Bribery Act 2010, or the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act of 1977,
or the FCPA, the U.S. domestic bribery statute contained in 18 &sect;201, the U.S. Travel Act, and other anti-corruption laws that apply
in countries where we do business. The U.K. Bribery Act, the FCPA and these other laws generally prohibit us and our employees and intermediaries
from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value,
to government officials or other persons to obtain or retain business or gain some other business advantage. Under the U.K. Bribery Act,
we may also be liable for failing to prevent a person associated with us from committing a bribery offense. We and our commercial partners
operate in a number of jurisdictions that pose a high risk of potential U.K. Bribery Act or FCPA violations, and we participate in collaborations
and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the U.K. Bribery
Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition,
we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject
or the manner in which existing laws might be administered or interpreted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are also subject to other
laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom
and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions and
embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations,
collectively referred to as the Trade Control laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is no assurance that
we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the U.K. Bribery Act, the
FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the U.K. Bribery Act, the FCPA and other
anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial
measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity.
Likewise, any investigation of any potential violations of the U.K. Bribery Act, the FCPA, other anti-corruption laws or Trade Control
laws by United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our relationships with customers, physicians
and third-party payors will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws,
health information privacy and security laws and other healthcare laws and regulations. If we are found in violation of these laws and
regulations, we may be required to pay a penalty or be suspended from participation in federal or state healthcare programs, which may
adversely affect our business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we obtain FDA approval
for our product candidates and begin commercializing them in the United States, our operations will be directly, or indirectly through
our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without
limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and Physician Payments Sunshine Act of
2010 and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition,
we may be subject to patient privacy laws by both the U.S. federal government and the states in which we conduct our business. The laws
that will affect our operations include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving,
offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or
in kind, in return for either the referral of an individual, or the purchase, leasing, furnishing or arranging for the purchase, lease
or order of a good, facility, item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs.
This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers
and formulary managers on the other. The PPACA amended the intent requirement of the federal Anti-Kickback Statute, such that a person
or entity no longer needs to have actual knowledge of this statute or specific intent to violate it;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
civil and criminal false claims laws and civil monetary penalty laws which prohibit, among other things, individuals or entities from
knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that
are false or fraudulent. The PPACA provides, and recent government cases against pharmaceutical and medical device manufacturers support
the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate
the False Claims Act of 1863;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit,
among other things, a person from knowingly and willfully executing a scheme or from making false or fraudulent statements to defraud
any healthcare benefit program, regardless of the payor (e.g., public or private);</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
(as amended by the Health Information Technology for Economic and Clinical Health Act of 2009), and their implementing regulations, which
impose certain requirements relating to the privacy, security and transmission of individually identifiable health information without
appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers,
and their respective business associates that perform certain functions or activities that involve the use or disclosure of protected
health information on their behalf;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
transparency laws, including the federal Physician Payment Sunshine Act, that require certain manufacturers of drugs, devices, biologics
and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program, with specific
exceptions, to report annually to the CMS information related to: (i) payments or other &ldquo;transfers of value&rdquo; made to physicians
and teaching hospitals and (ii) ownership and investment interests held by physicians and their immediate family members;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;
and</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
and foreign law equivalents of each of the above federal laws, state and local laws that require drug manufacturers to report information
related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and
foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other
in significant ways and may not have the same effect, thus complicating compliance efforts.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Efforts to ensure that our
business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude
that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse
or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions including monetary penalties,
damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded healthcare programs, such
as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar
agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required to curtail or restructure
our operations, any of which could adversely affect our ability to operate our business and our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The risk of our being found
in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or
the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if
we successfully defend against it, could cause us to incur significant legal expenses and divert our management&rsquo;s attention from
the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to
comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare
company may run afoul of one or more of the requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur substantial costs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to numerous
environmental, health and safety laws and regulations, including those governing laboratory procedures and the generation, handling, use,
storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and wastes, as well as laws and
regulations relating to occupational health and safety. We contract with third parties that conduct operations on our behalf that involve
the use of hazardous and flammable materials, including chemicals and biologic materials. Our contractors also produce and dispose of
hazardous waste products. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination
or injury resulting from our contractors&rsquo; use of hazardous materials, we could be held liable for any resulting damages and any
liability could exceed our resources, and our clinical trials or regulatory approvals could be suspended. We also could incur significant
costs associated with civil or criminal fines and penalties. Our third-party contractors may not carry specific biological or hazardous
waste insurance coverage, and their property, casualty and general liability insurance policies specifically exclude coverage for damages
and fines arising from biological or hazardous waste exposure or contamination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we maintain workers&rsquo;
compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous
materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive
materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, we may incur
substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to
become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts.
Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which
could adversely affect our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Computer system failures, cyber-attacks
or deficiencies in our or related parties&rsquo; cyber security could result in a material disruption of our product development programs,
compromise sensitive information related to our business or trigger contractual and legal obligations, any of which could potentially
expose us to liability or reputational harm or otherwise adversely affect our business and financial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have implemented our security
measures designed to protect the information (including but not limited to intellectual property, proprietary business information and
personal information) in our possession, custody or control. Our internal computer systems and those of current and future third parties
(such as vendors, CROs, collaborators or others) on which we rely may fail and are vulnerable to breakdown, breach, interruption or damage
from computer viruses, computer hackers, malicious code, employee error or malfeasance, theft or misuse, denial-of-service attacks, sophisticated
nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical
failures or other compromise. Despite our security practices, there is a risk that we may be subject to phishing and other cyberattacks
in the future. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer
hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks
and intrusions from around the world have increased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may not be able to anticipate
all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The
techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources,
including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments
or agencies. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines
and connection to the Internet, face the risk of systemic failure that could disrupt our operations. If such an event were to occur and
cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations.
For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture
of our product candidates or any future product candidates and to conduct clinical trials, and similar events relating to their computer
systems could also have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To the extent that any disruption
or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate use, disclosure of or access
to confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development
and commercialization of our product candidates or any future product candidates could be hindered or delayed. If we were to experience
a significant cybersecurity breach of our information systems or data, the costs associated with the investigation, remediation and potential
notification of the breach to counterparties, data subjects, regulators or others could be material. In addition, our remediation efforts
may not be successful. Moreover, if the information technology systems of our vendors, CROs, collaborators or other contractors or consultants
become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend
significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this
nature from occurring. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology
and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing
interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information.
Furthermore, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information
regarding clinical trial participants or employees, could harm our reputation, compel us to comply with federal and/or state breach notification
laws and foreign law equivalents, cause us to breach our contractual obligations, subject us to mandatory corrective action, and otherwise
subject us to liability under laws, regulations and contracts that protect the privacy and security of personal information, which could
result in significant legal and financial exposure and reputational damages. As cyber threats continue to evolve, we may be required to
incur significant additional expenses in order to enhance our protective measures or to remediate any information security vulnerability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The financial exposure from
the events referenced above could either not be insured against or not be fully covered through any insurance that we maintain. There
can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us
from liabilities or damages as a result of the events referenced above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, in response
to the ongoing COVID-19 pandemic, varying parts of our workforce are currently working remotely on a part or full-time basis. This could
increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions. Any of
the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Ownership of Our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not know whether an active, liquid
and orderly trading market will develop for our ADSs or what the market price of our ADSs will be. As a result, it may be difficult for
shareholders to sell their ADSs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to this offering, there
has been no public market for our ADSs, although our ordinary shares have been admitted to trading on the Main Market of the London Stock
Exchange. We cannot predict the extent to which an active market for our ADSs will develop or be sustained after this offering, or how
the development of such a market might affect the market price for our ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following this offering and
after our ADSs begin trading on Nasdaq, our ordinary shares will continue to be traded on the Main Market of the London Stock Exchange.
We cannot predict the effect of this dual listing on the value of our ADSs and ordinary shares. However, the dual listing of our ADSs
and ordinary shares may dilute the liquidity of these securities in one or both markets and may adversely affect the development of an
active trading market for our ADSs. The price of our ADSs could also be adversely affected by trading in our ordinary shares on the Main
Market of the London Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of our ADSs may experience substantial
dilution upon the exercise of outstanding options, warrants and convertible loan notes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of July 2, 2021, there
were 61,625,000 ordinary shares issuable upon the exercise of share options at exercise prices of between $0.062 and $0.214 per ordinary
share, of which 13,875,000 are currently exercisable and 47,750,000 are exercisable between July 6, 2021 and March 25, 2031. In addition,
there were 113,659,090 ordinary shares that currently may be issued upon the exercise of warrants to purchase ordinary shares at exercise
prices of between $0.006 and $0.14 per ordinary share, 94,203,862 ordinary shares that currently may be issued upon the conversion of
loan notes and 97,045,464 ordinary shares that currently may be issued upon the exercise of warrants issued along with the conversion
of loan notes to purchase ordinary shares at an exercise price of $0.006. The exercise of such options warrants and convertible loan notes
will result in dilution of your investment. As a result of this dilution, you may receive significantly less than the full purchase price
you paid for our securities in the event of liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of our ADSs have fewer rights than
our shareholders and must act through the depositary to exercise their rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Holders of our ADSs do not
have the same rights as our shareholders and may only exercise their voting rights with respect to the underlying ordinary shares in accordance
with the provisions of the deposit agreement. Holders of the ADSs will appoint the depositary or its nominee as their representative to
exercise the voting rights attaching to the ordinary shares represented by the ADSs. When a general meeting is convened, if you hold ADSs,
you may not receive sufficient notice of a shareholders&rsquo; meeting to permit you to withdraw the ordinary shares underlying your ADSs
to allow you to vote with respect to any specific matter. We will make all commercially reasonable efforts to cause the depositary to
extend voting rights to you in a timely manner, but we cannot assure you that you will receive voting materials in time to instruct the
depositary to vote, and it is possible that you, or persons who hold their ADSs through brokers, dealers or other third parties, will
not have the opportunity to exercise a right to vote. Furthermore, the depositary will not be liable for any failure to carry out any
instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, you may not be able to
exercise your right to vote and you may lack recourse if your ADSs are not voted as you request. In addition, in your capacity as an ADS
holder, you will not be able to call a shareholders&rsquo; meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The rights of our shareholders may differ
from the rights typically offered to shareholders of a U.S. corporation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated under
the laws of Guernsey. The rights of holders of ordinary shares and, therefore, certain of the rights of any potential future holders of
ADSs, are governed by the laws of Guernsey, including the provisions of the Guernsey Companies Law, and by our Memorandum and Articles
of Incorporation, or Articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. See
&ldquo;Description of Share Capital and Memorandum and Articles of Incorporation &mdash;-Differences in Corporate Law&rdquo; in this report
for a description of the principal differences between the provisions of the Guernsey Companies Law applicable to us and, for example,
the Delaware General Corporation Law relating to stockholders&rsquo; rights and protections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we engage in future acquisitions or strategic
partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities
and subject us to other risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We intend to continue to
evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary drugs, intellectual property
rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
operating expenses and cash requirements;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
assumption of additional indebtedness or contingent liabilities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation
of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
diversion of our management&rsquo;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership,
merger or acquisition;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention
of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs
or drug candidates and regulatory approvals; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition
or even to offset the associated acquisition and maintenance costs.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>As
an FPI, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than
U.S. public companies</I></B></FONT><B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an FPI, as defined
in the SEC rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable to companies organized
within the United States. For example, we are exempt from certain rules under the Exchange Act, that regulate disclosure obligations and
procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the
Exchange Act. In addition, our officers and directors are exempt from the reporting and &ldquo;short-swing&rdquo; profit recovery provisions
of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, we are not
required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies. Accordingly,
there may be less publicly available information concerning our company than there is for U.S. public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As an FPI, we will file an
annual report on Form 20-F within four months of the close of each fiscal year ended March 31 and reports on Form 6-K relating to certain
material events promptly after we publicly announce these events. However, because of the above exemptions for FPIs, our ADS holders will
not be afforded the same protections or information generally available to investors holding shares in public companies organized in the
United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>While we are an FPI, we are not subject
to certain Nasdaq corporate governance rules applicable to U.S. listed companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are entitled to rely on
a provision in Nasdaq&rsquo;s corporate governance rules that allows us to follow the laws of Guernsey and rules applicable to companies
admitted to listing on the standard segment of the Official List and to trading on the Main Market of the London Stock Exchange, including,
but not limited to, the Listing Rules and the Disclosure Guidance and Transparency Rules, or DTRs, of the FCA with regard to certain aspects
of corporate governance. This allows us to follow certain corporate governance practices that differ in significant respects from the
corporate governance requirements applicable to U.S. companies listed on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For example, we have elected
to rely on the exemption allowing us to follow the laws of Guernsey and rules applicable to companies admitted to listing on the standard
segment of the Official List and to trading on the Main Market of the London Stock Exchange instead of Nasdaq regulations that require
a listed U.S. company to (i) have a majority of the board of directors consist of independent directors, (ii) require non-management directors
to meet on a regular basis without management present and (iii) promptly disclose any waivers of the code for directors or executive officers
that should address certain specified items.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with our Nasdaq
listing, our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley Act and Rule 10A-3 of the
Exchange Act, both of which are also applicable to Nasdaq-listed U.S. companies. Because we have elected to rely on the exemption allowing
us to follow the laws of Guernsey and rules applicable to companies admitted to listing on the standard segment of the Official List and
to trading on the Main Market of the London Stock Exchange, however, our audit committee is not subject to additional Nasdaq requirements
applicable to listed U.S. companies, including an affirmative determination that all members of the audit committee are &ldquo;independent,&rdquo;
using more stringent criteria than those applicable to us as an FPI. Furthermore, Nasdaq&rsquo;s corporate governance rules require listed
U.S. companies to, among other things, seek shareholder approval for the implementation of certain equity compensation plans and issuances
of ordinary shares, however as an FPI, we may elect to follow the laws of Guernsey and rules applicable to companies admitted to listing
on the Main Market of the London Stock Exchange in lieu of these Nasdaq requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may lose our FPI status, which would
then require us to comply with the Exchange Act&rsquo;s domestic reporting regime and cause us to incur significant legal, accounting
and other expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As an FPI, we are not required
to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers.
We may no longer be an FPI as early as September 30, 2021 (the end of our second fiscal quarter in the fiscal year following this Nasdaq
listing), which would require us to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act
applicable to U.S. domestic issuers as of April 1, 2022. In order to maintain our current status as an FPI, either (a) a majority of our
outstanding voting securities must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a
majority of our executive officers or directors cannot be U.S. citizens or residents, (ii) more than 50% of our assets must be located
outside the United States and (iii) our business must be administered principally outside the United States. If we lose our status as
an FPI, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which
are more detailed and extensive than the requirements for FPIs. We may also be required to make changes in our corporate governance practices
in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required
to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur
as an FPI. As a result, we expect that a loss of FPI status would increase our legal and financial compliance costs and is likely to make
some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable
to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and
we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could
also make it more difficult for us to attract and retain qualified members of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an emerging growth company within
the meaning of the Securities Act of 1933 and will take advantage of certain reduced reporting requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an EGC, as defined
in the JOBS Act. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting requirements that
are applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act, or Section 404, exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved. As an EGC, we are required to report only
two years of financial results and selected financial data compared to three and five years, respectively, for comparable data reported
by other public companies. We may take advantage of these exemptions until we are no longer an EGC. We could be an EGC for up to five
years, although circumstances could cause us to lose that status earlier, including if the aggregate market value of our ADSs held by
non-affiliates exceeds $700 million as of any September 30 (the end of our second fiscal quarter) before that time, in which case we would
no longer be an EGC as of the following December 31 (our fiscal year-end). We cannot predict if investors will find our ADSs less attractive
because we may rely on these exemptions. If some investors find our ADSs less attractive as a result, there may be a less active trading
market for our ADSs and the price of our ADSs may be more volatile in the event that we decide to make an offering of our ADSs following
our Nasdaq listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B><I>If we fail to establish
and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could
be impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.05in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section 404(a) of the Sarbanes-Oxley
Act, or Section 404(a), requires that beginning with our second annual report following our IPO, management assess and report annually
on the effectiveness of our internal control over financial reporting and identify any material weaknesses in our internal control over
financial reporting. Although Section 404(b) of the Sarbanes-Oxley Act, or Section 404(b), requires our independent registered public
accounting firm to issue an annual report that addresses the effectiveness of our internal control over financial reporting, we have opted
to rely on the exemptions provided in the JOBS Act, and consequently will not be required to comply with SEC rules that implement Section
404(b) until such time as we are no longer an EGC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect our first Section
404(a) assessment will take place for our annual report for the fiscal year ending March 31, 2023. The presence of material weaknesses
could result in financial statement errors which, in turn, could lead to errors in our financial reports, delays in our financial reporting,
which could require us to restate our operating results or our auditors may be required to issue a qualified audit report. We might not
identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section 404 (a). In
order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting,
we will need to expend significant resources and provide significant management oversight.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Implementing any appropriate
changes to our internal control may require specific compliance training of our directors and employees, entail substantial costs in order
to modify our existing accounting systems, take a significant period of time to complete and divert management&rsquo;s attention from
other business concerns. These changes may not, however, be effective in maintaining the adequacy of our internal control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If either we are unable to
conclude that we have effective internal control over financial reporting or, at the appropriate time, our independent auditors are unwilling
or unable to provide us with an unqualified report on the effectiveness of our internal control over financial reporting as required by
Section 404(b), then in the event we have decided to make an offering of our ADSs following our Nasdaq listing, investors may lose confidence
in our operating results, the price of our ADSs could decline and we may be subject to litigation or regulatory enforcement actions. In
addition, if we are unable to meet the requirements of Section 404, we may not be able to remain listed on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur significant increased costs
as a result of operating as a company that publicly listed on Nasdaq in the United States, and our management will be required to devote
substantial time to new compliance initiatives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a U.S. public company,
and particularly after we no longer qualify as an EGC, we will incur significant legal, accounting and other expenses that we did not
incur previously. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 1987, the listing requirements
of Nasdaq and other applicable securities rules and regulations impose various requirements on non-U.S. reporting public companies, including
the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our senior management
and other personnel will need to devote a substantial amount of time to these compliance initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Moreover, these rules and
regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example,
we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability
insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for
our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">However, these rules and
regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application
in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty
regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to Section 404,
we will be required to furnish a report by our senior management on our internal control over financial reporting. However, while we remain
an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent
registered public accounting firm. To prepare for eventual compliance with Section 404, once we no longer qualify as an EGC, we will be
engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In
this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work
plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as
appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement
process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within
the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we
identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence
in the reliability of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>ADSs holders may not be entitled to a jury
trial with respect to claims arising under the deposit agreement, which could augur less favorable results to the plaintiff(s) in any
such action.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The deposit agreement governing
the ADSs representing our ordinary shares provides that holders and beneficial owners of ADSs irrevocably waive the right to a trial by
jury in any legal proceeding arising out of or relating to the deposit agreement or the ADSs, including claims under federal securities
laws, against us or the depositary to the fullest extent permitted by applicable law. If this jury trial waiver provision is prohibited
by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with a jury trial. To our knowledge,
the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated by a federal court. However,
we believe that a jury trial waiver provision is generally enforceable under the laws of the State of New York, which govern the deposit
agreement, by a court of the State of New York or a federal court, which have non-exclusive jurisdiction over matters arising under the
deposit agreement, applying such law. In determining whether to enforce a jury trial waiver provision, New York courts and federal courts
will consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently prominent such that a party
has knowingly waived any right to trial by jury. We believe that this is the case with respect to the deposit agreement and the ADSs.
In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or counterclaim sounding in
fraud or one which is based upon a creditor&rsquo;s negligence in failing to liquidate collateral upon a guarantor&rsquo;s demand, or
in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are applicable in the case of the
deposit agreement or the ADSs. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder
or beneficial owner of ADSs or by us or the depositary of compliance with any provision of the federal securities laws. If you or any
other holder or beneficial owner of ADSs brings a claim against us or the depositary in connection with matters arising under the deposit
agreement or the ADSs, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which
may have the effect of limiting and discouraging lawsuits against us and / or the depositary. If a lawsuit is brought against us and /
or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be
conducted according to different civil procedures and may augur different results than a trial by jury would have had, including results
that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge
or justice hearing such claims, and the venue of the hearing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Claims of U.S. civil liabilities may not
be enforceable against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated under
the laws of Guernsey. Certain members of our board of directors and senior management are non-residents of the United States, and all
or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be
possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us
based on civil liability provisions of the securities laws of the United States. As a result, it may not be possible for investors to
effect service of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them or us,
including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">See &ldquo;Description of
Share Capital and Memorandum and Articles of Incorporation&mdash;Enforcement of Civil Liabilities.&rdquo; Additionally, it may be difficult
to assert securities law claims in actions originally instituted outside of the United States. Foreign courts may refuse to hear a securities
law claim because foreign courts may not be the most appropriate forum in which to bring such a claim. Even if a foreign court agrees
to hear a claim, it may determine that the law of the jurisdiction in which the foreign court resides, and not U.S. law, is applicable
to the claim. Further, if U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be
a time-consuming and costly process, and certain matters of procedure would still be governed by the law of the jurisdiction in which
the foreign court resides.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The rights afforded to shareholders are
governed by Guernsey law. Not all rights available to shareholders under English law or U.S. law will be available to shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The rights afforded to shareholders
will be governed by Guernsey law and by our Articles, and these rights differ in certain respects from the rights of shareholders in typical
English companies and U.S. corporations. In particular, Guernsey law significantly limits the circumstances under which shareholders of
companies may bring derivative actions and, in most cases, only the corporation may be the proper claimant or plaintiff for the purposes
of maintaining proceedings in respect of any wrongful act committed against it. Neither an individual nor any group of shareholders has
any right of action in such circumstances. In addition, Guernsey law does not afford appraisal rights to dissenting shareholders in the
form typically available to shareholders of a U.S. corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The insolvency laws of Guernsey and other
jurisdictions may not be as favorable to you as the U.S. bankruptcy laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated under
the laws of Guernsey. In the event of a bankruptcy, insolvency or similar event, proceedings could be initiated in Guernsey or another
relevant jurisdiction. The bankruptcy, insolvency, administrative and other laws of our and our subsidiaries&rsquo; jurisdictions of organization
or incorporation may be materially different from, or in conflict with, each other and those of the United States, including in the areas
of rights of creditors, shareholders, priority of governmental and other creditors and duration of the proceeding. The application of
these laws, or any conflict among them, could call into question whether any particular jurisdiction&rsquo;s law should apply, adversely
affecting your ability to enforce your rights under the ordinary shares underlying our ADSs in those jurisdictions or limit any amounts
that you may receive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are a passive foreign investment company,
there could be adverse U.S. federal income tax consequences to U.S. holders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Internal Revenue
Code of 1986, or the Internal Revenue Code, we will be a PFIC for any taxable year in which (1) 75% or more of our gross income consists
of passive income or (2) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the
production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange
of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that
directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share
of the assets and received directly its proportionate share of the income of such other corporation. If we are a PFIC for any taxable
year during which a U.S. Holder (as defined below under &ldquo;Certain U.S. and Guernsey Tax Considerations-Material U.S. Federal Income
Tax Considerations for U.S. Holders&rdquo;) holds our shares, the U.S. Holder may be subject to adverse tax consequences regardless of
whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed
dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not believe that we
were a PFIC for our taxable year ended March 31, 2020 but cannot provide any assurances regarding our PFIC status for any past, current
or future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying
principles and methodologies which in some circumstances are unclear and subject to varying interpretation. In particular, the characterization
of our assets as active or passive may depend in part on our current and intended future business plans, which are subject to change.
In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes may be determined in part
by reference to the market price of our ordinary shares or ADSs from time to time, which may fluctuate considerably. Under the income
test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future
and our corporate structure. The composition of our income and assets is also affected by how, and how quickly, we spend the cash we raise
in any offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In certain circumstances,
a U.S. Holder of shares in a PFIC may alleviate some of the adverse tax consequences described above by making, where available, a qualified
electing fund, or QEF, election to include in income its pro rata share of the corporation&rsquo;s income on a current basis or a mark-to-market
election. A U.S. Holder may make a QEF election with respect to our ordinary shares or ADSs only if we agree to furnish such U.S. Holder
annually with a PFIC annual information statement as specified in the applicable U.S. Treasury Regulations. We currently do not intend
to prepare or provide the information that would enable U.S. Holders to make a QEF election if we are treated as a PFIC for any taxable
year, and prospective investors should assume that a QEF election will not be available. A U.S. Holder may be able to make a mark-to-market
election with respect to our ADSs if our ADSs are treated as &ldquo;marketable stock.&rdquo; Generally, stock will be considered marketable
stock if it is &ldquo;regularly traded&rdquo; on a &ldquo;qualified exchange&rdquo; within the meaning of applicable U.S. Treasury regulations.
A class of stock is regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities,
on at least 15 days during each calendar quarter. Our ADSs will be marketable stock as long as they remain listed on Nasdaq and are regularly
traded. There can be no assurance that out ADSs will be regularly traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For further discussion of
the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, see the section of this
report entitled &ldquo;Certain U.S. and Guernsey Tax Considerations-Material U.S. Federal Income Considerations for U.S. Holders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A change in our tax residence could have
a negative effect on our future profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we are incorporated
under the laws of Guernsey, our affairs are, and are intended to continue to be, managed and controlled in the United Kingdom for tax
purposes and therefore we are resident in the United Kingdom for U.K. and Guernsey tax purposes. It is possible that in the future, whether
as a result of a change in law or the practice of any relevant tax authority or as a result of any change in the conduct of our affairs
or for any other reason, we could become, or be regarded as having become, a resident in a jurisdiction other than the United Kingdom.
If we cease to be a U.K. tax resident, we may be subject to a charge to U.K. corporation tax on chargeable gains on our assets and to
unexpected tax charges in other jurisdictions on our income. Similarly, if the tax residency of any of our subsidiaries were to change
from their current jurisdiction for any of the reasons listed above, we may be subject to a charge to local capital gains tax on the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be unable to use net operating loss
and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable U.K. tax legislation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a U.K. resident trading
entity, we are subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses since inception. As of
March 31, 2021, we had cumulative carryforward tax losses of $9,583,601. Subject to any relevant restrictions, we expect these to be available
to carry forward and offset against future operating profits. As a company that carries out extensive research and development activities,
we benefit from the U.K. research and development tax credit regime for small and medium-sized companies, whereby we are able to surrender
the trading losses that arise from our qualifying research and development activities for a payable tax credit of up to 33.35% of eligible
research and development expenditures. Qualifying expenditures largely comprise employment costs for research staff, consumables and certain
internal overhead costs incurred as part of research projects. Certain subcontracted qualifying research expenditures are eligible for
a cash rebate of up to 21.67%. The majority of our pipeline research, clinical trials management and manufacturing development activities
are eligible for inclusion within these tax credit cash rebate claims. Our ability to continue to claim payable research and development
tax credits in the future may be limited because we may no longer qualify as a small or medium-sized company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may benefit in the future
from the United Kingdom&rsquo;s &ldquo;patent box&rdquo; regime, which allows certain profits attributable to revenues from patented products
to be taxed at an effective rate of 10%. We are the exclusive licensee or owner of several patent applications which, if issued, would
cover our product candidates, and accordingly, future upfront fees, milestone fees, product revenues and royalties could be taxed at this
tax rate. When taken in combination with the enhanced relief available on our research and development expenditures, we expect a long-term
lower rate of corporation tax to apply to us. If, however, there are unexpected adverse changes to the U.K. research and development tax
credit regime or the &ldquo;patent box&rdquo; regime, or for any reason we are unable to qualify for such advantageous tax legislation,
or we are unable to use net operating loss and tax credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes and uncertainties in the tax system
in the countries in which we have operations could materially adversely affect our financial condition and results of operations and reduce
net returns to our shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our tax position could be
adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the interpretation thereof
by the tax authorities in the United Kingdom, the United States and other jurisdictions as well as being affected by certain changes currently
proposed by the Organization for Economic Co-operation and Development and their action plan on Base Erosion and Profit Shifting. Such
changes may become more likely as a result of recent economic trends in the jurisdictions in which we operate, particularly if such trends
continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our actual effective tax
rate may vary from our expectation and that variance may be material. A number of factors may increase our future effective tax rates,
including: (1) the jurisdictions in which profits are determined to be earned and taxed; (2) the resolution of issues arising from any
future tax audits with various tax authorities; (3) changes in the valuation of our deferred tax assets and liabilities; (4) increases
in expenses not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with acquisitions;
(5) changes in the taxation of share-based compensation; (6) changes in tax laws or the interpretation of such tax laws, and changes in
generally accepted accounting principles; and (7) challenges to the transfer pricing policies related to our structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A tax authority may disagree
with tax positions that we have taken, which could result in increased tax liabilities. For example, Her Majesty&rsquo;s Revenue &amp;
Customs, or HMRC, the U.S. Internal Revenue Service, or IRS, or another tax authority could challenge our allocation of income by tax
jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies,
including methodologies for valuing developed technology and amounts paid with respect to our intellectual property development. Similarly,
a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection,
often referred to as a &ldquo;permanent establishment&rdquo; under international tax treaties, and such an assertion, if successful, could
increase our expected tax liability in one or more jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A tax authority may take
the position that material income tax liabilities, interest and penalties are payable by us, for example where there has been a technical
violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation,
in which case we expect that we might contest such assessment. High-profile companies can be particularly vulnerable to aggressive application
of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher taxes than applicable
law appears to provide. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment,
the implications could increase our anticipated effective tax rate, where applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><A NAME="a_005"></A><B>CAUTIONARY STATEMENT REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus contains
statements that constitute forward-looking statements. Many of the forward-looking statements contained in this prospectus can be identified
by the use of forward-looking words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential&rdquo; and &ldquo;should,&rdquo; among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Forward-looking statements
appear in a number of places in this prospectus and include, but are not limited to, statements regarding our intent, belief, or current
expectations. Forward-looking statements are based on our management&rsquo;s beliefs and assumptions and on information currently available
to our management. Such statements are subject to substantial risks and uncertainties, and actual results may differ materially from those
expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, those identified
under &ldquo;Risk Factors.&rdquo; In light of the significant uncertainties in these forward-looking statements, you should not regard
these statements as a guarantee by us or any other person that we will achieve our objectives and plans in any specified time frame, or
at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Forward-looking statements
include, but are not limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
development of product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical studies
or trials and related preparatory work, the period during which the results of the trials will become available and our research and
development programs;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan to develop them, and
any related restrictions, limitations or warnings in the label of an approved drug or therapy;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
plans to research, develop, manufacture and commercialize our product candidates;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
timing of our regulatory filings for our product candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
size and growth potential of the markets for our product candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to raise additional capital;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
impact of COVID-19 on our business and operations;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
commercialization, marketing and manufacturing capabilities and strategy;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
expectations regarding our ability to obtain and maintain intellectual property protection;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to attract and retain qualified employees and key personnel;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to contract with third party suppliers and manufacturers and their ability to perform adequately;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
estimates regarding future revenue, expenses and needs for additional financing; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
developments in the United States, European Union and other jurisdictions.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Forward-looking statements
speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments
or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence
of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, statements that
&ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon
information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such
statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an
exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned
not to unduly rely upon these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should read this prospectus
and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus
is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify
all of our forward-looking statements by these cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_006"></A>MARKET
and industry DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain industry data and
market data included in this prospectus were obtained from independent third-party surveys, market research, publicly available information,
reports of governmental agencies, and industry publications and surveys. All of the market data used in this prospectus involves a number
of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We believe that the information from
these industry publications and surveys included in this prospectus is reliable. The industry in which we operate is subject to a high
degree of uncertainty and risk due to a variety of factors, including those described in &ldquo;Risk Factors.&rdquo; These and other factors
could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>TRADEMARKS, SERVICE MARKS AND TRADENAMES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Solely for convenience, the
trademarks, service marks, logos and trade names referred to in this prospectus are without the &reg; and &trade; symbols, but such references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights
of the applicable licensors to these trademarks, service marks, and trade names. For the avoidance of doubt, &ldquo;OKYO,&rdquo; the OKYO
logo and other trademarks or service marks of OKYO Pharma Limited appearing in this prospectus are the property of OKYO or our subsidiary.
This prospectus contains additional trademarks, service marks, and trade names of others, which are the property of their respective owners.
All trademarks, service marks, and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners.
We do not intend our use or display of other companies&rsquo; trademarks, service marks, copyrights, or trade names to imply a relationship
with, or endorsement or sponsorship of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><FONT STYLE="text-transform: uppercase"><A NAME="a_008"></A><B>EXCHANGE
RATE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Fluctuations in the exchange
rate between Pounds Sterling and the U.S. dollar will affect the U.S. dollar amounts received by potential future owners of our ADSs on
conversion of dividends, if any, paid in Pounds Sterling on the ordinary shares and will affect the potential future U.S. dollar price
of our ADSs on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below shows the
period end, average, high and low exchange rates of U.S. dollars per Pound Sterling for the periods shown. Average rates are computed
by using the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the last business day of each month during
the relevant year indicated or each business day during the relevant month indicated. The rates set forth below are provided solely for
your convenience and may differ from the actual rates used in the preparation of our consolidated financial statements included in this
registration statement and other financial data appearing in this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Period End</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Average Rate for Period</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">High</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Low</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD COLSPAN="14" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;&nbsp;(U.S. dollars per pound Sterling)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,4381</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1.5080</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1.5882</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1.3867</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2537</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2118</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4027</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4264</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2398</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3032</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2524</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3142</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2712</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3349</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3074</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2129</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Month, 2021</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Period End</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Low</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; font-weight: bold">(U.S. dollars per Pound Sterling)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">April 2020 </TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1.2602</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1.2617</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1.2228</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>May 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2509</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2129</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>June 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2369</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2758</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2279</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>July 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2469</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>August 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3043</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2921</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2706</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>October 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2933</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3143</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2890</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>November 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3338</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2904</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>December 2020 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3662</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3662</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>January 2021 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3723</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3729</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3522</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>February 2021 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3644</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4106</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>March 2021 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3722</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>April 2021 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3838</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3734</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>May 2021 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4188</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4188</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3873</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>June 2021 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3806</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3806</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>July 2021 (to July 2, 2021) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3780</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3795</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>On July 2, 2021 the exchange
rate published by the Federal Reserve Bank of New York was $1.3795 per &pound;1.00.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Information presented on
a constant currency basis in this prospectus is calculated by translating current year results at prior year average exchange rates. Management
reviews and analyzes business results excluding the effect of foreign currency translation because they believe this better represents
our underlying business trends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>PRICE RANGE OF OUR ORDINARY SHARES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ordinary shares have
been trading on the Main Market of the London Stock Exchange under the symbol &ldquo;OKYO&rdquo; since July 17, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table presents,
for the periods indicated, the reported high and low sale prices, including intra-day sales, of our ordinary shares on the Main Market
of the London Stock Exchange in Pounds Sterling and U.S. dollars. For the convenience of the reader, we have translated Pounds Sterling
amounts in the table below into U.S. dollars at the noon buying rate of the Federal Reserve Bank of New York on July 2, 2021, which was
&pound;1.00 to $1.3795.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price Per<BR> Ordinary Share &pound;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price Per<BR> Ordinary Share $</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Year Ended March 31, 2022</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.078</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.060</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.107</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.082</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Second Quarter (to July 2, 2021)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.063</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.063</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.086</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.086</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Year Ended March 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.076</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.024</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.053</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.072</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.121</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.071</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.098</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.076</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.166</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.105</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Year Ended March 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">First Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.029</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.081</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.028</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.024</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.023</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.013</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.031</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.017</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Year Ended March 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Second Quarter (from July 17, 2018)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.06 9 </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">.0.019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.095</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.026</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.026</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.016</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On July 2, 2021, the last
reported sale price of our ordinary shares on the Main Market of the London Stock Exchange was &pound;0.063 per ordinary share ($0.086
per ordinary share based on the exchange rate set forth above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_010"></A><FONT STYLE="text-transform: uppercase"><B>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have never paid or declared
any cash dividends on our ordinary shares, and we do not anticipate paying any cash dividends on our ordinary shares in the foreseeable
future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Pursuant
to the Guernsey Companies Law, we may only pay a dividend if the directors who authorize the dividend make a prior solvency statement
in statutory form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_011"></A><B>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should read the information
in this &ldquo;Capitalization&rdquo; section together with &ldquo;Selected Consolidated Financial Data,&rdquo; &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our consolidated financial statements and the related
notes appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below sets forth
our cash and short-term deposits and short-term investments and capitalization as of March 31, 2021 derived from our unaudited consolidated
financial statements included elsewhere in this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
an actual basis;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
a pro forma basis to give effect to (i) the issuance of 149,900,410 ordinary shares in satisfaction of the conversion of outstanding
convertible loan notes in May 2021 and (ii) the issuance of 147,969,396 ordinary shares in satisfaction of a conversion of warrants in
May 2021.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of March 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Cash and short-term deposits and short-term investments</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,889,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,889,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total interest bearing loans and borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,902,895</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">535,497</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share premium</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,629,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">122,054,148</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other reserves</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(306,012</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,293,655</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(106,003,753</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(107,279,253</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,319,408</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,481,240</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total capitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,319,408</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,481,240</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table above excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,625,000
ordinary shares issuable upon the exercise of share options at exercise prices of between $0.062 and $0.214 per ordinary share of which
13,875,000 ordinary shares are currently exercisable and 47,750,000 are exercisable between July 6, 2021 and March 25, 2031;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113,659,090
ordinary shares that currently may be issued upon the exercise of warrants to purchase ordinary shares at exercise prices of between
$0.006 and $0.14 per ordinary share.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97,045,464
ordinary shares that currently may be issued upon the conversion of loan notes to purchase ordinary shares at exercise prices of $0.0055
per ordinary share.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97,045,464
ordinary shares that currently may be issued upon the exercise of warrants issued along with the conversion of loan notes to purchase
ordinary shares at exercise prices of $0.0055.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_012"></A><B>SELECTED
CONSOLIDATED FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following tables set
forth our selected consolidated financial data for the periods indicated. We have derived the consolidated statement of comprehensive
income for the years ended March 31, 2021, 2020 and 2019 and the consolidated balance sheet data as of March 31, 2021, 2020 and 2019 from
our audited consolidated financial statements included elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We maintain our books and
records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB. We report our financial
results in U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Years
Ended March 31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt"></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Consolidated statement of operations data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: bold; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(173,821</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(518,098</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,064,296</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">General and Administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,192,385</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,016,548</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,505,532</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Operating Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,366,206</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,534,646</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,569,828</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,295</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(85,701</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(365,477</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Loss Before taxation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Tax (expense)/credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,289</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,353,507</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,544,059</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,935,305</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Basic and diluted loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020&nbsp;(restated)</B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated balance sheet:
</B>&nbsp;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Cash and cash equivalents </TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,889,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">235,485</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">627,616</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total assets </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,091,322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">598,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">759,920</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total liabilities </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,771,914</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">738,857</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">426,753</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share capital </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,629,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,079,983</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,741,860</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other reserves </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(306,012</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,787,395</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,520,051</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Retained earnings </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(106,003,753</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(102,432,702</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100,888,643</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Equity (Deficit) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,319,408</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(140,114</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">333,166</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><FONT STYLE="text-transform: uppercase"><B>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AND
RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>The following discussion
of our financial condition and results of operations should be read in conjunction with the audited consolidated historical financial
statements as at March 31, 2021, 2020 and 2019.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>The following discussion
includes forward-looking statements that reflect our plans, estimates and beliefs and involves risks and uncertainties. Our actual results
could differ materially from those discussed in these statements. Factors that could cause or contribute to these differences include,
but are not limited to, those discussed below and elsewhere in this registration statement, particularly in &ldquo;Risk Factors&rdquo;
and elsewhere in this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a preclinical biopharmaceutical
company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain.
Our research program is focused on a novel GPCR which we believe plays a key role in the pathology of these inflammatory eye diseases
of high unmet medical need. We are presently developing OK-101, our lead preclinical product candidate, for the treatment of dry-eye,
uveitis and allergic conjunctivitis, and OK-201, a BAM lipidated-peptide preclinical candidate for the treatment of neuropathic ocular
pain. Our therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. We have
not as of yet submitted an application to the FDA for any of our product candidates. We are planning to file an IND on OK-101 to treat
dry eye disease, or DED, in the third quarter of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 21, 2018, we announced
that we successfully obtained (via assignment from Panetta Partners Limited, a related party) a license from OTT to patents owned or controlled
by OTT and a sub-license from OTT to certain patents licensed by OTT from TMC to support our ophthalmic disease drug programs. These licenses
gave us the right to exploit the IP estate which is directed to compositions-of-matter and methodologies for treating ocular inflammation,
DED with chemerin or lipid-linked chemerin analogues. We also have a license from TMC to a separate IP estate for treating symptoms of
ocular neuropathic pain and uveitis associated pain. On August 6, 2019, we signed a collaborative agreement with TMC on a research program
focused on ocular neuropathic pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 7, 2021 we announced
the appointment of Mr. Gabriele Cerrone as Executive Chairman and Director, and Gary S. Jacob, Ph.D. as Chief Executive Officer and Director.
The addition of these two individuals is a significant step for us, highlighting a careful realignment of the strategic focus of our research
and development program. We believe this realignment will allow us to file IND applications on our drug candidates from with FDA in the
shortest time possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Foreign currency translations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Items included in the financial
statements are measured using the currency of the primary economic environment in which the entity operates (the functional currency).
The consolidated financial statements are presented in U.S. dollars, which is our presentation currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Foreign currency transactions
are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and
losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary
assets and liabilities denominated in foreign currencies are recognized in the income statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The financial statements
of overseas subsidiary undertakings are translated into U.S. dollars on the following basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities at the rate of exchange ruling at the year-end date.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
and loss account items at the average rate of exchange for the year.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Exchange differences arising
from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such
investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Components of Our Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revenues</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To date, we have not generated
any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. If our development
efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product
sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operating Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">R&amp;D expenses consist
primarily of costs incurred in connection with the R&amp;D of our product candidates and are expensed as incurred. These expenses consist
of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
incurred under agreements with CROs, CMOs, as well as investigative sites and consultants that conduct our preclinical studies and other
scientific development services;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
scale-up expenses and the cost of acquiring and manufacturing materials for preclinical studies;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
expenses, including salaries, related benefits, travel and share-based compensation expense for employees engaged in R&amp;D functions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
related to compliance with regulatory requirements;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">facilities
costs, depreciation and other expenses, which include rent and utilities; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
for maintaining our third-party licensing agreements.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We recognize external development
costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our direct R&amp;D expenses
are tracked on a program-by-program basis for our product candidates and consist primarily of external costs, such as fees paid to outside
consultants, CROs and CMOs in connection with our preclinical development, manufacturing and clinical development activities. Our direct
R&amp;D expenses by program also include fees incurred under our license agreements. We do not allocate employee costs or facility expenses,
including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as
such, are not separately classified. We use internal resources primarily to oversee the R&amp;D as well as for managing our preclinical
development, process development, manufacturing and clinical development activities. These employees work across multiple programs and,
therefore, we do not track their costs by program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below summarizes
our R&amp;D expenses incurred by program:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Year ended March 31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Direct research and development expense by program:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">OK-101</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">170,417</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">449,580</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,884,226</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>OK-201</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,404</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,518</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,070</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total direct research and development expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">173,821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">518,098</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,064,296</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total research and development expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">173,821</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">518,098</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,064,296</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">R&amp;D activities are central
to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in
earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials and related product
manufacturing expenses. As a result, we expect that our R&amp;D expenses will increase substantially over the next several years as we
increase personnel costs and prepare for regulatory filings related to our product candidates. We also expect to incur additional expenses
related to milestone, royalty payments and maintenance fees payable to third parties with whom we have entered into license agreements
to acquire the rights related to our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The successful development
and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing
and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates
or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty is due to the numerous risks
and uncertainties associated with development and commercialization, including the uncertainty of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
scope, progress, outcome and costs of our preclinical development activities, clinical trials and other R&amp;D activities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
an appropriate safety profile with IND- and CTA-enabling studies;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
patient enrollment in, and the initiation and completion of, clinical trials;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
commercial manufacturing capabilities or making arrangements with third-party manufacturers;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining,
maintaining, defending and enforcing patent claims and other intellectual property rights;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
and changing government regulation;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
a continued acceptable safety profile of the product candidates following approval.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may never succeed in achieving
regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue,
delay or modify clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">General and administrative
expenses consist primarily of salaries, related benefits, travel and share-based compensation expense for personnel in executive, finance
and administrative functions. General and administrative expenses also include professional fees for legal, consulting, accounting and
audit services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We anticipate that our general
and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and
development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance,
director and officer insurance costs, as well as investor and public relations expenses associated with being a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Income (Expense)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other expense consists of
an impairment of a loan to West African Minerals Ltd, a related party as well as lease liability interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The results of operations
that follow reflect the historic periods under review and should not be taken as indicative of future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following tables summarizes
our results of operations for the year ended March 31, 2021 and 2020 and for the years ended March 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(173,821</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(518,098</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">344,277</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,192,385</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,016,548</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,175,837</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,366,206</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,534,646</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,831,560</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income/ (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,295</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(85,701</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,407</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Tax (expense)/ credit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">76,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(51,295</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,353,507</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,544,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,809,448</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">259,711</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,007,142</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,457,405</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,549,737</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(518,098</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,064,296</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,546,198</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,016,548</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,505,532</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">488,984</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,534,646</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,569,828</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,035,182</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income/ (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(85,701</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(365,477</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">279,776</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Tax (expense)/ credit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">76,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">76,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,544,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,935,305</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,391,246</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(289,249</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">375,903</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,457,405</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,224,554</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,767,149</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Research and development
activities were $173,821 for the year ended March 31, 2021 compared to $518,098 for the year ended March 31, 2020. The decrease of $344,277
is due to the temporary pause in R&amp;D activity in 2020 while the Scientific Advisory Board and team were established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Research and development
activities were $518,098 for the year ended March 31, 2020 compared to $3,064,296 for the year ended March 31, 2019. The decrease of $2,546,198
was primarily due to the one-off license fee cost incurred for both OK-101 and OK-201 in the year ended March 31, 2019 of $2,658,879.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">General and administrative
expenses were $3,192,385 and $1,016,548 for the year ended March 31, 2021 and 2020. The increase of $2,175,837 is predominantly due to
bonuses accrued of $1,200k, additional share-based payment charges of $360k fees, additional legal and audit costs of $126k and realized
foreign exchange losses of $468k.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">General and administrative
expenses were $1,016,548 and $1,505,532 for the years ended March 31, 2020 and 2019. Within general and administrative expenses, there
were decreases in legal and professional fees of approximately $400,000 as we finalized our restructuring during 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since our inception, we have
not generated any revenue and have incurred operating losses and negative cash flows from our operations. We have funded our operations
to date primarily with proceeds from the sale of ordinary shares and convertible loan notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">The
COVID-19 outbreak in the United States has caused business disruptions. The extent of the impact of COVID-19 on our operational and financial
performance will depend on certain developments, including the duration and spread of the outbreak, and impact on our clinical trials,
employees and vendors, all of which are uncertain and cannot be predicted. The economic effects of the outbreak could also have an adverse
effect on our ability to raise additional capital. At this point, the extent to which COVID-19 may impact our future financial condition
or results of operations is uncertain. There has not been a material impact on the Company&rsquo;s financial statements for ear end March
31 ,2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Through March 31, 2021, we
received net cash proceeds of $7,826,939 million from sales of our ordinary shares, exercise of options and issuance of convertible loan
notes. These convertible loan notes were raised to ensure our short-term liquidity and provide for contingencies. Cash received from these
financings are invested in a money market fund with a view of liquidity and capital preservation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our cash flows for each of the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Year
Ended March 31, </B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated balance sheet:</B></FONT></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,600,198</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,202,065</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,521,955</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,114</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,668</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(366,808</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by/ (used in) financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,826,939</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">963,310</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes on cash and cash equivalents</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">445,216</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,708</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(298,096</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net increase/ (decrease) in cash and cash equivalents</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,208,627</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(371,423</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,888,763</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25pt"><I>Net Cash Used in Operating
Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our use of cash in each of
the years ended March 31, 2021 and 2020 resulted primarily from our net losses, adjusted for non-cash charges and changes in components
of working capital. Net cash used in operating activities of $1,600,198 during the year ended March 31, 2021 increased by $398,133 compared
to the year ended March 31, 2020. The increase in net cash used in operating activities was primarily due an increase in accruals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our use of cash in each of
the years ended March 31, 2020 and 2019 resulted primarily from our net losses, adjusted for non-cash charges and changes in components
of working capital. Net cash used in operating activities of $1,202,065 during the year ended March 31, 2020 decreased by $319,890 compared
to the year ended March 31, 2019. The decrease in net cash used in operating activities was primarily due to a reduction in the research
and development costs of the Company as the large license payments were made in the year to March 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net Cash Used in Investing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended March
31, 2021 we used $18,114 of cash in investing activities for the purchases of property and equipment and a loan to West African Minerals
Ltd. During the year ended March 31, 2020, $132,668 was used for the same reason. The investing activity in the year ended March 31, 2019
is the loan provided to West African Minerals Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net Cash Provided by Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended March
31, 2021 and 2020, net cash provided by financing activities was $7,826,939 and $963,310, respectively, consisting of net cash proceeds
from our sale and issuance of ordinary shares and entering into fixed term convertible loan agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended March
31, 2020, net cash provided by financing activities was $963,310, consisting of net cash proceeds from our sale and issuance of ordinary
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Funding Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect our expenses to
increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities, manufacturing
and clinical trials of our product candidates. In addition, following our Nasdaq listing, we expect to incur additional costs associated
with operating as a public company. Our expenses will also increase as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing and distribution infrastructure in anticipation of commercializing any product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional clinical, medical and development personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand our infrastructure and facilities to accommodate our growing employee base; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, expand and protect our intellectual property portfolio.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that our existing
cash, will enable us to fund our operating expenses and capital expenditure requirements for the foreseeable future. We have based these
estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. If we
receive regulatory approval for our other product candidates, we expect to incur significant commercialization expenses related to product
manufacturing, sales, marketing and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because of the numerous risks
and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate
the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly
as a result of many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
scope, progress, outcome and costs of our preclinical development activities, clinical trials and other R&amp;D activities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
costs, timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
costs of future activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for
which we receive marketing approval;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
costs and timing of hiring new employees to support our continued growth;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending
intellectual property-related claims; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
extent to which we acquire technologies.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Until such time, if ever,
that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through equity offerings.
To the extent that we raise additional capital through the sale of equity, your ownership interest will be diluted. If we raise additional
funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution
arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates
or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity financings when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights
to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Borrowings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On May 29, 2020, we
entered into a fixed term unsecured loan agreement with existing shareholders for $606,980 at an interest rate of 20% per annum to
be repaid no later than 48 months after the date of the agreement. On May 4, 2021, $167,434 of the fixed term loan agreement plus
the associated interest accrued, was converted and 62,920,000 shares were issued accordingly at a price of $0.006 per share. As at May 4,
2021, there is a remaining fixed term unsecured loan agreement with existing shareholders for $439,546 at an interest rate of 20%
per annum to be repaid no later than May 29, 2024. The loan is convertible, and the holders have the option to convert the principal
plus any accrued interest into shares at a conversion rate of $0.006 per share. This is unlikely to occur prior to this filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On July 27, 2020, we entered
into a fixed term unsecured loan agreement with existing shareholders for $4,828,250 at an interest rate of 2.15% per annum to be repaid
no later than 36 months after the date of the agreement. On May 4, 2021, the fixed term loan agreement plus the associated interest accrued,
was converted and 43,889,863 shares were issued accordingly at a price of $0.117 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 17, 2020, we entered
into a fixed term unsecured loan agreement with existing shareholders for $1,982,485 at an interest rate of 2.15% per annum to be repaid
no later than 36 months after the date of the agreement. On May 4, 2021 the fixed term loan agreement plus the associated interest accrued,
was converted and 18,021,226 shares were issued accordingly at a price of $0.117 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 3, 2020, we entered
into a fixed term unsecured loan agreement with existing shareholders for $689,750 at an interest rate of 2.15% per annum to be repaid
no later than 36 months after the date of the agreement. On May 4, 2021 the fixed term loan agreement plus the associated interest accrued,
was converted and 6,269,980 shares were issued accordingly at a price of $0.117 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We did not have during the
periods presented, and we do not currently have, any off-balance sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our contractual commitments and obligations as of March 31, 2021 and March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">As at March 31, 2021</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payments Due by Period</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than <BR> 1 Year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Between <BR>
1&nbsp;and <BR>
3&nbsp;Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Between <BR> 3 and <BR> 5 Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">More than<BR> 5 Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Borrowings</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,370,836</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,370,836</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Operating lease obligations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">29,165</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">42,056</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">84,113</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">82,598</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,268,401</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">42,056</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">84,113</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,453,434</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">As at March 31, 2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payments Due by Period</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than <BR> 1 Year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Between<BR>
 1&nbsp;and <BR>
3&nbsp;Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Between<BR> 3 and <BR> 5 Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">More than<BR> 5 Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Borrowings</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">-</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">-</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">-</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">-</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1.5pt">Operating lease obligations</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">31,688</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">5,090</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">10,696</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">15,903</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">31,688</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,090</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,696</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,903</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Quantitative and Qualitative Disclosures about
Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are exposed to market risks
in the ordinary course of our business, which are principally limited to interest rate fluctuations and foreign currency exchange rate
fluctuations. We maintain significant amounts of cash and cash equivalents that are in excess of federally insured limits in various currencies,
placed with one or more financial institutions for varying periods according to expected liquidity requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Interest Rate Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our exposure to interest rate
sensitivity is impacted by changes in the underlying U.S. and U.K. bank interest rates. Our surplus cash and cash equivalents have been
invested in interest-bearing savings and money market accounts from time to time. We have not entered into investments for trading or
speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital preservation of investments
with short-term maturities, we do not believe an immediate one percentage point change in interest rates would have a material effect
on the fair market value of our portfolio, and therefore we do not expect our operating results or cash flows to be significantly affected
by changes in market interest rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Foreign Currency Exchange Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We maintain our consolidated
financial statements in the functional currency pounds Sterling. Monetary assets and liabilities denominated in currencies other than
the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary
assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing
at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination
of net income (loss) for the respective periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For financial reporting purposes,
our consolidated financial statements are prepared using the functional currency, and translated into the U.S. dollar. Assets and liabilities
are translated at the exchange rates at the balance sheet dates and revenue and expenses are translated at the average exchange rates
and shareholders&rsquo; equity is translated based on historical exchange rates. Translation adjustments are not included in determining
net income (loss) but are included in foreign exchange adjustment to accumulate other comprehensive loss, a component of shareholders&rsquo;
equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not currently engage
in currency hedging activities in order to reduce our currency exposure, but we may begin to do so in the future. Instruments that may
be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be used to selectively manage
risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies and Significant
Judgments and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our consolidated financial
statements are prepared in accordance with IFRS. The preparation of our consolidated financial statements and related disclosures requires
us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of
contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends
and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates
and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While our significant accounting
policies are described in more detail in our consolidated financial statements, we believe that the following accounting policies are
those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Accrued Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As part of the process of
preparing our consolidated financial statements, we are required to estimate our accrued R&amp;D expenses. This process involves reviewing
open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating
the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified
of actual costs. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based
on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers
and make adjustments if necessary. Examples of estimated accrued R&amp;D expenses include fees paid to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">vendors in connection with preclinical development activities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CROs and investigative sites in connection with preclinical studies and clinical trials; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CMOs in connection with drug substance and drug product formulation of preclinical study and clinical trial materials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We base our expenses related
to preclinical studies on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research
institutions and CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements
are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments
made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these
contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing
service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period.
If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount
of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our
understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and
may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments
to our prior estimates of accrued R&amp;D expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Valuation of Share-Based Compensation and Tranche
Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Share-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We recognize compensation
expense for equity option awards based on the grant date fair value of the option award. For equity option awards that vest based on a
service condition, the share-based compensation expense is recognized on a straight-line basis over the requisite service period. For
equity option awards that contain both performance and service conditions, we recognize share-based compensation expense ratably over
the requisite service period when the achievement of a performance-based milestone is probable based on the relative satisfaction of the
performance condition as of the reporting date. We use the fair value of our ordinary shares to determine the fair value of the equity
option awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To date, the share-based
option awards granted to our employees and directors have been in the form of time and/or performance vesting share options and have been
reported in our consolidated statements of operations as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">550,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">57,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The calculation of the fair
value of equity-settled share-based awards and the resulting charge to the statement of comprehensive income requires assumptions to be
made regarding future events and market conditions. These assumptions include the future volatility of the company&rsquo;s ordinary share
price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value of the awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Where employees, directors
or advisers are rewarded using share-based payments, the fair value of the employees&rsquo;, directors&rsquo; or advisers&rsquo; services
are determined by reference to the fair value of the share options / warrants awarded. Their value is appraised at the date of grant and
excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets). Warrants issued in association
with the issue of convertible loan notes are also considered as share based payments and a share-based payment charge is calculated for
these too.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with IFRS 2,
a charge is made to the statement of comprehensive income for all share-based payments including share options based upon the fair value
of the instrument used. A corresponding credit is made to a reserve, or Share Based Payment Reserve, in the case of options / warrants
awarded to employees, directors or advisers, and ordinary shares to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Reserve in the case of warrants
issued in association with the issue of convertible loan notes, net of deferred tax where applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If vesting periods or other
vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share
options / warrants expected to vest. Non-market vesting conditions are included in assumptions about the number of options / warrants
that are expected to become exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Estimates are subsequently
revised, if there is any indication that the number of share options / warrants expected to vest differs from previous estimates. No adjustment
is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised than originally
estimated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon exercise of share options
/ warrants, the proceeds received are allocated to share capital with any excess being recorded as share premium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Where share options are cancelled,
this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognized for services
received over the vesting period is recognized immediately within the statement of comprehensive income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect the impact of our
share-based compensation expense for share option awards granted to employees, directors and other service providers to grow in future
periods due to the potential increases in the value of our ordinary shares and headcount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In conducting the valuations,
we considered all objective and subjective factors that we believed to be relevant for each valuation conducted, including our best estimate
of our business condition, prospects and operating performance at each valuation date. Within the valuations performed, a range of factors,
assumptions and methodologies were used. The significant factors included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the lack of an active public market for our ordinary shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our results of operations, financial position and the status of our research and preclinical development efforts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the material risks related to our business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our business strategy;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the market performance of publicly traded companies in the life sciences and biotechnology sectors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the prices paid in recent transactions involving our ordinary shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the likelihood of achieving a liquidity event for the holders of our ordinary shares, such as an IPO, given prevailing market conditions; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any recent contemporaneous valuations of our ordinary shares prepared in accordance with methodologies outlined in the practice aid.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The dates of our valuations
have not always coincided with the dates of our share grants. In determining the value of our ordinary shares set forth in the table above,
our board of directors considered, among other things, the most recent sale and issuance of our ordinary shares, our stage of R&amp;D,
our operating and financial performance and current business conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The estimates of fair value
of our ordinary shares are highly complex and subjective. There are significant judgments and estimates inherent in the determination
of the fair value of our ordinary shares. These judgments and estimates include assumptions regarding our future operating performance,
and the determinations of the appropriate valuation methods. The assumptions underlying these valuations represent management&rsquo;s
best estimates, which involve inherent uncertainties and the application of management judgment. If we had made different assumptions,
our stock-based compensation expense, net loss and net loss per share could have been materially different. If we had made different assumptions,
our net loss and net loss per ordinary share could have been materially different.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The tax expense for a period
represents the total of current taxation and deferred taxation. The charges in respect of current taxation are based on the estimated
taxable profit for the relevant year. Taxable profit for the year is based on the profit as shown in the income statement, as adjusted
for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability for the year is
calculated using tax rates which have either been enacted or substantively enacted at the relevant balance sheet date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred tax is provided
in full, using the liability method on temporary differences arising between the tax base of assets and liabilities and their carrying
values in the financial statements. The deferred tax is not accounted for if it arises from initial recognition of an asset or liability
in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or
loss. Deferred tax is determined using tax rates which have been enacted or substantively enacted at the balance sheet date and are expected
to apply when the related deferred tax asset is realized, or the deferred income tax liability is settled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred tax assets are recognized
to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred tax is provided
on temporary differences arising on investments in subsidiaries and associates, except where the timing of the reversal of the temporary
difference is controlled by the group and it is probable that the temporary difference will not reverse in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_014"></A><FONT STYLE="text-transform: uppercase"><B>Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a preclinical biopharmaceutical
company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain.
Our research program is focused on a novel GPCR which we believe plays a key role in the pathology of these inflammatory eye diseases
of high unmet medical need. We are presently developing OK-101, our lead preclinical product candidate, for the treatment of dry-eye,
uveitis and allergic conjunctivitis, and OK-201, a BAM lipidated-peptide analogue candidate for the treatment of neuropathic ocular pain.
Our therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. We have not as
of yet submitted an application to the FDA for any of our product candidates. We are planning to file an IND on OK-101 to treat dry eye
disease, or DED, in the third quarter of 2022 (see Figure 1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Figure 1. OKYO Pipeline</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The evidence from over 40
years of scientific literature suggests inflammation as the most common underlying cause of DED. An increase in the levels of inflammatory
cytokines in both conjunctiva and tears is known to cause the chronic inflammation associated with DED. Consequently, development of new
therapeutic agents that target inflammatory pathways is crucial in improving symptoms in DED patients. On February 21, 2018, we announced
that we successfully obtained (via assignment from Panetta Partners Limited, a related party) a license from OTT to patents owned or controlled
by OTT and a sub-license from OTT to certain patents licensed by OTT from TMC to support our ophthalmic disease drug programs. These licenses
gave us the right to exploit the IP estate which is directed to compositions-of-matter and methodologies for treating ocular inflammation,
DED with chemerin or lipid-linked chemerin analogues. We also have a license from TMC to a separate IP estate for treating symptoms of
ocular neuropathic pain, uveitis and associated pain. The scope of our use of the TMC IP granted to us through the sublicense with OTT
is commensurate with the scope of use of the IP granted to OTT from TMC. This intellectual property forms the basis of our OK-101 program,
which is discussed in greater detail below</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>OK-101</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">OK-101, our lead preclinical
product candidate, is focused on keratoconjunctivitis sicca, commonly referred to as dry eye disease, or DED, which is a multifactorial
disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. DED is one of
the most common ophthalmic conditions encountered in clinical practice. Symptoms of DED include constant discomfort and irritation accompanied
by inflammation of the ocular surface, visual impairment and potential damage to the ocular surface. The disease affects over 35% of the
population aged 50+, with women representing approximately two-thirds of those affected. Prevalence of DED is anticipated to increase
substantially in the next 10-20 years due to aging populations in the U.S., Europe, Japan and China and use of contact lenses in the younger
population. We believe this increase in prevalence of dry eye syndrome represents a major expanding economic burden to public healthcare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At present, there are essentially
three major prescription drugs used to treat DED: 1) Restasis (cyclosporine), 2) Lacrisert (hydroxypropyl cellulose), and 3) Xiidra (liftegrast).
However, DED continues to be a major unmet medical need due to the large number of patients not well served by the treatments available
to them through the medical community. The development of new drugs to treat DED has been particularly challenging due to the heterogeneous
nature of the patient population suffering from DED, and due to the difficulties in demonstrating an improvement in both signs and symptoms
of the disease in well-controlled clinical trials. The evidence from over 40 years of scientific literature, however, suggests inflammation
as the most common underlying cause of DED. Consequently, development of new therapeutic agents that target inflammatory pathways is crucial
in improving symptoms in DED patients. OK-101 is focused on an anti-inflammatory pathway for treating dry eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OK-101 is designed to target a chemokine-like
receptor 1, or CMKLR1, or CHEMR23, which is a G protein-coupled receptor expressed on macrophages, neutrophils, monocytes, plasmacytoid/myeloid
dendritic cells, natural killer cells and nonhemopoietic cell types, such as endothelial and epithelial cells (See Figure 2). Activation
of CMKLR1 by its endogenous peptide ligand chemerin is known to modulate inflammation, but natural ligands for CMKLR1 have short half-lives
due to rapid inactivation. Discovery of OK-101, a stable, high potency CMKLR1 agonist by On Target Therapeutics (Note: technology licensed
to OKYO Pharma) provided an important step toward the development of a new class of anti-inflammatory therapeutics that can be applied
to the treatment of ophthalmic diseases including DED, uveitis and ocular pain.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Figure 2</B>. OK-101 binds
to CHEMR23 receptor producing an anti-inflammatory response</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A key driver in the development
of OK-101 to treat DED, uveitis and other ocular conditions was an analysis of the inherent advantages and difficulties associated with
the treatment of ocular conditions. One of the major issues with topical administration of any drug designed for treating DED is the requirement
that the drug have adequate drug &lsquo;residence&rsquo; time at the ocular site to afford a pharmacologic benefit before being washed
out through natural processes of tear enhancement and lacrimal tear drainage. The drug candidates we have developed are designed to combat
washout by including a lipid &lsquo;anchor&rsquo; within the candidate drug molecule to enhance the residence time of the drug in the
eye. We refer to our candidates for DED as &ldquo;lipidated-chemerin&rdquo; analogues to highlight this pharmacologic characteristic.
Figure 3 shows the significance of including a lipid anchor in the &ldquo;chemerin&rdquo; molecule on drug potency and wash resistance
conducted in a series of <I>in vitro</I> studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="image_004.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="image_005.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Figure 3</B> shows the
significance of including a lipid anchor in the &ldquo;chemerin&rdquo; molecule on drug potency and wash resistance conducted in a series
of <I>in vitro</I> studies. HEK293 cells were transiently transfected with cDNAs encoding human chemerin receptor CMKLR1. Twenty-four
hours after transfection, cells were stimulated with increasing concentrations of OK-101 for 15 min and luciferase activity was determined
as described (<I>Doyle J et al, J. Biol. Chem. 2014). </I>Data points represent the mean S.E. from at least three independent experiments,
each performed in triplicate. A lipidated stable chemerin analog showed higher potency against human chemerin receptor than the corresponding
non-lapidated peptide (Figure 3 top panel) . Signaling of lipidated stable chemerin analog persisted despite serial washes, whereas activity
of the non-lipidated peptide was markedly diminished (Figure 3 bottom panel).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The potency of OK-101 was
first determined in a cell-based PathHunter&reg; &beta;-Arrestin assay. This assay monitors the activation of a GPCR in a homogenous,
non-imaging assay format using a technology developed by DiscoverX called Enzyme Fragment Complementation (EFC) with &beta;-galactosidase
(&beta;-Gal) as the functional reporter. The enzyme is split into two inactive complementary portions (EA for Enzyme Acceptor and PK for
ProLink) expressed as fusion proteins in the cells. EA is fused to &beta;-Arrestin and PK is fused to human Chemokine-like receptor 1,
CMKLR1. Activation of CMKLR1-PK induces &beta;-Arrestin-EA recruitment, forcing complementation of the two &beta;-galactosidase enzyme
fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent signal, which is measured using
chemiluminescent PathHunter&reg; Detection Reagents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assay Design: PathHunter cell
lines co-expressing the ProLink&trade; (PK) tagged GPCR (human Chemokine-like receptor 1, CMKLR1) and the Enzyme Acceptor (EA) tagged
&beta;-Arrestin were expanded from freezer stocks according to standard procedures. Cells were seeded in a total volume of 20 &mu;L into
white walled, 384-well microplates and incubated at 37&deg;C for the appropriate time prior to testing. For agonist potency determination,
cells were treated with various concentrations of peptide to induce response and incubated at 37&deg;C for 90 minutes. Assay signal was
generated through a single addition of 12.5 or 15 &mu;L (50% v/v) of PathHunter Detection reagent cocktail, followed by a one-hour incubation
at room temperature. Microplates were read following signal generation with a PerkinElmer EnvisionTM instrument for chemiluminescent signal
detection. Compound activity was analyzed using CBIS data analysis suite (ChemInnovation, CA). Figure 4 below shows the agonist activity
of OK-101 against human chemerin receptor CMKLR1 determined using PathHunter&reg; &beta;-Arrestin assay. OK-101 was shown to have a sub-nanomolar
EC50 potency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Figure 4.</B> Agonist activity
of OK-101 using PathHunter&reg; &beta;-Arrestin assay</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To further characterize the
potential efficacy of OK-101 to treat DED, OK-101 was tested in a mouse model of acute dry eye disease. Animals were divided into five
separate cohorts that included: 1) non-stressed control animals untreated throughout the study, 2) animals treated with scopolamine to
induce acute DED, 3) animals treated with scopolamine to induce acute DED and treated with 0.1% cyclosporine as a positive control, 4)
animals treated with scopolamine to induce acute DED and treated with phosphate buffer solution (the vehicle used for OK-101 delivery),
and 5) animals treated with scopolamine to induce acute DED and treated with OK-101 in phosphate buffered solution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Animals in cohorts 1) and
2) were left untreated with test agents throughout the 5-day period, whereas animals in cohorts 3), 4) and 5) were treated with either
cyclosporine, or CS, vehicle or OK-101, respectively, twice a day during the 5-day period <I>via </I>bilateral topical administration
of the respective agents. On the fifth day, all of the animals were assessed for efficacy by evaluating corneal permeability, a measure
of dry-eye effectiveness, in live animals, as well as by exploring the impact of respective treatments on immune response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Figure 5 shows the results
from this animal study. Animals induced with scopolamine to generate acute DED showed a dramatic, statistically significant increase
in corneal permeability relative to na&iuml;ve non-stressed animals. The addition of cyclosporine to scopolamine-induced DED animals
showed a statistically significant reduction of permeability (p &le; 0.001). Notably, OK-101 demonstrated a dramatic reduction of DED-induced
corneal permeability as well (p &le; 0.001). OK-101&rsquo;s effect in reducing DED-induced corneal permeability was virtually identical
to that of the cyclosporine positive control and close to the baseline corneal permeability observed in non-stressed control animals.</P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_007.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Figure 5</B>. Effect of
various treatments on mouse corneal permeability. Corneal permeability was measured using Oregon Green Dextran (OGD) staining followed
by imaging. CS was positive control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the in-life portion
of the study, immunohistochemistry was performed on frozen sections of enucleated mouse eyes to measure CD4+ T-cell infiltration into
the conjunctival epithelium of the eye (Figure 6). Animals induced to develop acute DED and not treated with drug (Vehicle animals) showed
significant infiltration of CD4+ T cells within the conjunctival epithelium, whereas OK-101 demonstrated a statistically significant (p
&le; 0.01) reduction in dry-eye-induced enhancement of CD4+ T-cells. In fact, the level of CD4+ T cells observed in OK-101 treated animals
was equivalent to the CD4+ T cell level observed in na&iuml;ve untreated animals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_008.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Figure 6</B>. CD4+ T cells
in the conjunctival epithelium after acute DED induction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Immunohistochemistry was
also performed on enucleated intact conjunctiva of mouse eyes fixed in 10% formalin, embedded in paraffin, and sectioned and stained.
DED typically leads to a loss of goblet cell density as was observed following induction of DED in the mice administered Vehicle (Figure
7). Whereas administration of OK-101 significantly rescued the DED-induced loss of Goblet Cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_009.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Figure 7</B>. Goblet Cell
density following acute DED induction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A separate series of experiments
were also performed to evaluate ocular tolerance of OK-101 in rabbits <I>via</I> repeated ocular instillation followed by clinical ophthalmic
observations. Rabbit ocular tolerance tests on OK-101 showed no adverse signs such as inflammation, chemosis or hyperemia and no signs
of local irritation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on the results from
the DED animal model and ocular tolerance studies, we are moving forward with plans to file an IND on OK-101 to treat DED in 3Q2022. We
recently completed manufacturing a 25-gram batch of OK-101 drug substance needed for initiating the IND-enabling studies. To support this
work, we also recently signed an agreement with a major clinical CRO specializing in ophthalmic drug development who will be providing
the following services:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Preparation of the OK-101 Pre-IND briefing document</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Support in requesting and preparing for the OK-101 Pre-IND meeting with FDA</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                   </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Support for regulatory publishing and submission of IND in eCTD format</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                                                              </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Providing quality oversight for development of topical formulation for OK-101</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Providing quality oversight for development and qualification of a drug stability analysis method for OK-101 along with conducting
stability studies to establish formulated drug product is stable for at least 90 days</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                               </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD>Support for completing animal toxicology studies in two animal species</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Outlook and Strategy for Development of OK-101
to Treat DED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development of new drugs to treat DED has
been particularly challenging due to the heterogeneous nature of the patient population suffering from DED, and due to the difficulties
in demonstrating an improvement in both signs and symptoms of the disease in well-controlled clinical trials. The evidence from over 40
years of scientific literature, however, suggests inflammation as the most common underlying cause of DED. Consequently, development of
new therapeutic agents that target inflammatory pathways is looking to be an attractive approach in improving symptoms in DED patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the next 12 months, OKYO is committed to
a major effort to accomplish the IND enabling activities necessary for filing an IND on OK-101 to treat DED. These include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Topical formulation of the OK-101 drug product and initial stability studies</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                                </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Bioanalytical method development to support the OK-101 clinical program</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                           </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Engineering batch manufacture of cGMP OK-101 for clinical trials</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Toxicokinetic method development</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Toxicology studies in rabbits and dogs</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                          </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Clinical batch manufacturing and stability studies of OK-101</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once an IND on OK-101 to treat DED is in place,
the virtue of OK-101 being formulated as a topical drug that can be administered to patients in the form of eye drops, means that our
first clinical trial after IND submission is expected to be a Phase 1/2a trial in DED patients, potentially providing an early indication
of drug efficacy in DED patients. Should drug efficacy be borne out in this first human trial with OK-101, we will have validated proof-of-concept
in this very first study. With this success in hand, we believe that rapid further clinical development of OK-101 to treat DED will be
in order. We anticipate that OK-101, in addition to its potential to treat DED, can then also be evaluated to treat both uveitis and allergic
conjunctivitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Additional Applicable Disease Indications for
OK-101 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Ophthalmic diseases</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A second related ophthalmic
disease indication that is the target of our chemerin-based technology is uveitis. Uveitis is the third leading cause of blindness worldwide.
The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis can damage vital eye tissue,
leading to permanent vision loss. Uveitis is currently treated with corticosteroid eyedrops and injections that reduce inflammation, however,
the long-term use of corticosteroids causes increased risk of cataracts and glaucoma, requiring close monitoring for the drug&rsquo;s
potential side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once we are in the clinic
evaluating OK-101 to treat dry eye, we will also undertake the clinical plan to explore the drug candidate&rsquo;s potential to suppress
the inflammation associated with uveitis. In support of this plan, we will also be exploring preclinical development of OK-101 for the
uveitis indication by first establishing &lsquo;proof-of-concept&rsquo; for this indication utilizing animal model studies of anterior
uveitis to evaluate the potential of OK-101 to suppress the inflammation associated with uveitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A third related ophthalmic
disease indication that is the target of our chemerin-based technology is allergic conjunctivitis. Allergic conjunctivitis is inflammation
of the conjunctiva caused by an allergic reaction that affects about 20% of the global population and is typically treated with antihistamines,
mast cell stabilizers and corticosteroids. Although there are effective drugs for the treatment of ocular allergies, about one third patients
do not respond adequately to the currently marketed drugs. Further, patients who display poor response to antihistamines appear to suffer
from chronic and seasonal allergies. There is a lack of an optimal treatment for the perennial and severe forms of ocular allergies. We
plan on conducting &lsquo;proof-of-concept&rsquo; studies using OK-101 for the treatment of chronic and seasonal allergic conjunctivitis
using a conjunctival allergen challenge animal model to investigate the potential of OK-101 to suppress the inflammation associated with
allergic conjunctivitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Non-ophthalmic conditions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 19, 2021, we announced
that we submitted a patent application to the United States Patent and Trademark Office covering the use of chemerin and chemerin analogues
to treat the cytokine release syndrome associated with COVID-19 infections and other conditions such as acute respiratory distress syndrome
(ARDS). On January 15, 2021 we signed a research and material transfer agreement with the University of Alabama at Birmingham to evaluate
the potential of chemerin analogs to minimize the inflammation triggered by SARS-CoV-2 in a model of lung inflammation. <I>Ex vivo</I>
lung tissue will be experimentally induced to produce inflammation, and during the course of inflammation in the absence and presence
of a chemerin analogue, respectively, a panel of cytokines including TNF&alpha;, IL-6, IL-1&beta; will be measured. Currently, experiments
are underway at the University of Alabama, but there is nothing to report yet on the results of this study. Assuming the results are encouraging,
our plan is to advance this program as a potential prophylaxis to treat COVID-19 infections, and other conditions such as acute respiratory
distress syndrome (ARDS). We plan this work to be under the direction of Dr. Napoleone Ferrara, a member of our Scientific Advisory Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>OK-201</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our current focus is to develop
first-in-class drug candidates as non-opioid analgesics for ocular pain management without side effects and the potential abuse associated
with opioid medications. Ocular pain occurs in several ophthalmic conditions including DED, uveitis, diabetic retinopathy (DR), accidental
trauma, surgery, and is typically treated with oral steroids, neurotransmitters and opioids in severe cases. There is no FDA approved
drug yet for ocular pain in the form of eye drops. Damage to the ocular surface (nociceptive pain in response to inflammation) or to the
somatosensory nervous system (chronic neuropathic pain) due to the underlying pathogenesis of eye disease is the main cause of pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A lipidated cyclized BAM analogue
(OK-201), a promising candidate for the treatment of neuropathic and inflammatory pain, was licensed from TMC on February 21, 2018. OK-201
is designed to activate a human MAS-Related G Protein-Coupled Receptor, or MRGPR, which is a promising analgesic target (See Figure 8).
This receptor is expressed mainly in sensory neurons and is involved in the perception of pain. Activation of MRGPR by BAM, or bovine
adrenal medulla, peptide inhibits pain by modulating Ca2+ influx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_010.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Figure 8</B>. OK-201 binds to MRGPR
receptor producing a pain inhibiting response through modulation of Ca2+ influx</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 6, 2019 we signed
a collaborative agreement with TMC and Pedram Hamrah, MD, Professor of Ophthalmology at Tufts University School of Medicine, Boston, MA
as Principal Investigator to evaluate our proprietary lead compounds as non-opioid analgesics to suppress corneal neuropathic pain using
a mouse ocular pain model developed in Dr. Hamrah&rsquo;s laboratory. Since acquiring the rights to OK-201, we have synthesized a small
library of lipidated BAM analogues. The potencies of these analogues were determined using a cell-based assay, and a small number of these
analogues were evaluated for their analgesic properties in the neuropathic pain model developed by Dr. Hamrah&rsquo;s laboratory at TMC.
These collaborative studies have provided additional &lsquo;proof-of-concept&rsquo; results for BAM analogues as potential non-opioid
analgesics. Our goal is to develop OK-201, as well as explore additional analogues for their potential use in treating ocular pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the next year, we plan
to utilize the capabilities assembled to advance the OK-201 preclinical candidate in a series of preclinical studies that also include
further use of the corneal neuropathic animal model developed at TMC. A supplemental study characterizing corneal permeability of our
class of analogues is also needed for the development of future topical formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
consider the protection of our proprietary technologies and products, as well as our ability to maintain patent protection that covers
the composition of matter of our product candidates, their methods of use, and other related technologies and inventions, to be a critical
element in the success of our business. As of December 31, 2020, our owned and licensed intellectual property included 10 issued patents
and 11 pending-patent applications in the U.S. and abroad. The pending patent applications include multiple international patent applications
filed under the Patent Cooperation Treaty that may be used as the basis for multiple additional patent applications worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Issued
United States patent directed to lipidated chemerin fragments or analogs has a statutory expiration date of March 13, 2034, excluding
any patent term extension that might be available following the grant of marketing authorization. We have pending patent applications
for lipidated chemerin fragments or analogs and methods of use thereof that, if issued, would be expected to expire in the United States
and in countries outside of the United States between 2034 and 2042, excluding any patent term adjustment that might be available following
the grant of the patent and any patent term extensions that might be available following the grant of marketing authorizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Issued
United States patent directed to lipidated BAM8-22 peptides or analogs and methods of use thereof has a statutory expiration date of November
9, 2036, excluding any patent term extension that might be available following the grant of marketing authorization. We have pending patent
applications for lipidated BAM8-22 peptides or analogs and methods of use thereof that, if issued, would be expected to expire in the
United States and in countries outside of the United States between 2036 and 2040, excluding any patent term adjustment that might be
available following the grant of the patent and any patent term extensions that might be available following the grant of marketing authorizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
plan to protect our intellectual property position by, among other things, licensing or filing our own U.S. and foreign patent applications
related to our proprietary technologies and products, and any inventions or improvements that are important to the development and implementation
of our business. We also may seek patent protection, if available, with respect to biomarkers and diagnostic methods that may be used
to determine optimal patient populations for use of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Wherever
possible, we seek to protect our inventions by filing U.S. patent applications as well as foreign counterpart applications in select countries.
Because patent applications in the U.S. are maintained in secrecy for at least eighteen months after the applications are filed, and since
publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain that we were
the first to make the inventions covered by each of our issued or pending patent applications, or that we were the first to file for protection
of inventions set forth in such patent applications. Our planned or potential products may be covered by third-party patents or other
intellectual property rights, in which case continued development and marketing of our products would require a license. Required licenses
may not be available to us on commercially acceptable terms, if at all. If we do not obtain these licenses, we could encounter delays
in product introductions while we attempt to design around the patents, or we could find that the development, manufacture or sale of
products requiring such licenses are not possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
addition to patent protection, we also rely on know-how, trade secrets and the careful monitoring of proprietary information, all of which
can be difficult to protect. We seek to protect some of our proprietary technologies and processes by entering into confidentiality agreements
with our employees, consultants, and contractors. These agreements may be breached, we may not have adequate remedies for any breach and
our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees or our consultants
or contractors use intellectual property owned by others in their work for us, disputes may also arise as to the rights in related or
resulting know-how and inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Agreement for OK-101</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">OTT and TMC entered into a
license agreement on April 3, 2017 (the &ldquo;Master License&rdquo;) pursuant to which OTT licensed exclusive rights to certain patent
applications that describe and claim lipidated chemerin peptides and their uses in DED (&ldquo;Chemerin&rdquo;). The Master License remains
in effect until they royalty term has expired with respect to all licensed products in all countries. The Master License may be terminated
by either party in the event of a material breach and in addition, OTT may terminate the Master License at any time upon 90 days&rsquo;
notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On May 22, 2017, OTT entered
into a license and sublicense agreement with Panetta Partners Limited (&ldquo;Panetta&rdquo;), one of our principal stockholders, relating
to Chemerin (the &ldquo;Chemerin License Agreement&rdquo;) which was licensed from OTT and sublicensed from TMC. On May 1, 2018, we entered
into an assignment of the Sublicense with Panetta. Under the terms of the Chemerin License Agreement, we have exclusive rights to Chemerin.
Specifically, we have the benefit of the exclusive worldwide rights to a U.S. patent application (which if issued would expire in 2036).
In addition, we have exclusive worldwide rights to a Patent Cooperation Treaty, or PCT, patent which has been nationalized in the U.S.,
Europe, Japan, Australia and Canada and if issued it would expire in 2037. The Chemerin License Agreement provides for the payment by
us of up to $4.9 million in development milestone payments and up to $37 million in sales milestones as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Development milestone payments
being:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$300,000 upon first patient enrolled in a Phase I clinical trial;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$600,000 upon first patient enrolled on a Phase II clinical trial;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$1,500,000 upon first patient enrolled in a Phase III clinical trial; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$2,500,000 upon first commercial sale of a licensed product.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Sales milestones payments
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$2,000,000 on first achievement of annual net sales of $50,000,000;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$4,000,000 on first achievement of annual net sales of $100,000,000;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$6,000,000 on first achievement of annual net sales of $250,000,000;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$10,000,000 on first achievement of annual net sales of $500,000,000; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$15,000,000 on first achievement of annual net sales of $1,000,000,000.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The above payments equate
to low and declining single digit percentage royalties on net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that we have novel
composition-of-matter coverage on the lipidated chemerin peptide lead analogues and novel method-of-use claims in treating DED and other
ophthalmic diseases. Each patent office has different patentability requirements but we believe that the license patent applications 16/070,467
(U.S. patent application entitled &ldquo;Compounds and methods for treating inflammation&rdquo;; applicant: Tufts Medical Center / Trustees
of Tufts College) and PCT/US2017/014605 (U.S. patent application entitled &ldquo;Compounds and methods for treating inflammation&rdquo;;
applicant Tufts Medical Center / Trustees of Tufts College) contain patentable subject matter. The process for issuance of a patent involves
a correspondence with each local patent office in the jurisdictions in which the patent application is filed. That process, patent prosecution,
involves a discussion of any relevant prior art and typically a discussion of the scope of the claims. The patent prosecution process
can take several years depending on the jurisdiction and is not in the control of the patent owner, but in the control of the local patent
office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The subject matter of the
licensed IP may have been developed with government financial assistance and are subject to certain federal regulations under the Bayh-Dole
Act of 1980. In particular, the federal government retains a &ldquo;nonexclusive, nontransferable, irrevocable, paid-up license&rdquo;
for its own benefit to inventions produced with its financial assistance. The&nbsp;Bayh-Dole&nbsp;Act also provides federal agencies with
&ldquo;march-in rights&rdquo; and allows the government certain rights to require products to be manufactured in the United States. March-in
rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &ldquo;nonexclusive,
partially exclusive, or exclusive license&rdquo; to a &ldquo;responsible applicant or applicants.&rdquo; If the patent owner refuses to
do so, the government may grant the license itself.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>OK-201</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We entered into a license
agreement with TMC on May 1, 2018 relating to intellectual property and proprietary technology for the use of certain lipidated BAM peptides
in the treatment of neuropathic pain. Under the terms of the license agreement, we have acquired an exclusive license to certain patents
(pending and issued), inventions (including future patent filings on lipidated BAM molecules related to the licensed patents. The license
agreement requires an upfront license fee of $15,000 (&pound;11,000), which has been paid by us and annual maintenance fees of $15,000
(&pound;11,000) commencing on the first anniversary of the license agreement. The license agreement also provides for further development
and sales milestone payments and royalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 23, 2021, we announced
that patent No. 10,899,796 entitled &ldquo;Compounds and Methods for Treating Pain&rdquo; was issued by the United States Patent and Trademark
Office. The patent is directed to a class of BAM peptides linked to specific lipids that demonstrate potential for treating symptoms of
neuropathic pain, ocular pain, ocular inflammation and/or DED. The work recited in this patent lays out the potential of this class of
lipidated BAM analogues as non-opioid analgesics for ocular pain management without the side effects and potential abuse associated with
opioid medications and is the foundation of our OK-201 program. In addition to the license from TMC we have a collaboration agreement
with TMC pursuant to which TMC has agreed to make available the services of Dr Pedram Hamrah M.D. as principal investigator and nominated
reach associate to carry out investigative and research studies in furtherance of our OK-201 corneal neuropathic pain program. The patent
will expire in early 2036.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Government authorities in
most jurisdictions extensively regulate the research, development, clinical testing, manufacture, distribution and marketing of pharmaceutical
products such as those that the company is developing. Obtaining regulatory approvals and ensuring subsequent compliance with applicable
laws and regulations requires the expenditure of substantial time and financial and managerial resources. Regulatory requirements in different
jurisdictions vary, and the timing and success of efforts to obtain regulatory approvals can be highly uncertain. Development of a successful
drug candidate, from identification of a candidate drug compound, through preclinical and clinical testing, to filing of a marketing approval
application, to registration, typically takes more than ten years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Drug development is a highly
structured process divided into two major stages, preclinical and clinical. In the preclinical stage, the toxicology and mode of action
of an active compound is evaluated. The clinical stage is designed to prove the safety of any new pharmaceutical, determine dosage requirements
and, predominantly in the later phases, prove its therapeutic utility. This stage is carried out in three phases, which, as a developer
moves through the phases, require increasingly large, complex, expensive and time-consuming clinical studies. During Phase 1, the product
candidate is initially given to a small number of healthy human subjects or patients and tested for safety, tolerance, absorption, metabolism,
distribution and excretion. During Phase 2, additional trials are conducted in a larger, but still relatively limited, patient population
to verify that the product candidate has the desired effect and to identify optimal dosage levels. Furthermore, possible adverse effects
and safety risks are identified. The therapeutic utility of the product candidate for specific targeted diseases is also studied in more
depth. During Phase 3, trials are undertaken to further evaluate dosage, to provide statistically significant evidence of clinical effectiveness
and to further study the safety in an expanded patient population at multiple clinical trial sites. Phase 3 trials may require several
hundreds or thousands of patients and are therefore the most expensive and time-consuming to conduct. At any time during one of the phases,
a trial may produce a negative result, in which case the developer may choose to end the development project or a regulator could force
clinical trials to terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following completion of the
Phase 3 trials, the developer submits all the preclinical and clinical trial documentation as well as extensive data characterizing the
manufacturing process to the regulator to seek regulatory approval to market the formulation as a pharmaceutical product. The regulator
reviews all the information related to the safety of the active compound, and whether the pharmacological effect claimed by the developer
on the proposed label can be substantiated by the results of the clinical trials. The regulator has the option to decide to approve the
application as requested, ask for changes to the claims made by the developer, ask for more information, require that further clinical
trials are undertaken, or refuse to approve the formulation for sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even after initial regulatory
approval has been obtained, further studies, including Phase 4 post-approval safety studies, may be required to provide additional data
on safety and will be required to gain approval for the use of a product as a treatment for clinical indications other than those for
which the product was initially tested. There are also continuing, annual user fee requirements for any marketed products and the establishments
at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. In addition,
regulatory authorities require post-marketing reporting to monitor the adverse effects of the product. Results of post-approval programs
may limit or expand the further marketing of the products. Further, if there are any modifications to the product, including changes in
indication, manufacturing process or labeling, or a change in the manufacturing facility, an application seeking approval of such changes
or, as the case may be, notification, must be submitted to the relevant regulatory authorities before the modified product can be commercialized.
Moreover, an approved drug product may be subject to a REMS, which could impose a number of post-approval obligations, including (among
other things) a communication plan for physicians regarding safe use of the drug, distribution and use restrictions, and/or periodic assessments
of the effectiveness of the REMS. Finally, studies may be required as a contingency of regulatory approval (post-approval commitments),
and completion of these studies within a regulator mandated time frame may be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>European Union</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The development, marketing
and sale of medicinal products in the EU is subject to extensive pre- and post- marketing regulation by regulatory authorities at both
the EU and national levels. The requirements, regulatory approvals and processes governing the conduct of clinical trials, product licensing,
pricing and reimbursement vary from country to country, although there is some degree of EU wide harmonization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clinical Trials</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Clinical trials of medicinal
products in the EU must be conducted in accordance with EU and national regulations, focusing, in particular on traceability, apply to
clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the EU, it must
appoint an entity within the EU to act as its legal representative. The sponsor must take out a clinical trial insurance policy and, in
most EU countries, the sponsor is liable to provide &lsquo;no fault&rsquo; compensation to any study subject injured in the clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to commencing a clinical
trial, the sponsor must obtain a clinical trial authorization from the relevant regulatory authority, and a positive opinion from an independent
ethics committee. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and
an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation.
Currently, clinical trial authorization applications must be submitted to the regulatory authority in each Member State in which the trial
will be conducted. Under the new Regulation on Clinical Trials, which is currently expected to take effect in 2019, there will be a centralized
application procedure where one national authority takes the lead in reviewing the application and the other national authorities have
only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications
must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical trials must be
manufactured in accordance with cGMP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Marketing Approval</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the EU medicinal products
can only be commercialized after obtaining marketing authorization, or MA. There are three procedures for obtaining marketing approvals:
the centralized procedure, the decentralized procedure and the mutual recognition procedure/national procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Community marketing authorization,
which is issued by the European Commission through the centralized procedure, based on the opinion of the CHMP of the EMA, is valid throughout
the entire territory of the EU. The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal
products, orphan medicinal products, and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer,
neurodegenerative disorders, diabetes, autoimmune and viral diseases. The centralized procedure is optional for products containing a
new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical
innovation or which are in the interest of public health in the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Marketing approvals obtained
using the decentralized procedure are available for products not falling within the mandatory scope of the Centralized Procedure. An identical
dossier is submitted to the regulatory authorities of each of the Member States in which the marketing approval is sought, one of which
is selected by the applicant as the Reference Member State, or RMS. The competent authority of the RMS prepares a draft assessment report,
a draft summary of the product characteristics and a draft of the labeling and package leaflet, which are sent to the other the concerned
Member States, or CMSs, for their approval. A CMS can raise an objection, based on the assessment report, the summary of product characteristics,
the labeling and the package leaflet on the grounds of potential serious risk to public health. If no such objections are raised the product
will be granted a national marketing authorization in the RMS and all of the selected CMSs. Where a product has already been authorized
for marketing in a Member State, this decentralized procedure approval can be recognized in other Member States through the mutual recognition
procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Marketing approvals obtained
using the national procedure are issued by a single regulatory authority of one of the Member States and only apply to the territory covered
by the relevant regulatory authority. They are available for products not falling within the mandatory scope of the centralized procedure.
Once a product has been authorized for marketing in a Member State through the national procedure, any application in another Member State
must be by the mutual recognition procedure whereby the marketing approval can also be recognized in other Member States through the mutual
recognition procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the procedures described
above, before granting the MA, the EMA or the relevant regulatory authority of the Member States of the EU makes an assessment of the
risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and therapeutic utility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The holder of a marketing
authorization in any Member State of the EU is subject to various obligations under applicable EU regulations, such as pharmacovigilance
obligations, requiring it to, among other things, report and maintain detailed records of adverse reactions, and to submit periodic safety
update reports to the regulatory authorities. The holder must also ensure that the manufacturing and batch release of its product is in
compliance with the applicable requirements. The marketing approval holder is further obligated to ensure that the advertising and promotion
of its products complies with applicable laws, which can differ from Member State to Member State of the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Data Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17pt">MAAs for generic medicinal
products in the EU do not need to include the results of preclinical and clinical trials, but instead can refer to the data included in
the marketing approval of a reference product for which regulatory data exclusivity has expired. If a marketing approval is granted for
a medicinal product containing a new active substance, that product benefits from eight years of data exclusivity, during which generic
MAAs referring to the data of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity,
during which such generic products may not be placed on the market. The two-year period may be extended to three years if during the first
eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17pt">There is a special regime for
biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of
a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, the results
of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA detail the type of quantity of supplementary
data to be provided for different types of biological product. There are no such guidelines for complex biological products, such as gene
or cell therapy medicinal products, and so it is unlikely that biosimilars of those products will currently be approved in the EU. However,
guidance from the EMA states that they will be considered in the future in light of the scientific knowledge and regulatory experience
gained at the time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17pt"></P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Orphan Medicinal Products</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17pt">The EMA&rsquo;s Committee for
Orphan Medicinal Products, or COMP, may recommend orphan medicinal product designation to promote the development of products that are
intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than
five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment
of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales
of the product in the EU would be sufficient to justify the necessary investment in developing the medicinal product. The COMP may only
recommend orphan medicinal product designation when the product in question offers a significant clinical benefit over existing approved
products for the relevant indication. Following a positive opinion by the COMP, the European Commission adopts a decision granting orphan
status. The COMP will reassess orphan status in parallel with EMA review of a marketing authorization application and orphan status may
be withdrawn at that stage if it no longer fulfills the orphan criteria (for instance because in the meantime a new product was approved
for the indication and no convincing data are available to demonstrate a significant benefit over that product). Orphan medicinal product
designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity is granted
following marketing authorization. During this period, the competent authorities may not accept or approve any similar medicinal product,
unless it offers a significant clinical benefit. This period may be redacted to six years if the orphan medicinal product designation
criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market
exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 17pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>United States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Standard Procedure</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States, the
FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act of 1938 and its implementing regulations. The process of obtaining
regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires
the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during
the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial
sanctions, such as the FDA&rsquo;s refusal to approve pending NDAs or BLAs, withdrawal of an approval, imposition of a clinical hold,
issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The process required by the
FDA before a drug may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">completion of preclinical laboratory studies, animal studies and formulation studies in compliance with the FDA&rsquo;s good laboratory practice regulations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">submission to the FDA of an IND, which the FDA must approve before human clinical trials may begin;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approval of the human clinical trial by the institutional review board, or IRB, at each clinical site before each trial may be initiated;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as GCPs to establish the safety and clinical utility of the proposed product candidate for its proposed indication;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">submission to the FDA of a BLA or NDA;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">satisfactory completion of an FDA pre-approval inspection of the production facility or facilities where the product is produced to assess compliance with the FDA&rsquo;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product&rsquo;s identity, strength, quality, purity and potency;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">FDA review and approval of the BLA or NDA prior to any commercial marketing or sale of the product in the United States.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once an approval is granted,
the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after
the product reaches the market. Other potential consequences include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">fines, warning letters or holds on post-approval clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">product seizure or detention, or refusal to permit the import or export of products; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clinical Trials</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Clinical trials involve the
administration of the IND to human patients under the supervision of qualified investigators in accordance with GCP requirements, which
include the requirement that all research patients provide their informed consent in writing for their participation in any clinical trial.
Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in
monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments
must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review
and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be
submitted within specific timeframes to the National Institutes of Health for public dissemination on their website. Regulatory authorities,
IRBs or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients
are being exposed to an unacceptable health risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Marketing Approval</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assuming successful completion
of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating
to the product&rsquo;s chemistry, manufacture, controls, or CMC, and proposed labeling, among other things, are submitted to the FDA as
part of an NDA or BLA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA or
BLA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act guidelines that are currently in effect,
the FDA has a goal of ten months from the date of filing of a standard NDA for a new molecular entity to review and act on the submission.
This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to
make a filing decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, under the Pediatric
Research Equity Act of 2003<B><I>, </I></B>certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety
and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration
for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of
the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or
full or partial waivers from the pediatric data requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA conducts a preliminary
review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event,
the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the
FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews
an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured,
processed, packaged or held meets standards designed to assure the product&rsquo;s continued safety, quality and purity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA may refer an application
for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific
experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Before approving a BLA or
NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application
unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical
trial sites to assure compliance with GCP requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">After evaluating the NDA
or BLA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing
facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a CR letter. A CR letter generally contains
a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or
preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately
may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the
FDA&rsquo;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug
with specific prescribing information for specific indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if the FDA approves
a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included
in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&rsquo;s
safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions,
including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential
market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing
studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing
changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Orphan Drug Designation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Orphan Drug Act
of 1983, the FDA may designate a biologic product as an &ldquo;orphan drug&rdquo; if it is intended to treat a rare disease or condition
(generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable
expectation that the cost of developing and making a biologic product available in the United States for treatment of the disease or condition
will be recovered from sales of the product).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a product with orphan
status receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan
product exclusivity, meaning that the FDA may not approve any other applications to market the same drug or biologic product for the same
indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity
or if the party holding the exclusivity fails to assure the availability of sufficient quantities of the drug to meet the needs of patients
with the disease or condition for which the drug was designated. Competitors, however, may receive approval of different products for
the same indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication
for which the orphan product has exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Post-Approval Requirements for the EU and
United States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA and the relevant
regulatory authorities in the EU strictly regulate marketing, labeling, advertising and promotion of products that are placed on the market
in their respective territories. Drugs may be promoted only for the approved indications and in accordance with the provisions of the
approved label. The regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and
a company that is found to have improperly promoted off-label uses may be subject to significant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, drug manufacturers
and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the
relevant regulatory authorities and are subject to periodic unannounced inspections by them to confirm compliance with cGMP requirements.
Changes to the manufacturing process are strictly regulated and often require prior approval of the relevant regulatory authorities before
being implemented. Regulations laid down by the FDA and the regulatory authorities in the EU also require investigation and correction
of any deviations from the requirements of cGMP and impose reporting and documentation requirements upon the marketing approval holder
and any third-party manufacturers that the marketing approval holder may decide to use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Healthcare Laws in the EU and United
States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The company will also be
subject to healthcare regulation and enforcement by the U.S. federal government and the states and governments in the EU and any other
countries in which the company conducts its business, including its research, and the marketing and distribution of its product candidates
and products once they have obtained marketing approval. Failure to comply with these laws, where applicable, can result in the imposition
of significant civil penalties, criminal penalties, exclusion from participating in health care programs, additional reporting requirements
and oversight if the company becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance
with these laws and other sanctions. The healthcare laws and regulations that may affect the company&rsquo;s ability to operate in the
United States include: the federal fraud and abuse laws, including the federal anti-kickback and false claims laws; federal data privacy
and security laws; and federal transparency laws related to payments and/or other transfers of value made to physicians and other healthcare
professionals and teaching hospitals. Many US states have similar laws and regulations that may differ from each other and federal law
in significant ways. Moreover, several US states have enacted legislation requiring pharmaceutical manufacturers to, among other things,
establish marketing compliance programs, file periodic reports with the state, and make periodic public disclosures on sales and marketing
activities, and prohibiting certain other sales and marketing practices. Rules and legislation covering more or less the same subject
matter as those in the United States apply to in countries in the EU and to other countries. These can differ between jurisdictions and
can sometimes result in lower or higher exposure in those countries than in the United States. Where a product is sold in a number of
countries compliance efforts can therefore be complicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Coverage and Reimbursement in the EU and
United States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Sales of products developed
from the company&rsquo;s product candidates, if approved, will depend, in part, on the extent to which such products will be covered by
third party payors, such as government health care authorities, government health care programs, commercial insurance and managed healthcare
organizations. These third-party payors are increasingly limiting coverage or reducing reimbursements for medical products and services.
In the United States, no uniform policy of coverage and reimbursement for products exists among third party payors. Therefore, coverage
and reimbursement for products can differ significantly from payor to payor. In addition, the U.S. government, state legislatures and
foreign governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and
requirements for substitution of generic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Governments influence the
price of medicinal products in the EU through their pricing and reimbursement rules and control of national healthcare systems that fund
a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products
may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries
may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available
therapies. Other Member States allow companies to fix their own prices for medicines but monitor and control company profits. The downward
pressure on healthcare costs in general in the EU governments influence the price of medicinal products through their pricing and reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The adoption of price controls
and cost-containment measures, and the adoption of more restrictive policies in jurisdictions with existing controls and measures, could
further limit the company&rsquo;s net revenue and results. Decreases in third party reimbursement for the company&rsquo;s product candidates
or a decision by a third-party payor to not cover the company&rsquo;s product candidates could reduce physician usage of the company&rsquo;s
product candidates, once approved, and have a material adverse effect on the company&rsquo;s sales, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Privacy and Data Protection Laws in Europe</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to European
laws relating to our and our suppliers&rsquo;, partners&rsquo; and subcontractors&rsquo; collection, control, processing and other use
of personal data (i.e. any data relating to an identifiable living individual, whether that individual can be identified directly or indirectly).
We are subject to the supervision of local data protection authorities in those jurisdictions where we are established, where we offer
goods or services to EU residents and where we monitor the behavior of individuals in the EU (i.e. undertaking clinical trials). We and
our suppliers, partners and subcontractors process personal data including in relation to our employees, employees of customers, clinical
trial patients, healthcare professionals and employees of suppliers including health and medical information. The data privacy regime
in the EU includes the General Data Protection Regulation, or GDPR, the e-Privacy Directive (2002/58/EC) and the e-Privacy Regulation
(once in force) and the national laws and regulations implementing or supplementing each of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The GDPR requires that personal
data is only collected for specified, explicit and legal purposes as set out in the GDPR or local laws, and the data may then only be
processed in a manner consistent with those purposes. The personal data collected and processed must be adequate, relevant and not excessive
in relation to the purposes for which it is collected and processed, it must be held securely, not transferred outside of the European
Economic Area, or EEA, (unless certain steps are taken to ensure an adequate level of protection) and must not be retained for longer
than necessary for the purposes for which it was collected. In addition, the GDPR requires companies processing personal data to take
certain organizational steps to ensure that they have adequate records, policies, security, training and governance frameworks in place
to ensure the protection of data subject rights, including as required to respond to complaints and requests from data subjects. For example,
the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process
personal data, makes it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer
where sensitive personal data (i.e. health data) is processed on a large scale, introduces mandatory data breach notification throughout
the EU and imposes additional obligations on us when we are contracting with service providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, to the extent
a company processes, controls or otherwise uses &ldquo;special category&rdquo; personal data (including patients&rsquo; health or medical
information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances and the manner
in which a company is legally permitted to process that data. Finally, the GDPR provides a broad right for Member State to create supplemental
national laws which may result in divergence across Europe making it harder to maintain a consistent operating model or standard operating
procedures. Such laws, for example, may relate to the processing of health, genetic and biometric data, which could further limit our
ability to use and share such data or could cause our costs to increase, and harm our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We depend on a number of
third parties in relation to the provision of our services, a number of which process personal data on our behalf. With each such provider
we enter into contractual arrangements to ensure that they only process personal data according to our instructions, and that they have
sufficient technical and organizational security measures in place. Where we transfer personal data outside the EU, we do so in compliance
with the relevant data export requirements from time to time. We take our data protection obligations seriously, as any improper, unlawful
or accidental disclosure, loss, alteration or access to, personal data, particularly sensitive personal data (i.e., special category),
could negatively impact our business and/or our reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are also subject to EU
laws on personal data export, as we may transfer personal data from the EU to other jurisdictions which are not considered by the European
Commission to offer adequate protection of personal data. Such transfers need to be legitimized by a valid transfer mechanism under the
GDPR. There is currently ongoing litigation challenging the commonly used transfer mechanisms, the EU Commission approved model clauses.
In addition, the U.S. Privacy Shield is currently under review by the European Commission. As such, it is uncertain whether the Privacy
Shield framework and/or model clauses will be invalidated in the near future. These changes may require us to find alternative bases for
the compliant transfer of personal data from the EU to the United States and we are monitoring developments in this area. Invalidation
of any mechanism on which we rely could require operational changes and increased costs and may lead to governmental enforcement actions,
litigation, fines and penalties or adverse publicity that could have an adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The EU is in the process
of replacing the e-Privacy Directive with a new set of rules taking the form of a regulation, which will be directly implemented in the
laws of each Member State, without the need for further enactment. The draft e-Privacy Regulation imposes strict opt-in marketing rules
with limited exceptions for business-to-business communications and alters rules on third-party cookies, web beacons and similar technology.
Regulation of cookies and web beacons may lead to broader restrictions on online research activities, including efforts to understand
users&rsquo; internet usage. The current draft also significantly increases fining powers to the same levels as GDPR (i.e., the greater
of 20 million Euros or 4% of total global annual revenue). While no official timeframe has been provided, commentators have stated that
the e-Privacy Regulation is likely to be agreed in 2019 and to come into force during the second half of 2020 or during 2021 following
a transition period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are costs and administrative
burdens associated with compliance with the GDPR and the resultant changes in the EU and EEA member states&rsquo; national laws and the
introduction of the e-Privacy Regulation once it takes effect. Any failure or perceived failure to comply with global privacy laws carries
with it the risk of significant penalties and sanctions of up to &euro;20 million or 4% of global turnover. These laws or new interpretations,
enactments or supplementary forms of these laws, could create liability for us, could impose additional operational requirements on our
business, could affect the manner in which we use and transmit patient information and could increase our cost of doing business. Claims
of violations of privacy rights or contractual breaches, even if we are not found liable, could be expensive and time-consuming to defend
and could result in adverse publicity that could harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Property, Plant and Equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The below table contains
information regarding existing or planned material tangible fixed assets owned or leased by us and our subsidiary. We believe that suitable
additional or substitute space will be available as needed to accommodate any future expansion of our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; width: 24%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Location</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left; vertical-align: top; width: 22%"><FONT STYLE="font-size: 10pt"><B>Tenure</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left; vertical-align: top; width: 27%"><FONT STYLE="font-size: 10pt"><B>Principal use</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left; vertical-align: top; width: 24%"><FONT STYLE="font-size: 10pt"><B>Size</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Suite 1405</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.125in">Graybar Building</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.125in">420 Lexington Ave</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.125in">New York</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.125in">NY 10170</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">6 months</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">CEO Office</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_015"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth information regarding our directors as of March 5, 2021. The business address of all persons identified below is Martello Court,
Admiral Park, St. Peter Port, Guernsey GY1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 54%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Gabriele Cerrone</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">48</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Chairman</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Dr. Gary S. Jacob</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">73</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">CEO and Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Dr. Raj Patil</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">63</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Scientific Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Willy Simon</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">69</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Senior Non-Executive Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">John Brancaccio</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">73</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Non-Executive Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Gabriele Cerrone</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Gabriele Cerrone has been
the Executive Chairman of our company since January 2021. Mr. Cerrone is the Founder of Tiziana Life Sciences plc and has been its Executive
Chairman since April 2014. Mr. Cerrone has founded ten biotechnology companies in oncology, infectious diseases and molecular diagnostics,
and has listed seven of these companies on Nasdaq, two to the Main Market and AIM Market in London. Mr. Cerrone co-founded Cardiff Oncology,
Inc., an oncology company and served as its Co-Chairman; he was a co-founder and served as Chairman of both Synergy Pharmaceuticals, Inc.
and Callisto Pharmaceuticals, Inc. and was a Director of and led the restructuring of Siga Technologies, Inc. Mr. Cerrone also co-founded
FermaVir Pharmaceuticals, Inc. and served as Chairman of the Board until its merger in September 2007 with Inhibitex, Inc. Mr. Cerrone
served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myers Squibb Co in 2012. Mr. Cerrone is the Executive Chairman
and Founder of dual-listed Tiziana Life Sciences plc, an oncology focused therapeutics company; Co-Founder of Rasna Therapeutics Inc.,
a company focused on the development of therapeutics for leukaemias; Co-Founder of Hepion Pharmaceuticals, Inc.; Executive Chairman and
Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology using microRNA technology; Non-Executive
Chairman and Founder of Accustem Sciences Limited; and founder of BioVitas Capital Ltd. Mr. Cerrone graduated from New York University&rsquo;s
Stern School of Business with a master&rsquo;s degree in business administration (MBA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Gary S. Jacob</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">Dr.
Gary Jacob has served as Chief Executive Officer and a director of our company since January 2021. </FONT>From <FONT STYLE="background-color: white">November
2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company.
From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical
company, where he held various positions from July 2008 to November 2018</FONT> and he served as its Chairman from September 2013 to November
2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. <FONT STYLE="background-color: white">Since
March 19, 2014, Dr. Jacob has been Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served
as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals,
Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Virpax
Pharmaceuticals, Inc., Cardiff Oncology, Inc. and Rasna Therapeutics, Inc. Dr. Jacob has over 25 years of experience in the pharmaceutical
and biotechnology industries across multiple disciplines including research &amp; development, operations and business development. Prior
to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was
Director of Functional Genomics, Corporate Science &amp; Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director
of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology
Group at Oxford University, England</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Raj Patil</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">Dr.
Raj Patil has served as Chief Scientific Officer of our company since March 2021. </FONT>Dr. Patil has over 15 years of ophthalmic drug
development experience, <FONT STYLE="background-color: white">including research &amp; development, operations and business development.
Dr. Patil </FONT>previously worked with Ora Inc, as Vice President of Research &amp; Development, where he was responsible for driving
all anterior and posterior segment ocular research of Ora&rsquo;s R&amp;D Institute. From 2013 until 2018, Dr. Patil worked at iVeena
Delivery Systems as Vice President of Advanced Ocular Delivery Systems. Dr. Patil&rsquo;s tenure at iVeena included a two-year sabbatical
in Singapore, where he served as an Associate Professor of Ophthalmology at DUKE/NUS Medical School, and Principal Investigator at Singapore
Eye Research Institute. From 2004 until 2013, Dr. Patil also held a number of leadership roles at Alcon/Novartis Institute of Biomedical
Research, including Associate Director of Research and Head of Molecular Pharmacology - glaucoma and retina research. Prior to 2004, Dr.
Patil served as an Associate Professor of Ophthalmology, Cell Biology &amp; Genetics at the University of Nebraska Medical Centre in Omaha
from 2001 until 2004, and as an Assistant Professor of Ophthalmology, Molecular Biology &amp; Pharmacology at Washington University in
St. Louis from 1992 until 2000. Dr. Patil received his PhD in Biochemistry from National Chemical Laboratory/University of Pune, India,
and completed his postdoctoral training in Biochemistry and Molecular Biology at the University of Michigan, Ann Arbor, MI. He is the
recipient of the Olga Keith Wiess Special Scholar Award from the Research to Prevent Blindness Foundation, and NIH Director&rsquo;s New
Innovator Award. Dr. Patil has authored over 50 peer-reviewed research articles, serves as reviewer and editorial board member for numerous
journals, and is frequently invited to lecture at academic and industry events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Willy Simon</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Willy Jules Simon has been
a director of our company since November 2015. He is a banker and worked at Kredietbank N.V. and Citibank London before serving as an
executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999
to 2002. He acted as chairman of Bank Oyens &amp; van Eeghen from 2002 to 2004. He was chairman of AIM-traded Velox3 plc (formerly 24/7
Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a Nasdaq OTC listed company. Willy Simon
has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime since 2015. He is also
a non-executive director of Tiziana Life Sciences plc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>John Brancaccio </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">John
Brancaccio, a retired CPA, has served as a director of our company since June 2020. From April 2004 until May 2017, Mr. Brancaccio was
the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio served as a director
of Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and has been a director
of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) since April 2004, as well as a director of Hepion Pharmaceuticals, Inc. since
December 2013, Rasna Therapeutics, Inc. since September 2016, Cardiff Oncology, Inc. since December 2005 and Tiziana Life Sciences plc
since July 2020. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Scientific Advisory Board</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors is
assisted in its approach to its scientific strategy. Members of the Scientific Advisory Board are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Professor Napoleone Ferrara, MD - University
of California&rsquo;s Moores Cancer Center in San Diego</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dr Ferrara is Senior Deputy
Director for Basic Sciences at University of California&rsquo;s Moores Cancer Center in San Diego; and Distinguished Professor of Pathology
at the University of California&rsquo;s School of Medicine, also in San Diego. Dr Ferrara&rsquo;s research led to the development of the
anti-VEGF monoclonal antibody bevacizumab (Avastin&reg;) which was initially approved for the treatment of colorectal cancer and is now
one of the top ten selling global pharmaceutical products. Dr. Ferrara won the 2010 Lasker Award for his work on VEGF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Professor Pedram Hamrah, MD, FRCS, FARVO &ndash;
Tufts University School of Medicine, Boston, and Clinician-Scientist at Tufts Medical Center</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dr. Hamrah is an ophthalmologist
and cornea specialist, with a focus on corneal immunology and neuroscience, ocular imaging (immuno-imaging), ocular surface diseases,
and corneal neuropathic pain. He is currently on faculty at the departments of Ophthalmology and Bioengineering at Tufts University, where
he is the director of clinical research and director of the Center for Translational Ocular Immunology. In addition, he is a faculty member
at the immunology, neuroscience, and cell, molecular and developmental biology graduate programs at the Sackler School of Graduate Biomedical
Sciences at Tufts. Throughout his career, he has focused on discovery, patient care and teaching. Dr. Hamrah currently serves on over
a dozen editorial boards, is the associate editor for The Ocular Surface and TVST, section editor for Eye, and assistant editor at Ocular
Immunology and Inflammation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Foreign Private Issuer Exemption</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an FPI as defined
by the SEC. As a result, in accordance with Nasdaq listing requirements, we may rely on home country governance requirements and certain
exemptions thereunder rather than complying with Nasdaq corporate governance standards. While we voluntarily follow most Nasdaq corporate
governance rules, we may choose to take advantage of the following limited exemptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exemption from filing quarterly reports on Form 10-Q containing unaudited financial and other specified information or current reports on Form 8-K upon the occurrence of specified significant events.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exemption from Section 16 rules requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades in a short period of time, which will provide less data in this regard than shareholders of U.S. companies that are subject to the Exchange Act.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exemption from the Nasdaq requirement requiring disclosure of any waivers of the code of business conduct and ethics for directors and officers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exemption from the requirement that our board of directors have a remuneration committee that is composed entirely of independent directors with a written charter addressing the committee&rsquo;s purpose and responsibilities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exemption from the requirement to have independent director oversight of director nominations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We intend to follow the laws
of Guernsey and rules applicable to companies admitted to listing on the standard segment of the Official List and to trading on the Main
Market of the London Stock Exchange in lieu of Nasdaq corporate governance requirements as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We do not intend to follow Nasdaq Rule 5620(c) regarding quorum requirements applicable to meetings of shareholders. Such quorum requirements are not required under the laws of Guernsey. In accordance with generally accepted business practice, our Articles provide alternative quorum requirements that are generally applicable to meetings of shareholders.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We do not intend to follow Nasdaq Rule 5605(b)(2), which requires that independent directors regularly meet in executive sessions where only independent directors are present. Our independent directors may choose to meet in executive sessions at their discretion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we may rely on certain
home country corporate governance practices, we must comply with Nasdaq&rsquo;s Notification of Noncompliance requirement (Nasdaq Rule
5625) and the Voting Rights requirement (Nasdaq Rule 5640). Further, we must have an audit committee that satisfies Nasdaq Rule 5605(c)(3),
which addresses audit committee responsibilities and authority and requires that the audit committee consist of members who meet the independence
requirements of Nasdaq Rule 5605(c)(2)(A)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We intend to take all actions
necessary for us to maintain compliance as an FPI under the applicable corporate governance requirements of the Sarbanes-Oxley Act, the
rules adopted by the SEC and Nasdaq listing rules. Accordingly, our shareholders will not have the same protections afforded to shareholders
of companies that are subject to all of the corporate governance requirements of Nasdaq. For an overview of our corporate governance principles,
see the section titled &ldquo;Description of Share Capital and Memorandum and Articles of Incorporation&mdash;Differences in Corporate
Law.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to effectiveness of
this registration statement, we plan to adopt a Code of Business Conduct and Ethics applicable to our employees, executive officers and
directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Composition of Our Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors is
currently composed of five members. Our board of directors has determined that, of our five directors, three of these directors are &ldquo;independent&rdquo;
as that term is defined under Nasdaq rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with our Articles,
each of our directors for whom it is the third annual general meeting following the annual general meeting at which they were elected
or last re-elected, or who was appointed by the board since the previous annual general meeting, shall retire from office but shall be
eligible to stand for re-election. See &ldquo;Description of Share Capital and Memorandum and Articles of Incorporation&mdash;Articles&mdash;Board
of Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The expiration of the current
terms of the members of the board of directors and the period each member has served in that term are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 69%"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 14%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year Current<BR>
Term Began</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; width: 14%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year Current<BR>
Term Expires</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Gabriele Cerrone</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2024</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Willy Simon</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2018</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">John Brancaccio</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2024</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Gary Jacob</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2024</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Commencing with the 2021
annual general meeting we plan to adopt best practice for corporate governance in our country of incorporation so all directors will retire
and stand for re-election at each annual general meeting (as opposed to reliance upon rotational reappointment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of our directors&rsquo;
service contracts provide for benefits upon termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Committees of Our Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors has
three standing committees: an audit committee, a remuneration committee and a nominating committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The audit committee, which
consists of John Brancaccio and Willy Simon, assists the board of directors in overseeing our accounting and financial reporting processes.
Mr. Brancaccio serves as chairman of the audit committee. The audit committee consists exclusively of members of our board who are financially
literate, and Mr. Brancaccio is considered an &ldquo;audit committee financial expert&rdquo; as defined by applicable SEC rules and has
the requisite financial sophistication as defined under the applicable Nasdaq rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board has determined
that all of the members of the audit committee satisfy the &ldquo;independence&rdquo; requirements set forth in Rule 10A-3 under the Exchange
Act. The audit committee will be governed by a charter that complies with Nasdaq rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The audit committee&rsquo;s
responsibilities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">recommending the appointment of the independent auditor to the general meeting of shareholders;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit services;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">pre-approving the audit services and non-audit services to be provided by our independent auditor before the auditor is engaged to render such services;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">evaluating the independent auditor&rsquo;s qualifications, performance and independence, and presenting its conclusions to the full board of directors on at least an annual basis;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reviewing and discussing with management and our independent registered public accounting firm our financial statements and our financial reporting process; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reviewing, approving or ratifying any related party transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Remuneration Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The remuneration committee
consists of John Brancaccio and Willy Simon who serves as chairman of the remuneration committee. Under SEC and Nasdaq rules, there are
heightened independence standards for members of the remuneration committee, including a prohibition against the receipt of any compensation
from us other than standard board member fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The remuneration committee&rsquo;s
responsibilities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">identifying, reviewing and proposing policies relevant to the compensation and benefits of our directors and executive officers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">evaluating each executive officer&rsquo;s performance in light of such policies and reporting to the board; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">overseeing and administering our employee share option scheme or equity incentive plans in operation from time to time.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nominating Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The nominating committee
consists of John Brancaccio and Willy Simon who serves as chairman of the nominating committee. The nominating committee&rsquo;s responsibilities
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">drawing up selection criteria and appointment procedures for directors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">recommending nominees for election to our board of directors and its corresponding committees;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">assessing the functioning of individual members of our board of directors and executive officers and reporting the results of such assessment to the board of directors; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">developing corporate governance guidelines.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation of Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the year ended March
31, 2021, the aggregate compensation accrued or paid to the members of our board of directors and our executive officers for services
in all capacities was $1.4 million, $0.1 million for the year ended March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dr. Gary Jacob Employment Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We entered into an employment
agreement with Dr. Gary Jacob, our Chief Executive Officer, on December 21, 2020 and amended the agreement on January 19, 2021. Pursuant
to the agreement, Dr. Jacob has an annual salary of $350,000 and a cash bonus of up to 50% of his annual salary based on annual performance
goals. In addition, Dr. Jacob was granted options to purchase 40,000,000 ordinary shares. The options will vest over 4 years in 4 equal
tranches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dr. Jacob is also entitled
to the same fringe benefits as we provide to our other executives from time to time and is eligible to receive employee share incentives.
If Dr. Jacob&rsquo;s employment with the company is terminated without cause, or if he resigns for good reason, Dr. Jacob will also be
entitled to receive severance equal to continuation of his base salary as then currently in effect for 12 months following his date of
termination and will be eligible for a pro-rated bonus and for reimbursement for medical coverage premiums for 6 months following his
date of termination. Dr. Jacob&rsquo;s severance benefits are conditioned on, <I>inter alia</I>, his execution of our standard separation
agreement and a general release of claims in our favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The employment agreement provides
that Dr. Jacob&rsquo;s employment with us is at-will. If required by us, the employment agreement further provides that Dr. Jacob will
resign from his position on our board of directors effective as of the date of his termination for any reason. The employment agreement
further contains a 12-month non-solicitation covenant by Dr. Jacob.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Gabriele Cerrone Letter of Appointment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We entered into an appointment
agreement with Gabriele Cerrone on January 6, 2021 to serve as our non-executive chairman. This agreement entitles Mr. Cerrone to receive
a consultancy fee of &pound;120,000 per year. On April 28, 2021 we entered into an agreement with the Mr. Cerrone pursuant to which Mr.
Cerrone was awarded a retrospective bonus of $687,273 for the financial year ended March 31, 2020 and a further bonus of $554,400 for
the financial year ended March 31, 2021, in each case for services prior to his agreeing to become a director of the Company, on condition
that Mr. Cerrone agreed that Panetta Partners Limited and Planwise Group Limited exercise a total of 147,969,396 warrants at exercise
prices between &pound;0.006 and $0.0189 (being all of the warrants held by Mr. Cerrone and his associated entities). Mr. Cerrone also
agreed that his accrued but unpaid compensation from January 1, 2021 to May 4, 2021 and through to March 31, 2022, in the sum of $210,000
be waived and offset against the costs of the exercise of certain of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 31, 2021, 2020,
and 2019, we had 2, 2 and 2 employees, respectively. All of our employees were based in the US. All of our employees were engaged in either
administrative or R&amp;D functions. None of our employees are covered by a collective bargaining agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Insurance and Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to our Articles,
our directors (including any alternate director), secretary and other officer or employee for the time being shall be indemnified out
of the assets of the company to the fullest extent permitted by the Guernsey Companies Law from and against all actions, costs, charges,
losses, damages and expenses in respect of which they may lawfully be indemnified which they or any of them shall or may incur or sustain
by reason of any contract entered into or any act done, concurred in, or omitted, in or about the execution of their duty or supposed
duty or in relation thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We maintain directors&rsquo;
and officers&rsquo; insurance to insure such persons against certain liabilities. We have entered into a deed of indemnity with each of
our directors and executive officers prior to the filing of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Insofar as indemnification
of liabilities arising under the Securities Act may be permitted to our board of directors, executive officers, or persons controlling
us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public
policy as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Total Compensation for
the Non- Executive Chairman and Non-Executive Directors:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below sets out
the total remuneration received by the Chairman and the Non-Executive Directors for the year ended March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Position</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees earned<BR>
 or paid in<BR>
 cash <BR> ($)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<BR>
earned or<BR>
 paid in cash <BR> ($)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options<BR>
 awarded <BR> ($)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <BR> ($)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 26%; text-align: left">Gabriele Cerrone</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center">Non-Executive Chairman</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">35,701</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,160,347</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,196,048</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gary Jacob</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Executive Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,808</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,753</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">467,921</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">593,482</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Willy Simon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Non-Executive Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,941</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Kunwar Shailubhai<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Non-Executive Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,969</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,088</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Gregor MacRae<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Non-Executive Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,083</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,083</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The amounts have been translated into U.S. dollars from Pounds Sterling based upon the exchange rate as certified by the Federal Reserve Bank of New York for customs purposes as of March 31, 2021. These translations are merely for the convenience of the reader and should not be construed as representations that the Pounds Sterling amounts actually represent such U.S. dollar amounts or could be converted into U.S. dollars at the rate indicated.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents the fair value of incentive stock options granted during the year to March 31, 2021 using the Black-Scholes model for computing stock-based compensation expense as of the date of grant.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Resigned June 17, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Resigned June 9, 2020</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employee Share Option Plan with Non-Employee
Sub-Plan and US Sub-Plan </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The main features of the Unapproved Share Option
Plan are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Eligibility</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All executive directors and employees of the Company
and any of its subsidiaries are eligible to participate in the Unapproved Share Option Plan. The Remuneration Committee selects the individuals
to whom share options are to be granted from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Grant of options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Options may be granted at such time or times as
the Remuneration Committee (or the Board, excluding any interested Director, until a Remuneration Committee is formally established) determines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercise price and adjustments to options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">While the Ordinary Shares are admitted to trading
on the Main Market of the London Stock Exchange, the exercise price per Ordinary Share may not be less than the average of the middle
market quotations for an Ordinary Share for the five dealing days immediately prior to the date of grant. While the Ordinary Shares are
not admitted to trading on the Main Market of the London Stock Exchange, the exercise price will be the amount specified by the Remuneration
Committee. If the Ordinary Shares are newly issued the exercise price may not, in any event, be less than the nominal value of an Ordinary
Share. In the event of any variation in the share capital of the Company the exercise price and/or the number of Ordinary Shares comprised
in each option may be adjusted as the Remuneration Committee determines. No adjustment may be made which will reduce the exercise price
below the nominal value of an Ordinary Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Rights and restrictions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">An option granted under the Unapproved Share Option
Plan is not transferable. The option certificate will specify when the option will lapse, and such date may not be later than the tenth
anniversary of its date of grant. Except in the circumstances referred to below, an option will only be exercisable on or after the date
which is three years after the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">If the participant ceases to be employed by the
Company by reason of injury, disability, ill-health or redundancy; or because the business or company that employs him is transferred
out of the ultimate ownership of the Company, his option may be exercised within six months after such cessation or transfer provided
that this limit may be further extended by the Remuneration Committee in the event that any exercise of the options would trigger any
requirement upon the holder to make a general offer to shareholders under Rule 9 of the Takeover Code. In the event of the death of a
participant, the personal representatives of a participant may exercise his option within six months after the date of death. The extent
to which an option may be exercised in these circumstances will be determined by reference to any exercise conditions and time vesting
provisions set out in the option certificate unless the Remuneration Committee decides otherwise and is satisfied that any waiver of such
provisions does not constitute a reward for failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">On cessation of employment for any other reason
(or when a participant serves or has been served with, notice of termination of such employment), the option will lapse unless the Remuneration
Committee exercises its discretion to allow the exercise of the option for a period not exceeding 6 months from the date of such cessation
or notice. In such circumstances and where exercise is permitted, the extent to which an option may be exercised will be determined by
reference to any exercise conditions and time vesting provisions set out in the option certificate unless the Remuneration Committee decides
otherwise and is satisfied that any waiver of such provisions does not constitute a reward for failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Corporate events</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Options, to the extent not already exercisable,
will become exercisable immediately prior to a change in control of the Company, in the event of a takeover of the Company, in the event
that an officer becomes entitled or bound to acquire Ordinary Shares or in the event that the court sanctions a compromise or arrangement
for the reconstruction of the Company or its amalgamation with any other company. In such event, all share options may be exercised for
a limited period and will lapse to the extent not exercised. Options, to the extent not already exercisable, will become exercisable in
the event that the Company is proposed to be voluntarily wound up and all share options may be exercised within a limited period in connection
with the winding up, failing which they will lapse. In such circumstances and where exercise is permitted, the extent to which an option
may be exercised will be determined by reference to any exercise conditions set out in the option certificate unless the Remuneration
Committee decides otherwise and is satisfied that any waiver of such provisions does not constitute a reward for failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Performance conditions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The exercise of share options may be subject to
the satisfaction of such performance conditions, if any, as may be specified and subsequently varied and/or waived by the Remuneration
Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Issuance of Ordinary Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The Ordinary Shares issued upon the exercise of
share options granted under the Unapproved Share Option Plan will rank pari passu with the Company&rsquo;s issued Ordinary Shares on the
date of exercise, save as regards any rights arising by reference to a record date prior to the date of such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Plan limit</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Options may not be granted under the Unapproved
Share Option Plan if such grant would result in the total number of &ldquo;Dilutive Shares&rdquo; exceeding 15% of the Company&rsquo;s
issued share capital from time to time. &ldquo;Dilutive Shares&rdquo; means, on any date, all shares of the Company which (a) have been
issued, or transferred out of treasury, on the exercise of share options granted, or in satisfaction of any other awards made, under any
share incentive scheme (including the Unapproved Share Option Plan) in the shorter of the five years ending on (and including) that date
and the period since Admission; and (b) remain capable of issue, or transfer out of treasury, under any subsisting share options granted
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Alternative settlement on exercise</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Instead of delivering the number of Ordinary Shares
specified in the exercise notice, the Remuneration Committee may make a cash payment with the option holder&rsquo;s consent or deliver
Ordinary Shares equal to the value of the Ordinary Shares over which the option is exercised less the relevant exercise price, or may
deliver a combination of the above two.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Alteration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The Remuneration Committee may alter the Unapproved
Share Option Plan except that (apart from minor amendments to benefit the administration of the Share Option Plan, to correct typographical
or other errors, to take account of a change in legislation or to obtain or maintain favorable tax, exchange control or regulatory treatment
for participants or the Company) no alteration to the advantage of participants or to the Unapproved Share Option Plan limit described
above can be made without the prior approval of Shareholders in general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">No amendment may have a materially adverse effect
on share options granted before the amendment without the relevant option holder&rsquo;s consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Termination and Plan period</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The Remuneration Committee may terminate or suspend
the operation of the Unapproved Share Option Plan at any time, whereupon no further share options shall be granted but in all other respects
the provisions of the Unapproved Share Option Plan shall remain in force. In any event, no share options may be granted after the date
which is five years after the date the Unapproved Share Option Plan is adopted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_016"></A><B>RELATED
PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a description
of related party transactions we have entered into with the beneficial owners of 3% or more of our ordinary shares, which are our only
voting securities, and senior management and members of our board of directors, for the three-year period ended March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Loan to West African Minerals Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In 2018, we disposed of our
Cameroon operations by way of an in specie distribution of all of our shares in Ferrum Resources Limited (renamed West African Minerals
Limited, or WAML) to our shareholders. As part of this transaction, we agreed to a deed of release with WAML whereby we agreed to write
off $17,056,070 of loans in exchange for shares in WAML to be distributed as part of the in-specie distribution. A remaining amount of
$3,400,000 is still outstanding from WAML, however, after careful consideration of the operations of WAML and its subsidiaries, we decided
to impair this receivable down to nil in 2018 as we do not expect to recover any of this outstanding debt. In addition to the $3,400,000
outstanding there was a working capital loan advance of $600,000, which has been fully extended and also written down to nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Tiziana Life Sciences plc </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 1, 2018, we entered
into a Shared Services Agreement with Tiziana Life Sciences plc pursuant to which we share premises and other resources. The agreement
is renewed for successive three (3) month periods. For the years ended March 31, 2021 and 2020, we paid Tiziana $86,567 and $117,767,
respectively, under the Shared Services Agreement. We share common officers and directors with Tiziana, namely Gabriele Cerrone, Willy
Simon and John Brancaccio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Gabriele Cerrone Letter of Appointment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">We entered into an appointment
agreement with Gabriele Cerrone, on January 6, 2021, to serve as our non-executive chairman. This agreement entitles Mr. Cerrone to receive
a consultancy fee of &pound;120,000 per year. On April 28, 2021 we entered into an agreement with the Mr. Cerrone pursuant to which Mr.
Cerrone was awarded a retrospective bonus of $687,273 for the financial year ended March 31, 2020 and a further bonus of $554,400 for
the financial year ended March 31, 2021, in each case for services prior to his agreeing to become a director of the Company, on condition
that Mr. Cerrone agreed that Panetta Partners Limited and Planwise Group Limited exercise a total of 147,969,396 warrants at exercise
prices between &pound;0.006 and $0.0189 (being all of the warrants held by Mr. Cerrone and his associated entities). Mr. Cerrone also
agreed that his accrued but unpaid compensation from January 1, 2021 to May 4, 2021 and through to March 31, 2022, in the sum of $210,000
be waived and offset against the costs of the exercise of certain of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Panetta Partners Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Our Chairman, Gabriele Cerrone,
has a beneficial interest in Panetta Partners Limited, one of our principal stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">On May 1, 2018 we entered
into a Deed of Assignment with Panetta Partners Limited whereby we acquired the license and sub-license of certain research and development
assets in relation to our OK-101 product candidate for $2,793,488.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">We have also entered into
a Convertible Loan note agreement with Panetta Partners Limited, for a principal amount of $69,850, the conversion rights attaching to
which were exercised and the resulting ordinary shares issued on May 4, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Planwise Group Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On May 4, 2021 we allotted
and issued 18,329,094 ordinary shares to Planwise Group Ltd, a company in which our Chairman, Gabriele Cerrone, has a beneficial interest,
as a commission of $43,482 upon the conversion of our convertible loan notes for which conversion took place on May 4, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnity Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have entered into deeds
of indemnity with each of our directors and officers. See &ldquo;Management&mdash;Insurance and Indemnification.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Related Person Transaction Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors has
adopted a written related person transaction policy, to be effective immediately upon the effectiveness of the registration statement
of which this prospectus forms a part, setting forth the policies and procedures for the review and approval or ratification of related
person transactions. This policy will cover, any transaction or proposed transactions between us and a related person that are material
to us or the related person, including without limitation, purchases of goods or services by or from the related person or entities in
which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In
reviewing and approving any such transactions, our audit and risk committee is tasked to consider all relevant facts and circumstances,
including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&rsquo;s length
transaction and the extent of the related person&rsquo;s interest in the transaction. All of the transactions described in this section
occurred prior to the adoption of this policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_018"></A>SELLING SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The
selling shareholders acquired the ADSs being registered for resale pursuant to this prospectus, pursuant to ____________. We have agreed
to file this registration statement covering the resale of the ADSs sold in the offering. We are registering the ADSs in order to permit
the selling shareholders to offer the ordinary shares represented by ADS for resale from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Other
than the relationships described herein, to our knowledge, none of the selling shareholders are employees or suppliers of ours or our
affiliates. Within the past three years, other than the relationships described herein, none of the selling shareholders has held a position
as an officer a director of ours, nor has any selling shareholders had any material relationship of any kind with us or any of our affiliates.&nbsp;&nbsp;All
information with respect to share ownership has been furnished by the selling shareholders, unless otherwise noted.&nbsp;&nbsp;The ADSs
being offered are being registered to permit public secondary trading of such ADSs and each selling shareholders may offer all or part
of the ADSs it owns for resale from time to time pursuant to this prospectus. None of the selling shareholders has any family relationships
with our officers, other directors or controlling shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">Any
selling shareholders who are affiliates of broker-dealers and any participating broker-dealers are deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act, and any commissions or discounts given to any such selling shareholders or broker-dealer may
be regarded as underwriting commissions or discounts under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The
term &ldquo;selling shareholders&rdquo; also includes any transferees, pledgees, donees, or other successors in interest to the selling
shareholders named in the table below. Unless otherwise indicated, to our knowledge, each person named in the table below has sole voting
and investment power (subject to applicable community property laws) with respect to the ADSs set forth opposite such person&rsquo;s name.
We will file a supplement to this prospectus (or a post-effective amendment hereto, if necessary) to name successors to any named selling
shareholders who are able to use this prospectus to resell the ADSs registered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The
table below lists the selling shareholders and other information regarding the beneficial ownership of the ordinary shares held by the
selling shareholders. The second column lists the number of ordinary shares beneficially owned by the selling shareholders, based on its
ownership of ordinary shares, as of June 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The
third column lists the ADSs being offered by this prospectus by the selling shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The
fourth column assumes the sale of all of the ADSs offered by the selling shareholders pursuant to this prospectus. The selling shareholders
may sell all, some or none of their shares in this offering. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Name of Selling Shareholder</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of <BR>
Ordinary <BR>
Shares </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Beneficially<BR>
    Owned <BR>
Prior to<BR>
    Offering (1)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Maximum
                                            <BR> Number of<BR>
                                            </B></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Ordinary
                                            Shares <BR>
                                            to be Sold <BR>
                                            Pursuant <BR>
to this<BR>
                                            Prospectus</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Ordinary Shares<BR>
    Owned <BR>
    Immediately <BR>
    After Sale of <BR>
    Maximum <BR>
    Number of Share <BR>
    in this Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 64%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Beneficial ownership is
determined in accordance with SEC rules and generally includes voting or &#9;investment power with respect to securities. Ordinary shares
subject to warrants currently &#9;exercisable, or &#9;exercisable within 60 days of June 30, 2021 are counted as outstanding for computing
the percentage of the &#9;selling stockholder holding such options or warrants but are not counted as outstanding for computing the &#9;percentage
of any other selling stockholder.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_017"></A><FONT STYLE="text-transform: uppercase"><B>PRINCIPAL
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth information relating to the beneficial ownership of our ordinary shares as of [&nbsp;&nbsp;], 2021 by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary shares; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">each member of our board of directors and each of our executive officers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The number of ordinary shares
beneficially owned by each entity, person, board member, or executive officer is determined in accordance with the rules of the SEC, and
the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes
any ordinary shares over which the individual has sole or shared voting power or investment power as well as any ordinary shares that
the individual has the right to acquire within 60 days of June 30, 2021 through the exercise of any option, warrant or other right. Except
as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment
power with respect to all ordinary shares held by that person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The percentage of ordinary
shares beneficially owned before this offering is computed on the basis of 970,686,108 ordinary shares outstanding as of June 30, 2021.
Ordinary shares that a person has the right to acquire within 60 days of June 30, 2021 are deemed outstanding for purposes of computing
the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership
of any other person, except with respect to the percentage ownership of all board members and executive officers as a group. Unless otherwise
indicated below, the address for each beneficial owner listed is Martello Court, Admiral Park, St. Peter Port, Guernsey,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of<BR>
 Ordinary<BR>
 Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage of <BR> Ordinary Shares <BR> Beneficially Owned</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><B>Name and address of beneficial owner</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><B>Beneficially <BR>
    Owned</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Before Offering</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>After Offering</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">5% or Greater Shareholders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Panetta Partners Limited</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">510,966,362</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">52.64</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Executive Officers and Directors:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Gabriele Cerrone<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">542,981,215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gary Jacob</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Willy Simon<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Kunwar Shailubhai<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">John Brancaccio</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">All directors and officers as a group (5 persons)<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">552,231,215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Indicates beneficial ownership of less than 1% of the total outstanding ordinary shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 510,966,362 ordinary shares owned by Panetta Partners Limited and 32,014,853 ordinary shares owned by Planwise Group Limited.&nbsp;&nbsp;Mr. Cerrone is the ultimate beneficial owner of the ordinary shares held by Planwise Group Limited and Panetta Partners Limited.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 1,000,000 stock options which are currently exercisable or exercisable within 60 days of June 30, 2021.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 8,250,000 stock options which are currently exercisable or exercisable within 60 days of June 30, 2021. Dr. Shailubhai resigned as a director on June 17, 2021.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><SUP>(4)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 9,250,000 ordinary shares currently exercisable or exercisable within 60 days of June 30, 2021.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_019"></A>DESCRIPTION
OF SHARE CAPITAL AND MEMORANDUM AND ARTICLES OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We were originally incorporated
in the British Virgin Islands as a British Virgin Islands Business Company on 4 July 2007 under the BVI Business Companies Act 2004 with
company number 1415559 under the name Jellon Enterprises, Inc. Our legal and commercial name was changed to Minor Metals &amp; Mining,
Inc. on October 24, 2007, to Emerging Metals Limited on November 28, 2007, to West African Minerals Corporation on December 9, 2011, and
to OKYO Pharma Corporation on January 10, 2018. On March 9, 2018, shareholders approved the cancellation of the Company&rsquo;s AIM listing
and migration to Guernsey. On July 3, 2018, following the approval of the Guernsey Companies Registry, the Company was registered under
the Guernsey Companies Law under the name OKYO Pharma Limited, as a Guernsey company with limited liability, an indefinite life and company
number 65220. The Company is domiciled in Guernsey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our registered office is
located at Martello Court, Admiral Park, St. Peter Port, Guernsey, GY1 3HB and our telephone number is +44 (0) 20 7495 2379. Our website
address is www.okyopharma.com. The reference to our website is an inactive textual reference only and the information contained in, or
that can be accessed through, our website is not a part of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Current authorized share capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Current issued share capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of July 2, 2021, our issued
share capital was 970,686,108 ordinary shares, no par value. Each issued ordinary share is fully paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of July 2, 2021, there
were vested options to purchase 13,875,000 ordinary shares outstanding with a weighted average exercise price of $0.062 per ordinary share.
The remaining options to purchase 47,750,000 ordinary shares vest between July 6, 2021 and March 15, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of July 2, 2021, there
were warrants to purchase 113,659,090 ordinary shares outstanding as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">No. outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Final Exercise Date</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 23%; text-align: right">35,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right">0.063</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&pound;</TD><TD STYLE="width: 22%; text-align: right">0.045</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right"><FONT STYLE="font-size: 10pt">7/17/2023</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.008</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&pound;</TD><TD STYLE="text-align: right">0.0055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3/24/2025</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">909,090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.039</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&pound;</TD><TD STYLE="text-align: right">0.0275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">05/21/2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&pound;</TD><TD STYLE="text-align: right">0.140</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17/7/2022</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&pound;</TD><TD STYLE="text-align: right">0.004</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5/7/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&pound;</TD><TD STYLE="text-align: right">0.004</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5/7/2024</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Warrants to purchase 78,659,090
ordinary shares are exercisable immediately until the final exercise date. Warrants to purchase the remaining 35,000,000 ordinary shares
are exercisable based on the achievement of milestones, with a final exercise date of July 17, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information about the Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with our Articles,
the following summarizes the rights of holders of our ordinary shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">each holder of our ordinary shares is entitled to one vote per ordinary share on all matters to be voted on by shareholders generally;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the holders of the ordinary shares shall be entitled to receive notice of, attend, speak and vote at our general meetings; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">holders of our ordinary shares are entitled to receive such dividends as are recommended by our directors and declared by our shareholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Articles </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated in Guernsey
as a non-cellular company limited by shares under company number 65220. We are governed by our Articles and the Guernsey Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Articles were adopted
by a special resolution of our shareholders at our annual general meeting held on September 25, 2020. The summary below is not a complete
copy of the terms of the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Articles contain no specific
restrictions on our purpose and therefore our purpose is unrestricted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Articles contain, among
other things, provisions to the following effect:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Share Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our share capital currently
consists of ordinary shares. Subject to the Guernsey Companies Law and to any rights attached to existing shares, we may issue shares
with such rights or restrictions as may be determined by the board. In addition, shares which are to be redeemed, or are liable to be
redeemed at our option or the holder of such shares may be issued with the board determining the terms and conditions of such redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All of our issued and outstanding
ordinary shares are fully paid. Holders of ordinary shares do not have conversion or redemption rights. There are no provisions in our
Articles discriminating against a shareholder as a result of such shareholder&rsquo;s ownership of a particular number of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preferred Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors may
provide for other classes of shares, including series of preferred shares. If any preferred shares are issued, the rights, preferences
and privileges of our ordinary shares will be subject to, and may be adversely affected by, the rights of holders of such preferred shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to any rights or
restrictions attached to any shares, on a show of hands every shareholder who is present in person or by proxy at a general meeting shall
have one vote. On a poll, every shareholder present in person or by proxy at a general meeting shall have one vote for every ordinary
share held by such shareholder. A proxy need not be a shareholder of ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A shareholder shall not be
entitled, in respect of any shares held by such shareholder, to vote (either personally or by proxy) at any general meeting of ours unless
all amounts payable by such shareholder in respect of that share in our capital have been paid or credited as having been paid, or where
such shareholder is in default of the provisions in the Articles requiring disclosure of ownership of shares and we have served a direction
notice on such shareholder advising such shareholder that such shares may not be voted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Variation of Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All or any of the rights,
privileges or conditions attached to any class of shares in issue may only be varied with the consent in writing of the holders of 75
per cent. in value of the issued shares of that class (excluding treasury shares) or with the sanction of a special resolution passed
at a separate general meeting of the holders of the shares of that class. A quorum for the separate class meeting is two persons (in person
or by proxy) holding one-third of the voting rights of the shares of that class or group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Alteration of capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may by ordinary resolution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(a) consolidate and divide
all or any of our share capital into shares of a larger amount than our existing shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b) sub-divide all or any
of our shares into shares of a smaller amount than is fixed by our Articles or by ordinary resolution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(c) cancel any shares which,
at the date of passing the resolution have not been taken up or agreed to be taken up;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(d) convert the whole, or
any particular class, of our shares into redeemable shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(e) redesignate the whole,
or any particular class, of our shares into shares of another class;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(f) covert all or any of
our shares into shares of a nominal amount of a different currency, at the exchange rate; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(g) where our shares were
expressed in a particular currency, denominate or redenominate it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dividends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(a) Subject to the Guernsey
Companies Law, our directors may authorize dividends and distributions to be paid to Shareholders. If any share is issued on terms providing
that it shall rank for dividend or distribution as from a particular date, such share shall rank for dividend or distribution accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b) Our directors may direct
that any dividend or distribution shall be satisfied wholly or partly by the distribution of assets, and in particular of paid up shares,
debentures, or other securities of any other company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(c) No dividend or distribution
payable shall bear interest against us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(d) A transfer of shares
shall not pass the right to any dividend or distribution declared thereon before the registration of the transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(e) All dividends or distribution
unclaimed for a period of one year from the date on which such dividend or distribution was declared may be invested or otherwise made
use of by our directors for the benefit of until claimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(f) All dividends or distribution
unclaimed for a period of six years from the date on which such dividend or distribution was declared shall, if our directors so resolve,
be forfeited and shall revert to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(g) Subject to the Guernsey
Companies Law or in the terms of issue of any share in our capital, for the purposes of making any distribution or paying any dividend,
our directors may determine that those persons who are entered on the register of members at the close of business on a day determined
by our directors shall be the persons who are entitled to receive such dividends or distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(h) Payments of dividends
or distributions may be made by electronic transfer in such manner as agreed between the member and us or by cheque or warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transfer of Ordinary Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A shareholder may transfer
all or any of their shares (i) in the case of certificated shares by transfer in writing in any usual or common form or in any other form
acceptable to our directors; and (ii) in the case of uncertificated shares, in the manner provided for in the rules and procedures of
the operator of the &ldquo;relevant system&rdquo; (i.e., the CREST System) and in accordance with and subject to the CREST Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The instrument of transfer
of a certified share shall be signed by or on behalf of the transferor and, if the share is not fully paid, by or on behalf of the transferee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors may,
in its absolute discretion and without assigning any reason, decline to register any transfer of certificated share or uncertified shares
unless it is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in respect of a share which is fully paid up;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in respect of a share in which we have no lien;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in respect of only one class of share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in favor of a single transferee or not more than four joint transferees; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in relation to a certificated share, delivered for registration to our registered office (or such other place as our board of directors may from time to time determine) accompanied by the relevant share certificate(s) and such other evidence as our board of directors may reasonably require, to show the right of the transferor to make the transfer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors shall
not refuse to register any transfer or renunciation of partly paid shares which are listed on the Main Market of the London Stock Exchange
on the grounds that they are partly paid shares in circumstances where that refusal would prevent dealings in any such shares from taking
place on an open and proper basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Disclosure of Ownership</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our directors may by notice
in writing require a shareholder to disclose to us the identity of any person other than such shareholder who has, or has had, at any
time during the three years immediately preceding the date on which the notice is issued, any interest (whether direct or indirect) in
the shares held by such shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a shareholder, or any
other person appearing to be interested in shares held by that shareholder, has been issued with such a notice and has failed in relation
to any shares, or the Default Interests, to give the Company the information thereby required within the prescribed period from the service
of the notice, our directors may in their discretion serve a direction notice on such shareholder which may direct that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(a) the shareholder shall
not be entitled in respect of the Default Interests to be present or to vote (either in person or by proxy) at any general meeting or
at any separate meeting of the holders of any class of shares or on any poll or to exercise any other right conferred by membership in
relation to any such meeting or poll; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b) where the Default Interests
represent at least 0.25 per cent. of the number of shares in issue of the class concerned:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) any dividend, distribution
or other money payable in respect of the shares shall be withheld by us, which shall not have any obligation to pay interest on it; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) no transfer of the Default
Interests held by us shall be registered unless: (i) the shareholder is not themself in default as regards supplying the information requested;
and (ii) the shareholder proves to the satisfaction of our directors that no person in default as regards supplying such information is
interested in any of the shares the subject of the transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><B><I>Requirement to disclose
interests</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each shareholder shall be
under an obligation to comply with the disclosure and notification requirements set out in Chapter 5 of the DTRs. If the Company determines
that a shareholder, or the Defaulting Member, has not complied with the provisions of Chapter 5 of the DTRs with respect to some or all
of such shares held by such Shareholder, or the Default Shares, we shall have the right by delivery of notice to the Defaulting Member,
or a Default Notice, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(a) suspend the right of such
Defaulting Member to vote on the Default Shares in person or by proxy at any meeting of ours; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b) (i) withhold, without
any obligation to pay interest thereon, any dividend or other amount payable with respect to the Default Shares, (ii) render ineffective
any election to receive our shares instead of cash in respect of any dividend or part thereof, and/or (iii) prohibit the transfer of any
of our shares held by the Defaulting Member except with the consent of ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pre-emptive Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Neither the laws of Guernsey
nor the Articles provide shareholders with pre-emptive rights when new shares are issued by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Board of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise determined
by the company by ordinary resolution, the number of directors (other than any alternate directors) shall not be less than one, but there
shall be no maximum number of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The business and affairs
of the Company shall be managed by, or under the direction or supervision of the our directors who may pay all expenses incurred in promoting
and registering the Company, and may exercise all such powers necessary for managing, and for directing and supervising the management
of, the our business and affairs as are not, by the Guernsey Companies Law or by the Articles, required to be exercised by us in a general
meeting, subject to the Articles, to the provisions of the Guernsey Companies Law and to such regulations as may be prescribed by us by
special resolution provided that such regulations are not inconsistent with the Articles or the provisions of the Guernsey Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the Articles,
our directors may meet together for the dispatch of business, adjourn and otherwise regulate their meetings as they think fit. The quorum
necessary for the transaction of the business is two unless otherwise resolved by our directors. A meeting of our directors at which a
quorum is present shall be competent to exercise all powers and discretions for the time being exercisable by our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A director who is in any
way, directly or indirectly, interested in a proposed transaction or arrangement with us, or in a transaction or arrangement that has
been entered into by us, must declare the nature and extent of such director&rsquo;s interest to our directors. The declaration must be
made at a meeting of our board of directors, or by written notice, or by general notice, in accordance with the Guernsey Companies Law
and the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our directors shall have
power at any time and from time to time to appoint any person to be a director, either to fill a casual vacancy or as an addition to our
existing directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the provisions
of the Guernsey Companies Law and provided the director has disclosed their interest to our other directors, such director notwithstanding
their office may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(a) be a party to, or otherwise
interested in, any transaction or arrangement with us, or in which we are otherwise interested;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b) act by themself or through
their firm in a professional capacity for us be entitled to remuneration as if they were not a director;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(c) be a director or officer
of, or employed by, or a party to any transaction or arrangement with, a shareholder of or otherwise directly or indirectly interested
in, any corporate entity promoted by us, or with which we have entered into any transaction with or are interested in; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(d) not by reason of his
office, be accountable to us for any benefit which such director derives from any such office or employment or from any such transaction
or arrangement or from any interest in any such body corporate and no such transaction or arrangement shall be liable to be avoided on
the ground of any such interest or benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A director shall be counted
in the quorum at any meeting in relation to any resolution in respect of which such director has declared an interest and may vote thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A person must not be appointed
as a director unless such person has consented in writing and submitted their declaration that they are not ineligible to act as a director
under the Guernsey Companies Law. A director need not be a shareholder but shall be entitled to receive notice of and attend all of our
general meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No person shall, unless recommended
by our directors, be eligible for election to the office of director at any general meeting unless not less than three nor more than 21
days before the date appointed for the meeting there shall have been left at our registered office a notice in writing signed by a shareholder,
their intention to propose such a person for election (this must be accompanied by that persons willingness to be elected and their signed
declaration).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our directors shall be paid
such remuneration (by way of fee) for their services as may be determined by our directors in their absolute discretion. Our directors
shall also be entitled to be repaid all travelling, hotel and other expenses of travelling to and from board meetings, committee meetings,
general meetings, or otherwise incurred while engaged on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the provisions
of the Guernsey Companies Law, every director shall have the power to purchase and maintain insurance for or for the benefit of any persons
who are or were at any time our directors, officers or employees (including any other company which is its holding company or in which
we have any direct or indirect interest in) against any liability incurred by such persons in respect of any act or omission in the actual
or purported execution and /or discharge of their duties or exercise or purported exercise of their powers in relation to or in connection
with their duties, powers or offices in relation to us or any other such company or subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any director may at any time
by writing appoint any person to be their alternate director and may in like manner at any time terminate such appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The office of director shall,
ipso facto, be vacated if such director:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(a) resigns his office by
writing under his hand and it is deposited at our registered office and we may agree to accept this at a later date than specified;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b) shall have absented himself
from meetings of the directors for six months in succession and all our other directors have resolved that such director should vacate
his or her office;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(c) becomes bankrupt, suspends
payment or compounds with such director&rsquo;s creditors, or is adjudged insolvent or has his affairs declared en d&eacute;sastre;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(d) dies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(e) becomes ineligible to
act as a director under the Guernsey Companies Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(f) is removed by resolution
of our directors in writing signed by all of our other directors (being not less than two in number); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(g) if we shall by ordinary
resolution declare that such person shall cease to be a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Indemnity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our directors (including
any alternate director), secretary and other officer or employee for the time being shall be indemnified out of the our assets to the
fullest extent permitted by the Guernsey Companies Law from and against all actions, costs, charges, losses, damages and expenses in respect
of which they may lawfully be indemnified which they or any of them shall or may incur or sustain by reason of any contract entered into
or any act done, concurred in, or omitted, in or about the execution of their duty or supposed duty or in relation thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Limitations on the Rights to Own Our Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not aware of any limitations
on the rights to own our securities, including rights of non-resident or foreign shareholders to hold or exercise voting rights on our
securities, imposed by foreign law or by our Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General Meetings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An annual general meeting
of ours shall be held in each calendar year (provided that no more than fifteen months may elapse between one annual general meeting and
the next) at such time and place as may be determined by our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our directors may convene
a general meeting whenever they think fit. General meetings shall also be convened by the directors within twenty one days of a requisition
by our shareholders as provided for by the Guernsey Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless special notice is
required in accordance with the Guernsey Companies Law, not less than fourteen days&rsquo; notice in respect of all general meeting shall
be given to all Shareholders (other than those who, under the provisions of the Articles or otherwise, are not entitled to receive notices
from the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Every notice shall specify
the place, the date and the time of the meeting and the general nature of the business of the meeting. Any general meeting may be held
in Guernsey, or elsewhere, as our directors may from time to time determine. There is no age limit at which a director is required to
retire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the purpose of determining
which persons are entitled to attend and vote at any general meeting and how many votes such persons may cast, the Company may specify
in the relevant notice of general meeting a time, not more than forty eight hours (excluding any days which are not business days) before
the time fixed for the meeting, by which a person must be entered on the register of members in order to have the right to attend and
vote at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No business shall be transacted
unless the requisite quorum is present when the meeting proceeds to business. Two shareholders present in person or by proxy and entitled
to vote shall be a quorum, save where we only have one shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If within half an hour from
the time appointed for the general meeting a quorum is not present, if convened on the requisition of the shareholders the meeting shall
be dissolved. In any other case the meeting shall be adjourned to the same day in the next week at the same time and place and no notice
of such adjournment need be given. At any such adjourned meeting, those shareholders present in person or by proxy shall be a quorum.
If no shareholders are present at the adjourned meeting, the meeting shall be dissolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Every question submitted
to a general meeting shall be determined in the first instance by a show of hands of the shareholders present in person or by proxy or
by attorney and entitled to vote, but a poll may be demanded by no fewer than five shareholders having the right to vote on the resolution,
or one or more of the shareholders present in person or by proxy representing at least ten per cent. of the total voting rights of all
of the shareholders having the right to vote on the resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Corporate representatives</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any corporation which is
a shareholder may by resolution of its directors or other governing body authorize such person as it thinks fit to act as its representative
at any meeting of ours or of any class of shareholders, and the person so authorized shall be entitled to exercise the same powers on
behalf of the corporation which he represents as that corporation could exercise if it were an individual shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Borrowing Powers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the Articles and
the Guernsey Companies Law, our board of directors may exercise all of the powers of the company to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">borrow money;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">indemnify and guarantee;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">mortgage or charge;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">create and issue debentures and other securities; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">give security either outright or as collateral security for any debt, liability or obligation of the company or of any third party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Uncertificated Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the Guernsey Companies
Law, our board of directors may permit title to shares of any class to be issued or held otherwise than by a certificate and to be transferred
by means of a &ldquo;relevant system&rdquo; (i.e., the CREST System) without a certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors may
take such steps as it sees fit in relation to the evidencing of and transfer of title to uncertificated shares, any records relating to
the holding of uncertificated shares and the conversion of uncertificated shares to certificated shares, or vice-versa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors may
by notice to the holder of an uncertificated share, require that share to be converted into certificated form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors may
take such other action that the board considers appropriate to achieve the sale, transfer, disposal, forfeiture, re-allotment or surrender
of an uncertified share or otherwise to enforce a lien in respect of it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Winding up</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to any preferred,
deferred or other special rights, or subject to such conditions or restrictions to which any shares in our capital may be issued, on a
winding-up or other return of capital, the holders of our ordinary shares are entitled to share in any surplus assets pro rata to their
holdings of such ordinary shares. A liquidator may, with the sanction of a special resolution of ours and any other sanction required
by the Guernsey Companies Law, divide amongst our shareholders in specie or in kind the whole or any part of our assets (whether or not
the assets shall consist of property of one kind or shall consist of property of different kinds), those assets to be set at such value
as such liquidator deems fair. A liquidator may also vest the whole or any part of our assets in trustees on trusts for the benefit of
the shareholders as the liquidator shall think fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Where the Company is proposed
to be or is in the course of being wound up and the whole or part of its business or property is proposed to be transferred or sold to
another company the liquidator may, with the sanction of an ordinary resolution, receive in compensation for the transfer or sale, shares,
policies or other like interests in such other company for distribution among our shareholders or may enter into any other arrangement
whereby our shareholders may, in lieu of receiving cash, shares, policies or other like interests, or in addition thereto, participate
in the profits of or receive any other benefits from such company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Issue of shares and share rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our directors may exercise
the power of the company for an unlimited duration to issue an unlimited number of shares or grant rights to subscribe for, or to convert
any security into shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may issue shares which:
(i) are redeemable shares; (ii) confer preferential rights to distribution of capital or income; (iii) do not entitle the holder to voting
rights; and (iv) entitle the holder to restricted voting rights. Our directors may issue shares which have a nominal or par value, no
par value, in any number they see fit and in fractions of a share. Subject to &ldquo;Variation of Rights&rdquo; above, we may convert
all or any classes of our shares into redeemable shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our directors may make arrangements
on the issue of shares to distinguish between shareholders as to the amounts and the times of payments of calls on their shares and issue
shares that provide for the payment of dividends and distributions in differing proportions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acquisition of own shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the provisions
of the Guernsey Companies Law and the rights of holders of any class of shares, we may purchase our own shares, including redeemable shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liens, Calls on Shares and Forfeiture</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In respect of any shares
we issue that are not fully paid, we will have a first and paramount lien on every share (not being a fully paid share) for all moneys
payable at a fixed time or called in respect of such share. Our board of directors may make calls upon shareholders for any amounts unpaid
in respect of their shares, subject to the terms of allotment (whether in respect of nominal value or premium).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a call remains unpaid
after it has become due and payable, then, following notice by our board of directors requiring payment of the unpaid amount together
with any accrued interest and expenses incurred, such share may be forfeited by a resolution of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A shareholder whose shares
have been forfeited will cease to be a shareholder in respect of such share, but will, notwithstanding the forfeiture, remain liable to
us for all moneys which at the date of forfeiture were presently payable together with interest. A forfeited share may be sold, re-allotted
or otherwise disposed of as our board of directors sees fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Provisions that Would Delay, Defer or Prevent
a Change of Control</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no provisions in
our Articles that would have the effect of delaying, deferring or preventing a change in control of us and that would operate only with
respect to a merger, acquisition or corporate restructuring involving us or any of our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Relevant Laws and Regulations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Mandatory Bid</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The U.K. City Code on Takeovers
and Mergers, or Takeover Code, applies to the company. Under the Takeover Code, where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any person, together with persons acting in concert with him, acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares in which he is already interested, and in which persons acting in concert with him are interested) carry 30% or more of the voting rights of a company; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any person who, together with persons acting in concert with him, is interested in shares which in the aggregate carry not less than 30% of the voting rights of a company but does not hold shares carrying more than 50% of such voting rights and such person, or any person acting in concert with him, acquires an interest in any other shares which increases the percentage of shares carrying voting rights in which he is interested, such person shall, except in limited circumstances, be obliged to extend offers, on the basis set out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity share capital, whether voting or non-voting, and also to the holders of any other class of transferable securities carrying voting rights. Offers for different classes of equity share capital must be comparable; the U.K. Panel on Takeovers and Mergers, or Takeover Panel, should be consulted in advance in such cases.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An offer under Rule 9 of
the Takeover Code must be in cash and at the highest price paid for any interest in the shares by the person required to make an offer
or any person acting in concert with him during the 12 months prior to the announcement of the offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Takeover Code,
a &ldquo;concert party&rdquo; arises where persons acting together pursuant to an agreement or understanding (whether formal or informal
and whether or not in writing) cooperate, through the acquisition by them of an interest in shares in a company, to obtain or consolidate
control of the company. &ldquo;Control&rdquo; means holding, or aggregate holdings, of an interest in shares carrying 30% or more of the
voting rights of the company, irrespective of whether the holding or holdings give <I>de facto</I> control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholder Notification and Disclosure Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Shareholders are obliged
to comply with the shareholding notification and disclosure requirements set out in Chapter 5 of the DTRs. As the company is classified
as a &ldquo;non-UK issuer&rdquo; for the purposes of the DTRs, a shareholder is required pursuant to Rule 5 of the DTRs to notify the
company if, as a result of an acquisition or disposal of shares or financial instruments, the shareholder&rsquo;s percentage of voting
rights of the company reaches, exceeds or falls below 5%, 10%, 15%, 20%, 25%, 30%, 50% and 75%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The DTRs can be accessed
and downloaded from the FCA&rsquo;s website at <U>https://www.handbook.fca.org.uk/handbook/DTR/</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Shareholders are urged to
consider their notification and disclosure obligations carefully as a failure to make a required disclosure to the company may result
in disenfranchisement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.K. City Code on Takeovers and Mergers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a Guernsey public company
whose shares are traded on a multi-lateral trading facility in the United Kingdom, we are subject to the Takeover Code, which is issued
and administered by the Takeover Panel. The Takeover Code provides a framework within which takeovers are regulated and conducted. Under
the Takeover Code, where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any person, together with persons acting in concert with him, acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares in which he is already interested, and in which persons acting in concert with him are interested) carry 30% or more of the voting rights of a company; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any person who, together with persons acting in concert with him, is interested in shares which in the aggregate carry not less than 30% of the voting rights of a company but does not hold shares carrying more than 50% of such voting rights and such person, or any person acting in concert with him, acquires an interest in any other shares which increases the percentage of shares carrying voting rights in which he is interested;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">such person shall, except in limited circumstances,
be obliged to extend offers, on the basis set out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity
share capital, whether voting or non-voting, and also to the holders of any other class of transferable securities carrying voting rights.
Offers for different classes of equity share capital must be comparable; the Takeover Panel should be consulted in advance in such cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An offer under Rule 9 of
the Takeover Code must be in cash and at the highest price paid for any interest in the shares by the person required to make an offer
or any person acting in concert with him during the 12 months prior to the announcement of the offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Takeover Code,
a &ldquo;concert party&rdquo; arises where persons acting together pursuant to an agreement or understanding (whether formal or informal
and whether or not in writing) cooperate, through the acquisition by them of an interest in shares in a company, to obtain or consolidate
control of the company. &ldquo;Control&rdquo; means holding, or aggregate holdings, of an interest in shares carrying 30% or more of the
voting rights of the company, irrespective of whether the holding or holdings give de facto control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Shareholder rights under Guernsey Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a summary
of the rights of shareholders under the Guernsey Companies Law and other applicable laws in Guernsey. Prospective shareholders are advised
that this is not a complete statement of the rights of Shareholders under applicable law in Guernsey or under the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(a) Company alterations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Guernsey Companies
Law, it is possible for a Guernsey company to merge with another Guernsey company or an overseas company with the approval by a special
resolution of members, provided that there is a short form amalgamation process for amalgamations between a company and its wholly- owned
subsidiary or between two or more wholly- owned subsidiaries of the same company which does not require a special resolution of the members
of each company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Guernsey Companies
Law, a compromise or arrangement is permitted between the company and its creditors or shareholders, or any class thereof, whether for
the purpose of facilitating the company&rsquo;s reconstruction or its merger with another company, or otherwise. An application must be
made to court which court will then order a meeting of the company&rsquo;s creditors or shareholders. It is necessary for 75 per cent.
in value of the creditors or 75 per cent. of the voting rights of the shareholders, or class thereof, as the case may be, to agree to
the compromise or arrangement and if such compromise or arrangement is sanctioned by the court, it will be binding on the creditors or
shareholders, or class thereof, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Guernsey Companies Law
also requires the approval of the shareholders by special resolution for the removal of a company from the Guernsey Register of Companies
for the purpose of becoming registered as a company under the law of a district, territory or place outside Guernsey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Guernsey Companies
Law, amendments to a company&rsquo;s articles of incorporation so permitted may be authorized by way of a special resolution of the company&rsquo;s
shareholders (provided that certain provisions within a company&rsquo;s articles of incorporation can be embedded with a higher voting
threshold required for change).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(b) Rights of dissent and appraisal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Guernsey Companies Law
contains rights of dissent (the granting of which is discretionary on the part of the court), which are applicable where the company resolves
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i) amalgamate with another
corporation (other than vertical or horizontal short form amalgamations);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii) transfer of its registration
into another jurisdiction; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii) carry out a takeover
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(c) Shareholder derivative actions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The laws of Guernsey permit
derivative actions to be brought by a shareholder, or such person as the court directs who, in the discretion of the court, is a proper
person to make an application to court to bring a derivative action. Under the laws of Guernsey, the complainant must obtain permission
of the court to commence a derivative action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(d) Sale of undertaking</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Companies Law does not
contain provisions in relation to shareholder authority for the sale of a company&rsquo;s undertaking and, accordingly, the sale, lease
or exchange of all or substantially all the property of the company will be governed by the articles of incorporation of a company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(e) Unfair prejudice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A member of a company may
apply to the court on the ground that the affairs of the company are conducted in a manner that is unfairly prejudicial to the interests
of members generally or of some part of its members (including at least himself), or an actual or proposed act or omission of the company
is or would be so prejudicial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the court is satisfied
that an application is well founded it may make such orders as it sees fit, which may include without limitation: (a) requiring the company
to refrain from doing or continuing to do an act, or require it to do any act which the applicant has complained it has omitted to do;
or (b) providing for the purchase of shares of any member of the company by other members of the company or by the company itself (and
the reduction of the company&rsquo;s capital accordingly).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Differences in Corporate Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a non-cellular company
limited by shares incorporated in Guernsey, we are governed by the Guernsey Companies Law. The applicable provisions of the Guernsey Companies
Law differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between
the provisions of the Guernsey Companies Law applicable to us and the Delaware General Corporation Law relating to shareholders&rsquo;
rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety
by reference to the laws of Guernsey and Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Guernsey </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%"><FONT STYLE="font-size: 10pt"><B>Shareholder Meetings</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 37%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless a company&rsquo;s memorandum or articles
    of incorporation state otherwise, the directors are required to call a general meeting once the company receives requests to do so from
    shareholders who hold more than 10% of the capital of the company that carries the right of voting at general meetings (excluding any
    capital held as treasury shares).</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 3%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#9679;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#9679;</P></TD>
    <TD STYLE="width: 37%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shareholders generally do not have the right to
    call meetings of shareholders unless that right is granted in the certificate of incorporation or bylaws.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">May be held at such time or place as designated
    in the certificate of incorporation or the bylaws, or if not so designated, as determined by the board of directors</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Unless the shareholders pass a resolution exempting the company from holding an annual general meeting, a company must hold a general meeting of its members within a period of 18 months beginning on the date on which it was incorporated and thereafter at least once every calendar year (with no more than 15 months elapsing between one annual general meeting and the next).</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#9679;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#9679;</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">May be held inside or outside Delaware</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notice:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Subject to the articles of incorporation, a meeting may be held at any place in Guernsey or elsewhere.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; Whenever shareholders are required to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, if any, date and hour of the meeting, and the means of remote communication, if any.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Notice:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; A meeting must be called by at least 10 days&rsquo; notice or such longer period as provided by the articles of incorporation. </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; A meeting may be called by shorter notice if all shareholders entitled to attend and vote so agree.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; The notice shall specify the date, time and place of the meeting, the information of any resolutions to be passed at the meeting and such other information as is required by the articles of incorporation.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Shareholders&rsquo; Voting Rights</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Unless the memorandum or articles of incorporation provide otherwise, directors are appointed by ordinary resolution of the shareholders.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">With limited exceptions, and unless the certificate of incorporation provides otherwise, shareholders may act by written consent to elect directors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any shareholder may appoint another person or persons to be their proxy to exercise all or any of their rights to attend, speak and vote at a meeting.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each stockholder entitled to vote may authorize another person or persons to act for such shareholder by proxy.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Subject to the articles of incorporation, the quorum shall be two shareholders holding 5% of the total voting rights of the company between them.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The certificate of incorporation or bylaws may specify the number to constitute a quorum, but in no event shall a quorum consist of less than one-third of shares entitled to vote at a meeting. In the absence of such specifications, a majority of shares entitled to vote, present in person or represented by proxy, shall constitute a quorum.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Subject to certain limited exceptions, a provision of the articles of incorporation is void to the extent that it would have the effect of excluding or making ineffective a demand for a poll at general meeting.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The certificate of incorporation may provide for cumulative voting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-bottom: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-bottom: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; width: 18%"><FONT STYLE="font-size: 10pt"><B>Directors</B></FONT></TD>
    <TD STYLE="padding-bottom: 0; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">Subject to the articles of incorporation, the board of directors must consist of at least one director and is not subject to a maximum number of directors.</FONT></TD>
    <TD STYLE="padding-bottom: 0; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">The board of directors must consist of at least one director and is not subject to a maximum number of directors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Subject to the articles of incorporation, the board of directors may determine the remuneration or other benefits given to a director.</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The number of directors shall be fixed by the bylaws, unless the certificate of incorporation fixes such number, in which case a change in the number shall be made only by amendment of the certificate of incorporation.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">A person will cease to be a director if such person:</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">A classified board is permitted.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; provides written notice of his or her resignation to the company; </FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; is removed in accordance with the memorandum and articles of incorporation; </FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Removal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; becomes ineligible to be a director under the laws of Guernsey; </FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; dies; or </FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ndash; Any or all of the directors may be removed, with or without cause, by the holders of a majority of the shares entitled to vote unless the certificate of incorporation provides otherwise. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; otherwise vacates office in accordance with the memorandum and articles of incorporation.</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ndash; In the case of a classified board, shareholders may affect removal only for cause.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Interested Shareholders&rsquo; Transactions</B></FONT></TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Guernsey Companies Law does not contain any specific prohibition on interested shareholder transactions.</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Delaware General Corporation Law contains a business combination statute applicable to corporations whereby, unless the corporation has specifically elected not to be governed by such statute, it is prohibited from engaging in certain business combinations with an &ldquo;interested shareholder&rdquo; for three years following the date that such shareholder becomes an interested shareholder. An interested shareholder generally is a person or a group that owns at least 15% of the corporation&rsquo;s outstanding voting stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Interested Director Transactions</B></FONT></TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">A director must, immediately after becoming aware of the fact that such director is interested in a transaction or proposed transaction with the company, disclose to the board the nature and extent of such director&rsquo;s interest.</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Interested director transactions are permissible and may not be legally voided if:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Subject to the memorandum and articles of incorporation, a director who is interested in a transaction may vote, attend board meetings, sign documents and do any other thing in such director&rsquo;s capacity as a director in relation to a transaction in which such director is interested as if such director was not interested in the transaction provided that such director has made the necessary declarations.</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; the material facts of the director&rsquo;s interest are disclosed and a majority of the disinterested directors approve the transaction; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">A transaction in which a director is interested is voidable by the company at any time within 3 months of the date after which the transaction is disclosed to the board unless:</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; the material facts of the director&rsquo;s interest are disclosed and a majority of the shareholders entitled to vote approve the transaction; or </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; the director&rsquo;s interest was disclosed at the time the transaction was entered into or a disclosure was not required (for example, if the transaction is entered into in the ordinary course of business and on usual terms and conditions);</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; the transaction is determined to have been fair to the corporation at the time it is authorized, approved or ratified by the board of directors, a committee thereof or the shareholders.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; the transaction is ratified by the shareholders; or</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; the company received fair value for the transaction.</FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%"><FONT STYLE="font-size: 10pt"><B>Dividends</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">A company may pay a dividend if the board of directors is satisfied on reasonable grounds that the company will, immediately after payment of the dividend, satisfy the statutory solvency test contained in the Guernsey Companies Law as well as any other requirement of the memorandum or articles of incorporation.</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">The board of directors may declare and pay dividends, subject to any restrictions contained in the certificate of incorporation, upon the shares of the corporation&rsquo;s capital stock either: out of its surplus or, in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared or the preceding fiscal year.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A dividend may be of such amount, be paid at such time and be paid to such members as the board of directors thinks fit; <I>provided </I>that the directors must not authorize a dividend in respect of some but not all of the shares in a class or that is of a greater value per share in respect of some shares of a class than in respect of other shares of that class.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Subject to the articles of incorporation, there is no requirement for dividends to be paid out of a particular account or source.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt; width: 18%"><FONT STYLE="font-size: 10pt"><B>Variation of Rights of Class of Shares</B></FONT></TD>
    <TD STYLE="padding-bottom: 0pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">A company may only vary the rights of a class of shareholders in accordance with the provisions of the articles of incorporation or, in the absence of such provisions, with the consent in writing from the holders of at least 75% in value of the issued shares of that class or by means of a special resolution passed by at least 75% in value of the issued shares of that class at a separate meeting of shareholders of that class.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">A corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Mergers and Similar Arrangements</B></FONT></TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the articles of incorporation,
a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a company may be negotiated and approved
by the board of directors. Depending on the structure of such a transaction, a separate shareholder approval may be required.</P></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left">&#9679;</TD>
    <TD STYLE="padding-bottom: 0pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Delaware General Corporation Law, with
    certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a corporation must be
    approved by the board of directors and a majority of the outstanding shares entitled to vote thereon.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; text-align: justify">If, within a period of four months after the date
    of an offer being made in respect of a transfer of shares, the offer is approved or accepted by the shareholders comprising not less than
    90% in value of the shares affected, the offeree may, within two months immediately after the last day on which the offer can be approved
    or accepted, give notice to any dissenting shareholders of its desire to acquire the remaining shares. On the expiration of one month
    from the date of the notice to acquire, the offeror will be entitled to acquire the shares of the dissenting shareholder(s) by sending
    them a copy of the notice to acquire and by paying or transferring to them the consideration that such shareholder(s) are entitled to
    in respect of those shares, at which point the offeror shall be registered as the holder of those shares.</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left">&#9679;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">The Delaware General Corporation Law also provides
    that a parent corporation may, by resolution of its board of directors, merge with any subsidiary of which it owns at least 90% of each
    class of capital stock without a vote by the shareholders of such subsidiary.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Appraisal Rights</B></FONT></TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Guernsey Companies Law does not specifically provide for any appraisal rights of shareholders. The Guernsey Companies Law does, however, give the courts of Guernsey broad authority in respect of orders made pursuant to successful unfair prejudice claims under the Guernsey Companies Law.</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">A shareholder of a corporation participating in certain major transactions may, under certain circumstances, be entitled to appraisal rights under which the shareholder may receive cash in the amount of the fair value of the shares held by such shareholder in lieu of the transaction consideration.</FONT></TD></TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%"><FONT STYLE="font-size: 10pt"><B>Shareholder Suits</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">A shareholder may commence or continue a claim as a representative of those with the same interests in the claim. Unless the court directs otherwise, any judgment in which a party is acting as a representative will be binding on all persons represented.</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">Class actions and derivative actions generally are available to shareholders for, among other things, breach of fiduciary duty, corporate waste, and actions not taken in accordance with applicable law. In such actions, the court has discretion to permit the winning party to recover attorneys&rsquo; fees incurred in connection with such action.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Derivative actions are also available to shareholders in respect of a cause of action arising from an actual or proposed act or omission involving: negligence, default, breach of duty and/or breach of trust by a director of the company.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Costs are awarded by the court at its discretion. The normal order is for the winning party to recover its costs incurred in connection the action.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Limitations on Directors&rsquo; Liability and Indemnification of Directors and Officers</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A company may include in its articles of incorporation provisions limiting the liability of its directors (and officers or other persons); however, any provision that purports to exempt a director from any liability in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A corporation may include in its certificate of incorporation provisions limiting the personal liability of its directors to the corporation or its shareholders for monetary damages for certain breaches of fiduciary duty. However, such provisions may not limit liability for any breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, the authorization of unlawful dividends, stock purchases, or redemptions, or any transaction from which a director derived an improper personal benefit.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any provision by which a company directly or indirectly provides an indemnity for a director of the company, or any associated company, against any liability in connection with any negligence, default, breach of duty or breach of trust is void, except that:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A corporation may indemnify a director or officer of the corporation against expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred in defense of any action, suit or proceeding by reason of such person&rsquo;s position if (i) the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and (ii) with respect to any criminal action or proceeding, the person had no reasonable cause to believe the conduct was unlawful.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; a company is not prevented from purchasing and maintaining for a director of the company, or any associated company, insurance against any such liability; and </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; such restriction does not apply to a qualifying third-party indemnity provision, which is a provision for indemnity against liability incurred by a director to a person other than the company or an associated company that does not provide any indemnity against a prescribed list of liabilities, including certain fines and penalties and liabilities incurred in defending certain proceedings.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="padding-bottom: 0pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%"><FONT STYLE="font-size: 10pt"><B>Directors&rsquo; Fiduciary Duties</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: center"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">The duties of directors in Guernsey are generally owed to the company and its shareholders as a whole rather than to any other person or particular shareholders (subject to certain exceptions) and arise from customary laws, statutory laws and contractual obligations.</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: center"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">Directors of a Delaware corporation have a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of care and the duty of loyalty.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Customary law duties of directors include:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself or herself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; a duty to act in good faith, in the best interests of the company, and not for any collateral purpose; </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; The duty of loyalty requires that a director act in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; a duty to exercise powers for a proper purpose. Even if a director is acting in good faith and in the best interests of the company, such director must nevertheless use his or her powers for the proper purpose for which they were conferred; </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; a duty to avoid and mitigate conflicts of interest; and </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; a duty to account for profits. As a fiduciary, a director may not take a personal profit from opportunities arising from such director&rsquo;s office, even if the director is acting honestly and in the best interests of the company. Any such profit must be paid to the company. A director&rsquo;s entitlement to remuneration and payment of expenses will be governed by the company&rsquo;s articles of incorporation.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, such director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Statutory duties of directors include:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; a general duty to manage the business and affairs of the company; and </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&mdash; the directors are responsible for considering a solvency test in various circumstances, including in authorizing distributions by the company to its shareholders.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%"><FONT STYLE="font-size: 10pt"><B>Inspection of Books and Records</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">The register and index of members, register of directors, register of secretaries and copies of all resolutions of shareholders passed other than at general meetings and minutes of the proceedings of general meetings, in each case, in the last six years, must be open for the inspection by any shareholder of the company without charge during ordinary business hours. They must also be open to inspection by any other person upon payment of such fee as may be prescribed by the Guernsey Committee for Economic Development or such lesser fee as the company may request.</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">All shareholders have the right, upon written demand, to inspect or obtain copies of the corporation&rsquo;s shares ledger and its other books and records for any purpose reasonably related to such person&rsquo;s interest as a shareholder.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">When a company receives a request to inspect its records, the company must comply with that request or apply to the Guernsey courts for a direction not to comply.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%"><FONT STYLE="font-size: 10pt"><B>Amendments of Governing Documents</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">Subject to certain exceptions, such as the alteration of the statement of the company&rsquo;s name, a company may only make or alter a provision of its memorandum of incorporation in accordance with the terms of the memorandum of incorporation or by unanimous resolution of all of its shareholders.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%; text-align: justify"><FONT STYLE="font-size: 10pt">Amendments to the certificate of incorporation require the affirmative vote of the holders of a majority of the outstanding shares entitled to vote thereon, unless the certificate of incorporation provides otherwise. Bylaws may be amended with the approval of a majority of the outstanding shares entitled to vote and may, if provided in the certificate of incorporation, also be amended by the board of directors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A company may alter its articles of incorporation by means of a special resolution passed by at least 75% of the shareholders.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Dissolution and Winding Up</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A company may be dissolved by means of a compulsory or voluntary winding up or a compulsory or voluntary striking off.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Unless the board of directors approves the proposal to dissolve, dissolution must be approved by all of the shareholders. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&rsquo;s outstanding shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An application for voluntary winding up requires a special resolution of the members passed by a majority of at least 75%.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An application for the voluntary striking off of a company must be made by the board of directors and be accompanied by a declaration of compliance confirming that all requirements of Guernsey law with respect to the striking off have been complied with.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Guernsey Law Considerations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registered Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are required by the Guernsey
Companies Law to keep a register of our shareholders. Under the laws of Guernsey, the ordinary shares are deemed to be issued when the
name of the shareholder is entered in our share register. The share register therefore is prima facie evidence of the identity of our
shareholders, and the shares that they hold. The share register generally provides limited, or no, information regarding the ultimate
beneficial owners of our ordinary shares. Our share register is maintained by our registrar, Link Asset Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Potential future holders
of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our share register. The depositary,
the custodian or their nominees will be the holder of the shares underlying our ADSs. Potential future holders of our ADSs have a right
to receive the ordinary shares underlying their ADSs. For discussion on our ADSs and ADS holder rights, see &ldquo;Description of the
American Depositary Shares&rdquo; in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will perform all procedures
necessary to update the share register to reflect any ordinary shares being sold in any potential offering, including updating the share
register with the number of ordinary shares to be issued to the depositary upon the closing of any such offering in the future. We also
are required by the Guernsey Companies Law to register a transfer of shares (or give the transferee notice of and reasons for refusal
as the transferee may reasonably request) as soon as practicable and in any event within two months of receiving notice of the transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We, any of our shareholders,
or any other affected person may apply to the court for rectification of the share register if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the name of any person, without sufficient cause, is entered in or omitted from our register of members; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">default is made or unnecessary delay takes place in entering on the register the fact of any person having ceased to be a member or on which we have a lien, provided that such delay does not prevent dealings in the shares taking place on an open and proper basis.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A Shareholder may transfer
all or any of his shares (i) in the case of certificated shares by transfer in writing in any usual or common form or in any other form
acceptable to the Directors; and (ii) in the case of uncertificated shares, in the manner provided for in the rules and procedures of
the operator of the relevant system and in accordance with and subject to the CREST Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The instrument of transfer
of a certified share shall be signed by or on behalf of the transferor and, if the share is not fully paid, by or on behalf of the transferee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board may, in its absolute
discretion and without assigning any reason, decline to register any transfer of certificated share or uncertified shares unless it is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in respect of a share which is fully paid up;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in respect of a share in which the Company has no lien;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in respect of only one class of share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in favour of a single transferee or not more than four joint transferees; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in relation to a certificated share, delivered for registration to the registered office of the Company (or such other place as the Board may from time to time determine) accompanied by the relevant share certificate(s) and such other evidence as the Board may reasonably require to prove the right of the transferor to make the transfer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board shall not refuse
to register any transfer or renunciation of partly paid shares which are listed on the Main Market of the London Stock Exchange on the
grounds that they are partly paid shares in circumstances where that refusal would prevent dealings in any such shares from taking place
on an open and proper basis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 106 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Distributions and Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(a) Subject to the Guernsey
Companies Law, our directors may authorize dividends and distributions to be paid to shareholders. If any share is issued on terms providing
that it shall rank for dividend or distribution as from a particular date, such share shall rank for dividend or distribution accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b) Our directors may direct
that any dividend or distribution shall be satisfied wholly or partly by the distribution of assets, and in particular of paid-up shares,
debentures, or other securities of any other company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(c) No dividend or distribution
payable shall bear interest against us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(d) A transfer of shares
shall not pass the right to any dividend or distribution declared thereon before the registration of the transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(e) Unless otherwise directed,
any dividend or distribution may be paid by way of electronic transfer in such manner as agreed between the shareholder and us or by cheque
or warrant sent through the post to the registered address of such shareholder entitled thereto, or in the case of joint holders to that
one whose name stands first on our register of members in respect of the joint holding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(f) All dividends or distribution
unclaimed for a period of one year from the date on which such dividend or distribution was declared may be invested or otherwise made
use of by our directors for our benefit until claimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(g) All dividends or distribution
unclaimed for a period of six years from the date on which such dividend or distribution was declared shall, if our directors so resolve,
be forfeited and shall revert to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(h) Subject to the Guernsey
Companies Law or in the terms of issue of any share in our capital, for the purposes of making any distribution or paying any dividend,
our directors may determine that those persons who are entered on the register of members at the close of business on a day determined
by our directors shall be the persons who are entitled to receive such dividends or distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitation on Owning Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Articles do not restrict
in any way the ownership or voting of our shares by non-residents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purchase of Own Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Articles, a summary of
which is provided above, do not prohibit us from purchasing our own shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Articles do not have
conditions governing changes to our capital which are more stringent that those required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Shareholder Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain rights granted under
the Guernsey Companies Law, including the right to requisition a general meeting or require a resolution to be put to shareholders at
the annual general meeting, are only available to our members. For Guernsey law purposes, our members are the persons who are registered
as the owners of the legal title to the shares and whose names are recorded in our register of members. In the case of shares held in
a settlement system operated by the Depository Trust Company, or DTC, the registered member will be DTC&rsquo;s nominee, Cede &amp; Co.
If a person who holds their ADSs in DTC wishes to exercise certain of the rights granted under the Guernsey Companies Law, they may be
required to first take steps to withdraw their ADSs from the settlement system operated by DTC and become the registered holder of the
shares in our register of members. A withdrawal of shares from DTC may have tax implications, for additional information on the potential
tax implications of withdrawing your shares from the settlement system operated by DTC, see &ldquo;Material Tax Considerations&mdash;Guernsey
Taxation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exchange Controls and Other Limitations Affecting
Security Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">Under Guernsey law, there are
currently no restrictions on the export or import of capital, including foreign exchange controls or restrictions that affect the remittance
of dividends, interest or other payments to nonresidents holders of our ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<!-- Field: Page; Sequence: 107 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enforcement of Civil Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">U.S. laws do not necessarily
extend either to us or our officers or directors. We are incorporated under the laws of Guernsey. Some of our directors and officers reside
outside of the United States. Substantially all of the assets of both us and our directors and officers are located outside the United
States. As a result, it may not be possible for investors to effect service of process on either us or our officers and directors within
the United States, or to enforce against these persons or us, either inside or outside the United States, a judgment obtained in a U.S.
court predicated upon the civil liability provisions of the federal securities or other laws of the United States or any State in the
United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have appointed OKYO Pharma
US, Inc., as our agent to receive service of process with respect to any action brought against us in the United States under the federal
securities laws of the United States or of the laws of any state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A judgment of a U.S. court
is not directly enforceable in Guernsey, but constitutes a cause of action which may be enforced by Guernsey courts provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the applicable U.S. courts had jurisdiction over the case, as
recognized under Guernsey law;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the judgment is given on the merits and is final, conclusive
and non-appealable;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the judgment relates to the payment of a sum of money, not being
taxes, fines or similar governmental penalties;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the defendant is not immune under the principles of public international
law;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the same matters at issue in the case were not previously the
subject of a judgment or disposition in a separate court;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the judgment was not obtained by fraud; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the recognition and enforcement of the judgment is not contrary
to public policy in Guernsey.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Guernsey courts award compensation
for the loss or damage actually sustained by the plaintiff. Although punitive damages are generally unknown to the Guernsey legal system,
there is no prohibition on them either by statute or customary law. Whether a particular judgment may be deemed contrary to Guernsey public
policy depends on the facts of each case, though judgments found to be exorbitant, unconscionable, or excessive will generally be deemed
as contrary to public policy. Moreover, certain defendants may qualify for protection under Protection of Trading Interests Act 1980,
an act of the UK extended to Guernsey by the Protection of Trading Interests Act 1980 (Guernsey) Order, 1983. This Act provides that a
qualifying defendant is not liable for multiple damages, in excess of that required for actual compensation. A &ldquo;qualifying defendant&rdquo;
for these purposes is a citizen of the UK and its Colonies (as defined in the Act), a corporation or other limited liability entity organized
under the laws of the UK, Guernsey or other territory for whose international relations the UK is responsible or a person conducting business
in Guernsey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Guernsey courts cannot enter
into the merits of the foreign judgment and cannot act as a court of appeal or review over the foreign courts. It is doubtful that an
original action based on U.S. federal or state securities laws could be brought before Guernsey courts. In addition, a plaintiff who is
not resident in Guernsey may be required to provide a security bond in advance to cover the potential of the expected costs of any case
initiated in Guernsey. In addition, Clarivate has been further advised by our legal counsel in Guernsey that it is uncertain as to whether
the courts of Guernsey would entertain original actions or enforce judgments from U.S. courts against us or our officers and directors
which originated from actions alleging civil liability under U.S. federal or state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 108 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>DESCRIPTION
OF THE AMERICAN DEPOSITARY SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">[&nbsp;&nbsp;],
as depositary will issue the ADSs which you will be entitled to receive in this offering. Each ADS will represent an ownership interest
a designated number of ordinary shares which we will deposit with the custodian, as agent of the depositary, under the deposit agreement
among ourselves, the depositary and yourself as an ADR holder. In the future, each ADS will also represent any securities, cash or other
property deposited with the depositary but which they have not distributed directly to you. Unless certificated ADRs are specifically
requested by you, all ADSs will be issued on the books of our depositary in book-entry form and periodic statements will be mailed to
you which reflect your ownership interest in such ADSs. In our description, references to American depositary receipts, or ADRs, shall
include the statements you will receive which reflect your ownership of ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
depositary&rsquo;s office is located at [&nbsp;&nbsp;].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">You
may hold ADSs either directly or indirectly through your broker or other financial institution. If you hold ADSs directly, by having an
ADS registered in your name on the books of the depositary, you are an ADR holder. This description assumes you hold your ADSs directly.
If you hold the ADSs through your broker or financial institution nominee, you must rely on the procedures of such broker or financial
institution to assert the rights of an ADR holder described in this section. You should consult with your broker or financial institution
to find out what those procedures are.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">As
an ADR holder, we will not treat you as a shareholder of ours and you will not have any shareholder rights. The laws of Guernsey governs
shareholder rights. Because the depositary or its nominee will be the shareholder of record for the ordinary shares represented by all
outstanding ADSs, shareholder rights rest with such record holder. Your rights are those of an ADR holder. Such rights derive from the
terms of the deposit agreement to be entered into among us, the depositary and all registered holders from time to time of ADRs issued
under the deposit agreement. The obligations of our company, the depositary and its agents are also set out in the deposit agreement.
Because the depositary or its nominee will actually be the registered owner of the ordinary shares, you must rely on it to exercise the
rights of a shareholder on your behalf. The deposit agreement and the ADSs are governed by New York law. Under the deposit agreement,
as an ADR holder, you agree that any legal suit, action or proceeding against or involving us or the depositary, arising out of or based
upon the deposit agreement, the ADSs or the transactions contemplated thereby, may only be instituted in a state or federal court in New
York, New York, and you irrevocably waive any objection which you may have to the laying of venue of any such proceeding and irrevocably
submit to the exclusive jurisdiction of such courts in any such suit, action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
following is a summary of what we believe to be the material terms of the deposit agreement. Notwithstanding this, because it is a summary,
it may not contain all the information that you may otherwise deem important. For more complete information, you should read the entire
deposit agreement and the form of ADR which contains the terms of your ADSs. You can read a copy of the deposit agreement which is filed
as an exhibit to the registration statement of which this prospectus forms a part. You may also obtain a copy of the deposit agreement
at the SEC&rsquo;s Public Reference Room which is located at 100 F Street, NE, Washington, DC 20549. You may obtain information on the
operation of the Public Reference Room by calling the SEC at 1-800-732-0330. You may also find the registration statement and the attached
deposit agreement on the SEC&rsquo;s website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><B>Share
Dividends and Other Distributions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><B><I>How
will I receive dividends and other distributions on the ordinary shares underlying my ADSs?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
may make various types of distributions with respect to our securities. The depositary has agreed that, to the extent practicable, it
will pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities,
after converting any cash received into U.S. dollars (if it determines such conversion may be made on a reasonable basis) and, in all
cases, making any necessary deductions provided for in the deposit agreement. The depositary may utilize a division, branch or affiliate
of [&nbsp;&nbsp;] to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement. Such division,
branch and/or affiliate may charge the depositary a fee in connection with such sales, which fee is considered an expense of the depositary.
You will receive these distributions in proportion to the number of underlying securities that your ADSs represent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 109 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Except as stated below,
the depositary will deliver such distributions to ADR holders in proportion to their interests in the following manner:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.1pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Cash. </I>The depositary will distribute any U.S. dollars available to it resulting from a cash dividend or other cash distribution or the net proceeds of sales of any other distribution or portion thereof (to the extent applicable), on an averaged or other practicable basis, subject to (i) appropriate adjustments for taxes withheld, (ii) such distribution being impermissible or impracticable with respect to certain registered ADR holders, and (iii) deduction of the depositary&rsquo;s and/or its agents&rsquo; expenses in (1) converting any foreign currency to U.S. dollars to the extent that it determines that such conversion may be made on a reasonable basis, (2) transferring foreign currency or U.S. dollars to the United States by such means as the depositary may determine to the extent that it determines that such transfer may be made on a reasonable basis, (3) obtaining any approval or license of any governmental authority required for such conversion or transfer, which is obtainable at a reasonable cost and within a reasonable time and (4) making any sale by public or private means in any commercially reasonable manner. <I>If exchange rates fluctuate during a time when the depositary cannot convert a foreign currency, you may lose some or all of the value of the distribution.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Ordinary Shares. In the case of a distribution in ordinary shares, the depositary will issue additional ADRs to evidence the number of ADSs representing such ordinary shares. Only whole ADSs will be issued. Any ordinary shares which would result in fractional ADSs will be sold and the net proceeds will be distributed in the same manner as cash to the ADR holders entitled thereto.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Rights to receive additional ordinary shares.</I> In the case of a distribution of rights to subscribe for additional ordinary shares or other rights, if we timely provide evidence satisfactory to the depositary that it may lawfully distribute such rights, the depositary will distribute warrants or other instruments in the discretion of the depositary representing rights to acquire additional ADRs. However, if we do not timely furnish such evidence, the depositary may:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(i) sell such
rights if practicable and distribute the net proceeds in the same manner as cash to the ADR holders entitled thereto; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(ii) if it
is not practicable to sell such rights by reason of the non-transferability of the rights, limited markets therefor, their short duration
or otherwise, do nothing and allow such rights to lapse, in which case ADR holders will receive nothing and the rights may lapse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Other Distributions.</I> In the case of a distribution of securities or property other than those described above, the depositary may either (i) distribute such securities or property in any manner it deems equitable and practicable or (ii) to the extent the depositary deems distribution of such securities or property not to be equitable and practicable, sell such securities or property and distribute any net proceeds in the same way it distributes cash.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Elective Distributions. </I>In the case of a dividend payable at the election of our shareholders in cash or in additional ordinary shares, we will notify the depositary at least 30 days prior to the proposed distribution stating whether or not we wish such elective distribution to be made available to ADR holders. The depositary shall make such elective distribution available to ADR holders only if (i) we shall have timely requested that the elective distribution is available to ADR holders, (ii) the depositary shall have determined that such distribution is reasonably practicable and (iii) the depositary shall have received satisfactory documentation within the terms of the deposit agreement including any legal opinions of counsel that the depositary in its reasonable discretion may request. If the above conditions are not satisfied, the depositary shall, to the extent permitted by law, distribute to the ADR holders, on the basis of the same determination as is made in the local market in respect of the ordinary shares for which no election is made, either (x) cash or (y) additional ADSs representing such additional ordinary shares. If the above conditions are satisfied, the depositary shall establish procedures to enable ADR holders to elect the receipt of the proposed dividend in cash or in additional ADSs. There can be no assurance that ADR holders generally, or any ADR holder in particular, will be given the opportunity to receive elective distributions on the same terms and conditions as the holders of ordinary shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.1pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.1pt; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 110 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.1pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">If
the depositary determines in its discretion that any distribution described above is not practicable with respect to any specific registered
ADR holder, the depositary may choose any method of distribution that it deems practicable for such ADR holder, including the distribution
of foreign currency, securities or property, or it may retain such items, without paying interest on or investing them, on behalf of the
ADR holder as deposited securities, in which case the ADSs will also represent the retained items.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Any
U.S. dollars will be distributed by checks drawn on a bank in the United States for whole dollars and cents. Fractional cents will be
withheld without liability and dealt with by the depositary in accordance with its then current practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>The
depositary is not responsible if it fails to determine that any distribution or action is lawful or reasonably practicable.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><I>There
can be no assurance that the depositary will be able to convert any currency at a specified exchange rate or sell any property, rights,
shares or other securities at a specified price, nor that any of such transactions can be completed within a specified time period. All
purchases and sales of securities will be handled by the Depositary in accordance with its then current policies, which are currently
set forth in the &ldquo;Depositary Receipt Sale and Purchase of Security&rdquo; section of www.adr.com/Investors/FindOutAboutDRs, the
location and contents of which the Depositary shall be solely responsible for.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Deposit, withdrawal
and Cancellation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>How does the depositary
issue ADSs?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
depositary will issue ADSs if you or your broker deposit ordinary shares or evidence of rights to receive ordinary shares with the custodian
and pay the fees and expenses owing to the depositary in connection with such issuance. In the case of the ADSs to be issued under this
prospectus, we will arrange with the underwriters named herein to deposit such ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Ordinary
shares deposited in the future with the custodian must be accompanied by certain delivery documentation and shall, at the time of such
deposit, be registered in the name of the depositary, the custodian or a nominee of either.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
custodian will hold all deposited ordinary shares (including those being deposited by or on our behalf in connection with this offering
to which this prospectus relates) for the account and to the order of the depositary for the benefit of registered holders of ADRs, to
the extent not prohibited by law. ADR holders thus have no direct ownership interest in the ordinary shares and only have such rights
as are contained in the deposit agreement. The custodian will also hold any additional securities, property and cash received on or in
substitution for the deposited ordinary shares. The deposited ordinary shares and any such additional items are referred to as &ldquo;deposited
securities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Upon
each deposit of ordinary shares, receipt of related delivery documentation and compliance with the other provisions of the deposit agreement,
including the payment of the fees and charges of the depositary and any taxes or other fees or charges owing, the depositary will issue
an ADR or ADRs in the name or upon the order of the person entitled thereto evidencing the number of ADSs to which such person is entitled.
All of the ADSs issued will, unless specifically requested to the contrary, be part of the depositary&rsquo;s direct registration system,
and a registered holder will receive periodic statements from the depositary which will show the number of ADSs registered in such holder&rsquo;s
name. An ADR holder can request that the ADSs not be held through the depositary&rsquo;s direct registration system and that a certificated
ADR be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>How do ADR holders
cancel an ADS and obtain deposited securities?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">When
you turn in your ADR certificate at the depositary&rsquo;s office, or when you provide proper instructions and documentation in the case
of direct registration ADSs, the depositary will, upon payment of certain applicable fees, charges and taxes, deliver the underlying ordinary
shares to you or upon your written order. Delivery of deposited securities in certificated form will be made at the custodian&rsquo;s
office. At your risk, expense and request, the depositary may deliver deposited securities at such other place as you may request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
depositary may only restrict the withdrawal of deposited securities in connection with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.1pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">temporary delays caused by closing our transfer books or those of the depositary or the deposit of ordinary shares in connection with voting at a shareholders meeting, or the payment of dividends;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the payment of fees, taxes and similar charges; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">compliance with any U.S. or foreign laws or governmental regulations relating to the ADRs or to the withdrawal of deposited securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">This
right of withdrawal may not be limited by any other provision of the deposit agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><B>Record
Dates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
depositary may, after consultation with us if practicable, fix record dates (which, to the extent applicable, shall be as near as practicable
to any corresponding record dates set by us) for the determination of the registered ADR holders who will be entitled (or obligated, as
the case may be):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.1pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to receive any distribution on or in respect of deposited securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to give instructions for the exercise of voting rights;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to pay the fee assessed by the depositary for administration of the ADR program and for any expenses as provided for in the ADR;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to receive any notice or to act in respect of other matters; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all subject to the provisions of the deposit agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>How do I vote?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">If
you are an ADR holder and the depositary asks you to provide it with voting instructions, you may instruct the depositary how to exercise
the voting rights for the ordinary shares which underlie your ADSs. Subject to the next sentence, as soon as practicable after receipt
from us of notice of any meeting at which the holders of ordinary shares are entitled to vote, or of our solicitation of consents or proxies
from holders of ordinary shares, the depositary shall fix the ADS record date in accordance with the provisions of the deposit agreement
in respect of such meeting or solicitation of consent or proxy. The depositary shall, if we request in writing in a timely manner (the
depositary having no obligation to take any further action if our request shall not have been received by the depositary at least 30 days
prior to the date of such vote or meeting) and at our expense and provided no legal prohibitions exist, distribute to the registered ADR
holders a notice stating such information as is contained in the voting materials received by the depositary, stating that that each registered
holder of ADRs on the ADS record date will, subject to any applicable provisions of the laws of Guernsey, be entitled to instruct the
depositary as to the exercise of any voting rights pertaining to ordinary shares underlying such holder&rsquo;s ADSs, and describing how
you may instruct the depositary to exercise the voting rights for the ordinary shares which underlie your ADSs, including instructions
for giving a discretionary proxy to a person designated by us. For instructions to be valid, the depositary must receive them in the manner
and on or before the date specified. The depositary will try, as far as is practical, subject to the provisions of or governing the underlying
ordinary shares or other deposited securities, to vote or cause to be voted the ordinary shares or other deposited securities as you instruct.
The depositary will only vote or attempt to vote as you instruct. Holders are strongly encouraged to forward their voting instructions
to the depositary as soon as possible. Voting instructions will not be deemed to be received until such time as the ADR department responsible
for proxies and voting has received such instructions notwithstanding that such instructions may have been physically received by the
depositary prior to such time. The depositary will not itself exercise any voting discretion. Furthermore, neither the depositary nor
its agents are responsible for any failure to carry out any voting instructions, for the manner in which any vote is cast or for the effect
of any vote. Notwithstanding anything contained in the deposit agreement or any ADR, the depositary may, to the extent not prohibited
by law or regulations, or by the requirements of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials
provided to the depositary in connection with any meeting of, or solicitation of consents or proxies from, holders of deposited securities,
distribute to the registered holders of ADRs a notice that provides such holders with, or otherwise publicizes to such holders, instructions
on how to retrieve such materials or receive such materials upon request (<I>i.e.</I>, by reference to a website containing the materials
for retrieval or a contact for requesting copies of the materials).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">There
is no guarantee that you will receive voting materials in time to instruct the depositary to vote and it is possible that you, or persons
who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.8pt; text-align: justify; text-indent: 16.7pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><B>Reports
and Other Communications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.8pt; text-align: justify; text-indent: 16.7pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><B><I>Will
ADR holders be able to view our reports?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
depositary will make available for inspection by ADR holders at the offices of the depositary and the custodian the deposit agreement,
the provisions of or governing deposited securities, and any written communications from us which are both received by the custodian or
its nominee as a holder of deposited securities and made generally available to the holders of deposited securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Additionally,
if we make any written communications generally available to holders of our ordinary shares, and we furnish copies thereof (or English
translations or summaries) to the depositary, it will distribute the same to registered ADR holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.8pt; text-align: justify; text-indent: 16.7pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><B>Fees
and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.8pt; text-align: justify; text-indent: 16.7pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><B><I>What
fees and expenses will I be responsible for paying?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of ordinary shares,
issuances in respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared
by us or issuances pursuant to a merger, exchange of securities or any other transaction or event affecting the ADSs or deposited securities,
and each person surrendering ADSs for withdrawal of deposited securities or whose ADSs are cancelled or reduced for any other reason,
$5.00 for each 100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or surrendered, as the case may be. The depositary
may sell (by public or private sale) sufficient securities and property received in respect of a share distribution, rights and/or other
distribution prior to such deposit to pay such charge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
following additional charges shall be incurred by the ADR holders, by any party depositing or withdrawing ordinary shares or by any party
surrendering ADSs and/or to whom ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split
declared by us or an exchange of stock regarding the ADSs or the deposited securities or a distribution of ADSs), whichever is applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.1pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">a fee of U.S.$1.50 per ADR or ADRs for transfers of certificated or direct registration ADRs;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">a fee of up to U.S.$0.05 per ADS for any cash distribution made pursuant to the deposit agreement;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an aggregate fee of up to U.S.$0.05 per ADS per calendar year (or portion thereof) for services performed by the depositary in administering the ADRs (which fee may be charged on a periodic basis during each calendar year and shall be assessed against holders of ADRs as of the record date or record dates set by the depositary during each calendar year and shall be payable in the manner described in the next succeeding provision);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a fee for the reimbursement of such fees, charges and expenses as are incurred by the depositary and/or any of its agents (including, without limitation, the custodian and expenses incurred on behalf of holders in connection with compliance with foreign exchange control regulations or any law or regulation relating to foreign investment) in connection with the servicing of the ordinary shares or other deposited securities, the sale of securities (including, without limitation, deposited securities), the delivery of deposited securities or otherwise in connection with the depositary&rsquo;s or its custodian&rsquo;s compliance with applicable law, rule or regulation (which fees and charges shall be assessed on a proportionate basis against holders as of the record date or dates set by the depositary and shall be payable at the sole discretion of the depositary by billing such holders or by deducting such charge from one or more cash dividends or other cash distributions);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a fee for the distribution of securities (or the sale of securities in connection with a distribution), such fee being in an amount equal to the $0.05 per ADS issuance fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of such securities (treating all such securities as if they were ordinary shares) but which securities or the net cash proceeds from the sale thereof are instead distributed by the depositary to those holders entitled thereto;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">stock transfer or other taxes and other governmental charges;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">SWIFT, cable, telex and facsimile transmission and delivery charges incurred at your request in connection with the deposit or delivery of ordinary shares, ADRs or deposited securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">transfer or registration fees for the registration or transfer of deposited securities on any applicable register in connection with the deposit or withdrawal of deposited securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in connection with the conversion of foreign currency into U.S. dollars, [&nbsp;&nbsp;] shall deduct out of such foreign currency the fees, expenses and other charges charged by it and/or its agent (which may be a division, branch or affiliate) so appointed in connection with such conversion; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">fees of any division, branch or affiliate of the depositary utilized by the depositary to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -36.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">[&nbsp;&nbsp;]
and/or its agent may act as principal for such conversion of foreign currency. For further details see <U>www.adr.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements
from time to time between us and the depositary. The charges described above may be amended from time to time by agreement between us
and the depositary. The right of the depositary to receive payment of fees, charges and expenses as provided above shall survive the termination
of the deposit agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
depositary may make available to us a set amount or a portion of the depositary fees charged in respect of the ADR program or otherwise
upon such terms and conditions as we and the depositary may agree from time to time. The depositary collects its fees for issuance and
cancellation of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries
acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed
or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by
deduction from cash distributions, or by directly billing investors, or by charging the book-entry system accounts of participants acting
for them. The depositary will generally set off the amounts owing from distributions made to holders of ADSs. If, however, no distribution
exists and payment owing is not timely received by the depositary, the depositary may refuse to provide any further services to holders
that have not paid those fees and expenses owing until such fees and expenses have been paid. At the discretion of the depositary, all
fees and charges owing under the deposit agreement are due in advance and/or when declared owing by the depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Payment of Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">If
any taxes or other governmental charges (including any penalties and/or interest) shall become payable by or on behalf of the custodian
or the depositary with respect to any ADR, any deposited securities represented by the ADSs evidenced thereby or any distribution thereon,
such tax or other governmental charge shall be paid by the holder thereof to the depositary and by holding or having held an ADR the holder
and all prior holders thereof, jointly and severally, agree to indemnify, defend and save harmless each of the depositary and its agents
in respect thereof. If an ADR holder owes any tax or other governmental charge, the depositary may (i) deduct the amount thereof from
any cash distributions, or (ii) sell deposited securities by public or private sale (after attempting by reasonable means to notify the
ADR holder hereof prior to such sale) and deduct the amount owing from the net proceeds of such sale. In either case the ADR holder remains
liable for any shortfall. If any tax or governmental charge is unpaid, the depositary may also refuse to affect any registration, registration
of transfer, split-up or combination of deposited securities or withdrawal of deposited securities until such payment is made. If any
tax or governmental charge is required to be withheld on any cash distribution, the depositary may deduct the amount required to be withheld
from any cash distribution or, in the case of a non-cash distribution, sell the distributed property or securities (by public or private
sale) in such amounts and in such manner as the depositary deems necessary and practicable to pay such taxes and distribute any remaining
net proceeds or the balance of any such property after deduction of such taxes to the ADR holders entitled thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">By holding an ADR or an interest
therein, you will be agreeing to indemnify us, the depositary, its custodian and any of our or their respective officers, directors, employees,
agents and affiliates against, and hold each of them harmless from, any claims by any governmental authority with respect to taxes, additions
to tax, penalties or interest arising out of any refund of taxes, reduced rate of withholding at source or other tax benefit obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Reclassifications, Recapitalizations
and Mergers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we take certain actions
that affect the deposited securities, including (i) any change in nominal value, split-up, consolidation, cancellation or other reclassification
of deposited securities or (ii) any distributions of ordinary shares or other property not made to holders of ADRs or (iii) any recapitalization,
reorganization, merger, consolidation, liquidation, receivership, bankruptcy or sale of all or substantially all of our assets, then the
depositary may choose to, and shall if reasonably requested by us:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">amend the form of ADR;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">distribute additional or amended ADRs;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">distribute cash, securities or other property it has received in connection with such actions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">sell any securities or property received and distribute the proceeds as cash; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">none of the above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the depositary does not
choose any of the above options, any of the cash, securities or other property it receives will constitute part of the deposited securities
and each ADS will then represent a proportionate interest in such property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Amendment and Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>How may the deposit
agreement be amended?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may agree with the depositary
to amend the deposit agreement and the ADSs without your consent for any reason. ADR holders must be given at least 30 days&rsquo; notice
of any amendment that imposes or increases any fees or charges (other than stock transfer or other taxes and other governmental charges,
transfer or registration fees, SWIFT, cable, telex or facsimile transmission costs, delivery costs or other such expenses), or otherwise
prejudices any substantial existing right of ADR holders. Such notice need not describe in detail the specific amendments effectuated
thereby, but must identify to ADR holders a means to access the text of such amendment. If an ADR holder continues to hold an ADR or ADRs
after being so notified, such ADR holder is deemed to agree to such amendment and to be bound by the deposit agreement as so amended.
Any amendments or supplements which (i) are reasonably necessary (as agreed by us and the depositary) in order for (a) the ADSs to be
registered on Form F-6 under the Securities Act or (b) the ADSs or ordinary shares to be traded solely in electronic book-entry form and
(ii) do not in either such case impose or increase any fees or charges to be borne by ADR holders, shall be deemed not to prejudice any
substantial rights of ADR holders. Notwithstanding the foregoing, if any governmental body or regulatory body should adopt new laws, rules
or regulations which would require amendment or supplement of the deposit agreement or the form of ADR to ensure compliance therewith,
we and the depositary may amend or supplement the deposit agreement and the ADR at any time in accordance with such changed laws, rules
or regulations, which amendment or supplement may take effect before a notice is given or within any other period of time as required
for compliance. No amendment, however, will impair your right to surrender your ADSs and receive the underlying securities, except in
order to comply with mandatory provisions of applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>How may the deposit
agreement be terminated?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The depositary may, and shall
at our written direction, terminate the deposit agreement and the ADRs by mailing notice of such termination to the registered holders
of ADRs at least 30 days prior to the date fixed in such notice for such termination; provided, however, if the depositary shall have
(i) resigned as depositary under the deposit agreement, notice of such termination by the depositary shall not be provided to registered
holders unless a successor depositary shall not be operating under the deposit agreement within 60 days of the date of such resignation,
and (ii) been removed as depositary under the deposit agreement, notice of such termination by the depositary shall not be provided to
registered holders of ADRs unless a successor depositary shall not be operating under the deposit agreement on the 120<SUP>th</SUP> day
after our notice of removal was first provided to the depositary. After termination, the depositary&rsquo;s only responsibility will be
(i) to deliver deposited securities to ADR holders who surrender their ADRs, and (ii) to hold or sell distributions received on deposited
securities. As soon as practicable after the expiration of six months from the termination date, the depositary will sell the deposited
securities which remain and hold the net proceeds of such sales (as long as it may lawfully do so), without liability for interest, in
trust for the ADR holders who have not yet surrendered their ADRs. After making such sale, the depositary shall have no obligations except
to account for such proceeds and other cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><B>Limitations
on Obligations and Liability to ADR holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>Limits on our obligations
and the obligations of the depositary; limits on liability to ADR holders and holders of ADSs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to the issue, registration,
registration of transfer, split-up, combination, or cancellation of any ADRs, or the delivery of any distribution in respect thereof,
and from time to time in the case of the production of proofs as described below, we or the depositary or its custodian may require:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">payment with respect thereto of (i) any stock transfer or other tax or other governmental charge, (ii) any stock transfer or registration fees in effect for the registration of transfers of ordinary shares or other deposited securities upon any applicable register and (iii) any applicable fees and expenses described in the deposit agreement;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the production of proof satisfactory to it of (i) the identity of any signatory and genuineness of any signature and (ii) such other information, including without limitation, information as to citizenship, residence, exchange control approval, beneficial ownership of any securities, compliance with applicable law, regulations, provisions of or governing deposited securities and terms of the deposit agreement and the ADRs, as it may deem necessary or proper; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">compliance with such regulations as the depositary may establish consistent with the deposit agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The issuance of ADRs, the
acceptance of deposits of ordinary shares, the registration, registration of transfer, split-up or combination of ADRs or the withdrawal
of ordinary shares, may be suspended, generally or in particular instances, when the ADR register or any register for deposited securities
is closed or when any such action is deemed advisable by the depositary; provided that the ability to withdraw ordinary shares may only
be limited under the following circumstances: (i) temporary delays caused by closing transfer books of the depositary or our transfer
books or the deposit of ordinary shares in connection with voting at a shareholders meeting, or the payment of dividends, (ii) the payment
of fees, taxes, and similar charges, and (iii) compliance with any laws or governmental regulations relating to ADRs or to the withdrawal
of deposited securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The deposit agreement expressly
limits the obligations and liability of the depositary, ourselves and each of our and the depositary&rsquo;s respective agents, provided,
however, that no disclaimer of liability under the Securities Act or the Exchange Act, to the extent applicable, is intended by any provision
of the deposit agreement. In the deposit agreement it provides that neither we nor the depositary nor any such agent will be liable to
registered holders or beneficial owners of ADSs if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any present or future law, rule, regulation, fiat, order or decree of the United States, Guernsey, England and Wales or any other country or jurisdiction, or of any governmental or regulatory authority or securities exchange or market or automated quotation system, the provisions of or governing any deposited securities, any present or future provision of our charter, any act of God, war, terrorism, nationalization, expropriation, currency restrictions, work stoppage, strike, civil unrest, revolutions, rebellions, explosions, computer failure or circumstance beyond our, the depositary&rsquo;s or our respective agents&rsquo; direct and immediate control shall prevent or delay, or shall cause any of them to be subject to any civil or criminal penalty in connection with, any act which the deposit agreement or the ADRs provide shall be done or performed by us, the depositary or our respective agents (including, without limitation, voting);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it exercises or fails to exercise discretion under the deposit agreement or the ADRs including, without limitation, any failure to determine that any distribution or action may be lawful or reasonably practicable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it performs its obligations under the deposit agreement and ADRs without gross negligence or willful misconduct; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it takes any action or refrains from taking any action in reliance upon the advice of or information from legal counsel, accountants, any person presenting ordinary shares for deposit, any registered holder of ADRs, or any other person believed by it to be competent to give such advice or information.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -36.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We, the depositary and its
agents may rely and shall be protected in acting upon any written notice, request, direction, instruction or document believed by them
to be genuine and to have been signed, presented or given by the proper party or parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Neither the depositary nor
its agents have any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities
or the ADRs. We and our agents shall only be obligated to appear in, prosecute or defend any action, suit or other proceeding in respect
of any deposited securities or the ADRs, which in our opinion may involve us in expense or liability, if indemnity satisfactory to us
against all expense (including fees and disbursements of counsel) and liability is furnished as often as may be required. The depositary
and its agents may fully respond to any and all demands or requests for information maintained by or on its behalf in connection with
the deposit agreement, any registered holder or holders of ADRs, any ADRs or otherwise related to the deposit agreement or ADRs to the
extent such information is requested or required by or pursuant to any lawful authority, including without limitation laws, rules, regulations,
administrative or judicial process, banking, securities or other regulators. The depositary shall not be liable for the acts or omissions
made by, or the insolvency of, any securities depository, clearing agency or settlement system. Furthermore, the depositary shall not
be responsible for, and shall incur no liability in connection with or arising from, the insolvency of any custodian that is not a branch
or affiliate of JPMorgan Chase Bank, N.A. Notwithstanding anything to the contrary contained in the deposit agreement or any ADRs, the
depositary shall not be responsible for, and shall incur no liability in connection with or arising from, any act or omission to act on
the part of the custodian except to the extent that any registered holder of ADRs has incurred liability directly as a result of the custodian
having (i) committed fraud or willful misconduct in the provision of custodial services to the depositary or (ii) failed to use reasonable
care in the provision of custodial services to the depositary as determined in accordance with the standards prevailing in the jurisdiction
in which the custodian is located. The depositary shall not have any liability for the price received in connection with any sale of securities,
the timing thereof or any delay in action or omission to act nor shall it be responsible for any error or delay in action, omission to
act, default or negligence on the part of the party so retained in connection with any such sale or proposed sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The depositary has no obligation
to inform ADR holders or other holders of an interest in any ADSs about the requirements of the laws of Guernsey, rules or regulations
or any changes therein or thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 117 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Neither the depositary nor
its agents will be responsible for any failure to carry out any instructions to vote any of the deposited securities, for the manner in
which any such vote is cast or for the effect of any such vote. The depositary may rely upon instructions from us or our counsel in respect
of any approval or license required for any currency conversion, transfer or distribution. The depositary shall not incur any liability
for the content of any information submitted to it by us or on our behalf for distribution to ADR holders or for any inaccuracy of any
translation thereof, for any investment risk associated with acquiring an interest in the deposited securities, for the validity or worth
of the deposited securities, for the credit-worthiness of any third party, for allowing any rights to lapse upon the terms of the deposit
agreement or for the failure or timeliness of any notice from us. The depositary shall not be liable for any acts or omissions made by
a successor depositary whether in connection with a previous act or omission of the depositary or in connection with any matter arising
wholly after the removal or resignation of the depositary. Neither the depositary nor any of its agents shall be liable to registered
holders or beneficial owners of interests in ADSs for any indirect, special, punitive or consequential damages (including, without limitation,
legal fees and expenses) or lost profits, in each case of any form incurred by any person or entity, whether or not foreseeable and regardless
of the type of action in which such a claim may be brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the deposit agreement
each party thereto (including, for avoidance of doubt, each holder and beneficial owner and/or holder of interests in ADRs) irrevocably
waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any suit, action or proceeding
against the depositary and/or us directly or indirectly arising out of or relating to the ordinary shares or other deposited securities,
the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether based on contract,
tort, common law or any other theory).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The depositary and its agents
may own and deal in any class of securities of our company and our affiliates and in ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Disclosure of Interest
in ADSs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To the extent that the provisions
of or governing any deposited securities may require disclosure of or impose limits on beneficial or other ownership of deposited securities,
other ordinary shares and other securities and may provide for blocking transfer, voting or other rights to enforce such disclosure or
limits, you agree to comply with all such disclosure requirements and ownership limitations and to comply with any reasonable instructions
we may provide in respect thereof. We reserve the right to instruct you to deliver your ADSs for cancellation and withdrawal of the deposited
securities so as to permit us to deal with you directly as a holder of ordinary shares and, by holding an ADS or an interest therein,
you will be agreeing to comply with such instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Books of Depositary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The depositary or its agent
will maintain a register for the registration, registration of transfer, combination and split-up of ADRs, which register shall include
the depositary&rsquo;s direct registration system. Registered holders of ADRs may inspect such records at the depositary&rsquo;s office
at all reasonable times, but solely for the purpose of communicating with other holders in the interest of the business of our company
or a matter relating to the deposit agreement. Such register may be closed at any time or from time to time, when deemed expedient by
the depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The depositary will maintain
facilities for the delivery and receipt of ADRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: justify"><B>Pre-release of ADSs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In its capacity as depositary,
the depositary shall not lend ordinary shares or ADSs; provided, however, that the depositary may (i) issue ADSs prior to the receipt
of ordinary shares and (ii) deliver ordinary shares prior to the receipt of ADSs for withdrawal of deposited securities, including ADSs
which were issued under (i) above but for which ordinary shares may not have been received, each such transaction a &ldquo;pre-release.&rdquo;
The depositary may receive ADSs in lieu of ordinary shares under (i) above (which ADSs will promptly be canceled by the depositary upon
receipt by the depositary) and receive ordinary shares in lieu of ADSs under (ii) above. Each such pre-release will be subject to a written
agreement whereby the person/entity, or applicant to whom ADSs or ordinary shares are to be delivered (a) represents that at the time
of the pre-release the applicant or its customer owns the ordinary shares or ADSs that are to be delivered by the applicant under such
pre-release, (b) agrees to indicate the depositary as owner of such ordinary shares or ADSs in its records and to hold such ordinary shares
or ADSs in trust for the depositary until such ordinary shares or ADSs are delivered to the depositary or the custodian, (c) unconditionally
guarantees to deliver to the depositary or the custodian, as applicable, such ordinary shares or ADSs, and (d) agrees to any additional
restrictions or requirements that the depositary deems appropriate. Each such pre-release will be at all times fully collateralized with
cash, U.S. government securities or such other collateral as the depositary deems appropriate, terminable by the depositary on not more
than five (5) business days&rsquo; notice and subject to such further indemnities and credit regulations as the depositary deems appropriate.
The depositary will normally limit the number of ADSs and ordinary shares involved in such pre-release at any one time to thirty per cent.
(30%) of the ADSs outstanding (without giving effect to ADSs outstanding under (i) above), provided, however, that the depositary reserves
the right to change or disregard such limit from time to time as it deems appropriate. The depositary may also set limits with respect
to the number of ADSs and ordinary shares involved in pre-release with any one person on a case-by-case basis as it deems appropriate.
The depositary may retain for its own account any compensation received by it in conjunction with the foregoing. Collateral provided in
connection with pre-release transactions, but not the earnings thereon, shall be held for the benefit of the ADR holders (other than the
applicant).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Appointment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the deposit agreement,
each registered holder of ADRs and each person holding an interest in ADSs, upon acceptance of any ADSs (or any interest therein) issued
in accordance with the terms and conditions of the deposit agreement will be deemed for all purposes to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">be a party to and bound by the terms of the deposit agreement and the applicable ADR or ADRs; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appoint the depositary its attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions contemplated in the deposit agreement and the applicable ADR or ADRs, to adopt any and all procedures necessary to comply with applicable laws and to take such action as the depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the deposit agreement and the applicable ADR and ADRs, the taking of such actions to be the conclusive determinant of the necessity and appropriateness thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -36.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The deposit agreement and
the ADRs shall be governed by and construed in accordance with the laws of the State of New York. In the deposit agreement, we have submitted
to the jurisdiction of the courts of the State of New York and appointed an agent for service of process on our behalf. Notwithstanding
the foregoing, any action based on the deposit agreement or the transactions contemplated thereby may be instituted by the depositary
in any competent court in Guernsey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">By holding an ADS or an interest
therein, registered holders of ADRs and owners of ADSs each irrevocably agree that any legal suit, action or proceeding against or involving
us or the depositary, arising out of or based upon the deposit agreement, the ADSs or the transactions contemplated thereby, may only
be instituted in a state or federal court in New York, New York, and each irrevocably waives any objection which it may have to the laying
of venue of any such proceeding, and irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_020"></A><FONT STYLE="text-transform: uppercase"><B>ORDINARY
SHARES AND ads</B></FONT><B>s <FONT STYLE="text-transform: uppercase">ELIGIBLE FOR FUTURE SALE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to this offering, no
public market existed for our ADSs. Future sales of substantial amounts of ADSs in the public market, the availability of ADSs for future
sale or the perception that such sales may occur, however, could adversely affect the market price of our ADSs and/or ordinary shares
and also could adversely affect our future ability to raise capital through the sale of our ADSs and/or ordinary shares or other equity-related
securities at times and prices we believe appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on the number of our
ordinary shares outstanding as of [&nbsp;&nbsp;], 2021, upon the closing of the offering, we will have [&nbsp;&nbsp;] ADSs outstanding,
representing [&nbsp;&nbsp;] ordinary shares, and [&nbsp;&nbsp;] ordinary shares outstanding (including ordinary shares in the form of
ADSs), or, if the underwriters exercise in full their over-allotment option to purchase an additional [&nbsp;&nbsp;] ADSs, [&nbsp;&nbsp;]
ordinary shares (including [&nbsp;&nbsp;] ordinary shares in the form of ADSs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All of the ADSs sold in this
offering will be freely tradable without restrictions or further registration under the Securities Act, except for any shares sold to
our &ldquo;affiliates,&rdquo; as that term is defined under Rule 144 under the Securities Act. The outstanding ordinary shares held by
existing shareholders are &ldquo;restricted securities,&rdquo; as that term is defined in Rule 144 under the Securities Act. Restricted
securities may be sold in the public market only if the offer and sale is registered under the Securities Act or if the offer and sale
of those securities qualifies for exemption from registration, including exemptions provided by Rules 144 or 701 promulgated under the
Securities Act. Restricted securities may also be sold outside of the United States to non-U.S. persons in accordance with Rule 904 of
Regulation S under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the lock-up agreements
described below and the provisions of Rule 144 or Regulation S under the Securities Act, as well as our insider trading policy, these
restricted securities will be available for sale in the public market at various times beginning at least 135 days after the date of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, under Rule 144
as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a person who is not deemed
to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and who has beneficially
owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates,
is entitled to sell such shares without complying with the manner of sale, volume limitation, or notice provisions of Rule 144, subject
to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be
sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to
sell such shares without complying with any of the requirements of Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, under Rule 144,
as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell upon expiration of the
lock-up agreements described below, within any three-month period beginning 90 days after the date of this prospectus, a number of shares
that does not exceed the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1% of the number of ADSs then outstanding, which will equal approximately shares immediately after this offering&#894; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the average weekly trading volume of our ADSs during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Sales under Rule 144 by our
affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements
and to the availability of current public information about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 701</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Rule 701 generally allows
a shareholder who was issued shares pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate
of our company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without being required to
comply with the public information, holding period, volume limitation or notice provisions of Rule 144. Rule 701 also permits affiliates
of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders
of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares
pursuant to Rule 701.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Regulation S provides generally
that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_021"></A><FONT STYLE="text-transform: uppercase"><B>certain
U.S. AND GUERNSEY TAX CONSIDERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Material U.S. Federal Income Tax Considerations
for U.S. Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following discussion
describes the material U.S. federal income tax consequences relating to the ownership and disposition of our ADSs by U.S. Holders. This
discussion applies to U.S. Holders that purchase our ADSs pursuant to this offering and hold such ADSs as capital assets for U.S. federal
income tax purposes. This discussion is based on the Internal Revenue Code, U.S. Treasury regulations promulgated thereunder and administrative
and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive
effect. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders
in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as
certain financial institutions, insurance companies, dealers or traders in securities or other persons that generally mark their securities
to market for U.S. federal income tax purposes, tax-exempt entities or governmental organizations, retirement plans, regulated investment
companies, real estate investment trusts, grantor trusts, brokers, dealers or traders in securities, commodities, currencies or notional
principal contracts, certain former citizens or long-term residents of the United States, persons who hold our ADSs as part of a &ldquo;straddle,&rdquo;
&ldquo;hedge,&rdquo; &ldquo;conversion transaction,&rdquo; &ldquo;synthetic security&rdquo; or integrated investment, persons that have
a &ldquo;functional currency&rdquo; other than the U.S. dollar, persons who are subject to the tax accounting rules of Section 451(b)
of the Internal Revenue Code, persons that own directly, indirectly or through attribution 10% or more (by vote or value) of our equity,
corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and other pass-through entities, and investors in
such pass-through entities). This discussion does not address any U.S. state or local or non-U.S. tax consequences or any U.S. federal
estate, gift or alternative minimum tax consequences. Except as discussed below, this discussion does not address U.S. federal income
tax reporting obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As used in this discussion,
the term &ldquo;U.S. Holder&rdquo; means a beneficial owner of our ADSs that is, for U.S. federal income tax purposes, (1) an individual
who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes)
created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate the income
of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court within the United
States is able to exercise primary supervision over its administration and one or more United States persons have the authority to control
all of its substantial decisions or (y) that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust
for U.S. federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an entity treated as a
partnership for U.S. federal income tax purposes holds our ADSs, the U.S. federal income tax consequences relating to an investment in
such ADSs will generally depend upon the status and activities of such entity and the particular partner. Any such entity and a partner
in any such entity should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it (and, as applicable,
its partners) of the purchase, ownership and disposition of our ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not sought, nor will
we seek, a ruling from the IRS with respect to the matters discussed below. There can be no assurance that the IRS will not take a different
position concerning the tax consequences of the purchase, ownership or disposition of the ADSs or that any such position would not be
sustained. Persons considering an investment in our ADSs should consult their own tax advisors as to the particular tax consequences applicable
to them relating to the purchase, ownership and disposition of our ADSs, including the applicability of U.S. federal, state and local
tax laws and non-U.S. tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>Passive Foreign Investment
Company Rules</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, a corporation
organized outside the United States will be treated as a PFIC for any taxable year in which either (1) at least 75% of its gross income
is &ldquo;passive income,&rdquo; referred to as the PFIC income test, or (2) on average at least 50% of its assets, determined on a quarterly
basis, are assets that produce passive income or are held for the production of passive income, referred to as the PFIC asset test. Passive
income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or exchange
of property that give rise to passive income. Assets that produce or are held for the production of passive income generally include
cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive
income. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation
in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although PFIC status is determined
on an annual basis and generally cannot be determined until the end of the taxable year, based on the nature of our current and expected
income and the current and expected value and composition of our assets, and while not free from doubt, we do not believe we were a PFIC
for our 2020 tax year and we do not expect to be a PFIC for our current taxable year. Nevertheless, there can be no assurance that we
will not be a PFIC in future taxable years. Furthermore, even if we determine that we are not a PFIC for a taxable year, there can be
no assurance that the IRS will agree with our conclusion and that the IRS would not successfully challenge our position. Because of the
uncertainties involved in establishing our PFIC status, our U.S. counsel expresses no opinion regarding our PFIC status, and also expresses
no opinion with respect to our predictions or past determinations regarding our PFIC status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are a PFIC in any taxable
year during which a U.S. Holder owns our ADSs, the U.S. Holder would be liable for additional taxes and interest charges under the &ldquo;PFIC
excess distribution regime&rdquo; upon (1) a distribution paid during a taxable year that is greater than 125% of the average annual distributions
paid in the three preceding taxable years, or, if shorter, the U.S. Holder&rsquo;s holding period for our ADSs, and (2) any gain recognized
on a sale, exchange or other disposition, including, under certain circumstances, a pledge, of our ADSs, whether or not we continue to
be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined by allocating the distribution
or gain ratably over the U.S. Holder&rsquo;s holding period for our ADSs. The amount allocated to the current taxable year (<I>i.e</I>.,
the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC
will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the
highest marginal rates in effect for individuals or corporations, as applicable, to ordinary income for each such taxable year, and an
interest charge, generally applicable to underpayments of tax, will be added to the tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are a PFIC for any
taxable year during which a U.S. Holder holds our ADSs and one of our non-United States subsidiaries is also a PFIC (<I>i.e</I>., a lower-tier
PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC and would be
taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from the disposition of shares of
the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or dispositions. Any of our non-United
States subsidiaries that have elected to be disregarded as entities separate from us or as partnerships for U.S. federal income tax purposes
would not be corporations under U.S. federal income tax law and accordingly, cannot be classified as lower-tier PFICs. However, a non-United
States subsidiary that has not made the election may be classified as a lower-tier PFIC if we are a PFIC during your holding period and
the subsidiary meets the PFIC income test or PFIC asset test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are a PFIC, a U.S.
Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on our ADSs if a valid
&ldquo;mark-to-market&rdquo; election is made by the U.S. Holder for our ADSs. An electing U.S. Holder generally would take into account
as ordinary income each year, the excess of the fair market value of our ADSs held at the end of such taxable year over the adjusted tax
basis of such ADSs. The U.S. Holder would also take into account, as an ordinary loss each year, the excess of the adjusted tax basis
of such ADSs over their fair market value at the end of the taxable year, but only to the extent of the excess of amounts previously included
in income over ordinary losses deducted as a result of the mark-to-market election. The U.S. Holder&rsquo;s tax basis in our ADSs would
be adjusted annually to reflect any income or loss recognized as a result of the mark-to-market election. Any gain from a sale, exchange
or other disposition of our ADSs in any taxable year in which we are a PFIC would be treated as ordinary income and any loss from such
sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously
included in income) and thereafter as capital loss. If, after having been a PFIC for a taxable year, we cease to be classified as a PFIC
because we no longer meet the PFIC income or PFIC asset test, the U.S. Holder would not be required to take into account any latent gain
or loss in the manner described above and any gain or loss recognized on the sale or exchange of the ADSs would be classified as a capital
gain or loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 122 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A mark-to-market election
is available to a U.S. Holder only for &ldquo;marketable stock.&rdquo; Generally, stock will be considered marketable stock if it is &ldquo;regularly
traded&rdquo; on a &ldquo;qualified exchange&rdquo; within the meaning of applicable U.S. Treasury regulations. A class of stock is regularly
traded during any calendar year during which such class of stock is traded, other than in de minimis quantities, on at least 15 days during
each calendar quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ADSs will be marketable
stock as long as they remain listed on Nasdaq and are regularly traded. A mark-to-market election will not apply to the ADSs for any taxable
year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become a PFIC.
Such election will not apply to any of our non-U.S. subsidiaries. Accordingly, a U.S. Holder may continue to be subject to tax under the
PFIC excess distribution regime with respect to any lower-tier PFICs notwithstanding the U.S. Holder&rsquo;s mark-to-market election for
our ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The tax consequences that
would apply if we were a PFIC would also be different from those described above if a U.S. Holder were able to make a valid QEF election.
As we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to make a QEF election, prospective investors
should assume that a QEF election will not be available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>The U.S. federal income
tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own tax advisors with respect
to the impact of our possible PFIC status on the purchase, ownership and disposition of our ADSs, the consequences to them of an investment
in a PFIC, any elections available with respect to the ADSs and the IRS information reporting obligations with respect to the purchase,
ownership and disposition of ADSs of a PFIC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Distributions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the discussion
above under &ldquo;&mdash; Passive Foreign Investment Company Rules,&rdquo; a U.S. Holder that receives a distribution with respect to
our ADSs generally will be required to include the gross amount of such distribution in gross income as a dividend when actually or constructively
received by the U.S. Holder to the extent of the U.S. Holder&rsquo;s pro rata share of our current and/or accumulated earnings and profits
(as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because
it exceeds the U.S. Holder&rsquo;s pro rata share of our current and accumulated earnings and profits, it will be treated first as a tax-free
return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&rsquo;s ADSs. To the extent the distribution
exceeds the adjusted tax basis of the U.S. Holder&rsquo;s ADSs, the remainder will be taxed as capital gain. Because we may not account
for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to be
reported to them as dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Distributions on our ADSs
that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes
and generally will constitute passive category income. The amount of any dividend income paid in a currency other than the U.S. dollar
will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless
of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date
of receipt, a U.S. holder should not be required to recognize foreign currency gain or loss in respect of the dividend amount. A U.S.
Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 123 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Distributions paid on our
ADSs will not be eligible for the &ldquo;dividends received&rdquo; deduction generally allowed to corporate shareholders with respect
to dividends received from U.S. corporations under the Internal Revenue Code. Dividends paid by a &ldquo;qualified foreign corporation&rsquo;&rsquo;
to non-corporate U.S. Holders are eligible for taxation at a reduced capital gains rate rather than the marginal tax rates generally applicable
to ordinary income provided that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss,
during the 121-day period beginning 60 days before the ex-dividend date) and certain other requirements are met. Each U.S. Holder is advised
to consult its tax advisors regarding the availability of the reduced tax rate on dividends to its particular circumstances. However,
if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable year (see discussion above under &ldquo;&mdash;
Passive Foreign Investment Company Rules&rsquo;&rsquo;), we will not be treated as a qualified foreign corporation, and therefore the
reduced capital gains tax rate described above will not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A non-United States corporation
(other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year)
generally will be considered to be a qualified foreign corporation with respect to any dividend it pays on ADSs that are readily tradable
on an established securities market in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The amount of any dividend
income that is paid in Pounds Sterling will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date
of receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on
the date of receipt (actual or constructive), a U.S. Holder should not be required to recognize foreign currency gain or loss in respect
of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the
date of receipt (actual or constructive).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sale, Exchange or Other Taxable Disposition
of Our ADSs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the discussion
above under &ldquo;&mdash; Passive Foreign Investment Company Rules,&rdquo; a U.S. Holder generally will recognize capital gain or loss
for U.S. federal income tax purposes upon the sale, exchange or other disposition of our ADSs in an amount equal to the difference, if
any, between the amount realized (<I>i.e</I>., the amount of cash plus the fair market value of any property received) on the sale, exchange
or other disposition and such U.S. Holder&rsquo;s adjusted tax basis in the ADSs. Such capital gain or loss generally will be long-term
capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of sale, exchange or other
disposition, the ADSs were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate U.S. Holder that is not
long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. Any gain or loss
recognized from the sale or other disposition of our ADSs will generally be gain or loss from sources within the United States for U.S.
foreign tax credit purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Medicare Tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain U.S. Holders that
are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion
of their net investment income, which may include their gross dividend income and net gains from the disposition of our ADSs. If you are
a U.S. Holder that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding the applicability of this
Medicare tax to your income and gains in respect of your investment in our ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Information Reporting and Backup Withholding</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">U.S. Holders may be required
to file certain U.S. information reporting returns with the IRS with respect to an investment in our ADSs, including, among others, IRS
Form 8938 (Statement of Specified Foreign Financial Assets). In addition, each U.S. Holder who is a shareholder of a PFIC must file an
annual report containing certain information. U.S. Holders paying more than $100,000 for our ADSs may be required to file IRS Form 926
(Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties and other adverse circumstances
may be imposed upon a U.S. Holder that fails to comply with the required information reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 124 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dividends on and proceeds
from the sale or other disposition of our ADSs generally have to be reported to the IRS unless the U.S. Holder establishes a basis for
exemption. Backup withholding may apply to amounts subject to reporting if the holder (1) fails to provide an accurate U.S. taxpayer identification
number or otherwise establish a basis for exemption, or (2) is described in certain other categories of persons. However, U.S. Holders
that are corporations generally are excluded from these information reporting and backup withholding tax rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Backup withholding is not
an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a
U.S. Holder&rsquo;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to
the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">U.S. Holders should consult
their own tax advisors regarding the backup withholding tax and information reporting rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>EACH PROSPECTIVE INVESTOR
IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ADSs IN LIGHT OF THE INVESTOR&rsquo;S
OWN CIRCUMSTANCES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Guernsey Tax Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The summary below is based
on current Guernsey law and published practice in Guernsey as of the date hereof, both of which are subject to change, possibly with retrospective
effect. This summary is intended as a general guide of certain Guernsey tax matters related to the holders of ordinary shares of the Company
(&ldquo;<B>Shareholders</B>&rdquo;) only and is not, is not intended to be nor should it be construed to be, legal or tax advice or a
summary of all tax matters in Guernsey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Shareholders, whether corporations
or individuals, that are not residents of Guernsey for tax purposes and who do not conduct business in Guernsey through a permanent establishment
situated in Guernsey, will not be subject to Guernsey income or Guernsey withholding tax. Any distributions made by the Company to non-Guernsey
tax resident Shareholders will not be subject to Guernsey income or Guernsey withholding tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Individual Shareholders who
are residents of Guernsey for tax purposes will generally be subject to Guernsey income tax at the individual standard rate of 20% on
distributions received from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Corporate Shareholders that
are residents of Guernsey for tax purposes (and which do not have exempt company status under the Income Tax (Exempt Bodies) (Guernsey)
Ordinance, 1989, as amended) will generally be subject to Guernsey income tax at the company standard rate, which is currently 0%, on
distributions received from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Guernsey does not currently
levy capital gains tax (with the exception of a dwellings profit tax) and, therefore, Shareholders will not suffer capital gains tax in
Guernsey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No stamp duty is chargeable
in Guernsey on the issue, acquisition, transfer, conversion or redemption or other disposition of ordinary shares of the Company (provided
that it does not hold Guernsey real property).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Guernsey has implemented through
domestic legislation matters related to (i) the Foreign Account Tax Compliance Act (&ldquo;<B>FATCA</B>&rdquo;) contained in the United
States Internal Revenue Code of 1986 and the Treasury Regulations promulgated thereunder and (ii) the Organization for Economic Co-operation
and Development&rsquo;s regime known as the Common Reporting Standard (&ldquo;<B>CRS</B>&rdquo;). Pursuant to FATCA and CRS, disclosure
and reporting of information may be required, including disclosure of certain information about Shareholders, their ultimate beneficial
owners and/or controllers and their investment in the Company. You should consult your tax advisers regarding the possible implications
of FATCA, CRS and other similar regimes that may be relevant to your ownership and disposition of ordinary shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 125 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_022"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each
of the selling shareholders of the ADSs and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any
or all of their ADSs covered hereby on the Nasdaq Capital Market or any other stock exchange, market or trading facility on which the
ordinary shares or the ADSs are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling shareholders
may use any one or more of the following methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ordinary brokerage transactions and transactions in which the broker dealer solicits purchasers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">block trades in which the broker dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">purchases by a broker dealer as principal and resale by the broker dealer for its account;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">privately negotiated transactions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">settlement of short sales;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in transactions through broker dealers that agree with the selling shareholders to sell a specified number of such shares at a stipulated price per share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a combination of any such methods of sale; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other method permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The
selling shareholders may also sell shares under Rule&nbsp;144 or any other exemption from registration under the Securities Act, if available,
rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Broker
dealers engaged by the selling shareholders may arrange for other brokers dealers to participate in sales. Broker dealers may receive
commissions or discounts from the selling shareholders (or, if any broker dealer acts as agent for the purchaser of shares, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule&nbsp;2440; and in the case of a principal transaction a markup
or markdown in compliance with FINRA IM-2440.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In
connection with the sale of the ADSs or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the ADSs in the course of hedging the positions they assume.
The selling shareholders may also sell ADSs short and deliver these ADSs to close out their short positions, or loan or pledge the securities
to broker-dealers that in turn may sell these ADSs. The selling shareholders may also enter into option or other transactions with broker-dealers
or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other
financial institution of ADSs offered by this prospectus, which ADSs such broker-dealer or other financial institution may resell pursuant
to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The
selling shareholders and any broker-dealers or agents that are involved in selling the ADSs may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the ADSs purchased by them may be deemed to be underwriting commissions or discounts under the
Securities Act. Each selling shareholders has informed the Company that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the ADSs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 126 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We
are required to pay certain fees and expenses incurred by the Company incident to the registration of the ADSs. We have agreed to indemnify
the selling shareholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We
agreed to keep this prospectus effective until the earlier of (i)&nbsp;the date on which the ADSs may be resold by the selling shareholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule&nbsp;144, without the requirement
for the Company to be in compliance with the current public information under Rule&nbsp;144 under the Securities Act or any other rule
of similar effect or (ii)&nbsp;all of the ADSs have been sold pursuant to this prospectus or Rule&nbsp;144 under the Securities Act or
any other rule of similar effect. The ADSs will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the ADSs covered hereby may not be sold unless they have been registered or qualified
for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the ADSs may not simultaneously engage in market making
activities with respect to the ADSs for the applicable restricted period, as defined in Regulation&nbsp;M, prior to the commencement of
the distribution. In addition, the selling shareholders will be subject to applicable provisions of the Exchange Act and the rules and
regulations thereunder, including Regulation&nbsp;M, which may limit the timing of purchases and sales of the ADSs by the selling shareholders
or any other person. We will make copies of this prospectus available to the selling shareholders and have <FONT STYLE="background-color: white">informed
them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with
Rule&nbsp;172 under the Securities Act).&nbsp;</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Notice to prospective
investors in Australia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the &ldquo;<B>Corporations Act</B>&rdquo;);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission (&ldquo;<B>ASIC</B>&rdquo;), as a disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available under section 708 of the Corporations Act (&ldquo;<B>Exempt Investors</B>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The ordinary shares may not
be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the ordinary shares
may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any ordinary shares
may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise
in compliance with all applicable Australian laws and regulations. By submitting an application for the ordinary shares, you represent
and warrant to us that you are an Exempt Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As any offer of ordinary
shares under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those
securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under
Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the ordinary shares, you undertake to us
that you will not, for a period of 12 months from the date of issue of the ordinary shares, offer, transfer, assign or otherwise alienate
those ordinary shares to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2
of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 127 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Notice to prospective
investors in Canada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The ordinary shares may be
sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument
45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the ordinary shares must be
made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Securities legislation in
certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including
any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser
within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser should refer
to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars of these rights
or consult with a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to section 3A.3
of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements
of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Notice to prospective
investors in the European Economic Area</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In relation to each Member
State of the European Economic Area (each, a &ldquo;<B>Member State</B>&rdquo;), no ordinary shares have been offered or will be offered
pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the ordinary shares
which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member State and notified
to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of ordinary shares
may be made to the public in that Member State at any time under the following exemptions under the Prospectus Regulation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(c) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">provided that no such offer
of ordinary shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement
a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any ordinary shares or to whom
any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the Company that
it is a &ldquo;qualified investor&rdquo; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any ordinary
shares being offered to a financial intermediary as that term is used in the Prospectus Regulation, each such financial intermediary will
be deemed to have represented, acknowledged and agreed that the ordinary shares acquired by it in the offer have not been acquired on
a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances
which may give rise to an offer of any ordinary shares to the public other than their offer or resale in a Member State to qualified investors
as so defined or in circumstances in which the prior consent of the underwriters have been obtained to each such proposed offer or resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the purposes of this
provision, the expression an &ldquo;offer to the public&rdquo; in relation to ordinary shares in any Member State means the communication
in any form and by any means of sufficient information on the terms of the offer and any ordinary shares to be offered so as to enable
an investor to decide to purchase or subscribe for any ordinary shares, and the expression &ldquo;Prospectus Regulation&rdquo; means Regulation
(EU) 2017/1129.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 128 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Notice to prospective
investors in the United Kingdom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, in the United
Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at
persons who are &ldquo;qualified investors&rdquo; (as defined in the Prospectus Regulation as it forms part of domestic law by virtue
of the European Union (Withdrawal) Act 2018) (i) who have professional experience in matters relating to investments falling within Article
19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &ldquo;<B>Order</B>&rdquo;) and/or
(ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to
(d) of the Order (all such persons together being referred to as &ldquo;relevant persons&rdquo;) or otherwise in circumstances which have
not resulted and will not result in an offer to the public of the ordinary shares in the United Kingdom within the meaning of the Financial
Services and Markets Act 2000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any person in the United
Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as a basis for taking
any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively
by relevant persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Notice to prospective
investors in Japan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The ordinary shares have
not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none
of the ordinary shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of,
any &ldquo;resident&rdquo; of Japan (which term as used herein means any person resident in Japan, including any corporation or other
entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit
of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial
Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_023"></A><B>Expenses
of This Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We estimate that our expenses
in connection with this offering, other than underwriting discounts and commissions, will be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%"><FONT STYLE="font-size: 10pt">SEC registration fee</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; width: 9%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Nasdaq Capital Market listing fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Printing and engraving expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Transfer agent and registrar fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Miscellaneous costs</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All amounts in the table are estimates except
the SEC registration fee, the listing fee, and the FINRA filing fee. We will pay all of the expenses of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 129 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_024"></A><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain legal matters with
respect to English law and Guernsey law in connection with the validity of our ordinary shares registered hereby will be passed upon
for us by Orrick Herrington &amp; Sutcliffe (UK) LLP, United Kingdom and Carey Olsen (Guernsey) LLP, respectively. Certain matters of
U.S. federal law will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_025"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated financial
statements of OKYO Pharma Limited as of March 31, 2021, 2020 and 2019, and for each of the years then ended, have been included herein
and in the registration statement in reliance on the report of Mazars LLP, an independent registered public accounting firm, appearing
elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. The registered business address of Mazars
LLP is Tower Bridge House, St Katherine&rsquo;s Way, London E1W 1DD, United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_026"></A><B>SERVICE OF PROCESS AND ENFORCEMENT OF LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated and currently
existing under the laws of Guernsey. In addition, certain of our directors and officers reside outside the United States, and most of
the assets of our non-U.S. subsidiaries are located outside the United States. As a result, it may not be possible for investors to effect
service of process within the United States upon OKYO or those persons or to enforce against OKYO or them, either inside or outside the
United States, judgments obtained in U.S. courts, or to enforce in U.S. courts, judgments obtained against them in courts in jurisdictions
outside the U.S., in any action predicated upon civil liability provisions of the federal securities laws of the United States. Both in
original actions and in actions for the enforcement of judgments of U.S. courts, there is doubt as to whether civil liabilities predicated
solely upon the U.S. federal securities laws are enforceable in Guernsey. See &ldquo;Description of Share Capital and Memorandum and Articles
of Incorporation&mdash;Enforcement of Civil Liabilities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_027"></A><B>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have filed with the SEC
a registration statement (including amendments and exhibits to the registration statement) on Form F-1 under the Securities Act. This
prospectus, which is part of the registration statement, does not contain all of the information in the registration statement and its
exhibits. For further information with respect to us and the ADSs offered by this prospectus, we refer you to the registration statement
and the exhibits and schedules to the registration statement. Statements contained in this prospectus as to the contents of any contract
or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other
document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by the filed exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You may review a copy of
the registration statement, including exhibits and any schedule filed therewith, and obtain copies of such materials at the SEC&rsquo;s
Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference
Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet website (www.sec.gov) that contains reports, proxy and information
statements and other information regarding issuers, like us, that file electronically with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon completion of this offering,
we will be subject to the information reporting requirements of the Exchange Act applicable to FPIs. Accordingly, we will be required
to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. Those reports may be
inspected without charge at the locations described above. As an FPI, we will be exempt from the rules under the Exchange Act related
to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting
and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the
Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities
are registered under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We also maintain a website
at www.okyopharma.com contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website
address in this prospectus is an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 130 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_028"></A>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
PHARMA LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="#f_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting
    Firm</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#f_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#f_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Comprehensive Income</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#f_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholders&rsquo;
    Equity</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#f_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statement of Cash Flows</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#f_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 131; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="f_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors and Shareholders of OKYO Pharma Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Opinion
on the Consolidated Financial Statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of OKYO Pharma Limited and its subsidiary (the Group) as of March 31, 2021,
2020 and 2019, the related consolidated statements of operations and comprehensive loss, shareholders&rsquo; equity, and cash flows for
each of the three years in the period ended March 31, 2021 and the related notes (collectively referred to as the consolidated financial
statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of
the Group as of March 31, 2021, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the
period ended March 31, 2021, in conformity with International Financial Reporting Standards as issued by the International Accounting
Standards Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Material
uncertainty related to Going Concern</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the group will continue as a going concern. We draw attention
to Note 2 in the consolidated financial statements, which sets out the Directors&rsquo; view on the Group&rsquo;s requirement to secures
sufficient investment to fund their pre-clinical activity. As stated in Note 2, these events or conditions, along with the other matters
as set forth in Note 2, indicate that a material uncertainty exists that may cast significant doubt on the Group and Parent Company&rsquo;s
ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the
outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinion is not modified in respect of this matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Basis
for Opinion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Group&rsquo;s management. Our responsibility is to express an opinion
on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. The Group is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit procedures we
are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Group&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mazars
LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London,
England</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
23, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have serviced the Group as auditors since 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Pharma Limited </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="f_002"></A>Consolidated
Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020 (restated)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Current assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,889,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">235,485</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">627,617</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Related party receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,664</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Taxation receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,387</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other receivables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">236,947</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">131,198</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,986,686</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">568,009</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">758,815</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and Equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,057</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">635</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,105</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Right of use asset</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">98,579</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">30,099</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 20pt">Total non-current assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">104,636</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">30,734</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,105</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 20pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,091,322</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">598,743</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">759,920</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,673,154</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">663,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">419,614</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Related party payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,139</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Lease liabilities - current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,148</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,091</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,707,302</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">712,259</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">426,753</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Lease liabilties - non current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">64,612</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,598</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,771,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">738,857</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">426,753</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shareholders&rsquo; Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Share capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,629,173</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,079,984</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,741,860</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share options reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">636,313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93,441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrants reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">861,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">639,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,242</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible Loan Note reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,370,836</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrants to be issued reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Foreign currency translation reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,174,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,520,740</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,607,394</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Retained earnings</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(106,003,753</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(102,432,702</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(100,888,643</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,319,408</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(140,114</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">333,166</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 20pt">Total liabilities and shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,091,322</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">598,743</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">759,920</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 133 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Pharma Limited </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="f_003"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Operations and Comprehensive Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Revenue</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cost of revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Gross Profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%">Research</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(173,821</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(518,098</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(3,064,296</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Operating Expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,192,385</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,016,548</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,505,532</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total operating expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,366,206</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,534,646</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,569,828</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income/(expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finance Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,123</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Finance (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,158</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Impairment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,172</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(132,668</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(365,477</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Loss from operations before income taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,378,501</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,620,347</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,935,305</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Income tax provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,289</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Loss for the year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,353,507</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,544,059</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,935,305</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other Comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Currency translation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(289,249</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,007,142</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,457,405</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,224,554</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Basic and diluted loss per share attributable to common shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 134 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Pharma Limited </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="f_004"></A>Consolidated
Statements of Shareholders&rsquo; Equity</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">No. of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Convertible Loan Note reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant to be issued reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Retained Earnings</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Translation Reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; font-weight: bold; padding-bottom: 1.5pt; width: 41.5%; text-indent: -9pt">Balance at 1&nbsp;April&nbsp;2018</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; padding-bottom: 1.5pt; text-align: right">388,395,417</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">108,958,365</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right">(95,953,338</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 0.5%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 5%; font-weight: bold; text-align: right">(10,318,145</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 0.5%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 0.5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,686,882</TD><TD STYLE="width: 0.5%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">Issue of share capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,712,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,783,495</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,783,495</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Options charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt">Warrants charge</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30,242</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30,242</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Total transactions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,783,495</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,870,838</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-decoration: underline; text-align: left; text-indent: -9pt">Comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,935,305</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,935,305</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Currency translation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(289,249</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(289,249</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt">Total comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,935,305</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(289,249</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,224,554</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; font-weight: bold; padding-bottom: 1.5pt; text-indent: -9pt">Balance at 31 March 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">524,108,283</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">111,741,860</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">57,101</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">30,242</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(100,888,643</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,607,394</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">333,166</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">Issue of share capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,188,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">965,171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">965,171</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Options charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt">Warrants charge</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(627,047</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">609,661</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,386</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Total transactions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">338,124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">609,661</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">984,125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-decoration: underline; text-align: left; text-indent: -9pt">Comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,544,059</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,544,059</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt">Currency translation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt">Total comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,544,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,457,405</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; font-weight: bold; text-align: left; text-indent: -9pt">Balance at 31&nbsp;March&nbsp;2020 (restated)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">636,297,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">112,079,984</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">93,441</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">639,903</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(102,432,702</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(10,520,740</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(140,114</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt">Issue of share capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,269,253</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Options charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,870</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,515</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,515</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,870</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Options forfeiture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,751</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,751</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Warrants charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,006</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Convertible loan note issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(558,395</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,151,777</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,593,382</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Convertible loan note interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">219,059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(219,059</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Total transactions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(450,812</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">542,872</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,370,836</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(217,544</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,466,664</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-decoration: underline; text-align: left; text-indent: -9pt">Comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,353,507</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346,365</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,007,142</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Currency translation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: left; text-indent: -9pt">Total comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; font-weight: bold; text-indent: -9pt">Balance at 31 March 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">672,816,302</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">111,629,173</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">636,313</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">861,214</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">8,370,836</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(106,003,753</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(10,174,375</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,319,408</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 135 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Pharma Limited </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="f_005"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Loss from operations before income taxes</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(3,378,501</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(1,620,347</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,935,305</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">/Noncash license and corporate finance fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,783,494</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share option charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrant charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,242</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">426</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">219</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Depreciation of right of use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,553</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss on foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,915</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,175</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options forfeiture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,751</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Impairment of loan to West African Minerals Ltd</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,668</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">365,477</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss on disposal of right of use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(818</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amortisation of right of use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,601</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (increase) in related party receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,862</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(543</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net (decrease)/increase in related party payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46,311</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net /decrease/(increase) in operating assets/other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,931</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(122,190</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,021</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net (decrease)/increase in trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">886,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">271,218</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">310,012</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Cash inflow from taxation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,600,198</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,202,065</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,521,955</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>PPE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,943</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,331</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loan to West African Minerals Ltd</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,171</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,668</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(365,477</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,114</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,668</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(366,808</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issuance of ordinary shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">990,639</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from issuance of convertible loan notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,593,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Processed from options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,870</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loan to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(518,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loan repayment from related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">496,810</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Repayment of leasing liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,331</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,139</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,826,938</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">963,310</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase/(decrease) in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,208,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(371,423</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,888,763</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash and cash equivalent, beginning of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">627,616</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,814,475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Exchange difference</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,708</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(298,096</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash and cash equivalent, end of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,889,329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,485</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">627,616</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 136 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0"><A NAME="f_006"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
GENERAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (the &ldquo;Company&rdquo; or &ldquo;OKYO&rdquo;) is a company domiciled in Guernsey and listed on the standard market
of the London Stock Exchange (LON:OKYO).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain.
Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through
our collaboration with pioneer scientists in the field.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies
have been applied consistently to all the years and periods presented unless otherwise stated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of preparation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS)
as issued by the International Accounting Standards Board, IFRIC interpretations and the Companies (Guernsey) Law 2008 as applicable
to companies reporting under IFRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group and Company incurred losses during the year and has net assets at the year ended March 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group and Company is in the early stages of developing its business focusing on drug candidates for the treatment of dry-eye, uveitis,
ocular and chronic pain. The Directors expect the Group and Company to incur further losses and to require significant capital expenditure
in continuing towards the clinical stage for these candidates. The Group and Company has successfully secured additional investment funds
to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment
to fund that operation. On the basis of those projections, the directors conclude that the company will be able to meet its liabilities
as they fall due a period beyond the next 12 months from the date when these financial statements are issued and accordingly the Directors
have prepared the financial statements on a going concern basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there is a material uncertainty about
the Group and Company&rsquo;s ability to continue as a going concern after December 2022, and therefore about the applicability of the
going concern basis of preparation. The financial statements do not include the adjustments that would be required if the going concern
basis of preparation was considered inappropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"></P>

<!-- Field: Page; Sequence: 137 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary
undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following:
(a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability
to use its power over the investee to affect the amount of the investor&rsquo;s return.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered
when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control
and are de-consolidated from the date at which control ceases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inter-company
transactions, balances and unrealized gains on transactions between group companies are eliminated upon consolidation. Unrealized losses
are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted
by the Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Segment
reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and
assess the performance of the segments. The Board considers there to be only one operating segment being the research and development
of biotechnological and pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax credit for the year represents the total of current taxation and deferred taxation. The credit in respect of current taxation is
based on the estimated taxable loss for the year. Taxable profit or loss for the year is based on the profit or loss as shown in the
statement of comprehensive income, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes.
The current tax asset for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance
sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities
and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have
been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realized, or the
deferred liability is settled. Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will
be available against which the temporary differences can be utilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development tax credits are provided for in the year that the costs are incurred. These are estimated based on eligible research
and development expenditure. Any difference rebated are recognized in the following year, when the cash is received from the UK tax authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Functional
currency and foreign currency translation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements of each of the Group&rsquo;s entities are measured using the currency of the primary economic environment
in which the entity operates (the functional currency), which is Pounds sterling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in US dollars, which is the Group&rsquo;s presentation currency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 138 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of overseas subsidiary undertakings are translated into US dollars on the following basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets and liabilities at the rate of exchange ruling
    at the year-end date.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit and loss account items at the average rate of
    exchange for the year.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
fees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
related to the acquisition of rights to a product or technology are capitalized as intangible assets if it is probable that future economic
benefits from the asset will flow to the entity and the cost of the asset can be reliably measured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire
an asset. License fees expenses are recognized as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment
inherent in the development of the Group&rsquo;s products, the criteria for development costs to be recognized as an asset, as set out
in IAS 38 &lsquo;Intangible Assets&rsquo;, are not met until a product has been granted regulatory approval and it is probable that future
economic benefit will flow to the Group. The Group currently has no qualifying expenditure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument
in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an
equity instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component.
Such components shall be classified separately as financial assets, financial liabilities or equity instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument
of another entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Financial assets, initial recognition and measurement and subsequent measurement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
recognition is at cost and subsequent measurement of financial assets depends on their classification. Financial assets such as receivables
and deposits are subsequently measured at amortized cost using the effective interest method, less loss allowance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Financial liabilities, initial recognition and measurement and subsequent measurement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 139 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition, financial liabilities are measured at their fair value minus, if appropriate, any transaction costs that are directly
attributable to the issue of the financial liability. All financial liabilities are subsequently measured at amortized cost using the
effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss
on derecognition is also recognized in profit or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&rsquo;s financial liabilities include trade and other payables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Impairment
of financial assets measured at amortized cost</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date the Group recognizes a loss allowance for expected credit losses on financial assets measured at amortized cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
establishing the appropriate amount of loss allowance to be recognized, the Group applies either the general approach or the simplified
approach, depending on the nature of the underlying group of financial assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
approach</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted
cash and cash and cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the general approach the Group recognizes a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses,
unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is
recognized at an amount equal to the lifetime expected credit losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Simplified
approach</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
simplified approach is applied to the impairment assessment of trade receivables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the simplified approach the Group always recognizes a loss allowance for a financial asset at an amount equal to the lifetime expected
credit losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Impairment
of non financial assets </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
assets are impaired when its carrying amount exceed its recoverable amount. The recoverable amount is measured as the higher of fair
value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts
discounted back to present value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares of the company are classified as equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property,
plant and equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(i)
Recognition and measurement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
of property, IT and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures
that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related
equipment is capitalized as part of that equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
parts of an item of property, IT and equipment have different useful lives, they are accounted for as separate items (major components)
of property, IT and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the
revaluation reserve are transferred to retained earnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"></P>

<!-- Field: Page; Sequence: 140 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(ii)
</I>Depreciation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is recognized in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, IT and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current period and the comparative period are as follows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 84%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT and equipment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3 years</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixtures and fittings</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5 years</B></FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line
of the income statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
leases are accounted for by recognising a right-of-use asset and a lease liability except for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
                                            of low value assets; and</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
                                            with a duration of 12 months or less.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have any short-term leases or leases of low value assets. Variable lease payments which do not depend on an index or a rate
(such as lease payments based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset.
The Group classifies its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 11).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Measurement
and recognition of leases as a lessee</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
lease commencement date, the Group recognises a right-of-use asset and a lease liability in its consolidated statement of financial position.
The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs
incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made
in advance of the lease commencement date (net of any incentives received).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 3.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group depreciates the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful
life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such
indicators exist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 3.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted
using the Group&rsquo;s incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible
to determine the interest rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would
have to pay to borrow the same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate
is adjusted should the lessee entity have a different risk profile to that of the Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.15pt 0pt 3.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.15pt 0pt 3.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 141 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.15pt 0pt 3.2pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments
based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably
certain to be exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.15pt 0pt 3.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to initial measurement, the liability will be reduced by lease payments that are allocated between repayments of principal and finance
costs. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
have assessed the categorisation of the fair value measurements using the IFRS 13 fair value hierarchy. Categorisation within the hierarchy
has been determined on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset
as follows;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - valued using quoted prices in active markets for identical assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - valued by reference to valuation techniques using observable inputs other than quoted prices included within Level 1;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - valued by reference to valuation techniques using inputs that are not based on observable market data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
based payments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
company&rsquo;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value
of the awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
employees, directors or advisers are rewarded using share based payments, the fair value of the employees&rsquo;, directors&rsquo; or
advisers&rsquo; services are determined by reference to the fair value of the share options / warrants awarded. Their value is appraised
at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).
Warrants issued in association with the issue of Convertible Loan Notes are also considered as share based payments and a share based
payment charge is calculated for these too.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with IFRS 2, a charge is made to the Statement of Comprehensive Income for all share-based payments including share options
based upon the fair value of the instrument used. A corresponding credit is made to a Share Based Payment Reserve, in the case of options
awarded to employees, directors, advisers, and other consultants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate
of the number of share options expected to vest. Non market vesting conditions are included in assumptions about the number of options
that are expected to become exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
are subsequently revised, if there is any indication that the number of share options expected to vest differs from previous estimates.
No adjustment is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are exercised
than originally estimated. Exercise of share options / warrants, the proceeds received are allocated to share capital with any excess
being recorded as share premium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
share options are cancelled, this is treated as an acceleration of the vesting period of the options. The amount that otherwise would
have been recognized for services received over the remainder of the vesting period is recognized immediately within the Statement of
Comprehensive Income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 142 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
goods and services received in exchange for the grant of any share based payment are measured at their fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
are issued by the Group in return for services and as part of a financing transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrants
issued in return for services.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued in return for services fall within scope of IFRS 2. The financial liability component is measured at fair value and charged to
the Consolidated Statement of Income. There is no remeasurement of fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrants
issued as part of a financing transaction.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued as part of a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed
amount of cash is exchanged for a fixed amount of equity. The relative fair value is recognised within equity and is not remeasured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
of these instruments is governed by the so-called &lsquo;fixed&rsquo; test for non-derivatives, and the &lsquo;fixed for fixed&rsquo;
test for derivatives. Under the fixed test, a non-derivative contract will qualify for equity classification only where there is no contractual
obligation for the issuer to deliver a variable number of its own equity instruments. Under the fixed for fixed test, a derivative will
qualify for equity classification only where it will be settled by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued by the Group are classified as equity instruments because a fixed amount of cash is exchanged for a fixed amount of equity of
the Group. No other features exist that would result in financial liability classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
is measured at the residual between the subscription price for the entire instrument and the liability component and is not remeasured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
loan notes </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Where
there is no option to repay in cash or the Company has the choice of settlement, and the interest rate is fixed,</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group considers these to be convertible equity instruments and records the principal of the loan note as equity in a Convertible loan
note reserve. The accrued interest on the principal amount, for which there is no obligation to settle in cash, is also recorded in the
Convertible loan note reserve. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the
convertible loan note reserve to share capital and share premium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Where
the above conditions are not met </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group considers these to be convertible debt instruments and records the principal of the loan note as a debt liability in the liabilities
section of the statement of financial position. The accrued interest on the principal amount is recorded in the income statement and
as an increase in the debt liability. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from
the debt liability to share capital and share premium. Under IAS 32 the liability and equity components of convertible loan notes must
be presented separately on the statement of financial position. The Group has examined the terms of each issue of convertible loan notes
and determined their accounting treatment accordingly. Convertible loan notes are treated differently depending upon a number of factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial information in accordance with generally accepted accounting practice, in the case of the Group being International
Financial Reporting Standards as adopted by the European Union, requires the Directors to make estimates and judgements that affect the
reported amount of assets, liabilities, income and expenditure and the disclosures made in the financial statements. Such estimates and
judgements must be continually evaluated based on historical experience and other factors, including expectations of future events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are considered to be critical accounting estimates:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share-based
payments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group accounts for share-based payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement
of the cost of employee services received in exchange for the options on our ordinary shares, based on the fair value of the award on
the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors selected the Black-Scholes-Merton option pricing model as the most appropriate method for determining the estimated fair value
of our share-based awards without market conditions. For performance-based options that include vesting conditions relating to the market
performance of our ordinary shares, a Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that
have to be met as conditions to vesting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resulting cost of an equity incentive award is recognised as expense over the requisite service period of the award, which is usually
the vesting period. Compensation expense is recognised over the vesting period using the straight-line method..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used for estimating fair value for share-based payment transactions are disclosed in note 16 to our consolidated financial
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"></P>

<!-- Field: Page; Sequence: 143 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are considered to be critical accounting judgments:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred and are typically made up of clinical and preclinical activities, drug development
and manufacturing costs, and third-party service fees, including for clinical research organizations and investigative sites. When entering
into agreements with third parties which provide the rights to conduct research into specific biological processes the Group accounts
for these agreements as an expense if the agreements are 'milestone' in nature and relate to the Group's own research and development
costs. Such agreements involve periodic payments and are evaluated as representing payments made to fund research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
16 defines the lease term as the non-cancellable period of a lease together with the options to extend or terminate a lease, if the lessee
were reasonably certain to exercise that option. This will take into account the length of time remaining before the option is exercisable,
current trading, future trading forecasts as to the ongoing profitability of the organisation and the level and type of planned future
capital investment. The judgement is reassessed at each reporting period. A reassessment of the remaining life of the lease could result
in a recalculation of the lease liability and a material adjustment to the associated balances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
CHANGES IN ACCOUNTING POLICIES AND PRIOR YEAR ADJUSTMENT</B>S</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IFRS
16 Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
group has adopted IFRS 16 retrospectively from 1 April 2019 but has not restated comparatives for the 2019 reporting period, as permitted
under the specific transitional provisions in the standard. The reclassifications and the adjustments arising from the new leasing rules
are therefore recognized in the opening balance sheet on 1 April 2019 and there was no cumulative effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
adoption of IFRS 16, the group recognized lease liabilities in relation to leases which had previously been classified as &lsquo;operating
leases&rsquo; under the principles of IAS 17 Leases. These liabilities were measured at the present value of the remaining lease payments,
discounted using the lessee&rsquo;s incremental borrowing rate as of 1 April 2019. The weighted average lessee&rsquo;s incremental borrowing
rate applied to the lease liabilities on 1 April 2019 was 3.34%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group assesses whether a contract is or contains a lease at inception of the contract. The Group recognizes a right-of-use assets and
corresponding lease liabilities at the lease commencement date, except for short term leases and leases of low value. For these leases,
the lease payments are recognized as an operating expense on a straight-line basis over the term of term of the lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liabilities adjusted for any lease
payments made at or before the commencement date, plus any initial costs incurred. The right-of-use assets are subsequently measured
at cost less accumulated depreciation and impairment losses. The right-of-use assets are from the commencement date depreciated over
the shorter period of lease term and useful life of the underlying asset. The estimated useful lives of right-of-use assets are determined
on the same basis as those of property and equipment. In addition, the right-of-use assets are periodically reduced by impairment losses,
if any, and adjusted for certain remeasurements of the lease liabilities, e.g. revised discount rate, change in the lease term or change
in future lease payments resulting from a change in an index.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted
using the interest rate determined by the Group&rsquo;s borrowing rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2019<BR>
    $</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 88%; text-align: left; text-indent: -0.125in">Operating lease commitments disclosed under IAS17 as at 31 March 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">42,001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Remaining lease commitments discounted using the Group&rsquo;s incremental borrowing rate as at the date of initial application</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,652</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Lease Liability recognised as at 1 April 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,652</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Of which:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Current lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,965</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Non-current lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,687</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
associated right-of-use assets for all leases were measured at the amount equal to the lease liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 144 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
recognized right-of-use assets relate to the following types of assets:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>31 March<BR>
    2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>1 April <BR>
    2019</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Properties</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">30,099</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">35,652</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,652</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying IFRS 16 for the first time, the Group has used the following practical expedients permitted by the standard:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
use of a single discount rate of 3.34% to a portfolio of leases with reasonably similar characteristics;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Impairment
loss reclassification</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ending March 31, 2020, the Group reviewed its accounting classification for its expenses regarding West African Mineral Ltd
(WAML). See Note 19 for more information. These costs were determined to be an impairment loss and not a Research and Development expense,
so a reclassification was made of $365,477 in the Statements of Operations and Comprehensive Loss for the year ending March 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accounting
for warrants issued as part of a cash fundraise &ndash; Prior year adjustment</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ending March 31, 2021, the Group reviewed the accounting for warrants that were issued as part of a cash fundraise that took
place in March 2020. The accounting treatment of relative fair value was identified as the most appropriate methodology, rather than
the separate valuation of the warrants as a cost of fundraising. The impact of the change in accounting treatment resulted in a reduction
in share capital of $1,435,508 and a corresponding increase in the warrant reserve of $1,435,508.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
OPERATING LOSS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
loss is stated after charging:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Year Ended&nbsp;March 31</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; font-style: italic">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2019</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><I>Group</I></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD STYLE="text-align: center"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 1.7pt">Director fees including bonus</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">278,224</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">122,101</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">130,034</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.7pt">Chairman&rsquo;s bonus</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,160,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 1.7pt">Audit fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,874</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,402</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,895</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.7pt">FX Gains and losses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,061</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,918</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 1.7pt">Depreciation</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,512</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">212</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">219</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 145 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
SEGMENTAL REPORTING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year under review management identified the Group&rsquo;s only operating segment as the research and development of biotechnological
and pharmaceutical products. This one segment is monitored and strategic decisions are made based upon it and other non-financial data
collated from industry intelligence. The form of financial reporting reported to the Board is consistent with those presented in the
annual financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
EMPLOYEES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<BR>
$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2020</B><BR><B>$</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2019<BR>
</B><B>$</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0; text-indent: 0"><U>Group</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Staff costs comprised:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 64%; text-align: left; text-indent: -0.125in">Directors&rsquo; salaries</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,438,571</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">122,101</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">129,994</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Wages and salaries</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,702</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">244,655</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Social security costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,543</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,757</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Recruitment Costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,922</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 4pt; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,582,739</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">420,188</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">424,406</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">The average monthly number of employees, including directors, employed by the group during the year was:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Corporate and administration</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 4pt; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group and Company made $2,904 (2020: $2,774) of payments to a defined contribution pension schemes on behalf of Directors or employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 146 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
REMUNERATION OF KEY MANAGEMENT PERSONNEL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
of the Group and Company received the following remuneration during the period:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-align: center; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="30" STYLE="font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-align: center; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&rsquo;<BR> fees</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based payment expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors&rsquo;<BR> fees</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based payment expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 20%; text-align: left; text-indent: -0.125in">G. Cerrone (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">35</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1,160</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right"><B>-</B></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">G Jacob (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">468</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>-</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">W Simon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>41</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-style: normal; font-weight: normal; text-align: right"><B STYLE="font-style: normal; font-weight: normal">4</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">K. Shailubhai</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>38</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-style: normal; font-weight: normal; text-align: right"><B STYLE="font-style: normal; font-weight: normal">31</B></TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">J Brancaccio (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>-</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">G Macrae (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>8</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">L Zambeletti (5)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><B>36</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 4pt; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">158</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,201</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">85</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">503</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right"><B>122</B></TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">41</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Year ended March 31,</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">$&rsquo;000</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2019</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Directors<BR> fees</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share based<BR>
 payment<BR>
 expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">W Simon</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">42,017</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,424</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">K. Shailubhai</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,496</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Leopoldo Zambeletti (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,742</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gregor MacRae (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">John Brancaccio (3)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">129,994</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">48,661</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele Cerrone&rsquo;s bonus awarded for $1,224k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19 indication when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring, backing and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory appointments to the Board with the result that the Company now has a clear and accelerated path to the clinic.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary Jacob became an employee and Director of the Company on 7 January 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Brancaccio was appointed as Director on 10 June 2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregor Macrae was appointed as Director on 18 December 2019 and resigned on 10 June 2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leopoldo Zambeletti resigned as Director on 18 December 2019</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following share options were granted to Directors in the year:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 64%; text-align: left; text-indent: -0.125in">W. Simon</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">L Zambeletti</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">K Shailubhai</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">J Brancaccio</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">G. Jacob</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">40,000,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 4pt; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">40,450,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">22,000,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key management personnel of the Group are considered to be represented by the Directors and officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director as yet benefitted from any increase in the value of share capital since issuance of the options and no director exercised share
options in the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 148 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
TAXATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021<BR>
$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<BR>
$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019<BR>
$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 0; font-weight: bold; text-indent: 0"><U>Group</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 64%; text-align: left; text-indent: -0.125in">Current year tax (credit)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(24,952</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Adjustments due to R&amp;D Tax credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,289</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Total tax (credit) for the period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(76,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 21.49%. The difference can be reconciled as follows:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Loss before taxation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,378,501</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,620,347</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,935,305</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Loss charged at standard rate of corporation tax 19%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(641,915</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(307,866</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(937,708</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Tax losses arising in the year not recognized</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">660,594</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">340,114</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">820,856</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Expenses not deductible for taxation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,623</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Tax increase from effect of capital allowances and depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(334</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(211</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Research and Development tax claim</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,432</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Adjustments due to R&amp;D Tax credit in prior periods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,289</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Consolidation adjustment in relation to foreign exchange movements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32,504</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Loans written off</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">69,441</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Total tax (credit) for the period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(76,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
deferred tax asset has been recognised in respect of trading losses carried forward because of uncertainty as to when these losses will
be recoverable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has tax losses of $9,411,521 (2020: $4,421,886) to carry forward for use against future profits<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 149 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
FINANCE INCOME AND COSTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021<BR>
$&rsquo;000</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020<BR> $&rsquo;000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019<BR> $&rsquo;000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Group</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in"><U>Finance Income</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Finance income interest received on loan</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">48,125</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Total finance income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-decoration: underline; text-align: left; text-indent: -0.125in">Finance Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Interest expense on lease liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,122</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,158</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Total finance expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,122</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,158</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">Net finance expense recognized in Statement of Comprehensive Income</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,122</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">46,967</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
PROPERTY, PLANT AND EQUIPMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Group&lsquo;s property, plant and equipment are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$000</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>IT&nbsp;equipment</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cost</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At 1 April 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,257</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,257</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,944</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,944</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposals</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign exchange</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">142</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At 31 March 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,343</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,343</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Depreciation</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At 1 April 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">635</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">635</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charge in year</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,593</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,593</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign exchange</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At 31 March 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,286</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,286</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Book Value as at 31 March 2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,057</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,057</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$000</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IT&nbsp;equipment</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cost</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At 1 April 2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,323</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,323</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposals</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign exchange</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At 31 March 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,257</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,257</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Depreciation</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At 1 April 2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign exchange</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charge in year</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">416</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">416</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At 31 March 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">622</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">622</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Book Value as at 31 March 2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">635</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">635</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$000</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IT&nbsp;equipment</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cost</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At 1 April 2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,323</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,323</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposals</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At 31 March 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,323</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,323</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Depreciation</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At 1 April 2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charge in year</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>At 31 March 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net Book Value as at 31 March 2019</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,105</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,105</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 150 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
OTHER RECEIVABLES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Group</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Security deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Other receivables</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,499</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">222,492</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,508</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">VAT receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,103</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,971</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Prepayments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,072</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,352</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,719</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,370</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">236,947</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">131,198</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no differences between the carrying amount and fair value of any of the trade and other receivables above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
TRADE AND OTHER PAYABLES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">$000</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Group</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Trade payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">210,992</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">595,057</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">381,790</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Accruals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,261</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,627</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chairman&rsquo;s Bonus accrual</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,224,083</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other creditors</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27,964</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,197</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,673,154</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">663,282</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">419,614</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
CAPITAL AND RESERVES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
Management</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of the Group&rsquo;s capital management, capital includes called up share capital, share premium, share based payments for
options, share based payments for warrants and all other equity reserves attributable to the equity holders of the parent as reflected
in the statement of financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s objectives when managing capital are to safeguard the Company&rsquo;s ability to continue as a going concern and to maximise
shareholder value through the optimisation of the debt and equity balance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group manages its capital to maximise the return to the shareholders through the optimisation of equity. The capital structure of the
Group at 31 March 2021 consists of equity attributable to equity holders of the Company, comprising issued capital, reserves and retained
deficit as disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group manages its capital structure and makes adjustments to it, in light of economic conditions and the strategy approved by shareholders.
To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders
or issue new shares and release the Company&rsquo;s share premium account. No changes were made in the objectives, policies or processes
during the year ended 31 March 2021 and 31 March 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
capital and premium</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorised to issue an unlimited number of nil par value shares of a single class. The Company may issue fractional shares
and a fractional share shall have the corresponding fractional rights, obligations and liabilities of a whole share of the same class
or series of shares. Shares may be issued in one or more series of shares as the Directors may by resolution determine from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share in the Company confers upon the shareholder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
right to one vote at a meeting of the shareholders or on any resolution of shareholders;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
right to an equal share in any dividend paid by the Company; and</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
right to an equal share in the distribution of the surplus assets of the Company on its liquidation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may by resolution of the Directors redeem, purchase or otherwise acquire all or any of the shares in the Company subject to regulations
set out in the Company&rsquo;s Articles of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 151 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Authorized</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue an unlimited number of nil par value shares of a single class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Shares</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Share capital</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-align: justify; border-bottom: Black 1.5pt solid; text-indent: -0.125in"><B>Issued ordinary shares of US$0.00 each</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>$</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 76%; padding-bottom: 4pt; text-indent: -0.125in">At 31 March 2018</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">388,395,417</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">108,958,365</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Shares issued on lieu of fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,712,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,783,494</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 4pt; text-indent: -0.125in">At 31 March 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">524,108,283</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">111,741,860</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Shares issued - private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,188,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">965,171</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">Relative fair value charge for warrants issued in conjunction with private placement</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(627,047</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">At 31 March 2020 (restated)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">636,297,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,079,984</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Shares issued - private placement</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">36,269,253</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Relative Fair value charge for warrants issued in conjunction with private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(138,305</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">CLNs issued in lieu of fundraising commission</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(558,395</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,870</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 4pt; text-indent: -0.125in">At 31 March 2021</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">672,816,302</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">111,629,173</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Issuance
of ordinary shares</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
1 May 2018, the Company acquired the OK-101 Project and the BAM-8 Project. These acquisitions were settled via the issue of 135,000,000
Ordinary Shares credited fully paid at a price of 1.5 pence each.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
21 May 2018, the Company engaged Stockdale securities Ltd. &pound;2,500 of the corporate finance fee was satisfied by the issue to Stockdale
of 200,000 new ordinary at an issue price of 1.25p per ordinary share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
22 October 2018, 512,866 ordinary shares were issued at an issue price of 1.5p per ordinary share as part of an amendment to a collaboration
agreement with On Target Therapeutics LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, 36,363,636 ordinary shares were issued at an issue price of 1.1p per ordinary share by way of a placing of ordinary shares
to raise finance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, 75,825,130 ordinary shares were issued at an issue price of 1.1p per ordinary share by way of a further placing of ordinary
shares to raise finance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, 36,269,253 ordinary shares were issued at an issue price of 0.005p per ordinary share by way of a placing of ordinary shares
to raise finance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, 250,000 ordinary shares were issued in relation to an exercise of options at an issue price of 0. 045p per ordinary share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
options reserve</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
reserves comprise the cumulative share-based payment charge on outstanding options in issue as at 31 March 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant&rsquo;s
reserve</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
reserves comprise the cumulative share-based payment charge on outstanding warrants in issue as at 31 March 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors paid no dividend during the year to 31 March 2021 and 31 March 2020<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 152 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
INVESTMENT IN SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s interest in subsidiary undertakings is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%; padding-right: 0; padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
    activity</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 26%; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered
    Address</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage<BR>

    shareholding</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country
    of<BR>
 incorporation</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
    Pharma US Inc</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    stage biotechnology company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108
    West 13<SUP>th</SUP> Street,</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wilmington</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19801</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma US Inc was incorporated on 2 July 2018. This entity was set up to house the Company&rsquo;s US operations<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the prior year, the Company undertook an impairment review of its investments in subsidiaries. The Company had been funding its subsidiary
operations from funds raised by the Company for the development of its project portfolio. The subsidiary&rsquo;s activities had all been
to support the Company in achieving its goals for progression of the project portfolio. The funding provided to the subsidiaries prior
to 2020 had been recognised in the Company as investment in its subsidiaries, and the Company did not expect the amounts to be repaid.
The IP relating to the project portfolio belongs to the Company and hence any future benefits will also belong to the Company. It is
highly unlikely that these benefits would be distributed to the subsidiaries. The Company therefore determined in the prior year that
the investment should be impaired .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 153 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
SHARE OPTIONS AND WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Options</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates share-based payment arrangements to remunerate Directors and key employees in the form of a share option scheme. It
also issues options in lieu of fees to key suppliers and collaborators. The exercise price of the option is normally equal to the market
price of an ordinary share in the Company at the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center; text-indent: -0.125in">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<BR>
 Average<BR>
 exercise<BR>
 price (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<BR>
 Average<BR>
 exercise<BR>
 price (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<BR>
 Average<BR>
 exercise<BR>
 price (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 28%; text-indent: -0.125in">Outstanding at 1 April</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">6.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">19,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">5.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">23,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.87</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.21</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(750,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5.58</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,500,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.21</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(250,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Outstanding at 31 March</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">60,750,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.58</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.87</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Exercisable at 31 March</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(6.21</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,250,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.58</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,875,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ending 31 March 2021, 250,000 options were exercised. No options were exercised in the years to 31 March 2020 and 31 March 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total outstanding fair value charge of the share option instruments is deemed to be approximately $2,710,263 (2020: $495,243, 2019: $81,199).
A share based payment charge for the year of $522,615 (2020: $37,495, 2019: $50,872) has been expensed in the statement of comprehensive
income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average contractual life of options outstanding at March 31, 2021 is 8.07 years. (2020: 5.27 years).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
value of options granted</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have used the Black-Scholes option pricing model to estimate the fair value of most of the options applying the assumptions
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any dividends on share capital since its inception and does not anticipate paying dividends on its share capital
in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has estimated a forfeiture rate of zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the year ended 31 March 2021 valued under the Black Scholes Valuation model included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 154 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any dividends on share capital since its inception and does not anticipate paying dividends on its share capital
in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has estimated a forfeiture rate of zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">20 August 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">6 January 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">12 January <BR>
2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 58%; text-align: left">Grant date share price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">15.5p</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.8p</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">0.79p</TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Exercise share price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.5p</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.5p</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.79p</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Vesting periods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25% each year</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25% each year </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33% in 6 months and 67% in 1 year</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0.01</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.4%, 0.6%</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66.7%, 83.7%</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 months to 1 year</FONT></P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Option life</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.79p</TD><TD STYLE="text-align: left"></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warrants</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the acquisition of the Chemerin project, the underlying scientific founders of the Chemerin Project (inukshuk Holdings),
who will continue to be involved in the development of the Project, received 35,000,000 warrants as consideration. The warrants are exercisable
at a price of 4.5 pence each and are split into four distinct tranches and each tranche becomes exercisable upon satisfaction of a specific
developmental milestone. The warrants are exercisable until 17 July 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, warrants were granted over 36,363,636 shares at an exercise price of 1.35p per share in connection with a private placement.
The warrants are exercisable until 19 May 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, warrants were granted over 40,000,000 shares at an exercise price of 0.55p per share in connection with a private placement.
The warrants are exercisable until 23 March 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, warrants were granted over 35,825,130 shares at an exercise price of 0.55p per share in connection with a private placement.
The warrants are exercisable until 28 May 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, warrants were granted over 36,174,870 shares at an exercise price of 0.55p per share in connection with a private placement.
The warrants are exercisable until 28 May 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, warrants were granted over 909,090 shares at an exercise price of 2.75p per share in in lieu of professional fees. The warrants
are exercisable until 21 May 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, warrants were granted over 750,000 shares at an exercise price of 14p per share in in lieu of broker fees. The warrants are
exercisable until 20 July 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <BR> Average <BR> exercise<BR>
 price <BR> (cents)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <BR> Average <BR> exercise<BR>
 price <BR> (cents)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> exercise<BR>
 price <BR> (cents)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%">Outstanding at 1 January</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">147,188,766</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6.2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">35,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,83,3960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,188,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Outstanding at 31 December</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">185,022,726</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">147,188.766</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Exercisable at 31 December</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">149,568,181</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 155 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have estimated the fair value of the warrants in services provided using the Black-Scholes valuation model based on the assumptions
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>July
    2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>May
2020</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 57%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant date
    share price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise share price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting periods</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully&nbsp;vested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50% of these warrants shall
    only vest if the 5-day VWAP of the Company exceeds a 100% premium to
    the Exercise Price, and the remainder shall only vest if the 5-day VWAP of the Company exceeds a 200% premium to the Exercise Price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk free rate</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.68%</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88.1%</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
    years</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.95%</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79.6%</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    years</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option life</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8p</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining fair value of the warrant instruments is deemed to be approximately $108,873 (2020: $118,658). For the consideration warrants,
the charge has been expensed over the vesting period. For all other warrants, the charge has been expensed over the service period. A
share-based payment charge for the year of $83,006 (2020: $42,846) has been expensed in the statement of comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 156 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, the Company decided to raise convertible equity finance from supportive existing shareholders. &pound;440,000 was raised from
the issuance of Convertible Loan Notes. The four year Loan Notes carry a coupon of 20% per annum and are convertible (together with all
accrued interest) into ordinary shares of nil par value each in the capital of the Company at a conversion price of 0.4p, they are not
convertible into cash. The Loan Notes are convertible at the election of the noteholder until the maturity date of the Notes, at which
point they will convert automatically, or at the election of the noteholder on completion of the next non-qualifying equity financing
or on the making of a takeover offer for the Company (as defined in the City Code on Takeovers and Mergers), and such election may be
made on an immediate basis or conditional on any such takeover offer being declared, or becoming, unconditional.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
May Convertible Loan Notes also have attached an obligation to receive warrants on a one for one basis when the notes convert.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&pound;26,400
of commission was due on these notes has been satisfied by the issuance of an identical convertible instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
July 2020 and September 2020, a further &pound;5,437,104 was raised from the issuance of Convertible Loan Notes. These three-year Loan
Notes are short term instruments and carry a coupon of 2.15% per annum and are convertible (together with all accrued interest) into
ordinary shares of nil par value each in the capital of the Company at a conversion price of 8.5p, they are not convertible into cash.
All conversion conditions are the same as the notes above. &pound;407,783 of commission was due on these notes has been satisfied by
the issuance of identical convertible instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal amount of the Convertible Equity Instrument that was recorded as in the convertible loan note reserve is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March 2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">Par value of Convertible loan notes issued</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,593,381</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Plus: Par value of Convertible loan notes issued in lieu of fees</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">558,396</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,151,777</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">219,059</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,370,836</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
FINANCIAL INSTRUMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main risks arising from the Group&rsquo;s financial instruments are liquidity risk, interest rate risk and credit risk. The Directors
regularly review and agree policies for managing each of these risks which are summarised below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&rsquo;s policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves
of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated
from by private and public offerings of equity and debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarises the maturity profile of the Group and Company&rsquo;s financial liabilities based on contractual undiscounted
payments:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Group</TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"><B>$</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Less than 3<BR>
 months</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>3 to 12<BR>
 months</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Total</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Trade and other payables</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">110,179</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100,813</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">210,992</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Related party payables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">110,179</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100,813</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">210,992</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Group</TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"><B>$</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Less than 3<BR>
 months</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>3 to 12<BR>
 months</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Total</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Trade and other payables</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">141,564</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">481,343</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">622,997</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Related party payables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,790</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">38,096</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,886</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">147,443</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">519,439</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">666,883</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Credit
risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk is managed on a Group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial
institutions.as well as outstanding receivables. The Group reviews its banking arrangements carefully to minimise such risks and currently
has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the Group as part of their
internal reporting and assess outstanding receivables for ability to be repaid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interest
rate risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has limited exposure to interest-rate risk arising from its bank deposits. These deposit accounts are held at variable interest
rates based on Allied Irish Bank base rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result
for the year or the equity position at the year-end for either the year ended 31 March 2021 or 31 March 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dividend
payments to shareholders. The Group may also return capital to shareholders or issue additional shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 158 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
related party transactions occurred on an arm&rsquo;s length basis and in the normal course of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">West
African Minerals Limited (&ldquo;WAML&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WAML
is a related party of the Company as it shares a common director, Willy Simon. In 2018, the Company disposed of it Cameroon operations
by way of an in specie distribution of all of its shares in Ferrum Resources Limited (renamed West African Minerals Limited) to shareholders.
As part of this transaction, the Group had agreed to a deed of release with WAML whereby it agreed to write off $17,056,070 of loans
in exchange for shares in WAML to be distributed as part of the in-specie distribution. A remaining amount of $3,400,000 was outstanding
from WAML, however, after careful consideration of the operations of WAML and its subsidiaries, the Company decided to impair this receivable
down to &pound;nil in 2018 as it does not expect to recover any of this outstanding debt. In addition to the $3,400,000 outstanding was
a working capital loan advance of $600,000 which has been impaired as the Group does not expect to recover any of this outstanding debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended March 31, 2021, the Group had funded $11,172 (2020: $132,668) towards this $600,000 loan facility and as at the year-end
no further amounts were payable under this facility. The amounts funded in the year have been immediately written off as the Group has
no reasonable expectation of recovering the contractual cash flows of the loan in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended 31 March, 2020 and 31 March 2019, the Group had funded $132,668 and $365,477, respectively, towards this $600,000 loan
facility. As at the 31 March 2020 approximately $10,000 was still payable under this facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences PLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences PLC is a related party as it shares common Directors and officers. The Company share premises and other resources with
Tiziana Life Sciences PLC and there is a shared services agreement in place between Company and Tiziana Life Sciences PLC. As at 31<SUP>st
</SUP>March 2021, the Company had incurred $86,567 (2020: $117,767) worth of costs in relation to this agreement and at 31<SUP>st</SUP>
March 2021 $26,224 was receivable from Tiziana Life Sciences PLC. At 31<SUP>st</SUP> March 2020, $43,886 was due to Tiziana Life Sciences
PLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had also extended a short-term loan facility of &pound;400k to Tiziana Life Sciences PLC in 2018 with interest payable of 20%
per annum. This loan was fully repaid during the year and no amounts were owing as at 31<SUP>st</SUP> March 2021, $21,190 was due as
of March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Panetta
Partners Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Panetta
Partners Limited is a related party as it is a shareholder of the Company and also a vendor. The Company has entered into a Deed of Assignment
with Panetta Partners whereby the Company has the licence and sub-licence of certain research and development assets in relation to the
Chemerin product, assigned to it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.
BASIC AND DILUTED LOSS PER SHARE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is calculated by dividing the loss attributable to equity holders of the Group by the weighted average number of ordinary
shares in issue during the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">(Loss) attributable to equity holders of the company ($)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(3,921,550</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(1,544,059</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(4,935,305</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">672,816,302</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">595,474,039</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">513,900,867</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Basic loss per share (cents per share)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.01</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Group is reporting a loss from continuing operations for the year and periods then, in accordance with IAS 33, the share options
are not considered dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings
per share as presented on the face of the Comprehensive statement of income are therefore identical. All earnings per share figures presented
above arise from continuing and total operations and therefore no earnings per share for discontinued operations are presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.
LEASES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, the group terminated from its lease early resulting in the right of use asset of $27,069 and lease liability of $27,887
being written off to the profit and loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
new lease was subsequently entered into in January 2021. The initial recognition resulted in a right of use asset and a lease liability
of $104,377 respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 159 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Right-of-use assets</TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Property</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>$</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">At 1 April 2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">30,099</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Impact of Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,030</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Depreciation of early terminated lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,060</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Early Termination write off</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,069</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Depreciation of new lease</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,799</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">At 31 March 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Right-of-use assets</TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Property</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>$</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">At 1 April 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">38,050</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Additions</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">At 30 March 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,050</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">At 1 April 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,537</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Charge in year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,553</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Foreign exchange movements</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(139</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">At 30 March 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,951</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Net book value as at 31 March 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">30,099</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Lease Liabilities</TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>31 March<BR> 2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>31 March <BR> 2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">At 1 April</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">31,689</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">35,513</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">740</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,542</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(6,139</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Foreign exchange movements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,155</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Early Termination write off</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(27,887</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">382</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">At 31 March 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">98,760</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">31,689</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liabilities are presented in the statement of financial position as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>31 March <BR> 2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>31 March <BR> 2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>1 April <BR> 2019</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>$</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Current</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">34,148</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5,091</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,965</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Non-current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">64,612</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,598</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30,687</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">98,760</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">31,689</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">35,652</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease liabilities are secured by the related underlying assets. Future minimum lease payments as at 31 March 2021 were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Minimum lease payment due</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Within 1 year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">1-2 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2-5 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Over 5 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">31 March 2020</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: justify">Lease payments</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">36,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">36,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">30,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">102,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Finance charges</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,852</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,082</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(304</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,240</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Net present values</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">34,148</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">34,916</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">29,696</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">98,760</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 160 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total net cash outflow for leases in the year to 31 March 2021 was $12,331 (2020: $6,139).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.
COMMITMENTS AND CONTINGENCIES</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&rsquo;s main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain
nature of scientific research and development and the length of time required to reach commercialisation of the products of this research
and development, pre-clinical, clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that
the obligation will become payable. Contractual commitments are detailed where amounts are known and certain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BAM8
&ndash; The Group are committed to paying an annual license maintenance fee until the first commercial sale. The annual license maintenance
fee is $15,000 until May 2021, and $10,000 thereafter.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
                                            &ndash; The Group has retained the services of of Ora, Inc., a world-class ophthalmology
                                            contract research organization (&quot;CRO&quot;) to work with Group towards an IND submission
                                            for OK-101. As yet, there are no firm financial commitments for this contract.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group also has a commitment to issue warrants on a one-to-one basis when Convertible Loan Notes issued in May 2020 are converted. The
warrants have the same exercise price as the Convertible Loan Note. Some notes were converted post year end and the associated warrants
were issued (see note 23).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.
POST BALANCE SHEET EVENTS</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
7 May 2021, the Company&nbsp;announced that 297,869,806 additional Ordinary Shares had been admitted to trading on the main market for
listed securities of London Stock Exchange plc as the result of the conversion of certain loan notes and exercise of certain warrants
as detailed in the prospectus of the Company published on 5 May 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
17 June 2021, the Group announced that Dr Kunwar Shailubhai had decided to stand down as a director of the Company with immediate effect
to focus on his other executive appointments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;On
29 June 2021, the Group announced it had retained the services of Ora, Inc., a world-class ophthalmology contract research organization
(&quot;CRO&quot;), to guide the company's upcoming product development and lead the regulatory strategy of OK-101 for the treatment of
dry eye.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 161 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B></B> [&nbsp;&nbsp;]
<B>American Depositary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Representing
</B>[&nbsp;&nbsp;] <B>Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OKYO Pharma Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Preliminary Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 162 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise indicated,
all references to &ldquo;OKYO&rdquo; or the &ldquo;company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo; or similar terms
refer to OKYO Pharma Limited and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 6. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the company&rsquo;s
memorandum and articles of incorporation, the directors (including any alternate director), secretary and other officer or employee for
the time being of the company shall be indemnified out of the assets of the company to the fullest extent permitted by the Companies (Guernsey)
Law, 2008 from and against all actions, costs, charges, losses, damages and expenses in respect of which they may lawfully be indemnified
which they or any of them shall or may incur or sustain by reason of any contract entered into or any act done, concurred in, or omitted,
in or about the execution of their duty or supposed duty or in relation thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The underwriting agreement
the registrant will enter into in connection with this offering of ADSs being registered hereby provides that the underwriters will indemnify,
under certain conditions, the registrant&rsquo;s board of directors and its officers against certain liabilities arising in connection
with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7. Recent Sales of Unregistered Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following list sets forth
information regarding all unregistered securities issued by us since January 1, 2018 through the date of the prospectus that is a part
of this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On January 4, 2018, we issued
293,202 ordinary shares to Brad Mills, 432,820 ordinary shares to Gerard Holden, 338,808 ordinary shares to Jim Mellon, 307,100 ordinary
shares to Willy Simon, 307,100 shares to Andrew Gutmann and 5,558,549 to BurnBrae, all in lieu of directors fees of &pound;175,673, at
a price of between &pound;0.022 and &pound;0.025 per ordinary share, following which we had 388,395,417 ordinary shares in issue.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On May 1, 2018, we issued 135,000,000
ordinary shares to Panetta Partners Ltd. to acquire OK-101 and OK-201 at a price of &pound;0.015 per ordinary share, in lieu of consideration
of &pound;2,025,000, following which we had 523,395,417 ordinary shares in issue.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On May 22, 2018, we issued
200,000 ordinary shares to Shore Capital in consideration of a corporate finance fee, at a price of &pound;0.0125 per ordinary share,
in lieu of fees of &pound;2,500, following which we had 524,108,283 ordinary shares in issue.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 163; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On October 22, 2018, we issued
512,866 ordinary shares to Kopin &amp; Co. at a price of &pound;0.015 per ordinary share as part of an amendment to a collaboration agreement
with On Target Therapeutics LLC., following which we had 88,933,928 ordinary shares in issue.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(v)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On May 22, 2019, we issued
36,363,636 ordinary shares to Panetta Partners Ltd. by way of a placing of ordinary shares to raise &pound;400,000, at a price of &pound;0.011
per ordinary share, following which we had 560,471,919 ordinary shares in issue.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(vi)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On March 24, 2020, we issued
40,000,000 ordinary shares to Veneto Seed Ventures Ltd. and 35,825,130 to Panetta Partners Ltd. by way of a placing of ordinary shares
to raise &pound;379,126, at a price of &pound;0.0055 per ordinary share, following which we had 636,297,049 ordinary shares in issue.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(vii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On May 29, 2020, we raised
&pound;440,000 through the issue of convertible loan notes which carry an interest rate of 20% compounding and have maximum term of 4
years. The convertible loan notes convert into ordinary shares at a price of &pound;0.004 per share and, if converted, the shares will
be issued with a warrant attached at an exercise price of &pound;0.004, with a maximum life of 5 years from the date of issue of the
convertible loan notes, regardless of the conversion date).</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(viii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On June 5, 2020, we issued
36,269,253 ordinary shares to Panetta Partners Ltd. by way of a placing of ordinary shares to raise &pound;181,346 at a price of &pound;0.0055
per ordinary share, following which we had 672,566,302 ordinary shares in issue.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(ix)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On July 27, 2020, we raised
&pound;3,500,000 through the issue of convertible loan notes which carry an interest rate of 2.15% compounding and have maximum term
of 3 years. The convertible loan notes convert into ordinary shares at a price of &pound;0.085 per share.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(x)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On August 17, 2020, we raised
&pound;1,437,104 through the issue of convertible loan notes which carry an interest rate of 2.15% compounding and have maximum term
of 3 years. The convertible loan notes convert into ordinary shares at a price of &pound;0.085 per share.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left"><FONT STYLE="font-size: 10pt">(xi)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On September 3, 2020, we raised
&pound;500,000 through the issue of convertible loan notes which carry an interest rate of 2.15% compounding and have maximum term of
3 years. The convertible loan notes convert into ordinary shares at a price of &pound;0.085 per share.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the foregoing transactions involved any
underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, we believe these transactions
were exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act (and Regulation S promulgated
thereunder), or Rule 701 promulgated under Section 3(b) of the Securities Act as transactions by an issuer not involving any public offering
or pursuant to benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each
of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in
connection with any distribution thereof, and appropriate legends were placed upon the share certificates issued in these transactions.
All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made
without any general solicitation or advertising.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 164 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8. Exhibits and Financial Statement Schedules.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ITEM 19: EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 89%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">3.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Memorandum and Articles of Incorporation of OKYO Pharma Limited</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">2.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Deposit Agreement. &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">2.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of American Depositary Receipt (included in Exhibit 2.1).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">5.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Opinion of Carey Olsen (Guernsey), LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">OKYO Pharma Limited Share Option Plan With Non-Employee Sub-Plan And US Sub-Plan</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.3**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Executive Employment Agreement dated December 21, 2020 between Gary S. Jacob and OKYO Pharma Limited as amended on January 19, 2021.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.4*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Deed of Indemnity for directors and officers</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.5*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Collaboration Agreement between On Target Therapeutics, LLC and OKYO Pharma Limited dated June 4, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.6*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amendment to Collaboration Agreement between On Target Therapeutics, LLC and OKYO Pharma Limited dated October 22, 2018</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.7*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">License Agreement dated as of May 1, 2018 by and between Tufts Medical Center, Inc. and OKYO Pharma Limited</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.8*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Shared Services Agreement dated as of January 1, 2018 by and between OKYO Pharma Limited and Tiziana Life Sciences plc</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.9*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">License and Sublicense Agreement dated May 22, 2017 by and between On Target Therapeutics, LLC and OKYO Pharma Limited</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.10**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First Amendment to the License and Sublicense Agreement dated March 25, 2021 by and between On Target Therapeutics, LLC and OKYO Pharma Limited.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.11**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Collaboration Agreement dated August 6, 2019 between Tufts Medical Center, Inc. and OKYO Pharma Limited.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.12**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amendment No. 1 to Collaboration Agreement dated November 10, 2020 between Tufts Medical Center, Inc. and OKYO Pharma Limited.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">10.13**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Letter of Appointment between OKYO Pharma Limited and Gabriele Cerrone dated January 6, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">10.14**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Letter Agreement between OKYO Pharma Limited and Gabriele Cerrone dated April 28, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">21.1**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">List of Subsidiaries.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">23.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consent of Mazars LLP, independent registered public accountants regarding the financial statements of OKYO Pharma Limited as of March 31, 2020 and 2019 and for each of the years then ended. </FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">23.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consent of Carey Olsen (Guernsey), LLP (included in Exhibit 5.1)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">24.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="#poa"><FONT STYLE="font-size: 10pt">Power of Attorney (included on signature page)</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>*</B></TD><TD STYLE="text-align: justify"><B>To be filed by amendment.</B></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><B>**</B></TD><TD STYLE="text-align: justify"><B>Previously filed.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 165 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statement Schedules.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All financial statement schedules
are omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements
or the notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The undersigned registrant hereby undertakes that:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 166 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="poa"></A><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of London, United Kingdom, on the [&nbsp;&nbsp;]<SUP>th</SUP> day of [&nbsp;&nbsp;],
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>OKYO PHARMA LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ </I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Gary S. Jacob</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer and Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and
on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 18%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Gabriele Cerrone</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Executive Chairman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Gary S. Jacob</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Keeren Shah</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Finance Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Willy Simon</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">John Brancaccio</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="6"><FONT STYLE="font-size: 10pt"><B>OKYO Pharma US, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 18%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ </I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Authorized U.S. Representative</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">, 2021</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Gary S. Jacob</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">II-5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MEC_:K_;B\;>+O$4WFZEI.FNGA2PEY73+)IMDIC4_=DV^2'<8+&9QPI"CZ/\
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MW3XY8QD1V5K##(W^Z?E&?J16<,/G:]UUZ?K[.5_N]HD?3T\/FOPNK#UY'_\
M)I'@=I_P4OTWQNNWP/\ #'XJ>,I&XCGM]&$-D?\ >F+G8/<KBOC/_@MS9_%S
MXA?!3P;\4/$7@K1OAVO@'74CTSR=:-]J\#W.TB0O&!$J"6W@./OJVWWK]1/
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MOPG^SSX/\$? &U^%VG:2R> [/1CX>ATJ:[GN%33S$8?LWF2.TNP1'8 7^50
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..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #J FD# 2(  A$! Q$!_\0
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MX>[?\%(/^CI?%7_A)?#7_P"8R@#_ $$J*_S[?^'NW_!2#_HZ7Q5_X27PU_\
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MVS)([?,QQNP,  #GC_P5Y_X*.J"6_:H\4 # )/A3X:  DX )/@SC)X&>IX%
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M3"RN;NT6&XN+-9YUM9I'MUFF6,2-!Y$&U4\F+:C^8B^6FU'))+JN,*Y))W
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M3?#S]F2?4O$FK7T7PGN?AEX"T_6Y?$7P[UX:/KNF>%_!'C;]I[56^'6E:_\
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MNU_Y^(?^_B?XT?:[7_GXA_[^)_C7^E+_ ,(#\/\ _HGW@#_PA_"O_P J*/\
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M^5U '^8']LM/^?F#_OZG^-1S7EIY4O\ I,'^K?\ Y:I_=/O7^H!_PJKX7_\
M1-_ 7_A'^'O_ )74?\*J^%__ $3?P%_X1_A[_P"5U '^99XWO+4>+M<!N8 ?
M/M.#*@/_ ""[#WKEOMEI_P _,'_?U/\ &O\ 3ET+X8_#6YTFTGG^'7@.2619
M=[MX/\.Y;;/*BYQIH'"JHZ=N>:U_^%5?"_\ Z)OX"_\ "/\ #W_RNH _S:_
M?[2WQE^%_@?Q/\-/A_\ %"_\,?#_ ,:7TFI^+?"5M8>%;_2?$&HR:?'I0OM1
M76M#U.YDNH-/BCMK&:*YB?3<-/IQM;J66=_%5NK)%5$N( J*%4><IPJ@ #)8
MDX  R22>Y)K_ $_O^%5?"_\ Z)OX"_\ "/\ #W_RNH_X55\+_P#HF_@+_P (
M_P /?_*Z@#_,#^V6G_/S!_W]3_&NF\57EJ+C0LW, _XHSP@>94Z'0[;!Z]#V
MK_36_P"%5?"__HF_@+_PC_#W_P KJR='^&/PTGAO#+\.O ;F+5M6@C+>#_#N
M5BAOYTBC!&G<K&@"KG)"@*#@   _S&?MEI_S\P?]_4_QKU7X4_M ?%GX%ZAK
M6J_!OXJ>)/AOJ'B33[32]?N/#&IV]NNKV6G7R:II:WMM=0W=I)=Z-JB)J>A:
MFMNFJZ#J(-]HU[8W3-*W^E/_ ,*J^%__ $3?P%_X1_A[_P"5U'_"JOA?_P!$
MW\!?^$?X>_\ E=0!_F#S:E%<337-S?BYN;F::YN;FXNC/<W-S<2--<7-S<32
M/-<7%Q,[S3SS.\LTSO+*[.[,8_MEI_S\P?\ ?U/\:_T_/^%5?"__ *)OX"_\
M(_P]_P#*ZC_A57PO_P"B;^ O_"/\/?\ RNH _P RC5+RU_X1;P:?M,&#/XOP
M?-3!QJ&E9QSVKF6N[)E96N+=E8%64R1D,I&"""<$$'!!X(K_ $YK3X8_#235
M]7@?X=> VBMX=,,*?\(?X=Q&9DNGE(QIH)+LJEB23\H'0 5K_P#"JOA?_P!$
MW\!?^$?X>_\ E=0!_G&Q?MC_ +2T%]X"U*/]H#QY]L^%^C:CX=\!22:Q93P^
M']"U?0M/\+:MI;64]E)8:[:ZGX8TC2/#E^/$]KK<EUH6D:3I4TCV6F6,,$,W
M[7_[2%SX/\5> ;CX^^/;CP?XXO\ Q?JOC#19]<MY3XBU'X@Z@=5\>W>HZM);
M-KI?QI?$OXH2#5((=:MR=.OHIM,)LS_H\?\ "JOA?_T3?P%_X1_A[_Y74?\
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M&G_'SXJ^ _@/%XEUR\\0>'[W38_'GP[\+>&6?7]0T:]UW5&?3-6^6?6+NX4
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M#.C*R2(\;O')')&P>.6*6-EDBEBD59(I8V62*15DC9756']AO_!'[]I[X_\
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M"# @@+R>,V8P08'D0D^7#@&-5(%?VN_:[3_GYM_^_P!'_P#%4?:[3_GYM_\
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MN+_NK_(5B:]=6IT/60+FW).DZB /.CY)LYO]JM-;NUVK_I-O]T?\MH_3_>H
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M@"E_9FF?] W3O_ "T_\ C-']F:9_T#=._P# "T_^,U=HH I?V9IG_0-T[_P
MM/\ XS5+4M,T[^S=1VZ;I^[[!>[=MA:[L_9I<;<0YSGICG/2MJK>G@'4+ $
M@WMH"",@@W$>00>"#W%)NR;[)O[DW^@'H\>BZ/Y<>=(TP'8N1_9]J,':,C'D
MC'/; QTI_P#8NC?] G3/_ "U_P#C5?P0_%;X]?'BU^+'Q8M;7XY?&>UM;7XJ
M?$FUM;6V^*GCR"VM;6V\;Z[!;6UM!%KZ106]O!''#!!$B10Q(D<:JBJHX/\
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M_P >%IZ?]<J37_\ D!:U_P!@G4?_ $CFK43[B_[J_P A0!G?V+HW_0)TS_P
MM?\ XU1_8NC?] G3/_ "U_\ C5:=% &9_8NC?] G3/\ P M?_C5']BZ-_P!
MG3/_   M?_C5:=% ')>'='TA]&LF;2M,+%9LDV%KDXN)@/\ EEZ"MK^Q=&_Z
M!.F?^ %K_P#&JK>&_P#D"6/^[-_Z4S5N4 9G]BZ-_P! G3/_   M?_C5']BZ
M-_T"=,_\ +7_ .-5IT4 9G]BZ-_T"=,_\ +7_P"-5C:)H^D-!?;M*TPXUK65
M&;"UX5=0G '^JZ <#VXKK*Q-"_U%_P#]AO6O_3C<4 6/[%T;_H$Z9_X 6O\
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M/_ "U_\ C59^E6UM::QKT5K;P6T972G,=O#'"A<V\X+%8E52Q  +$$X &<
M='6'8_\ (<UW_KGI/_HBXH W**** "O)]=_Y&35_^O?1_P#T1=5ZQ7D^N_\
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MA 09*?"KX7Q^.-&^)J?#GP0OQ(\.Z!'X4T#QZOAG21XOT;PU#!+:P:%INO\
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M%7=;E8=E_P AS7?^N.D?^BKNMR@ HHHH **** "BBB@ K#L?^0YKO_7/2?\
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MU\J/_2M9_P!6G_,>UG^Z/^GZI/[#M?\ GZUG_P 'VL__ "=0!LT5C?V':_\
M/UK/_@^UG_Y.H_L.U_Y^M9_\'VL__)U &S16-_8=K_S]:S_X/M9_^3J/[#M?
M^?K6?_!]K/\ \G4 ;-%8W]AVO_/UK/\ X/M9_P#DZC^P[7_GZUG_ ,'VL_\
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MX2"V7[5K&#HUZV?[<UC=D7VGCAOMN0.>0#@]QD#&Q_8=K_S]:S_X/M9_^3J
M-FBL;^P[7_GZUG_P?:S_ /)U']AVO_/UK/\ X/M9_P#DZ@#9HK&_L.U_Y^M9
M_P#!]K/_ ,G4?V':_P#/UK/_ (/M9_\ DZ@#9HK&_L.U_P"?K6?_  ?:S_\
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M_P#"!\-?_-]1_P /V_V,O^A7^/\ _P"$#X:_^;ZOY&J*/^):?"__ )\\1_\
MB0UO_G:'_$6^,?\ GYE7_AJI_P#S6?UR_P##]O\ 8R_Z%?X__P#A ^&O_F^H
M_P"'[?[&7_0K_'__ ,('PU_\WU?R-44?\2T^%_\ SYXC_P#$AK?_ #M#_B+?
M&/\ S\RK_P -5/\ ^:S^N7_A^W^QE_T*_P ?_P#P@?#7_P WU?E7_P %.O\
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M7\UGZV8K_P#(Q6O_ &!;[_TNTZMJL5_^1BM?^P+??^EVG5M4 %%%% !1110
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ME0R,L42,\C*@(+E4!8(""Q&T<D4VJ.J?\@S4O^P?>_\ I++1_7Z_H!_.Y/\
M\$"?CG<7%S<I^T)\)@ES=75T@;PEXQ+*ES<23HK'[8/F59 #P.0:B_X<"?';
M_HX7X2_^$CXQ_P#DVOZFH?\ 51?]<T_]!%25^XKZ17BJDDLYRNR22_XQW*=D
MDET[)'YU_P 0JX+>OU#&:MO_ )&N.ZMO]6?RP_\ #@3X[?\ 1POPE_\ "1\8
M_P#R;1_PX$^.W_1POPE_\)'QC_\ )M?U/44?\3%^*W_0YRO_ ,1W*/\ (/\
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MK5I+:*UC0H1?LL/2M""<G5JU2BBBOBCZ Q7_ .1BM?\ L"WW_I=IU;58K_\
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MG:X0#1)L.S6UQ:E6SK60H2Y9^,'<JCH2*]+HH \[_P"$+U3_ *#EC_X))_\
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M-A2::"8N3_;F[>K0*H ^4AFSR!5OR=?_ .@AH_\ X)[W_P"7E;%% &/Y.O\
M_00T?_P3WO\ \O*/)U__ *"&C_\ @GO?_EY6Q10!C^3K_P#T$-'_ /!/>_\
MR\H\G7_^@AH__@GO?_EY6Q10!C^3K_\ T$-'_P#!/>__ "\H\G7_ /H(:/\
M^">]_P#EY6Q10!C^3K__ $$-'_\ !/>__+RCR=?_ .@AH_\ X)[W_P"7E;%%
M &/Y.O\ _00T?_P3WO\ \O*/)U__ *"&C_\ @GO?_EY6Q10!C^3K_P#T$-'_
M /!/>_\ R\H\G7_^@AH__@GO?_EY6Q10!SU[8:[>V=W92:EI,:7=M/:NZ:/>
M%T2XB>)G0-KFTLH<E0W!(&>*L"'7P !J&CG  _Y ][VX_P"@Y6S10!C^3K__
M $$-'_\ !/>__+RCR=?_ .@AH_\ X)[W_P"7E;%% &/Y.O\ _00T?_P3WO\
M\O*/)U__ *"&C_\ @GO?_EY6Q10!S=AINN:?:0V<>IZ5(D(<*\FCW8=@\CR'
M<%UL+P7(X[ =ZN>3K_\ T$-'_P#!/>__ "\K8HH Q_)U_P#Z"&C_ /@GO?\
MY>4>3K__ $$-'_\ !/>__+RMBB@#'\G7_P#H(:/_ .">]_\ EY52ST[7+))D
MCU/2G$]W=WC%]'NP5>[G>X=%VZW]Q&<JA/S%0"W.:Z.B@#'\G7_^@AH__@GO
M?_EY1Y.O_P#00T?_ ,$][_\ +RMBB@#'\G7_ /H(:/\ ^">]_P#EY1Y.O_\
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MVT_\"8?_ (NC[?8_\_MI_P"!,/\ \77B_P#9^G_] ^P_\ K7_P"-4?V?I_\
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M8?\ XNC[?8_\_MI_X$P__%UXO_9^G_\ 0/L/_ *U_P#C5']GZ?\ ] ^P_P#
M*U_^-4 >T?;['_G]M/\ P)A_^+H^WV/_ #^VG_@3#_\ %UXO_9^G_P#0/L/_
M  "M?_C5']GZ?_T#[#_P"M?_ (U0![1]OL?^?VT_\"8?_BZ/M]C_ ,_MI_X$
MP_\ Q=>+_P!GZ?\ ] ^P_P# *U_^-4?V?I__ $#[#_P"M?\ XU0![1]OL?\
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M_P"-TG]E:3D+_9NG;B"0/L=MD@$ D#R\D LH)Z D9ZB@"7^T=/\ ^?ZS_P#
MF#_XNC^T=/\ ^?ZS_P# F#_XNH_[)TK_ *!FG_\ @%;?_&Z/[)TK_H&:?_X!
M6W_QN@"3^T=/_P"?ZS_\"8/_ (NC^T=/_P"?ZS_\"8/_ (NH_P"R=*_Z!FG_
M /@%;?\ QNC^R=*_Z!FG_P#@%;?_ !N@"3^T=/\ ^?ZS_P# F'_XNC^T=/\
M^?ZS_P# F#_XNL)]+TO_ (2"V7^S=/V_V-?-C[%;8R+W3P#_ *KL"1^)K9_L
MG2O^@9I__@%;?_&Z )/[1T__ )_K/_P)@_\ BZ/[1T__ )_K/_P)@_\ BZC_
M +)TK_H&:?\ ^ 5M_P#&Z/[)TK_H&:?_ . 5M_\ &Z )/[1T_P#Y_K/_ ,"8
M/_BZ/[1T_P#Y_K/_ ,"8/_BZC_LG2O\ H&:?_P" 5M_\;H_LG2O^@9I__@%;
M?_&Z )/[1T__ )_K/_P)@_\ BZ/[1T__ )_K/_P)@_\ BZC_ +)TK_H&:?\
M^ 5M_P#&Z/[)TK_H&:?_ . 5M_\ &Z )/[1T_P#Y_K/_ ,"8/_BZ/[1T_P#Y
M_K/_ ,"8/_BZC_LG2O\ H&:?_P" 5M_\;H_LG2O^@9I__@%;?_&Z )/[1T__
M )_K/_P)@_\ BZ/[1T__ )_K/_P)@_\ BZC_ +)TK_H&:?\ ^ 5M_P#&Z/[)
MTK_H&:?_ . 5M_\ &Z )/[1T_P#Y_K/_ ,"8/_BZ/[1T_P#Y_K/_ ,"8/_BZ
MC_LG2O\ H&:?_P" 5M_\;H_LG2O^@9I__@%;?_&Z )/[1T__ )_K/_P)A_\
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M9,VFZ>25FR396W/^D3#_ )Y5M_V3I7_0,T__ , K;_XW0!)_:.G_ //]9_\
M@3!_\71_:.G_ //]9_\ @3!_\74?]DZ5_P! S3__  "MO_C=']DZ5_T#-/\
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MC_LG2O\ H&:?_P" 5M_\;H_LG2O^@9I__@%;?_&Z )/[1T__ )_K/_P)@_\
MBZ/[1T__ )_K/_P)@_\ BZC_ +)TK_H&:?\ ^ 5M_P#&Z/[)TK_H&:?_ . 5
MM_\ &Z )/[1T_P#Y_K/_ ,"8/_BZ/[1T_P#Y_K/_ ,"8/_BZC_LG2O\ H&:?
M_P" 5M_\;H_LG2O^@9I__@%;?_&Z )/[1T__ )_K/_P)@_\ BZL130SJ7@EB
MF0':6BD610P )4LA(! (.,YP0>]4_P"R=*_Z!FG_ /@%;?\ QNL[2X(+;6-=
MCMX(;>/9I3>7!$D2%C!."Q6-5!8@ %B,D #. , '0T444 %>3Z[_ ,C)J_\
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MM)M9U#RKN>=4N&C"@>[WO_'SH_\ V$9?_33JE &C1110 44J@%E!(4$@%CT
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MUAL7B\,IOB#/4YK#8O%X93:6 :3FL,IM)M)S:3:2;_K^_P"%W_!;_HKWPO\
M_"_\*?\ RVH_X7?\%O\ HKWPO_\ "_\ "G_RVK^0'[/;_P#/"'_OTG_Q-'V>
MW_YX0_\ ?I/_ (FM?^)>\J_Z*C-/_#9EO_S2<_\ Q/)Q'_T;KA[_ ,2'/O\
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M%OO_ $NTZMJL5_\ D8K7_L"WW_I=IU;5 !1110 4444 %%%% !1110 4444
M%%%% &3K_P#R M:_[!.H_P#I'-6HGW%_W5_D*R]?_P"0%K7_ &"=1_\ 2.:M
M1/N+_NK_ "% #J*** "BBB@##\-_\@2Q_P!V;_TIFK<K#\-_\@2Q_P!V;_TI
MFK<H **** "L30O]1?\ _8;UK_TXW%;=8FA?ZB__ .PWK7_IQN* -NBBB@ H
MHHH P[+_ )#FN_\ 7'2/_15W6Y6'9?\ (<UW_KCI'_HJ[K<H **** "BBB@
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M ?91X%T]Y+34+8:BW@Y+*VA\-:AJJWVJ:/;1FUL[Z*VEFBD]A\.?#3P!X/\
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M5'\FW_#*/[3G_1 _BG_X2MY1_P ,H_M.?]$#^*?_ (2MY7]9-%'_ !,%G_\
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M** ,/_BI?^H'_P"3]'_%2_\ 4#_\GZW** ,/_BI?^H'_ .3]'_%2_P#4#_\
M)^MRB@##_P"*E_Z@?_D_1_Q4O_4#_P#)^MRB@##_ .*E_P"H'_Y/T?\ %2_]
M0/\ \GZW** ,/_BI?^H'_P"3]'_%2_\ 4#_\GZW** .7:T\2-J$=_OT,&.SG
MM/+VZAR)IK>8OOW<;3;A=NSG<3N&,&Y_Q4O_ % __)^MRB@##_XJ7_J!_P#D
M_1_Q4O\ U __ "?K<HH P_\ BI?^H'_Y/T?\5+_U _\ R?K<HH P_P#BI?\
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(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $- :@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG=5'&IR\TEKRJFM+JW.YQOI ]*HHHJSYT**** "BBB@ HHHH **** "BBB@
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M:L:&&R'&4:"G!0HJMF-;"X"E+$RE&4^;%4:F*6#P[]E*4Z,93BI)^S]DK?\
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MVIR6T U?5FZ)?#.@V/ANUM/C!H/B?Q%=VOB/]FA?&EKJ?PB^-NI_$!/!NG_
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ME[(H'],MU86>H6%SIFI6MKJ-A?6DUA?V5[;Q7-E?6=S"UO=6MW:3K+!<6MS
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M//SN4HQXZ-*LZ_#E58N=*IQM1>*S%QS&OEM3+OKF=T\75HY=E^68>+QE*O\
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M]1JHB#:BJ@]% 4?D *=1109[[Z^H4444 %%%% !1110 4444 %%%% !1110
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M:G*4)5Z,<31C*/-&49U:$E5A!QYI0YFHWA45.S1116)V!1110 4444 %%%%
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M0/\ Y84 =S17#?\ "S_AI_T4/P-_X5N@?_+"C_A9_P -/^BA^!O_  K= _\
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M7+*E>I).2A>57VC:IQ7O.-MU%-\JTC_+H>@Z=Y; GRP&8!NVWH <' ZD9Q@
MYS@9R=>J-C$4B!)Y( _  8/UQC)YYST[WJ\>;O)GW%"+C3BGNU=V5OZW"BBB
MI-@HHHH **** "BBB@ HHHH ^8/ 'PZ^'WBGQQ^T+JGB;P)X,\1:G_PN6WM?
M[2UWPOH>KWYMH/@]\)#!;F\U"QN+EH(/,?R8C*4B#L(U4$BO5/\ A2_P=_Z)
M/\-/_"$\+?\ RJKG/A%_R-7[0O\ V6Q/_5._"&OQD\3_ +7'QB^'7[<'PZL_
M$'Q.\42_!>']NC]L3X=_$#P_=W\/]@6/PRT/]E3]G34O MM=P^7"4T;P7\2O
M&TFMZ>'G(M;WQ%J,I%S)/! .S"8*IC'65*45*C2E5:ES7GRQJODCRI^]+V34
M;Z.4HKJ>/F^<X?)HX.>)IU9PQF*IX53IN"5%SGAH.M5YVOW4/K49S<?>C"%2
M6T3]OO\ A2_P=_Z)/\-/_"$\+?\ RJH_X4O\'?\ HD_PT_\ "$\+?_*JOYO_
M -G/]O7]IS1+O]G+Q%\6_'?B/7I?&?[.?_!1[5_%V@ZG<"72?^%E^"OCUXFU
MOX'0R6;Q132:QI'A_P .CX7>&[9HY&2UN1I6R21XI6N_ K]K/]I[Q%\%/BYJ
MOBGXP^/)/%GA']GG_@DK*]S<:G#)<Z;X]^('[1/BWX<?'/6[9_LB!+[XCV_A
MV2R\2R&,?:[3$:16S#Y?1GD&)IN7-6H-1E3AS+VC4G.K.CI97M&4+M]5*-EJ
MCYVCQ]EE=4^3!8]3J4Z]5TY_5XRA"CA:.+7.W.W-4IUK1BM5*G5YG:#/Z,_^
M%+_!W_HD_P -/_"$\+?_ "JH_P"%+_!W_HD_PT_\(3PM_P#*JOYJ/&?[>?[1
M>K>&?VA_ TGQ2\;>$O''P<\)?\%2]3TO4M$U.R36_$?PYT'XW?#O2_V=/B+8
M0VMI-+_:O@"W3XH?#/P[)]FDN;:]\+S+<K=WEXBU^E_[2/BCQ?\ #+]E;]D[
MX;_#+XM_M(Z8O[0_[6_P(^ >O?%OXI7.H:+^T[HG@/XH>.M<U/Q;,;SQKX.T
MW5/#GBQ],T>;POHU[JGA*UU#0]"OH;NRC^UVUG=-E5R>M1E0A.M34J]7DC:-
M245!4)XF55R32:5*#E&$8N<W>*<7%HZL-QE@\73QU:AA,3*E@<+[>HY5</"I
M.M+'4<NIX6-*46XREBZ\(5*U2I&E1C:I*%2$X,_2C_A2_P '?^B3_#3_ ,(3
MPM_\JJ/^%+_!W_HD_P -/_"$\+?_ "JK\(];U/\ :6\%?MBZ-\ _BY^TQ^T7
MJD7PN_8K^(_Q4\"W/PDU75KWP_XTU'0OVB?C)H_PI\4?M*ZGH/@-=*.J-\(-
M)\(Z#X^US6H/"OAW5?&.FF.+4+C4+Q7N_8OV;OC_ /&KQ5XX_P""*UCXB^)?
MBK5[+X\_L'_&3XB_&.UO+Y9(?B-XXT/X9_L[:MI'B;Q,OE#[;JNG:EXI\07M
MM<*8RD^JW;8(D(J:F4SA3C4CB:-6,J,ZR<854G".'Q&*CRRE\7/3P\E\,>2<
ME&2?+*3O#\6T:V(J8:IEV,PU2GBZ."E&I6PDYQK5,QR[*ZBJ0IM^S5'$YC3E
M_$J^VH4Y5:;@ZE.DOUZ_X4O\'?\ HD_PT_\ "$\+?_*JO-_BS\&/A'#\-?B+
M/#\*?AFC1> ?&DB.O@'PIOCD3PUJC1LC_P!D%@RN%8$$=,8()!^)/^"<_B/X
MUWWQ.^/7A;X\?'7XCZ_\7/"2I#\8/V?/BKI.FA?!?BG4/'OC:7P+\7_@%K^D
MV&E:9<?L\_$[X;0:7IVAZ5I,>JVECXB\+WZZC=Z9XCCUNPE_2_XL#/PL^)7_
M &('C+_U'=2%<6*P[PE>5%U(5>6,)<\(S4)*I!33CSI.46FG&<7*%2+C.$K2
M<8>WEF/CFV!IXR-"KA>>I6A["M.E.K3E0K3HRC5]BVJ=12@XU:$U"M0JQJ4:
MT%*$9U_(O"%DS_#CX=M@Y/P\\"DGDGY?">CKD],\@YY/<=>*YK6].R'^7[P;
M<!T./<^O?I@@_6O5? 5EYGPP^&[8_P":?>"@#CIM\,Z6OH<].1UP>F#FL?5]
M-#%R1R3SG^]T'3!!'/O@8Y))KHP]32.O1?U_74\W'X?6=ENWTZ'R]XBTK/S!
M0&PP) (^[RN>HY!Z9R<8/ X\<U?2N7&PA6)'0_+R3R.G7IGIU/M]7>(-)WQO
M\GS*0?4 GC/& ?E)&<G!()//'D.L:/NW':>X/&2IY^8#V/4#WP*]W#54TN_]
M?U_PY\3F.%:E)VWU_K3?0^7=5TMT#J 5/UXQ]",8P.>1UQ@XQ7FFK:>?FW1M
MC)P5 SGMD$@=<C@^G3=7T]JNC$[ODP0#@L,_3G@]P1^'/)KS/5M$#%CLY&<\
M=1TZ=<YP#S]>HKUZ-7;7\?ZV_(^/QN%O>Z_#_AF?-.J:4L@8@ G) R"#SG)Y
M /3D@]!W')KSG5-$SDA2,<\@G YP/FY(/7@DC.<FOI/5-$(#?(-O)S@Y/YC.
M.Q';D_3S_4='=-WRG'0@CKV(!(.#[CN17ITJJZ_AM]W_  #Y;%8-W=K]=UZ_
MU_2/E35]#9GD;8IR6X.<$< #/0'@=#SDY'0G@+_P[*^=L3'ZKTR1R<@*1CIV
M].<U]<7WAU!N*Q @<Y(!)ZX.3G! /T';/4^?ZCIEFM['IK3P+J4]G<7\%B74
M7<MA:3VEK=7D<?):VMKF^LH)I!E4ENX$/S2*3W0FG:[Z]/RW^ZQXE>F]5&+=
MK[K9+=V72V_37H?*=]X3D.6=< @XQE@>>3CC ZY[]^3C')WOA:*/<6C+!026
M?E0H!).U=O '/?)P.^#]77N@8SE.W*E1D 9]CG@C X!P>>17 ZUH0VF!$.6
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M\<,"@^6%MRWECY97E/E!R-Y+EW225%QEA<.CR,2 #Z'8:8OFQ1@%%5+>,(I
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M.?'&X\:-XF\,_ +X#:3>VOC&QETO4$GT_P 9_'K2])O-6TU%2S3Q+<^$=/\
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ME(&0#&^<#I@*^.N,<$'/9SR1Z#I/AK!0-'GH<8X'4?3TR<]^>^>VLM$5<%D
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M* /GG_A4WQB_Z.F^(G_AO/@;_P#.VH_X5-\8O^CIOB)_X;SX&_\ SMJ^AJ*
M/GG_ (5-\8O^CIOB)_X;SX&__.VH_P"%3?&+_HZ;XB?^&\^!O_SMJ^AJ* /G
MG_A4WQB_Z.F^(G_AO/@;_P#.VH_X5-\8O^CIOB)_X;SX&_\ SMJ^AJ* /GG_
M (5-\8O^CIOB)_X;SX&__.VK-UKX(?%77]'U;0=2_:D^)#Z=K>F7^D7Z0^ /
M@;%,UEJ5I+972Q2_\*T;RI3!/((Y-K;'PQ5@,'Z8HH R/#^BVGAO0=$\.V#3
MO8Z#I&FZ+9/<NLER]II=G#8VS7$B)&DD[0P(976.-7D+,J("%&O110 4444
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C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Q ;4# 2(  A$! Q$!_\0
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MHKYL^_"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?%37_"MC\.[/1)? ^EZ/H,'A^T\*6_C74;:XDCUZ#P'J?BG4++0[BXCEM);
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M/X6A\&^,KS0-47XD+>3-IX\*1^.+*[NO&6NZC;1@'[^45YW\)/ >G?##X8^
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /A_\
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MDA52ZHQ=%<@;E5RJ%U#9"L40L "54G F,U)R2O>+L_6U^Q^@<8>'.=\%\/\
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M!HGA.ZU33)K;SOMS1>*?$FA>&CIUN)-5;7]3M]'2Q;4"]NG>?$CXK_#KX/\
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M X*GF6-R'.L'EM:A@,51S#%Y3F6&P-7#9I/&TLLQ%+&8C!4<-4H9C4RW,:>
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M%OH/B77(?"VI_$7X2:5\)K*^U'4O&_EZE<:;KVC-'::E>>$=#NM5L]<T#2=
M\0WDO[/_  B_LBS^"OPP_L7QC/\ $#0;7X7>"O[)^(.I-,+KQMI$'A/3?L'C
M&_<A[@3^)+-8M;NF(:827LA(+\$ _$G_ ()9?!?X>^"OC].=#US]G3PQXZ^#
MGP4\7?"KQ;X-\&^#_B1\-OVF_BPOB3QYX2\20_%;]HCX7_%C0O#FK>!;[25T
M:"*WM_"J>+M"OM5\9:@UCXQB\,1>&M#C_H'K\-/^"5?A32=.^)7Q,^(GA0?%
M]?"/QCT6^\<:<;G]GKQAX0^ 5Z;G5M)2WUKP#\<OC=K/C#X[^/&UFT":AHUE
MJNN^'/"U]IUUJ.IZ=X+L([6P6T_<N@!D@=D=8W\MV1@DA4.$<@A7*$@-M.&V
MD@-C!(S7C ^$VL:-X)T'PKX%^(FL^%=4TJ]U+4M7\27>C:)XFD\8ZCXADO[O
MQ/J/B?2]4@6VNK_5]8U*ZUZ*>TFLUL=3$,8BN-(6;2I_:J* /&4_9[^#%SX7
M\%>$_$WPV\%>/;#P!X=L/"_AJ[^('A3PYXPU2RTNPMK>V"1WFLZ5<F![D6T<
MUVMG':V\DPW);QHL<:>>?L2PPV_[+WPIMK>*."WMK+Q+;V]O"BQ0V]O!XU\2
M0P001(%CB@@B1(H8HU6.*-%C1510!]4U\M?L5_\ )LGPP_ZX>*O_ %.?$U/H
M_E^HNJ^?Z'U+1112&%%%% !1110!1DU33(=1MM'EU&PBU:]MKF]L]+DN[=-1
MN[.R>".\N[:R:07,]M:27-M'<SQ1/% ]Q LKHTL8;Y)^/GPN^+#_ !D^$/[1
M/P<T/P5\0/$OPR\)_$?X?ZG\-/'_ (BO/!]EJ&@_$BY\)7\_B;P;XPMM \41
M>&O&.D7O@^ST^Z-[H5S:ZYX7U;5M-:[L9X[?[3\L_'%OBDG[1_[8;?# 7I^.
MX_9>_9U_X45_9J:+)XM7X2'XF^.E^/[_  PB\3,-!E\8I(87M$O/]#?Q2/ *
M:L#"VGAO([+P_P#MQ^,9=<T70/&'[8'A#X>+XF^-FI>#-?\ '$/@#2OBQ/H&
MC?L]^!K[X5Z5XEDCT:[MH['5?C1%XC@L%>RAU[48!+8:_/:3W=VZ8RG>\>63
MU=G'HXO1W::3TOKI9K1WT_I;@SPQJY6L!Q-A^.N",MH8SAG+XYMEW&-+$RPV
M.ROC;AJ5?-L'3PF6YSEF98O+YX+%4LMPM; UJ&9XO'95GU?#8_+5DD\#F.SJ
M7_!/CX\-XL^%?QCLM6^%%O\ $CX;>*_CA^T!#X.:?4IOA1%\6/B?\6/ GC.V
M^%]O9WF@->'P/#X1T?Q-;+X_CM+'7M%^)4VG^/M-T19#);1?</QU^#/Q.^,_
MP _:-\':3\2[?Q-<_&[P'+I7P[\-:W:>&+#PE\/+B^TUXKC3[/Q9X6T)=:\1
M:7>W,J23:IK3:M.@MD-B(HII$;YW^&M[^U%K7Q=T1_CG%^TU8WFH>'?A\_A7
M2?A[HGPYA_9UD\/WWP5T2;Q[#\9);J&;6K'QK_PMJ3QE:ZO:6US!J=A#%X3A
M\%++I$E_-7S1\,OAK^V_\%O@U\-? VDWW[0TOP^E^#O[-VI_%#1= M/ =Y\3
MOAC-!XH^(&C_ !6\"? 2.?3H+:RU33?#=O\ #HZAHUY_;FK0Z"-5U;P]J%SX
MDN%CI+E2E:$[2NI:N][<JTLMTWW2WMT7Z!F%/BSB+'<.XK-_$OPJI\0\'XW(
ML;PQ?*<%/*IX">=RXPQ&797F\L^Q53%TLKSWA[*XX:%..1ULXQ-6OPT\YIRQ
M&(Q6.^L?%7[)_P 9M9_:;/B6S7P%_P *A\0_M _ S]I?7/&$^MZE'X\T'6O@
MK\)!\-7^&VG^%UT-[/5++Q)?:=I.IVGB4^([&'2=$U#Q)IMQI%S<R6KS_5O[
M-GPK\3?"30?BKI_BJ?299_&?[0OQQ^*>E-I5S-<PQ>&OB)X[U/Q+H45Z]Q;6
MAAU.'3[N-=1MXUE@M[@.D5S.@$A_-U;#_@I!J'@[QWK>FZK\5[/Q%H'P 9OA
M!H_B-? EIJ&O76J_'GQY8P7WQ'T_3H/[)OOV@])_9RB\/WK:7:WEKH$/C&?2
M9[JUFUHSQPEL/VWA\-/ 0\6:Q^TUJ7P^O/B3\4/[9_X5EX4\/:9^TEI6DCPI
MI$7PHTK6X_B$US>:OX G\:+XMN]3UF_LK'6A;7'ABP\1K'X;@N;HBDDVU"?V
MGKMK96VVU;ZV6NMU;R,_X3XCXCR*AD&/\4/"&>!P?^KO#-6AE=2NLQKO)Z6:
M\083&0E+./9XS,JU/*L!@:\*6)RW"8[$X6.6T*^!QF6YCB.(_P!FM-U[0]9D
MNH=(UG2=5ELEM'O8M-U&SOI+1-0@%U8/=):S2M;K>VI%S:-*$%S 1-"7C^:M
M6OQZ_88\):[X ^-OPB\#W^CW'A_Q9X6_X)R?"_0_CYH6RWCGTGQKIOQ(G@^%
MEEXLCL&DM(_$T.@GXF+I\=P_VI="X@_XEOV,#]+/C'XGUC0_"]MH?A.<0>._
MB#J]KX%\$S>7YW]G:MJ\%U/J'B:6':XDM?!?ARRUOQ?=1NICN(]$%D3YEW$K
M:1E>/,U:UU;SLM/6[MZ_.WX1QOP#2X8XRP_"V59Q#.,-C,+A,9A<UK4Z&'I?
M5,1C.)</+'5OJE?&T%E_U+AJKGV'Q="M5AB,CQV#Q=-U?:T:F,Y;2H_^%N_$
MNX\1W*^?\.?A%K5[H_A"V=6:S\5?%*R$VG^)_%\B.!'=6'P^+W7A#PT2KQ+X
ML?QCJ14W&C>';V'Z"KGO"7A;1O!/AG0O"/A^W-KHWAW3+32M/B=O,G:"TB6/
M[1=S[5:ZOKMP]U?WDH,U[>S3W4[/--(QZ&J2[[O5^O\ DME_P3XW.<?2QN)A
M2P:G3RO+Z2P.54:B49QPE.<I2Q->$7**QN98AULRQ\DY/ZSBH4%4G1P&&L44
M5\3?MP?M(:E^SIX T+4?#KWJ>*_$FIWMOHWE6FF7&G"'38+;[<^J'4[#4%$<
M<FIV#0V]LEM<W#>81>11PR1S5%.326[/(;LKOH?1GCBXNO$&H6/PWTJXFMI-
M;M'U+Q?J%L[1W&C^"HYC;7$-O.C*UMJGBJZ5]"TR52)H+)-?U6U9;G1XPWHU
MK:VUC:VUE96\-I9V=O#:VEK;QI#;VUM;QK#!;P0QA8XH88D2.*-%5$1550%
M%?,W[)'CF#XK_">U^*T\M]=>(O&VIZB_B&ZU*WLK>>.31KF72]*TNT73X+:T
M.EZ;I45M]E,%O;B>ZNM0O[BV@O[Z]C'U!0U9V?31^H+77O\ D%%%%(84444
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M-KY3V\UU=) ]W(=,CFDU&&6V3N;#XW_!W5?%.K^"--^)_@2^\6^'[/5K_7-
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M@7]HWQ'H/@7P9<:_\.Q\+/%<VH_$C3?A#^VA\ O#/P]\0CQMX9;2_ $7A/\
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M\KJI_-/P+\./VIK;POX?\;Z[X@^*LWQ;L/&G[/>CVNC^(O'AO/"%EX-?X/\
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M[;_$I;(****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'_"#XC^*H;ZWGM+21[S4;3P5X;\21>&[BY>X\U=)U&YCN(?WD4?G+ TAY?\
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M=G%/$Y;E,7I.CE]_89UFB6\?;)_V%@JFG-*MG5:G)JBY+J****9\Z%><>/\
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M]T&T@:64J$C!E"L[*,XS7Y ?L>?M$:IXO_:A\<7/_"O?'E]J/C>&_GGMM/\
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M *!_Q)_\/Y\>_P#YY=?3]%%WW"R['S!_PQY\"O\ H'_$G_P_GQ[_ /GET?\
M#'GP*_Z!_P 2?_#^?'O_ .>77T_11=]PLNQ\P?\ #'GP*_Z!_P 2?_#^?'O_
M .>77C?[0?[*7@'0O@UX]U;X;Z;\76\<66DP2>'?[%^-?QYU751>'5+".0V.
MGM\0KQ;F7[*]QN0VLV(O,;:-NX?H'7B_Q;\56FF^&/&-MJ]C\0-(T_2='LM1
ML_$?A74K31)]?UJYO[2UT7P=X8U2RU&;6AXAU[6+BRT6&WDTB"TN);T0"Z</
M@EV&G8XD_L>? HG_ )!WQ('L/CW\>P!]/^+F4G_#'GP*_P"@?\2?_#^?'O\
M^>77KOPI\.^)?"GP\\*Z%XR\0ZEXI\5VNFB;Q!K.JWW]I7,NJW\\VH7EE'?F
M*![NPTB6Z;2-+N)HA<S:98VDMVTET\TC^A47?<++L?,'_#'GP*_Z!_Q)_P##
M^?'O_P">71_PQY\"O^@?\2?_  _GQ[_^>77T_11=]PLNQ\P?\,>? K_H'_$G
M_P /Y\>__GET?\,>? K_ *!_Q)_\/Y\>_P#YY=?3]9VK7\FEZ;>ZA#IFHZS+
M9P/.FEZ2EI)J5\R=+>R2^N["S:=^B"XO+:+^]*M%WW"R['RM\#/AS)\,OCM\
M?- T.V\=6_PYE\&_ Z_\,#Q3XJ\=>,-'?7YI/BI'XN/A_5O&VM:[*MT(X?#O
M]MVFGWP2$G3)+B&,S0E_KJOCG_A/-4E_:)T"6Y\3O?:'KL^F>";#X8Z5XTEL
M_%/@'Q!'X&U[QAK6I?$+X=6EA=:9K&GSP/9QRZ]'XBFCT>27P^]G'=P7$LA^
MQJ'^B!?YA1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !6!I?A7PSHFH:EJNC>'M%TK4]8<R:KJ&G:99V
M=YJ,AD>9FO+BWACEN"\\DMP_F,P>YEFN'W32R.V_10 4444 %%%% $;11.\4
MCQ1O)"6:&1D5GA9T,;M$Q!:,O&S(Q0@LC%3E210D44;2-'''&TS^;,R(JM+)
ML2/S)"H!D?RXXX][9;9&B9VJH$E% !7SS=_M5_ 73_BQJGP0OO'B6?Q+TCQ;
MX$\!WF@W'A[Q4EK_ ,)I\2O!^M^/_!?ABV\0_P!AGPW>ZQK'@SP[K'B$VEIJ
M\SZ?I]JKZG]CDN;6.?Z&K\7?B)\ OVB/&W[67Q[\4?"[P=I&GZIX'_:I_93_
M &CO VM?& >*_#'PE^)OAWPG^R5XG^#OB;0] \:^%M \4WC^(=%\2Z\W]HVL
M>BR+9)91&X9UN8TH _6'P7\4_ WC_3+[5_#>L2/8Z?XK\8>"9VUG2]7\,W#^
M(O FL7^A>)[6TLO$ECI5Y?6MC?Z9>>3JEE!/I>H6<0U#3[RZL72X;M'U+3HY
MVM9+^R2Z2*.9[9[J!9UAE\TQ3-"T@D6*003&.0J$?R9=I/EOC^7G]L#]B#]H
M30U\9>%K?X/6_P"TKXJ^-?A_X_6'@2ZC\(?$#Q7X-^ WB7XN_M'^./B;I/B/
MX?\ CC3[NRLO 7CFXT'QMIFF>.-7\>:?X/\ #T>F>#=#N-.\9:YI=OK'A"Z^
MQ?&W_!,SXT^(?C5K_CFR;X"WG]I_%OXE?%6'XY:[JWCZ/X^W/AWX@? +QA\*
M-$^!^I65KX=O_#9\!_#G6]>TZ;1)H?$'V*3PYH^ES6'AO2=?35I=5 /V^_M?
M2?LUQ>_VGIWV.SE,-W=_;;;[-:S#R\Q7$_F^5!*/.AS'*ZM^]CX^=<^ _"S]
MJG]G_P",'CO5?AU\,_&::[XRM- UOQG?V">%_%6D0W6B>&?'FJ?"77M5M]8U
M?0=.TC5GTCQQX:O_  O?1V5_=WD$UC"S1"QDM)Y/RGM/^"4/COP3X:T?2?!=
MA\!O$7A?29?V1_$WBGX"^+;[QIIOP>^-?C?X-_"+XC?#GXLZC\13IWAW4YA<
M^(?$7BWPO\1/#6MWGA_Q0=?\1>"-*D\;Z(SQ6L]KL_LI_L[_ +17[+?QB\->
M%]-^%6E>+-1^'O[+'C3PFFM>'[GQ!X;^ BZ[\9?VX-5^*B^%O"?C?Q99S:[?
M0?#;X:>(Y]6U6PFTJXUNXCT%=-M$OKV]MY& /V+3XK> '^)&O?"3_A([9/B!
MX8\!Z)\3=>T&:WO8!IO@;Q%K'B#0-(\03ZG-;)I'V:ZU;PMKUJT*7[W=L-/>
M>ZMX;>6"67M9-2TZ&*VGEO[**&]*BSFDNH$BNRT+W*BVD:0).6MXY+A?*+YA
M1Y1F-68?EW^UW^P[\4/CO\8/%WQ/\+ZM\-]4\.:AX%_9LT2;X3_$&\\2VGA3
MXL_\*3^+OQ1^('B?X>_%"?0](U%[;P#XKTWQWI$MA-;VOB&,^)O#MJGB+POJ
MF@F>VN?S+_:F_8@^._PZ^&GA+P;;_!ZT_:/UOQ+\'/VG_ W@_P"''ASP3\0?
M&_P9_9E\6_&;XEW'C/P3!\#?$=M>QZKX-U#P)I6J6G@O1O$WQ'T7PCX?A\-Z
M':W-AXK\*Z597?@^X /Z./'/Q@\ ?#KQ!\,/"GBC69(/$OQD\6S>"OASH>GZ
M=J.L:CXAUFST'5/%.JS);Z7:W;66B:%X<T;4=8U[Q!J'V71=(LX8C>WT4MW9
MQ7'G?A3]KW]FSQU8?!S4O!_Q;\,^(;3]H+5_'6@_!E].&I._Q UGX9Q:S+XZ
MT[1XI;"*6&?PY_8&J17QU-+"(W,$-I!)-<WMC%<_'_QR^#_QET?QK^PKKWA+
M0;[6=2\$_!+X]_L[ZQK-C;WFM:1\-/B3\5?@UX-LO /Q&\3G2+2[U*U\$VWB
MWX;3^%?$/BBRLYETA/%&G3S1K:W4S+\S_!__ ()'?$#X,^.?A-XLTSXE^$K[
MP_\ L]^,O@!XN^"WA=F\0^3X,:]L-!MOVY7MF71I)9+SXTWFAMJ_@Y%\V.-[
MVZT[55TM)6F< _9_X1_%SP#\<O >E?$GX::T^N>%-7N];TV*XN-.U+1=1L=8
M\,ZYJ/AGQ+H6LZ)K5I8:QHNMZ!XATC4]&U?2]3LK:\L[ZRFBDBVA';T:6&&=
M56:*.94DBF198UD59H)%EAE4."%DAE1)(I!AHY%5T(901\/_ + WA#Q=X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #J ;<# 2(  A$! Q$!_\0
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M/"U\7*.,G6P>%PGNJMAJ,#\S_%NC>#S^S=XG^&^L_"?Q3KGQXB\.ZJ=?@M/
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M:O-1-O;^)[^7P*EUKM[:Z*]Y/I]MI^I-=QQ+I]VT5/\ :>^#,G[1/[.WQL^
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M_P#LYR^_]49\"J?1_+\Q=5\_R/IRBBBD,**** "BBB@ HHHH **** "BBB@
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M8_X*6W&AQ>)?$GA]_%^@? K2?!EC\#/&/_!/7P9XZ\41"]UE_%VD_%^S^/\
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M:>UNKM9(HI%N9XI)E>*-PX9%(K7_ (#\#ZK=:/?:IX-\*:E>^'K5['0+R_\
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M\#O@8[+#;6T<4$09V>1]B+OD=Y'W.[,7W^7YAV^?Y'U-1112&%%%% !1110
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M8>C";JNIT_PJ\)7_ (0\&V5MKSP7'B[6[J_\5^.;VVVF&\\9>);E]4UT6\@
M,FG:;<3KHFAA\FWT#2]*LU(CMD4>C444TK*QY&-Q=;,,9B<=B'%U\77J5ZBA
M'DIQ=25XTZ5--JG1HTXTJ%"DFXTL/A\/2C[M)-E%%%!RA1110 4444 %%%%
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MX!N"CPQZC8B^AMKWQ9XQ2"26%O&NMV=DUE%-/!X7\/\ AB.[U,ZG[,2 "20
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M@W+2VFOJ?JQ>:GING(9-0U"QL4 R7O+N"U0#!.2T\B # )R3C -<K<?$KP'
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M;=75U%?Z9;:5H6MZ;?W(N[6U>VU![/7HK?4+6(3VT=W;2M;7,T$B$=%>>$]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $9 9(# 2(  A$! Q$!_\0
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M+6?&WQ?^)&HJ\^O>-/$-[=BX$*WM[<73Z9I%F8]/TBQDCM+9&VO+( ?.DO\
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M\9?^'?G_  4>_P"DS/QD_P#$9O@1_P#&:^:OC#_P2 _X* >(?'.@_M->"O\
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MP?X]_P""A/[+7ACQ/;Z1JM[H6JSZ/J.O:S'=Q:=KFFR0ZCI-VR_ZJ^L9HKF
M_-&ZFOTQ_95_8Y^"'[&?A/Q%X*^!FG>+].T'Q3KX\2ZO%XP^(/C/XB7KZH+1
M+(/;:EXUUG6K^SMA!&H^R6UQ';E\R&,R,6(!]2T444 %%%% !1110!#<6]O=
MP36MU!#<VMS%)!<6UQ$DT%Q!,ACEAFAD5HY8I8V9)(Y%9'1BK*02*_!7]M+X
M0?"O]G?0M,_8I_8(^'VE? [X]_\ !1'XFKI_C_X@_"J"._\ $?PH\#SW3:GX
MX^-'C#PY=W-[J3_#F^ATZ\\ 7B6']GZ':7_B=$ABCE5MG[9_$WXG>!?@[X'\
M0_$7XD>(K'POX1\,:;=ZGJNIWS,6\FSMIKIK:PLX5DO-4U.XC@=+#2M.@N=0
MOY]MO:6\TS*A_GG_ ."6G[6_PU_;?_;B^/'[8GQ$TK6?"=_\1M,O_A=_P3HO
M_B)9?\(]K?B3]EKP?K$5C\7+#2$M2FF27>K?&;3FUW_A&M<D;QE96P5A:_9H
M)V4 _H,^#OPH\$? SX7>!/A#\-_#ND>$O _P]\-Z=X:\.>'=!M?L.CZ78V,6
M##86FY_L\$EPTUQY>YL/,V22:])HHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^9OVK?V/
M/V</VW?AG:?!_P#:B^&MI\4_AQ8>*=+\:VGAN]U_Q7X<BA\3Z-::GI^FZH+_
M ,'Z[X>U5GM[/6=3MQ;27S6<JW;&:WD=(FC^F:_+G_@JKX?_ &7_ (A?#G]E
M_P""/[5_PL\;_%?P%^T1^VE\'O@=X8T[P+\1O%?PRO/"OQ$\8^&/B3=^'_&V
MMZ[X,\3>%-=OO#>CZ?HFMVFHZ+:ZA/\ ;)M4LYOL4SVB20@'S]KW_!O%_P $
M;].T?4=0@_9D'PVEL;:2\C\>>%OCY\?/!NO^%'MU,J:WIOB6/XJQC2;C3W5;
MI+F<O:JT2FZBFA#QMZ?_ ,$0_B[X\^+_ .PQ#<>,_B9XA^.6A_#/]H#]I3X'
M_![X^>+;Y-7\3?'+X%_!_P",7BGP3\*OB5KOB")$A\4:GJ/AK2X-'N_%4:!O
M$DNAMK-P\]W>7%Q-\+Z=_P $<_\ @BI<_MGZK^Q3??LJ?%CQ#XYT3]FW0_VG
MM1N_%7[1?[0NO?"O5O!.O?$O6_A;;^&[ZPO_ (X3WFI:Y%K>BS:C=:??: =%
M?39;9Q?S7 EM$_HL^'/PX\ _"#P)X4^%_P +/!OAOX>_#KP+HECX;\'>"?"&
MD66@^&O#6A:;$(;+2]'TC3H8+.RM($&1'#$I>1I)I2\TDCL =I1110 45\H7
MW[;O[,5E^T_X6_8WC^*N@:I^T7XM\.>(_%EC\.M#E_MG4M-T/PJMLVKW7B*7
M3_/M_#TB"ZB%O:ZK);7-T=_DQ,%)KY__ &E_^"N7[#G[)OQ7M_@W\7OB5K4/
MBZ,:/_PE%SX0\$^)?&_ACX<MKVJQZ/I<7Q.\3^&[&^TCP'-<W,L<WD^(;BSE
MCLG6\D1("&//@\7A<PH1Q.!KTL9AIUL9AX5\-)UJ,ZV7XJ>!QU.-6G&4)/"8
MRG/"UY*3I0Q$725:<W%3;3CC/[/E&4<?[;!X=8&4)K&RQ&8T7B<OPT,(X+$U
M<3CL/&5?!X6CAZV*Q5*,JF'PU:,9-?I?17QE^TW^W[^RY^R7\//!_P 2_BI\
M0?MVB_$2YL+?X>:1\.M+O?B1XO\ 'L>H1B>/4/!WA3PDFI:SXATFWMRMS?:K
MIMM/864$D4D\Z"6,-Z!^RS^UA\"?VS/A-H_QI_9]\:V_C+P5JTUU9S"2VN-)
M\0^']5LKB:UO-$\5>&]02'6/#>M6TD+-+IFK6MM=")HYE1HI$<]LJ-:,J\)4
M*\)X:52&(C.A7A+#SI5HX>M&M&=&$J4J.(G##UE44/8XF<,-5]EB91P[4?WD
M:DZ?[R%&6'A7G3_>0H3Q=.M6PD*\X<\:$\71PV)K82%>5&>+HX;$UL+#$T</
MB*M#\N/^"^.F>,-;_9__ &2M%^'?BRS\ _$'5?\ @H5^RU9>"O'>HZ/'XCT[
MP=XBFU_618:_?>'I6CBUNWL7RTFG22(DX."PQD?I7^RA\./VI_AMX2\2:9^U
M9^T3X9_:-\6W_B 7WAWQ+X8^%.E?"6UT/0/LD<1T:?1]*U'4H=1G-VLER+^2
M5'5'$(0JN:_-3_@OC#XZN?V?OV2K;X6:CX9T?XGS_P#!0K]EJ/X?:OXUL[G4
MO!FF>*6U_6?[-O/%6G6;)>7VB129:\MK5UFD7 1@>:_2O]E'1?VR=$\)>)(/
MVS_&WP+\<>-I?$ E\*W_ ,!_"_BOPKX?M/#7V1%-KJ]IXLO;Z\N-5-Z))!/;
MR+ +<JA7>":R ^J:*** "BBB@ HHHH _%?\ X+R:-X+\8_L4^&/AMXLM?%L6
MI_%#]IK]G_X?_#WQCX#\0W>@>*_A)\2/$_B\Z;X.^,.GQ6*R7&O6_P /M4F3
M5=0\/M&UIJ=JSQ7C)"K..<_9Q_X)_P#QO\7>,/@"/VJ_!OPO^%7PM_88\;/X
MN^ '@SX+ZVFHWOQG^,-O;W6G7/[2_P 1=:M+'2I_#LWBNTU'6+_6/A=Y%Y:W
M&O:Q<ZIJ%]+)! #M^/RG[3?_  6B^%_@6QFFT&R_X)Y_!#4OBCXZTS70=4T+
MXL#]IW2)_#O@[^P]*5C9V&J?#N_\-7.H2ZMJD$MQ'-=H-,>%R7K]L* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K\Z/^"G/[,G@S]I/X!>$M0\:?M1ZO\ L9P?LU_&
M?P7^U'H/[1NE2^ H(OAQXD^&NC^+-'L=6UBX^)<$_@VWT9+3QEJ#7$VL*(%N
M4M WFQM);S?HO7XG?\%V/ ?B+X@_LV_LVV$?[/?Q<_:I^$WAS]O']G#Q[^TK
M\!/@OX0?Q_XK^(OP$\#IXX\2:]HU[X+%_ID'B;PY_P )G8> Y]5T:^OK?3K]
MXK2WO9%MW=@ ? 7A3]B#3_%PU[_@HUX/_P"#D;XEZ_I%I\-S\"_$G[4NE)^Q
ME>> M,^'OA;Q5>^-W\ :OXG30&\#Z1)I/BK5+S6IX+I+77UGOPLTK6T\,3?M
M-_P3%^(?A#XF_LJ:/XE\#?MJ^*_^"@7A^+QU\0=$B_:8\7^$]$\'WWBB]T3Q
M!-I^HZ'I]CX;\+>$=#U'1?"MY%-H^G:[IFF7%GJR027%OJE_#LE'\L.K^'?V
M:_%7_!1/6OVBO%/_  0>_P""ET_[(B? _P  R^'OV6M,_8RTO2OA!??M@^'?
M$_BC2=7^.WBO]GG2_'FG_"K5=4MO@O<>%/!>BZY?VVHBYN(=:FO]$-\T&J2_
MV#_L>_&/1OCE\"?#/C?P[^SM\8OV6-"BO-7\-Z3\&/CG\,=,^$'CGPW8^';Q
MM.MYE\":/J>K:=I7A_4$C%QH+6MTL=Q9%9%MX!A: /I^L?Q#HEGXFT#6_#FH
MO=QZ?K^D:EHM])I]W-87Z6>J6<UC<O97ULR7%E=K#.[6]W;NDUO,$FB9712-
MBBAJZ:>S5GZ/1_@QQDXRC*+<91E&49+=2BU*+6^JE&+6CU2T>Q_*S\/OV%OV
M9_V&/^"[/[(>A_L]Z!K.F:C\2/V;?VF_$'Q#UGQ7XTUOQYXO\2ZDAT"?3[O6
MM9\1WM]JSK%)+,EH995A$2B*(?NVK5^ FE^ -:T'_@Y#@^)UGX+N-2N/C1\1
M6\56FK/ILLRV-I^S_:S^&Y-4BN&::"T34([6;3FF6.#[?&&MV,R K^Z/BW]A
M_P"!GC']K_X9_MP:E8^(+;X[?"OP+XI^'6@:EIVM2VNAW_ACQ8+07]MKNC")
MXM1FMOL<9L)S+&UMN?AMW'Q_^T[_ ,$2?V./VHOCIXF^/NO7OQ@^&?B?XEZ=
MH>D?'/P_\'?B)>>!O!/[0&G>']8@U>Q@^+_AVVM+JW\4LQM8-.NIS):S7.EQ
M):2.1ES^:9)P1CZ>48[#YSGF/J8BM0\7\NPN35N3-.%:^$XVX^RWB+A:6=Y=
M2S#*L1B<'D>1Y=++L+A<OQ>'Q&6T:\,%1A",JV(P_9AZV%I\1O'3IXB.">:<
M*YS4S:G&E5XBIYC@\LQ:S[&Y=*MBW&CCXYIBJDLOQF(S##U<32J3K2K99=X>
M7XQ?\$[IM3U']I+_ ((%M\48])7[-_P3\_:$3X<OKC6,5U<0KHOA2+2WTI9I
M-USJ!L1 +5XPUZT(4HNWFOT0_P""1UM;Z3^WI_P62T/P);:?:_"NV_:KT&Y@
MMM#CMDT*W\53_#KPT]ZMNMKB&"^F#W4M_#$J?OMS2HLF:^]/VK?^"6W[*/[6
M/@#X,>"-=T'Q)\)M1_9QOM*N_@#\1/@9K\OP[^(OPAM]*BBMUT?P5XCLH;E]
M.T.]MK>VM]0TQX)H+J.VM]P#1Y/LG[&O[%?P0_89^%)^%7P5T[69(=3UB^\3
M^-O''C#57\1?$/XE>+M1GEEO?%GC[Q/-%#/KVO3)*MJ+N2&)8[2""".-50EO
MTNCA<+A,[S7-HYCFN;O'2\2O9U.(*%+$9AAZ?&W&'#N?9;@\%C</G-6GA<HR
MW 91B9XC 8C!XZO'.8Y;]3QE3"T<3F-?XNCPNH<-</Y*^(N(*6-R'B#@S.*^
M/H5:*J\54.%Z/&T:V'XKQ2G0J8Z5;_6K#8##QCA:]-95@(T'/!2IJEB_S@_X
M+XS>.K;]G[]DJY^%FG>&M9^)\'_!0K]EJ7X?:/XUO;G3?!NI^*5U[6?[-L_%
M.HV:O>6.BRR96\N;5&GC3!12:],T7Q]_P71EU[1X_$'[/G_!/.U\.R:O81ZY
M<Z7\8/C%/J=MHCWD2ZG/IT-QH"PSW\-B9GM(IV6*2X6-)2J%B/,/^"^OC*P^
M''[/?[)OQ$U72/$GB'2_ _\ P4(_9;\2:AH'@S29?$'C'6K73]?UEY=/\+Z#
M 1/K.LS@A;33X6$D[?*IK]+OV4?VL_"O[7/A+Q'XP\*?##XZ_"VS\->(!X>N
M-*^//POU?X6>(=0G-HEV+_2-(UB6:>_TH(XB-]&PC%PKPD;E)H/ISZFCWE$,
M@42%%\P(25#X&\*3R5#9"D\D8S3Z** "BBB@ KS_ .+'CF+X9_##XA?$*46$
MA\%>"_$WB>"WU2^CTVQO;S1=&O-0LM/N+V5E6W74+NWALA("7#3J(U9RJGT"
MOQD_X*_:C+\=_!_PM_X)Q^"$O;SXA?M@^./#5AXFU_PW=QWFM_ CX5>#M>L_
M&.H?&KQ%X8@G@O[_ ,%OK?AFU\$37)F@LQJ6NQ12O(JR(H!UW_!'?P5/KG[-
M,O[87C-=9N/BW^V]XHUW]H3Q;;>++)F\0?#32O%EX$T7X):+K&H1)KL_P^\!
M#3I6\+Z?J)C6U_M*ZDB@5)$8_K;65H6F)HFB:1HZ&)DTK3+#3@T,$=M$_P!B
MM8K??';Q!8H$<QEUBC4)&#M4  5JT %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q#^
MV1\*/VW?'*>!/%W[$/[4G@3X$^-/ _\ PD(U_P"'7QE^#MC\5_@M\:;75_[(
MDTS3_&MWIFI>'OB7X&N?#\^F7/\ 9OB'P!X@CN&M]9U*#4=)U("T-O\ ;U?%
M?[9/[9&I_LA:;X#U#3/V0_VR?VLI/'-_KUC)IO[(7PDT?XJ:AX+70[;3;A;[
MQS%K'C7P9%HEEK)U$P:'+#-?/?7&GZDC1P"V5I0#X E^-?\ P<.:*;K0[K]A
MW_@G'XVU&&1;>U\=^&/VL/BGX:\(W8#%3J!\*>)OAQ<>*XX'7;*UI)?17,/S
M1J]P0"?HK]EWX8_\%8?$'Q<T3XO?MP?M'_LW>"?A_HMEK,=K^R+^R3\,=:U;
MPKK=[JNDW>GZ?J/Q%^/?Q>DD\?ZI<^'+BZ34[72/!7A[PKI%WJ5I:O>75W:1
M26]QX)_P^I\6?](;?^"U7_B(?@;_ .?I7Z>_LN?M 7G[37PBTKXL7WP(_: _
M9PN=3U;7=*?X6?M,^!;#X=?%?3!HFH26*:GJ?AG3/$7BFS@TK6507VB7<>L3
M&\L9$E>*!]T2@'T/1110 4444 %%%% 'X6?\%[_'GA[X5_ #]DGXH^+KK4K#
MPG\/?^"A?[+7BKQ)?:-IE[K>KVFDZ;K^LR74^F:+ID<NI:K>(I_=6-A%+<SG
MY8T8\5^EO[*G[9'P._;.\)>(O&WP*U/Q;JF@>%M?'AK5Y?%WP_\ &7P]O(]5
M-HEZ$MM-\::-HM]>6_D2*?M=M!);A\QF0."M?FQ_P7G\:^%OAK\"/V0_B-X[
MUNU\,^!O W_!0_\ 98\2>+O$E_#+<6&A:%I^OZR][J=Y;P0W$TT%LAW.D5O,
MY'W8V(Q7Z?\ [-G[6G[-W[77AG7O&/[-/Q4\-?%CPQX;UL>']>UCPS#J<-KI
M^MM;+>"QG&J:=ILS3-;2),&CBDC*L/GSD4 ?1U%%% !116;J>LZ/HL4$^LZK
MINDPW-S%96TVIWUK817%Y/GR;2"2ZEB26YFVMY4$9:63:=B'!H -9UG2?#VE
M:AKNO:GI^BZ+I-I/?ZIJVK7EOI^FZ=96R&2XN[Z^NY(K:UMH8U+RSSR)'&H+
M,P%?CG_P39T'5_VH?C'\<?\ @IK\2-*U"&;XE7VK?!G]E70?%^C3Z+X\^$7[
M/7@[7KC3_%7AF_:'RM-UG0_B1\0M#;XD^'M31;II-'U"P>.X,<JENX_X+/\
MQ%D\-_L8:C\(8-'.KM^UU\1? ?[(M]=6UQ+_ &IX,T3X\7]QX1U7XBZ?IEJK
MW6KR>"X95U0V2B.W8A&NYX8 Q/Z._!KX=0_"#X0_"SX3V^JSZ[;_  Q^'7@K
MX?0:W=6\5K<ZO#X-\.:;X>BU.YMH2T4$]^FG+=311LR1R2LJLP&2 >DT444
M%%%% !1110 4444 %%%% 'YK_P#!8/XR?$G]GW_@FC^UY\9?A#XVU+X;_$;P
M%\-(-7\,>.](ATR?4_"MQ+XL\.:=>ZQ91ZS8:II?GVNEWM\R/>Z?=PQ9,IA9
MD7'P7\+_ -LC]FC]GC]FC]M?]L3X,?\ !4GXV?\ !3N#]FK]GS6?&GB3X7_$
M+XH_ ;QAX9\-ZZEM>ZGX+> _"7X%_"O6M"U/QAK>B/X:CO\ 5M4U.SBTNXU-
MTTLWD,<\?Z:?\%+_ -FKQ_\ MA?L)_M)?LU?"O4O">D?$/XL>!K?0O"6H>.K
MW5-.\(0:O9>)-"UZ%?$%_HFD:]JUGIUPFDR6TMS8:-J5Q$9E=;64 BO&E^#?
M[87[7?P@_:$_9>_;T^!?[*'PH^!OQL^!_C#X9R^(/V9?V@_BA\4_'(U7Q59+
MH:2G1?'_ .SG\(M)TFWT?3[R]UW2]7CUW6+B#7--TNVDT>>UN+BY@ .7_9B_
M9B_;TOM'^"'[2'Q@_P""C'Q2UCXM^,;3P/XZ^-7P!3X5_!0?LE0>&_$EKIVM
M^)_A'\.?!UEX+T[XK>%KSP[8W"^'?#GQ4O/C%KNNWE]IC^(-<T._CUF^TA/U
MUK\D?V>/ G_!7?X;:/\ "KX&_%?QM^Q#KGPN^$T?A+P_XD_:JTZ?XP7_ ,:O
MBU\-O!0L[9DO/@#J/AS0_AY\._B3XK\/6,.G^)O&?_"Y_&_AG3-2;5]?TCP7
M+]ML-.TOX^N_C+\8_P!FCX4:K^SW\3?&_P 0;?\ : \1^"_V:?$OC/\ ::TK
M]JCQS\>_!$_P:^(_[5'@?X%_$_XG^'(_B%#I]C\ _%-MHOCNYU'PW)IOA"ST
M.;39I=<T?Q+>S_#Z^@T\ _HOK\R_B+_P4VTKX=>//%_@.7]A3_@IIXUD\(>(
M=4\//XN^'7[&GC/Q=X#\2-I5W+:'6?"'B>TU:*UU_P /:@8OM&EZM;QI%?6C
MQSHH5P*[+]C7Q!XFM/C-^V_\&?\ A-/&7Q#^%?P4^,/PZTOX8>(_'?BW6_B)
MXAT6?QQ\$_!'CKX@?#F?X@^([W5-?\2VW@_Q5K$E_9P:_J^KZWX<M_$Z>';F
M^^PZ=IMI:<?\1?\ @F/X?^(WCSQ?X]G_ &WO^"F7@V;QAXAU3Q#+X4^'7[;?
MQ-\'> _#LFJW<EVVC^$/"FG+]@\.^'K R&WTO2+/_1["T2.WB^1!0!V'_!1G
M]K?Q7^R=_P $^/CG^U1\//#:R?$/P[\/O#)^&OAKQYI]S8QV'Q&^*GB7PM\/
M/A_!XUT=)%NH(=#\7>-]&N/$NCFXAE,=A?:<UW;LQN(_B33;[]K/]@O]M+]@
M;X9?%#]LWXJ?M@?#;]NG4/C#\*?BWI?QI\)?"72)/A[\;O GPDU/XO\ A;QQ
M\#9?A=X%\#77A+P-KLWASQ3X7U3X=>);OQK!IVF76D7=MKUQ?6 F/Z)_MI_L
MA:;^U]^Q1\8?V/[SQOK7AMOB-\-;/PCH/Q*U57\5Z_X=\7>&+G2-=\#>.]66
MYN;*;Q%J>C>,/#FA>(=3\R]L[G5I[:X(N[:>X$\?Q_\ #C]EC]O'XX_M1?LM
M?'K]O+5/V7O#/AO]BG2OB3?_  V\'?LV:Y\2O&US\9OC1\2/ H^&-]\8/'>H
M?$CP5X%B^&^@:#X/O/$LWA?X9>'X/&M[:Z]XEFN=4\?:A:Z7:6\P!I?\%@OC
MW\6?V>?A7\"/&.C_ !0\7_L^_LP:E\>-%\-?ML_M)_"_0?"_B7XM? _X+:SX
M?URT\->(O!6F>+=*\3Z=866O?%>3P1X2\8^*]/\ !/CCQ#X3\-ZS=:KHOAJ[
MG622'QW_ ()__MO7^A?LK?MH?M2_%_\ :'\4_M$_L)_!;XC>(+O]E/\ :8^(
M>D^"[7XW_%_X5^%O"&B1>-;76M'\ :+X1T_Q/<M\:)->\ _!N[O_  9X/\<^
M/DDTVVN_#<:W6@3WW>?M!?LI_M\_'MOV,_CYXL'['_B'X_?L@_'3XW_$&;]G
M74-6^+%I^RS\6?#GC+3_ !!X&^$GBFZ\6ZAX9\6>,O"7QL^%7@ZXTOQ5H'B*
MZ\ >,- T?QWJGBA=&LK.!]*U6U\S^'W_  1]U3XP3_M=>,OVPM9T7X.ZC^U;
M\>_V>/V@+/X-_L*_$?QUX+\%_"/X@?LV^'IM/\.?$2U^(VH>&O!6I^,OBEX[
M\32V?C3Q]XD7X=>%;2\UGPMX-N'M=3U;1!K<H!%_P2O^.G[;_P 0OVVOV[_
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MNXUE:.-,?>] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0L/%?@'Q_J_B;3=)U_2=9^'WB:QU7PK=>%=5LDG\.W&G36$4MS:+;W,ODW[
M_P"P=\;O@W\:/V@?VUOVU?BUX ^.W[;'[1.B^$?A[>ZQ\+/"VK^#_A#\&O@?
M\/Q+=>&/@U\)--\1W6H>)8]#U#Q#<7'BWQ?K&L2)>^(->&GW=Y;37MA/J6I^
MJ_\ !-#]E+XD_LD? 'QIX8^,FL>#=5^+/QA_:3_:._:8^(%I\.;O5M0^'_AC
M7/CU\5-?\<P>$/!^H:[HWAW5=0TOP]HMYI-C<ZA=Z#I#7VLKJMW'9+%-'+*
M?H51110 4444 %%%% 'X5_\ !?'1O$_B/]G_ /9*\.^"/&DOPV\:ZY_P4*_9
M:TWPI\1;?2K;7I_ VMW&O:RMGXDAT*](LM8?3W_>"PNSY$_W7XK]+?V4_A!^
MT+\'?"?B31OVBOVH]1_:H\1ZIX@&I:'XLU+X8^$OA=+X>T86J0G0DTGPA--9
M7R-<*UW]MN&$ZES"!L4&OS2_X+XV7C;4OV?OV2].^&7B#0_"/Q*OO^"A/[+=
MMX"\5^)])?7_  UX<\3R:]K(T[5M>T*)XY-8TRU?+7%A'(C3J0 PZU^E?[*'
M@_\ :\\&^$O$=E^V'\9/A9\9_&=UKXN?#&M_"GX;WGPUTC2_#GV1$.FZCI=[
MJFJR7U^;P/.+Q9T41,L6TE=Q /JFBBOS*_:3_:;^)WQ,^)>H_L8?L2W%A=_&
M<6L#?''XY7, U+P)^RSX3U#:))M0>-A:Z[\8-6M)!_PBO@5+B.]L(KN'Q'J*
M"TM3%0!X!^T 8OV\_P#@HS\/?V2ALU+]G_\ 8CE\(_M(?M$Z7?VL]DGB/XT7
M*R:M^S2W@/Q?I9E^T7WP]\0:=K-_\0/#5U/; 0WFG07MOEHO,^Z_VJ?V#OV=
MOVQ)_">H_%_0O$=OX@\'7,8T[Q;\/_%NL_#_ ,6ZAX?,TEQ?>!?$'B'PY-::
MCKO@#6)Y#+K'A'4)IM(OY!ODA#,Y?T/]F;]F7X:_LK?#:U^'?P\@U"^GNKZ[
M\0^-O'/B2Z_M7QS\2?&^KF.;Q#XX\;:[(JSZKX@UV[3[3=2'9;P#9!:PQ11J
M#]#4 <[X1\(^%_ /AC0O!?@GP_I'A7PEX8TRUT;P]X<T&QM],T?1M*LHQ%:V
M&GV%JD=O;6T,8 2.- ,Y9LLS$]%110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!R7C/Q]X%^'&BR>(_B%XS\*>!/#T,T-O+KOC'Q
M#I'AG1XY[AMD$#ZEK5W96:S3O\L41F#R,"$4D5I^'?$GAWQAHFG>)?"6O:+X
MH\.:Q;_:M)U_P]JECK6BZI:EWC^T:?JFFSW-C>P>9&\?FVT\B;T=-VY6 _GN
M_;Y^'GA+]K/_ (+'_L&_LH?'#1=7\9?L^:7\$?CQ\9->^&&MB1OAAX_\9^&;
M;1E\+W.OZ6LH@\0W/AM[FYECAN@([0W(VJVXYUO^"+UJOP3_ &CO^"FW[&'@
MZZU@_ OX ?M&V4?P7\+ZCJ=S?Z=\./#VO^$-$UK4O"7AF*=G73_#\NKZI=ZA
M:64;;(7=]@P37S_"F?4^*GCGAJ56,*&(X_IT9*@Z<:,?#[B/)N&<?0Q\Z^83
ME+%YGB,=F6:9;5RW#U\#'+<OHX;'+!9KC%1CQ9]F6!X96"6=SKX.KFV>\&</
MY)"G16.AFF,XSR_B#'X:HZN#K3_LRC@99'#"55F%*4\34QWMX/"4,)4A7]#_
M ."]VNZ[X6^ 7[(_B?PMX'UOXG^)_#__  4,_9:U7P_\,_#-Q:VGB7Q]JEMK
M^LM;>&-!NK]DL;?4]1;Y+>:[=8$()=@*]CL/^"MWP^\%>#=0U']J?X,?$+]F
M3XJ2>-+;P3X2_9]U+5- ^+GQ>\4WFI:1'J6B:G-X<^$TGB.;PGH>M7$]OIEC
MK'BE=-TMKFXAD>]6!P]?-G_!QE%IL_[('[/L&LZ?\2]7T>;]NG]FA-3TGX*7
M,UG\9=2LSKFL>;:?"R\MWCGM?&LHP-'GA=)$ER58&O/_ -E3]HG]GG]G'Q#I
MR?#3_@E7_P %+#\1?%::7X+\6_M!_%?X!CQ7\5_%NFW&M)+;7WQ.^)VK>*;G
M6M7L=)DEA=[B=S'9:=8PK'$1;C=] =I]3'XV_P#!4+]K]1X.^&/[-4G_  3Z
M\(+<MHGQ*^)7[0VM:3XO^*4OAW7XS"FO_L_:3X!O=2\/)XL\.V\-U/(?'L2:
M>EY=6 11)"Y/Z._LU_LU?"_]E?X9:=\,OAAI<L-JD\VK>*/$^JS/J/B[Q]XM
MU!VN-;\9>,]=N6DOM;U_6+R26>:>ZFDCM(FCL+%+>QMX((_?8VWHC[63>BMM
M<8==P!VL.S#.&'8@BG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!^3/\ P4*_X)[_ !>_:,^+G[.G[5W[)_QYL?V?
MOVK/V:;W7-/\+:WXNT2[\5?"_P 9^ ?&1M4\:>#O'?A?3VBOK^#4X;"T2TN;
M:>-K?9(KJP967T+_ ()P_L(:]^QEX3^+/B;XK_$X?&C]I/\ :2^(EQ\5_C]\
M2+/3Y=(\-:GXL-J-)T[3/!.BW7F7VC>%]*T2VL;2VLKJ>69YHI)G(RH'Z245
MSX3"87 )+"8;"T%%9Y&BZ>"R^G4PU/B;-<LSWB*CAJ]++Z&)I4L[SO)LNS;,
MXO$UIXO'X=UJE90K8C#5JE+FHU:$H49TZ^*R['5N?#X:I4GC,HP^/PF68CV]
M7#U<33J8'"YGC\/0]AB,/!4\3)5*=:4*$Z'X5?\ !?+QSI'PO_9^_9+^)OB&
M'7[G0/ /_!0K]EKQ/K-MX4TB\\0>*9]/T[7M9DGC\/:#IZM?ZSJK+Q;:?9J;
MB=N$&0:_2S]E#]L#X8_MC>$O$?C3X7>'?BUX<TKPOX@'AO4+;XN_"WQ7\*]8
MGOS:)>>=IND^++.SO-0T\12*IOK>-H!-F(D."*\__P""@'[%4G[<GPF\$> -
M,^,WB_X!>+_AG\9OA[\<_ /Q/\$Z-HVOZUX?\:?#>\N[W16_LG7S_9EY:2RW
M;BYCGSE5 4<FODMO^"?/_!1YCD_\%F_C,.IPO[-'P*4<^@$(X]/05T$G[ ^)
M?$WAWP;H&K^*O%NN:5X:\-:!8SZGK>OZY?6VF:1I&G6R[[B^U'4+R2*UL[2!
M/FEGGE2*->68"K^FZC8:QIUAJ^E7MMJ.EZI96NHZ;J%E-'<V=_87T$=S9WMI
M<1,\5Q;75O+'/!-$S1RQ2)(C%6!/X3_&#_@DY^VY\?/A=X\^"WQ8_P""P/QN
M\1_#7XG>&=3\&^.-!M_V>?@II4^K>&]9A-MJ=A%J5FB75DUS 6B,\#"0(S*#
MAC73^$O^"9W_  4 \"^%?#/@CPM_P60^-=AX8\&^']&\*^'+&7]G'X'W4MEH
M/A[3K?2=(M);J:-IKF2VT^TMX&N)6:68Q^8Y+,30!^WK,%4LQ"JH+,Q.  !D
MDD\  <DGH*YGP?XV\'_$'0X?$W@7Q/H/B_P]<7-]90:WX;U2SUG2IKO3+N:P
MU&VCOK":>V>>QO;>>TNXED+P7,,D,H61&4?D.W_!/;_@HZRLI_X+.?&H!E92
M5_9K^!BL P*DJRQ!E8 Y5E(*MA@00*\;^ ?_  1T_; _9?\ AKI_P@^!W_!7
M?XX^$_AWI6L^)O$%AHEW\ /@QK<\&K>,M?O_ !1XCN/[0U!9+IX[[7M4O[Y(
M68I;FX:./"8% '[MV7C?P=J/BS6_ >G^*-!O?&OAO3M,U?Q!X3M=5LI_$.BZ
M5K/FC2-1U32(YFOK&RU,PS"QN;B&.&Z,4GDN^QL>?>/?C!X>TWP)\=-3\"^)
M/"_B/QK\&?!OBC5==\/VVJ6NHS^'?$>G>$M0\2:+I?BFPLIWN],:_CMH+@6U
MRL%Q/9.9805(:OQC\/?\$<OVOO"GQR^(W[2F@?\ !77XXV?QH^+?A'P;X$^(
M'BE_@!\&)[76/"OP^>^D\(:=!HT@-AI\FEMJ5\6NK:-9;G[3()2<UD>%O^"*
MG[57@KQ'^T-XN\,_\%;_ (ZZ?XA_:MO[35/CS?-\!_@Y<+XNO[#PJ?!%G<6,
M$H:/0&@\,'^S4&FB,#:DW^L4$ 'ZE_\ !.S]H/QO^U;^Q'^S;^T7\2=.T+2?
M'7Q<^&]AXN\3:=X9CN8=!M-2NKV_MWBTN*\DEN4M1';1L@FD=]S-ECQ7VC7X
M*_!G_@DK^VQ^SY\+/ _P4^$?_!8'XX>'?AI\-]"@\->#-#N_V?/@KK%SIFB6
MLDLEO:3:G>H]W>&)II LL[,^PJF<**]-'_!/C_@H\"#_ ,/F_C.<'.#^S3\"
MR./4>5R/4=Z /UT\,>./!OC4ZZ/"'BG0/$Y\+Z]>^%_$8T+5;+5#H7B331&=
M0T'5OL<TWV#5[$2Q&[T^Y\NZ@\Q/-B7<,]37\_/P;_X(X_M?_L^GXFM\)/\
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MIF@>)/!GQ!\'1>-M;_:)O;?PU8_$;Q)-HWBB.]M?^$%M4\)27NF:>PANMU_
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MJ_VPL;1Q=7,)U)5X8?!TX\BIX[-)O+LZEA:<LL_?+_@I]^V!X[_8[_9Z\/\
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M\=?L5_LQK\0?A5X3TKQC\5?'WQ*^'OP1^'%AKEXEKH^D^,/BOKB>%M$\5:M
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M.:+&-(U;1/"W@[X?0^-=-\(^)-9N#,EYXDO"WV2?4GA58I90# 0F#X%\/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME< '[WT5_,1\+/AS\?\ _@J5IO[>G[7EU^VS^U=^SQJ/P>_:-_:4_9V_8D\
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MI:*OAOQGXI\/+;+#KFDW&JVFG07D<A /W-HK\</BU_P5MUCPU^U'^TM^QO\
M /\ 86_:;_:K^.O[,=K\-/$/C&R^&MU\-_#?@2;P1\1?AKI7Q'M_$,_Q"\>^
M*M!T+1]:1-4/AOPYX!G^U>,_&^M:?J4V@:4^D64^HIT.J_\ !8G]GVY_8Z_9
MF_:O^&/P_P#B[\7M>_;&\66WPP_9R_9M\)Z+HEE\;?''Q@2Y\0V'BCX>ZG9Z
M]KFG>%_"7_"NK[PCXH'Q%\6:WX@B\+^&;#1+G47U"[BN=/2\ /UNHK\L+[_@
MIS/\+?V<OB3\;OVK_P!C[]I+]F?QQX!^(_@OX1>&_@/JMOX!^)_C3X]?$GXH
MWNE:3\*O"G[.OB/X:>+M;\&_%+4/'&O:Q:>'HU@U;2#H&KV^J)X@6PL=,N+Z
MI?@;_P %*=<\7_&;6OV;_P!IG]D3XR_L;?'>7X,^)_C_ /##PA\0_%OPI^(_
MASXR?#+P5<V-CXR?P7\0OA+XN\4>&(?&W@R[U?0U\6^!-:FL-9TBSUK3]3C:
M]TYY+B, _4JBOY\/AU_P<!>#/'_PG^"'[44_[#G[6W@[]BOXJ^)OA]\/?%'[
M5WBRS^'6F^"OAM\0OB-XFM/!&E6\O@]_& ^(?C3X<:3XWU"R\(:]\7?#7AQ_
M!\6OR2V&D/K,D2>=/K/_  48_;LTC_@L[\1OV0-!_8Z^)GQ#_9]\/_LU_#+Q
M/IV@Z/X[_9NT66QA\1?'3Q)X1U;]K9O$&O>*-,\47/@&^T&%/"R?"M]1N/&E
MK?\ A+4=5C\(Q-J=M/, ?T$45^/7@G_@K/??%S]L/XK_ +'_ ,$OV*OVC/BC
MJO[/'[0UC\%/VBOB[I][\/= ^$?PE\,:Q9^&[C1/BA<^(/$'B2RNO%8U%M9U
MFY;X=>%K'4/'-AH/A+5]>OK&"WN]'@U"CXM_X*Q^/OA/XX\"7_Q^_P""=W[4
MWP)_9=^)/QQ\,_L_^&?VFO''B'X*7)T_QGX[\5-X'\ :WX[^!_ASX@ZS\5_
MO@+QAXIDTZPT[Q-K&EM+;0:MI]UJ&E6IN8+>4 _9.BOY^->_X*,?MV:-_P %
MGO'_ .Q_X?\ V.OB9\0_V?M"_9F^''BG3]!TCQY^S=HLMK%K_P =M?\ ".J_
MM;_\)!KWBC3/%$_@"ZT&,>$Q\*I-1G\:6^H>%+_5XO",9U.VN)?;_@A^V5^S
M5\%/^'O?QP\<>-_C_H/@+]E7]J#7HOCKJGQJ^(#?$?POHNLZ1\)?AYK8TO\
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M%.E_#_0H_$MH5R<"TUPW]LF<$I$I(4D@?:M%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %2 ;D# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_\ !9G_ *0-R?\ BT']E'_YE:_;RB@#\0_^&[?^"S/_ $@;D_\ %H/[*/\
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M?^"S/_2!N3_Q:#^RC_\ ,K1_PW;_ ,%F?^D#<G_BT']E'_YE:_;RB@#\0_\
MANW_ (+,_P#2!N3_ ,6@_LH__,K1_P -V_\ !9G_ *0-R?\ BT']E'_YE:_;
MRB@#\0_^&[?^"S/_ $@;D_\ %H/[*/\ \RM'_#=O_!9G_I W)_XM!_91_P#F
M5K]O** /Q#_X;M_X+,_](&Y/_%H/[*/_ ,RM'_#=O_!9G_I W)_XM!_91_\
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M\_\ JK/%= 'SM_P1S_Y1/?\ !-W_ +,D_9H_]5)X5K](Z_-S_@CG_P HGO\
M@F[_ -F2?LT?^JD\*U^D= !1110 4444 %%%% !1110 4444 %%%% !1110
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MT57]^M?KW!4I3R*$IRE.7UW&KFG*4Y64Z-ES3E.5ET7-9=$C_:3Z"F+Q>-\
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MHHH ^@_V(O\ E(__ ,$X_P#LYOQ/_P"LN?M%5_?K7\!7[$7_ "D?_P""<?\
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M%%% !1110 4444 %%%% '^:;_P %]?\ E,!^V+_UX_LV?^LW_#NOR!K]?O\
M@OK_ ,I@/VQ?^O']FS_UF_X=U^0-?QEXB?\ );\2_P#8PC_ZA9>?],GT,/\
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M&I2?J)!,MQ!#.JLJSQ1S*KC:ZK(@<*Z_PL P##L<B@#\T]5_8*\1WG@GQ#X
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M "E._;(_[%S]E7_U34U?#U?AO%'_ "4&:?\ 7^'_ *C88_P(^EI_RD;XK?\
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MA@)4?ZI\./'3PSX-X6R'),_\&\MXMQ^6X',\'C<9C,/P3*E+'XS%\05Z/%V
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M=7U"X@L-)O[>WNK^6> /?)<11VPACCGG_<JOXM/^"@7_ "D^_;M_Z[_LL?\
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M%EZO_A_G\5O^D=VK?^)9?"[_ .8ROQIHI+Z'7A$O^7_&;]>(J#^ZV11LOO\
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MBBOC#^G HHHH _4G_@A__P I@/V!/^QY^.G_ *R;\=Z_TYZ_S&/^"'__ "F
M_8$_['GXZ?\ K)OQWK_3GK^L?"#_ )(G#?\ 8TSC_P!2J!_SU_M'/^4H\^_[
M(;PY_P#5#F@5_%I_P4"_Y2??MV_]=_V6/_6=/#M?VEU_%I_P4"_Y2??MV_\
M7?\ 98_]9T\.U_;_ -$__D]F0_\ 8EXJ_P#5(C_#K]H3_P HN\6?]E1X??\
MK4R/FJBBBO\ 6 _Y\ HHHH *]2_90_Y2.?\ !-+_ +.8^)'_ *QK^U!7EM>I
M?LH?\I'/^":7_9S'Q(_]8U_:@K\C\?/^3,>)/_9+XC_U/R0_HKZ(W_*3?@C_
M -EY@O\ U4\4G]QU%%%?XUG_ $O'\-'_  52_P"4IW[9'_8N?LJ_^J:FKX>K
M[A_X*I?\I3OVR/\ L7/V5?\ U34U?#U?AO%'_)09I_U_A_ZC88_P(^EI_P I
M&^*W_8^P'_K,\,!1117@G\[!1110!]!_L1?\I'_^"<?_ &<WXG_]9<_:*K^_
M6OX"OV(O^4C_ /P3C_[.;\3_ /K+G[15?WZU^P\$?\B&'_8;C?\ TNB?[9_0
M+_Y1\P7_ &6_&_\ ZG9*%?Y@'_!T3_RF%^*__9$/V??_ %%M3K_3_K_, _X.
MB?\ E,+\5_\ LB'[/O\ ZBVIU_J-^RE_Y3?\,?\ LGO$[_U@L>?T_P <_P#)
M-8W_ *^X+_U*@?SW4445_P!<)^"A1110 5^KW_!"K_E,)_P3]_[+-XB_]4Q\
M4J_*&OU>_P""%7_*83_@G[_V6;Q%_P"J8^*5?R;]/#_E#3Z2W_9I>(/_ %.X
M4/=X7_Y*+)O^P^E_Z37/]8KQQ_R)?B__ +%?Q!_Z:;NO\"^O]]#QQ_R)?B__
M +%?Q!_Z:;NO\"^O^+D_HL_W\+Q+F2TNH[.5+>\>WG2UGEC\V.&Y:-A!+)%D
M>8D<I5WCR-ZJ5SS7Y6^'?VA+GP)\!Y?@#\3_ (,?M4^)?VB+#PWX@\*:MIFA
M?#[Q]XGG^(OCK6%U5;[QWX'^-EA!)X*T_P -^(M9NYM=TOQ-=^+-!7P18W4-
MM<6NE-HIM8/U:HH \[^$6G>-]'^%/PTTGXEZ@NK?$33/ 7A*P\=:FLZ70U#Q
M?::#80>(KO[5&JQW9GU:.[D:[1$2Y9C.J(L@4>B444 %%%% !11TZU\^6W[4
MWP-U#PXOBK1_&-QK^D2>(?&7ABV_X1_PMXOUO4K[4OAZLLOC2;3M%TW0;C6-
M1T7P_:Q?;;OQ%96,^@364UE<V.I746HZ>UT ?0=?,O[:W_)FW[6O_9LOQY_]
M59XKKMO#W[0'PD\6>)=*\+>'/%T.L7VO/=V^@ZC9Z;K$GA?7M1L-#M?$]_HN
MB>+_ .SQX8U;7;'P[>0ZU=Z+8:M/J4&GI>3/; Z;J2VG$_MK?\F;?M:_]FR_
M'G_U5GBN@#YV_P"".?\ RB>_X)N_]F2?LT?^JD\*U_*C_P %<_VE/VJ='_X*
MA?M@^!/!O[6W[57PU\!^ K_X$:7X/\"_"O\ :$^*/PT\&Z!9ZY^S7\)?%VL"
MQ\-^"_$FBZ4+G5/$NO:SK-_?36TMY=7>H2^9.8DACC_JN_X(Y_\ *)[_ ()N
M_P#9DG[-'_JI/"M?QW_\%??^4M?[>'_8?_9S_P#62?@=7I933A4QL8U(0J1]
ME7?+.*E&Z@FG9Z73U3Z,_O/]FOP3P=XA?2OX7X8X[X7R#C'AS$\&^(V+Q&1<
M2Y7A<XRFOBLOX<P.(P.(JX'&1E0G7P=><ZV&J27-1J2E.%FV?*W_  TO^V-_
MT?=^WA_XF+^T!_\ -W1_PTO^V-_T?=^WA_XF+^T!_P#-W7D=%?3_ %3"?] N
M&_\ !$#_ *0/^)2?HM_]([^#/_BO.'?_ )2?0%M^UM^UO; W*_M8?M-2^(CX
M2O/ W_"=W/QW^)MS\1%\+WNJ2ZU+I2>.YO$K^)T@CU27[;;*NI 6MQ%!) J-
M!$5YO_AI?]L;_H^[]O#_ ,3%_: _^;NO(Z*2PF$7_,+A_G1@_P#AA+Z(_P!%
MI7M]';P85W=V\/.'M7W_ (1ZY_PTO^V-_P!'W?MX?^)B_M ?_-W7Z _\$E_V
ME?VJM6_X*@_L:>!O&'[7'[5GQ(\">/M=^.&D>,? OQ3_ &AOBG\2?!GB"PT;
M]F;XQ^+=)34/#/C/Q+K.DR3Z9XET#1=9L+Q+:.[M+W3H7BF52ZM^45??7_!(
M_P#Y2T?L"_\ 8X?M!_\ K(OQYKEQV&PT,%B90P]"$HTKQE&E",HOGI*Z:U3L
MVKKHWW/Y;^FS]&WZ/G!WT4?'/B?A/P2\+>&^(\EX*^MY1GN2<$Y)EV;99BO]
M8N$</]9P..PU*-?"U_88K$T?:TFI>SQ%:&U21_H?4445\B?\N)_FF_\ !?7_
M )3 ?MB_]>/[-G_K-_P[K\@:_7[_ (+Z_P#*8#]L7_KQ_9L_]9O^'=?D#7\9
M>(G_ "6_$O\ V,(_^H67G_3)]##_ )19\$_^R1K?^M/Q>%%%%?&'].!1110!
M^I/_  0__P"4P'[ G_8\_'3_ -9-^.]?Z<]?YC'_  0__P"4P'[ G_8\_'3_
M -9-^.]?Z<]?UCX0?\D3AO\ L:9Q_P"I5 _YZ_VCG_*4>??]D-X<_P#JAS0*
M_BT_X*!?\I/OV[?^N_[+'_K.GAVO[2Z_BT_X*!?\I/OV[?\ KO\ LL?^LZ>'
M:_M_Z)__ ">S(?\ L2\5?^J1'^'7[0G_ )1=XL_[*CP^_P#6ID?-5%%%?ZP'
M_/@%%%% !7J7[*'_ "D<_P"":7_9S'Q(_P#6-?VH*\MKU+]E#_E(Y_P32_[.
M8^)'_K&O[4%?D?CY_P F8\2?^R7Q'_J?DA_17T1O^4F_!'_LO,%_ZJ>*3^XZ
MBBBO\:S_ *7C^&C_ (*I?\I3OVR/^Q<_95_]4U-7P]7W#_P52_Y2G?MD?]BY
M^RK_ .J:FKX>K\-XH_Y*#-/^O\/_ %&PQ_@1]+3_ )2-\5O^Q]@/_69X8"BB
MBO!/YV"BBB@#Z#_8B_Y2/_\ !./_ +.;\3_^LN?M%5_?K7\!7[$7_*1__@G'
M_P!G-^)__67/VBJ_OUK]AX(_Y$,/^PW&_P#I=$_VS^@7_P H^8+_ ++?C?\
M]3LE"O\ , _X.B?^4POQ7_[(A^S[_P"HMJ=?Z?\ 7^8!_P '1/\ RF%^*_\
MV1#]GW_U%M3K_4;]E+_RF_X8_P#9/>)W_K!8\_I_CG_DFL;_ -?<%_ZE0/Y[
MJ***_P"N$_!0HHHH *_5[_@A5_RF$_X)^_\ 99O$7_JF/BE7Y0U^KW_!"K_E
M,)_P3]_[+-XB_P#5,?%*OY-^GA_RAI]);_LTO$'_ *G<*'N\+_\ )19-_P!A
M]+_TFN?ZQ7CC_D2_%_\ V*_B#_TTW=?X%]?[Z'CC_D2_%_\ V*_B#_TTW=?X
M%]?\7)_19_O\4444 %%%% !1110!QGQ$\(2>/_ WBKP3%XBUGPF?%.BWFB2^
M(?#WV$:UIEMJ$9@NY=.;4;2^M([B6U>:V$TEM(\*S-+;M%<)%-'\9^$_V8_C
M'\-]='BSP]XO\ ^,=5LO$GQM31]$U_37\#Z#8^#_ (K:/X#@THQMX-\,W,-O
MJGAO5_AYHK7&D1:-)IUWHEW?V.G:KIDT5NS_ '_10!^?GP*_9"\9?!_2_@W\
M-;GQ-X<UGX;?!'XE>*_BEH?B2)]6B\<>)]4\3>$O$FBQ>']5T*:Q;1]'L=,U
MKQWXJOWU:V\1ZK+>Z38>'=+32[.674;N'VG]M;_DS;]K7_LV7X\_^JL\5U]-
M5\R_MK?\F;?M:_\ 9LOQY_\ 56>*Z /G;_@CG_RB>_X)N_\ 9DG[-'_JI/"M
M?QW_ /!7W_E+7^WA_P!A_P#9S_\ 62?@=7]B'_!'/_E$]_P3=_[,D_9H_P#5
M2>%:_CO_ ."OO_*6O]O#_L/_ +.?_K)/P.KU<F_WZ/\ UYQ'_IM'^C?[*?\
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M!_Z:;NO\"^O]]#QQ_P B7XO_ .Q7\0?^FF[K_ OK_BY/Z+/]_BBBB@ HHHH
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MKH ^=O\ @CG_ ,HGO^";O_9DG[-'_JI/"M?QW_\ !7W_ )2U_MX?]A_]G/\
M]9)^!U?V(?\ !'/_ )1/?\$W?^S)/V:/_52>%:_CO_X*^_\ *6O]O#_L/_LY
M_P#K)/P.KU<F_P!^C_UYQ'_IM'^C?[*?_E,OA#_LA?%'_P!9;+S\^J***^K/
M^IT**** "OOK_@D?_P I:/V!?^QP_:#_ /61?CS7P+7WU_P2/_Y2T?L"_P#8
MX?M!_P#K(OQYKDS#_<<7_P!>?_<E$_D#Z?O_ "AI](;_ +(+_P!^?@H_T/J*
M**^*/^08_P TW_@OK_RF _;%_P"O']FS_P!9O^'=?D#7Z_?\%]?^4P'[8O\
MUX_LV?\ K-_P[K\@:_C+Q$_Y+?B7_L81_P#4++S_ *9/H8?\HL^"?_9(UO\
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M?YG_ %->WH?\_P"A_P"#J/\ \N+%%5_M=I_S\V__ '^C_P#BJ/M=I_S\V_\
MW^C_ /BJ/ZW7^8>WH?\ /^A_X.H__+BQ7WU_P2/_ .4M'[ O_8X?M!_^LB_'
MFOS]^UVG_/S;_P#?Z/\ ^*K[6_X)>^/? GP__P""H_["GB[Q[XV\(>!_"FE>
M,?CR-3\3^,?$VB^&/#VG&]_9/^.=C9+?:UK=]8Z;:M>7UQ;V5HL]RC7-Y<06
ML DGFBC;DS#_ ''%_P#7GR_Y^4?,_D'Z?=:C+Z&OTA8QJTI2? 6D8U:4I/\
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M^96OT:HH*]I4_P"?E3_P94_^3/SE_P"'/_\ P2I_Z1R_L4_^(U_"7_YE:/\
MAS__ ,$J?^D<O[%/_B-?PE_^96OT:HH#VE3_ )^5/_!E3_Y,_.7_ (<__P#!
M*G_I'+^Q3_XC7\)?_F5IK_\ !'O_ ()2R#;)_P $XOV)G4'(#_LT_"1@#ZX;
MPJ1GWK]'**!.<VK.<VGNG.;3]4YM/YIGYO?\.=?^"3__ $C<_8B_\1F^$/\
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<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Y 2D# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>/?\-#_ #_HN7P>_\.9X*_\ EW2']HC]G\ D_'/X.@ $DGXF^"@ !R22=;P
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M);>VT_0+G3K.UTO3H]$L(P\TMY=7-W>RONAB6.,_EQ_Q%I_\%0O^D;/P5_\
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M*6K9C3SE,C\G^N'"7_15<-_^'[)__GD<7^OG W_1:<(_^)-D/_SV/]0&BO\
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M_ >I6ND>+-)^QZC::@S:3J-[I^J6MNUXMHVGWAEL+CS=/N[N%!')(LL?8T4
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M_P#5+^#*_0&OS^_X)/?\HOO^"=G_ &9)^R]_ZI?P97\K_P#P<I_';]MK3?\
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MAS_E.=JW_9AGPG_]6'XRK\O*_A7Q[_Y./CO^Q/D/_J'BC_-/Z4'_ "=O,/\
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M +,K\ _^K+\&U_?)7^C/AK_R;_@S_LG<M_\ 3=<_UK\(?^36^'__ &2>3_\
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MI:,EM& ?9->-_M%_\F^?';_LC?Q/_P#4)URO9*\;_:+_ .3?/CM_V1OXG_\
MJ$ZY0!\Q?\$GO^47W_!.S_LR3]E[_P!4OX,K^3K_ (.)?^4U?[-/_:/'4O\
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MRQW&I'4-<L;&&Z$FLW4,5YKTMNT$NO7L4=[K#WUTBS#Z<H ^>_C+^R;^S/\
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M=0T_PZ;]_A<K?V7:7UY=7<5N%P+BXFE)+R,3Q7_$)3\ ?^D@W[=__@[^#O\
M\Z^OYT\2?!K/>->*L1G^ S?)\'AJV!RW"QH8V&8RKJ>"H5J523>&I3I<DW43
MA:7-9/F2=C^3O%[Z/W$GB+QMB>)\LSW(<OPE?+,IP,<-F%+-9XE5,OP^(HU9
MR>$HSH<E25:+II2<E%/G2=C^3"BOZS_^(2GX _\ 20;]N_\ \'?P=_\ G7U\
M6:#_ ,&XOPGU?_@H;\3OV.Y?VY_VTH_!G@?]C_X/?M$V'B:/5OA</$UUXH^(
MOQ?^,/P[U;0[N5OA^^D/H5CI7PZT>_T]8=+@U$7^I:C]IO);9+2,?!_\2W<4
M_P#10\._^"LX_P#E!^8_\2B<:?\ 15\*?^",_P#_ )F/P#HK^L__ (A*?@#_
M -)!OV[_ /P=_!W_ .=?1_Q"4_ '_I(-^W?_ .#OX.__ #KZ/^);N*?^BAX=
M_P#!6<?_ "@/^)1.-/\ HJ^%/_!&?_\ S,?G9_P:[?\ *5?]L[_LROP#_P"K
M+\&U_?)7\N_P1_X-BO"/[-OCOQ+\3_@/_P %/_\ @HA\*OB#XQ\-6?@[Q1XN
M\'>*?A!I6M:[X7T^]M]1LM#U"[C^%S-/86M]:6US!$0/+DB4JP!8'ZG_ .'-
M'[17_2<+_@J[_P"'*^$__P ZROZGX3R>OP_PSD.1XFK1KXC*<KPF K5J"J*A
M5J8>-2,ITE54:JIR<URJHE/1W6Q_:W!&0XCA?@_AGAS%UZ&)Q61Y+@<LQ&(P
MRJK#UJN%A4A.I15=1K*G)S3BJL5.R?,EH?O#7^6%_P '-_\ RF\_:#_[(M^S
MQ_ZKG1:_M<_X<T?M%?\ 2<+_ (*N_P#AROA/_P#.LKX:^-G_  :<? W]H_XF
M:M\9?CM_P4/_ &]/BI\4]=TS1]&UCQWXQUWX.ZKXBU#2M LX]/T6PN;Z3X7A
MGMM-LX8[>UCV@1QKCDDD_P!0_16\7\E\ _I!>&7B_P 0Y3FN>Y+P-G6-S/'Y
M3DE3 4LUQM+$\/\ $&40I8.IF=2E@(U(U\XHU9/$U(P]E2JJ+=1TT_4SS+ZF
M:Y5C<OHU*=*IB:<80J55)TXN-6E4;DH)RM:FU[JO=KI<_P [6BO[^?\ B#,_
M8T_Z//\ VS__  -^#7_SL*/^(,S]C3_H\_\ ;/\ _ WX-?\ SL*_W3_XK;^!
M7_1F?&#_ ,.?AW_\\3\Q_P"(;9G_ -#'+_\ P#%__('\ U%?V5:+_P &L'[,
M>J?\%"?B)^R(_P"U1^UTOP_\&?L?_"C]H6V\9QGX8C7)?&GQ ^,/Q9^'M_X8
MO+\_#Z303I5MH7P^TW5M.M4TZWUAKR\U.2:YFLH;=%^S_P#B#,_8T_Z//_;/
M_P# WX-?_.PH_P"*V_@5_P!&9\8/_#GX=_\ SQ#_ (AMF?\ T,<O_P# ,7_\
M@?P#5_8)_P &8?\ R<M_P4>_[)C^SE_Z>_B-7WK_ ,09G[&G_1Y_[9__ (&_
M!K_YV%?0_P"SC_P:_P#@C]D+6/&?B#]F+_@IQ_P4,^"&M?$2RT73O'&I?#[Q
M/\']#NO$]CX<EO9M"MM7DA^%S?:8]*DU*_:R! ,)O+@*<2L#_$?T]OVBGAK]
M+7P>R'PXX/\ #_CWA7,\I\0<HXPK9AQ1B^%,1E]7!9=DG$65U<)2AD>+KXM8
MNI5SFA5IRG!8?V=&LIR4W33^EX6X1QF0YA5QF(Q>%KPJ82IAU"A&NIJ4ZM*:
MDW5BH\J5-IV=[M6TN?U(45^$,?\ P1I_:&66-IO^"WW_  5>EA$D9FB7XG?"
MB%I8@X,L2S+\*RT+21[D6558QL0X5MNT_NI86OV&QL[+[3=WGV.TM[7[7?S?
M:+ZZ^SPI#]IO+C:GGW<^SS;B;8OFS,[[5W8'^0Y]\6J*** "BBB@ HHHH **
M** "BBB@ HHHH **** *OV&R-Z-2-G:G45M6L1?_ &>+[:+)I5G:S%UL\\6K
M3HDS6XD\HRJLA0NH86J** "BBB@ HHHH **** "JJV-DM[)J*V=JNH2VT=G+
M?K;Q"]DM(9))H;62Z">>]M%--++' SF)))9'50SL3:JM9WMGJ-M'>:?=VM]:
M2F0175G<175M(8I'AE$<\#O$YCFCDBD"L=DB.C896  +-%%5;6]LKT7!LKNU
MNQ:74UE=&UN(K@6U[;D+<6EQY3OY-U Q FMY-LL1(#HI(H M4444 %%%% !1
M110!$MO D\MRD,2W$\<,4UPL:+/-%;M,T$4LH4221P-<3M"CL5B:>8H%,C[I
M:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\+_B?_ ,%!?'GP:_:5
M_P""G7POUWPY^U%\1M)^&_@KX-:G\#YO@G^SGXL^+OA3X17OB/\ 9ND\2ZY-
MK_B;P5X7O[31;O4?&+Q^)Y;7QM>W*QV<7VJW$6D[X5\?L_\ @MKI?P&^ G[,
M>A_$'1=)^,WQFM?^"?/[,7[6/[1&M^)_BQX5^$WB+Q%#\5OAW)JO]G_"#PL/
M".KQ?%[XR^*[GPEXQ\00^ M/@^'WA:-[CP]I:^+["]\165A:_M%:?LM?#&S\
M8?M1>-X9/$_]M?M=Z1X3T3XLA]:5K*.R\&?#>7X6:.?"=M]B!T&8^&)G:\D>
M2^^T:IMO0L8'DU\]0?\ !-/X0>'+?X5GX4?%C]I#X%:S\,?@%\*?V8[SQ-\(
M?BA9>']<^*?P:^"5C>6'PQ\._%7^U_"OB'2-=UCPC'J_B-M&\;Z'I/AGQSIH
M\4^(+73_ !'::??+9P 'D/Q"_P""K_@[X=_M'?!+X-ZCX*\"WW@_X[>/_@?\
M./"NJ6?Q]\+G]H#3]6_: TC1+KP/XB\2?LO'PNWB#PQX,MM9\2:-HWB"Y\3^
M.]#\96%M)>>(;7P-J&BVT-S>?(/P@_:\_:_^'/B+]G3X<_"SP5X2^.&E?M ?
M\%-?^"I/PL\>7GQ<^+^O>&=?TKPW\*?''[2_C7P;X4\'ZS=>%O'+Z-I7AW2?
M \5]I\WV/4-/@TKPS:_#G3= TJ+Q#:>)= _1+Q#_ ,$P?@-X@^+]W\6AX]_:
M T2TU3]HKX3_ +6>O_";0/BA]A^$?B?]HCX.P>!;/PU\3?$N@2Z#=>(-9U#4
MM/\ AOX/M/$FA7GBJ3PCJ<^DPZY#X>LO$P76TZ#6_P#@G'\$-1T'P3IF@>+O
MC/\ #[Q!\./VG?C!^UGX&^(G@/Q[;Z1X[\.?$WX\ZI\1+WXK:9:ZA?:!JNC7
M?@7Q9IGQ4\9^%KKPQJNA:@MMX=U"WBLKVWU2PL]6A /SZ^!/[;WQM^"GQ/\
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MQ?M/A]H&E_$.S^)VMZQ9ZEHL?QE\0Q^)]:ET:Z_X3&WLM.@&GZ 8A*H!X_\
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MFU.7XR?'M/@1XU_:'L_VL_&'[)*^(?!4OP-\0_M!V?C/2OB4WBZ\OKGP%/\
M%Z#PKJ'Q.T32_BAJ_P *K'XGVOPVU/X@6K:W=>''M+N]TJY .8^'O_!473_&
M?Q1\&>%M;_9?^-W@#X2>/_VG_C1^QMX4_:"\2:K\,)_!VJ_M ?!K5_BK87>D
MQ>$M'\:W_P 1(? 7BJV^#WC"/P_\1;KPU;Z0GB2VB\.:E:V8EBU63EOV5/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $A 3$# 2(  A$! Q$!_\0
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MQEXOU7]H7PWK?Q.\(_'..S_:4\*VGA7X>7+>&(_"T6ER:Q9W!7]M: "BBB@
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M&7_^#MG_ *21_P#!/W_PT&F__0MU_5910!_*G_PR_P#\';/_ $DC_P""?O\
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M)1_PA?A3_H :9_X#)1_Q1&\<?^CT^$'_ (:/$7_YB#_B).6?]"W,/_!F$_\
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MX=U31M8<VFF^([N\LTM-3M-U];VZS.8#*C?('_!O[_R1[_@HO_VF._X*$?\
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M;U_N0>!_^1+\(?\ 8K^'_P#TTVE?\N7[9O\ Y2QX=_[,GP5_ZT''1^V>'?\
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M_3)8UT%?O\?AA_@I_P#INF?]FN1_\B3)/^Q+DW_JGR@****9Z84444 >M?\
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M;W$+C*2PS1>+7CEC<<J\;,C#D$BOSI_X*0_\%^/^"=O_  4[^'G@/X>_&/\
M9?\ ^"K'PEC^&_BF]\6>&?%'[/7BSX7>!_$1O=3L(]+U*PUI-5U#Q#HVM:7=
M64:B.*ZTT75C<*)[&[@$EU%<?B?\!YYU^"/PC59I54?#[PV !(X 'V)>  <
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M+OCA_P D5^+_ /V2[X@?^HGJU?<GZ0?X@OPU_P"1,TCZWW_IPNJ[NN$^&O\
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M/@?PWK7@3X6>#_B;K_@JY\<:++\%/'?B/1;OPW;6OBK6Y[6RN-<T'3-<F/\
M250 45^8'CO]NGXQ_!75_P!IR#XR_ +PG;:'\,+#X-WGP3UCX;_%D>,CXYUW
MX]?%&Z^#GPZ^&'Q2L[_PEX>N?AO\1[SQ3+X:\1WUOHT7C3P]'X(\41W]CK%_
M>Z1/!>^\? []L'P/XY\+>-!\6]=\!?"/X@_"KXR>/_@%\0=)UCQEI^E^&[_Q
M_P##J/0]0O\ 4O NI>*7T/4-8\,Z_P"&/%7A+Q;I0NK*'4]/L/$=KI^J1?:[
M=YI@#\VO^#?W_DCW_!1?_M,=_P %"/\ U//#=5O^#GO_ )0A_MH_]>WP5_\
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MP4(_]3SPW5;_ (.>_P#E"'^VC_U[?!7_ -:!^%M '\?GA'_D4?"7_8J^&_\
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MQM8Z#\3'\6^*(M6^&UOK&J:Y/I?CAM*7M='_ ."HOP__ &8_!OQ,T;]K6_\
MC'XMN/A?^UO\8_V8?"GQ ^&WP&^)'QEUKQEI/@#PW\/_ (A>&=8^(5I\#O .
MK:9X=\5OX0^)FDZ)J5V^B>'--\2ZUX:US4M)TZ)EO;>W /+O^#?W_DCW_!1?
M_M,=_P %"/\ U//#=5O^#GO_ )0A_MH_]>WP5_\ 6@?A;7/?\&X7C/0OB/\
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M-=!7[_'X8?X*?_INF?\ 9KD?_(DR3_L2Y-_ZI\H"BBBF>F%%%% 'K7_!,_\
MY3X?\$V/^Q#_ &I/_5)_$BO]'ZO\X'_@F?\ \I\/^";'_8A_M2?^J3^)%?Z/
MU?CW$_\ R/<P_P ='_U%PQ_RZ_3V_P"4N?&G_L=Y'_ZQ?"(5^;'_  6/_P"4
M47_!17_LSC]H#_U7&OU^D]?FQ_P6/_Y11?\ !17_ +,X_: _]5QK]> ?R"?Y
MF'P(_P"2)?"3_LG_ (<_](EKU:O*?@1_R1+X2?\ 9/\ PY_Z1+7JU?YC\1?\
ME#Q!_P!C_/?_ %=9L?XW<6?\E7Q5_P!E/Q)_ZT&>!1117CG@!1110!R2?\G+
M?\$_/^S^?V9/_5AZ37^N;7^1DG_)RW_!/S_L_G]F3_U8>DU_KFU_<_@#_P F
MXPG_ &.L^_\ 4S"G^E?T7_\ DTF7_P#90<3_ /JPP85Y=\</^2*_%_\ [)=\
M0/\ U$]6KU&O+OCA_P D5^+_ /V2[X@?^HGJU?M)_0I_B"_#7_D3-(^M]_Z<
M+JN[KA/AK_R)FD?6^_\ 3A=5W=?]NWT3/^46_HY_]F0\,/\ UC\K/YMS[_D>
M9O\ ]C+&_P#J1,****_H(\D**** .'^(?_(MO_V$M(_].-O7^Y!X'_Y$OPA_
MV*_A_P#]--I7^&_\0_\ D6W_ .PEI'_IQMZ_W(/ _P#R)?A#_L5_#_\ Z:;2
MO^7+]LW_ ,I8\._]F3X*_P#6@XZ/VSP[_P"1%6_[&6)_]-84ZBBBBO\ )0^\
M"BBB@ HHHH _,GXL_P#!-B+XK?$;4/&US^U7^T+X?\,VOQ3\*?&3X?\ PATU
M?A?>?#3X?>-]'^(?AOXL^*YK.TU7X?7GB;Q!I7C[XA^#_#^OZI8Z]XENKCP]
M%+XHTGP??Z%IWBS4X!]8_LK_  'E_9K^!WA/X27WC:\^).O:7J?CGQ5XO^(%
M]HEGX9G\9^._B;X_\4?$WQUXBC\-:==7UAX=LM3\7>+]9GTS0;2^O8-&TQK3
M38[RZ%MY\GT+10 4BLKJKHP96 964AE96&0RD9!!!!!!((.17\[G[1&H>(/
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M\0?]C_/?_5UFQ_C=Q9_R5?%7_93\2?\ K09X%%%%>.> %%%% '))_P G+?\
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M_P!BOX?_ /33:5_AO_$/_D6W_P"PEI'_ *<;>O\ <@\#_P#(E^$/^Q7\/_\
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M_P 0_P#D6W_["6D?^G&WK_<@\#_\B7X0_P"Q7\/_ /IIM*_PW_B'_P BV_\
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M7"3XQBY0=3#5'"3C%N#BW&+;2_!.BOWL_P"(8[X]?])3;C_Q"[X>_P#SUZ^
MOV(O^"-/[0?[7_CG]NCP=<?\%#$\#I^QQ^V/X\_94M+^U_93\!>(6\>6W@KP
MWX3UX>-+JWD\>Z2OAZYOI?$LED^A13:PEJ; R?VI*9O+C?\ KIE'\F._\)Z?
M_P T';_Q54^C7_T)/%O_ ,1')/\ Z,SX0HK][/\ B&.^/7_24VX_\0N^'O\
M\]>C_B&.^/7_ $E-N/\ Q"[X>_\ SUZ/]=,H_DQW_A/3_P#F@/\ BJI]&O\
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MI8>24K-72DTGI=[G\05%?V^_\082_P#22C7_ /Q%?P]_\^:OS_T[_@VAEO\
M_@J%XD_X)TG]NG4XK70/V(M#_:^7XH?\,^Z&U_=7.L?&F\^$C>!CX/\ ^%F+
M#%;6\=J-=_X2$>('9WD&GG2DP+EOU3_BLY]$[_HG/&S_ ,0OA[_Z.CA_XAWG
MO_/[+?\ PIJ__,I_,%17]OO_ !!A+_TDHU__ ,17\/?_ #YJ/^(,)?\ I)1K
M_P#XBOX>_P#GS4?\5G/HG?\ 1.>-G_B%\/?_ $=!_P 0[SW_ )_9;_X4U?\
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MUUH/BOP;XT\%^+]+T+Q?X*\8^&-:LKK3->\+^*=$TC7-+NHMMU8QI)"\GJU
M!1110 4444 %<K_P@O@D^-5^)7_"'>%O^%BKX8?P2OC[_A'])_X30>#9-4CU
MR3PD/%/V3^W!X9?6H8M7;0?MW]EMJD:7YM?M2B4=510 4444 %%%% !1110
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M0^&)=5T./6H;_P .WOB;P?JM@VK6*W.A^*-4B:5E=HI/LVB@#\3/B]_P1M\
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M'P)\/^#;'PM:Z3KOP\^!OA^*TN((;2YCUW6EMK.PL?0OB9_P3/\ VEM8TO\
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #F F0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (W1_P )1J/_ $*NL?\ ?(_^-UV5%']GYI_T/\1_X;,J_P#D0^MX'_H54O\
MPMQW^9QO_"4:C_T*NL?]\C_XW1_PE&H_]"KK'_?(_P#C==E11_9^:?\ 0_Q'
M_ALRK_Y$/K>!_P"A52_\+<=_F<;_ ,)1J/\ T*NL?]\C_P"-T?\ "4:C_P!"
MKK'_ 'R/_C==E11_9^:?]#_$?^&S*O\ Y$/K>!_Z%5+_ ,+<=_F<;_PE&H_]
M"KK'_?(_^-T?\)1J/_0JZQ_WR/\ XW7944?V?FG_ $/\1_X;,J_^1#ZW@?\
MH54O_"W'?YG&_P#"4:C_ -"KK'_?(_\ C='_  E&H_\ 0JZQ_P!\C_XW7944
M?V?FG_0_Q'_ALRK_ .1#ZW@?^A52_P#"W'?YG&_\)1J/_0JZQ_WR/_C='_"4
M:C_T*NL?]\C_ .-UV5%']GYI_P!#_$?^&S*O_D0^MX'_ *%5+_PMQW^9QO\
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MA9SE.<YX;#RG.I"-.<IRH4I2E.$)2A"<I-RE",I1C*4HQ;204445F= 4444
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M.IA9QA.I"HJU&I&I2HXBA6P]2"2KX?$X;$X;$X>O%1A5P^(I5$HN3A#U&BN
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MI_\ ZEU3L:***]H\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN4)I2=W%IN+LVW)J2LVKM)IM)*5EZ#1115GSX4444 %%%% !1110 5@>*?\
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MH6II>S4%RJ\^QHKXJ_:(_;)M/@+XOUGPS;?##Q#X_L_ 'PKMOC?\7]<TO7]
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MHHHKJ, HJ"YE\BVN)]K/Y,$LNQ 6=O+C9]J* 26;;A0 220 #7\].C_M-_\
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MGI8?.?A;]D+]HJ]^#GQ?\)^)?"OA7P[XDM?V$/"O[&W@"TMO&UGK5E\0-?\
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M8*;NIVYJM"ELJMU[U6/6$TM-Y02TG$_++Q#!<6P,%O;^6KB[ND<R.3:L//\
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M9,?R(I0!8^/+55]3U/\ 9A\8V[W/E:98:G_9<%KJFJ-I>H65X+)M7\D:7:7
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M,J56%.I5Q,\/&MC*WL\'B&ZE?_:73I<OLXTZ5-/]-Z***\X^I"BBB@ HHHH
M*X[PCU\0?]A^]_FM=;-*D$,L\AVQPQO*Y]$C4NQ_  URG@J-SI$EY(N&U&_O
M+WZJ\FQ3^)1B/4'N,&O$QGOYYDM..LJ5#.,3-?RTI8?"86+?92K5%&/=QDE>
MS/1P_NY;F,GHIU<OHQ\YJK7KM+_#3AS/LFNYU]%%%>V><%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 UUW*P]0>V?TK"GLPY^;[I[8(X/;OCT_
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M1P\9+F5*+G)*55I%%%%>N< 4444 %%%% !1110 4444 %%%% !1110 4444
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M_?\ [*C_ (1:^_Z&G6_^_O\ ]E78T4?ZOY5_SYQ'_ARS7_YYA_:N._Y^4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
